2013 National Report (2012 data) to the EMCDDA by the Reitox National Focal Point. Ireland: new developments, trends and in-depth information on selected issues. by unknown
  
 
 
 
 
 
 
 
 
2013 NATIONAL REPORT (2012 Data)  
TO THE EMCDDA 
by the Reitox National Focal Point 
 
 
IRELAND 
New Developments, Trends and in-depth 
information on selected issues 
 
 
 
 
 
 
 
 
 
 
 
REITOX  
 
 
  2 
Acknowledgements 
 
Addiction service managers, drug treatment facilities and general practitioners 
Central Statistics Office 
Central Treatment List 
Coroner Service 
Customs Drugs Law Enforcement of the Revenue Commissioners 
Department of Education and Skills 
Department of Health  
Department of Justice and Equality  
Department of Social Protection 
Forensic Science Laboratory 
Garda National Drugs Unit 
General Mortality Register 
Health Protection Surveillance Centre 
Health Service Executive 
Hospital In-Patient Enquiry scheme 
Irish Prison Service 
The Garda Síochána 
Office for the Minister for Children and Youth Affairs 
Voluntary and community groups and academic researchers 
 
We would specially like to thank the following: 
Dr Joe Barry, Ms Theresa Barnett, Ms Elaine Butler, Dr Des Corrigan, Ms Caroline 
Comar, Mr Michael Conroy, Mr John Craven, Mr Niall Cullen, Ms Gretta Crowley, Ms 
Aileen Dooley, Mr Joe Doyle,  Dr Brian Farrell, Mr Liam Hughes, Dr Pierce Kavanagh, 
Dr Eamon Keenan, Dr Alan Kelly, Mr John Moloney, Ms Niamh Murphy, Dr Kate 
O’Donnell, Dr Dan O’Driscoll, Ms Dairearca Ní Néill, Mr Brendan Ryan, Ms Susan 
Scally, Dr Bobby Smyth, Ms Sandra Tobin, Dr Lelia Thornton and Professor Miriam 
Wiley.  
 
Finally, we would like to express our sincere thanks to our Health Research Board 
colleagues working in the area of alcohol and drug related research Fiona Bannon, 
Anne Marie Carew, Ita Condron, Mary Dunne, Louise Farragher, Ena Lyn, Vivion 
McGuire, Deirdre Mongan, Joan Moore, Mairea Nelson and Simone Walsh who 
provided access to literature, analysed data from reporting systems or summarised 
literature for Drugnet Ireland.  
 
Brian Galvin 
Head of the Irish Focal Point 
 
This report was written by: 
Johnny Connolly 
Carrie Garavan 
Justine Horgan 
Martin Keane 
Jean Long 
Suzi Lyons 
 
Brigid Pike 
Dr Justine Horgan, prevalence expert at the Irish National Focal Point, died in August 
this year. Justine’s colleagues and friends in the Health Research Board were deeply 
saddened by her untimely death.  Justine was a highly dedicated scientist with a 
commitment to ensuring that evidence of the highest quality was available to those 
making policy in the drugs field.  We have lost an excellent colleague and a good friend 
and we will remember her time working with us with both fondness and regret. 
 
This report was compiled by Mairea Nelson and Brigid Pike. 
 
Please use the following citation: 
Health Research Board, Irish Focal Point (2013) 2013 National Report (2012 data) to 
the EMCDDA by the Reitox National Focal Point. Ireland: new developments and 
trends. Dublin: Health Research Board. 
  3 
Contents 
Summary of each chapter................................................................................ 6 
Main points ............................................................................................................................ 6 
Part A: New Developments and Trends........................................................ 12 
1. Drug policy: legislation, strategies and economic analysis....................... 12 
1.1 Introduction ............................................................................................................. 12 
1.2 Legal framework ...................................................................................................... 13 
1.2.1 Laws, regulations, directives or guidelines in the field of drug issues (demand 
& supply) ....................................................................................................... 13 
1.2.2 Laws implementation ...................................................................................... 14 
1.3  National action plan, strategy, evaluation and co-ordination .................................. 17 
1.3.1 National action plan and/or strategy ................................................................ 17 
1.3.2 Implementation and evaluation of national action plan and/or strategy .......... 18 
1.3.3 Other drug policy developments e.g. government declaration, civil society 
initiatives ........................................................................................................ 23 
1.3.4 Co-ordination arrangements ............................................................................ 25 
1.4 Economic analysis ................................................................................................... 26 
1.4.1 Public expenditures ......................................................................................... 27 
1.4.2 Budget ............................................................................................................. 27 
1.4.3 Social costs ...................................................................................................... 28 
2. Drug Use in the General Population and Specific targeted-Groups .......... 29 
2.1 Introduction ............................................................................................................. 29 
2.2 Drug use in the general population (based on probabilistic sample) ....................... 30 
2.3 Drug use in the school and youth population (based on probabilistic sample) ....... 36 
2.4 Drug use among targeted groups/settings at national and local level (university 
students and conscript surveys, migrants, music venues gay clubs, gyms) ............. 39 
3. Prevention ..................................................................................................... 40 
3.1 Introduction ............................................................................................................. 40 
3.2 Environmental prevention ....................................................................................... 41 
3.2.1 Alcohol and tobacco policies .......................................................................... 41 
3.2.2 Other social and normative changes ................................................................ 42 
3.3 Universal prevention ................................................................................................ 42 
3.3.1 School .............................................................................................................. 42 
3.3.2 Family ............................................................................................................. 44 
3.3.3 Community ...................................................................................................... 44 
3.4 Selective prevention in at-risk groups and settings ................................................. 47 
3.4.1 At-risk groups .................................................................................................. 47 
3.4.2 At-risk families ................................................................................................ 48 
3.4.3 Recreational settings (incl. reduction of drug and alcohol related harm) ........ 49 
3.5 Indicated prevention ................................................................................................ 50 
3.5.1 Children at risk with individually attributable risk factors (e.g. children with 
Attention Deficit (Hyperactivity) Disorder, ,children with externalising or 
internalising disorders) Externalising : sensation seeking, conduct disorders; 
Internalising : extreme shyness, depression. .................................................. 50 
3.6 National and local media campaigns ....................................................................... 51 
4. Problem Drug Use (PDU) .............................................................................. 52 
4.1 Introduction ............................................................................................................. 52 
4.2 Prevalence and incidence estimates of PDUs .......................................................... 52 
4.2.1 Indirect estimates of problem drug use ........................................................... 52 
4.2.2 Estimates of incidence of problem drug use ................................................... 53 
4.3 Data on PDUs from non-treatment sources (police, emergency, needle exchange 
etc) ........................................................................................................................... 53 
4.3.1 PDUs in data sources other than TDI .............................................................. 53 
4.4 Intensive, frequent, long-term and other problematic forms of use ......................... 57 
  4 
4.4.1 Description of the forms of use falling outside the EMCDDA’s PDU definition 
(in vulnerable groups) .................................................................................... 57 
4.4.2 Prevalence estimates of intensive, frequent, long term and other problematic 
forms of use, not included in the PDU definition .......................................... 57 
5. Drug-related treatment: treatment demand and treatment availability ...... 58 
5.1 Introduction ............................................................................................................. 58 
5.2 General description, availability and quality assurance ........................................... 60 
5.2.1 Strategy/policy ................................................................................................ 60 
5.2.2 Treatment systems ........................................................................................... 62 
5.2.2.1 Organisation and quality assurance ................................................................. 66 
5.2.2.2 Availability and diversification of treatment ................................................... 69 
5.3 Access to treatment .................................................................................................. 73 
5.3.1 Characteristics of treated clients (TDI data included) ..................................... 73 
5.3.2 Trends in treated population and treatment provision (incl. numbers) ............ 77 
6. Health Correlates and Consequences ......................................................... 78 
6.1 Introduction ............................................................................................................. 78 
6.2 Drug-related infectious diseases .............................................................................. 80 
6.2.1 HIV/AIDS and viral hepatitis .......................................................................... 80 
6.2.2 STI’s and tuberculosis ..................................................................................... 85 
6.2.3 Other infectious morbidity (e.g. abscesses, sepses, endocarditis, wound 
botulism) ........................................................................................................ 85 
6.2.4 Behavioural data .............................................................................................. 85 
6.3 Other drug-related health correlates and consequences ........................................... 87 
6.3.1 Non-fatal overdoses and drug related emergencies ......................................... 87 
6.3.2 Other topics of interest e.g. psychiatric and somatic co-morbidity, traffic 
accidents, pregnancies and children born to drug users ................................. 90 
6.4 Drug-related deaths and mortality of drug users ..................................................... 97 
6.4.1 Drug-induced deaths (overdoses/poisonings) ................................................. 97 
6.4.2 Mortality and causes of deaths among drug users (mortality cohort studies) 100 
6.4.3 Specific causes of mortality indirectly related to drug use (e.g. HIV/AIDS and 
HCV related to IDU, suicides, accidents) .................................................... 100 
7. Responses to Health Correlates and Consequences ............................... 105 
7.1 Introduction ........................................................................................................... 105 
7.2 Prevention of drug-related emergencies and reduction of drug-related deaths ..... 105 
7.3 Prevention and treatment of drug-related infectious diseases................................ 106 
7.4 Responses to other health correlates among drug users ........................................ 111 
8. Social Correlates and Social Reintegration ............................................... 113 
8.1  Introduction ........................................................................................................... 113 
8.2 Social exclusion and drug use ................................................................................ 113 
8.2.1 Social exclusion among drug users ............................................................... 113 
8.2.2 Drug use among socially excluded groups .................................................... 115 
8.3 Social reintegration ................................................................................................ 117 
8.3.1 Housing ......................................................................................................... 117 
8.3.2 Education, training ........................................................................................ 123 
8.3.3 Employment .................................................................................................. 124 
9. Drug-related crime, prevention of drug-related crime and prison ........... 125 
9.1 Introduction ........................................................................................................... 125 
9.2 Drug-related crime ................................................................................................. 127 
9.3 Drug law offenses .................................................................................................. 127 
9.4 Other drug-related crime........................................................................................ 130 
9.5 Prevention of drug-related crime ........................................................................... 132 
9.6 Interventions in the criminal justice system .......................................................... 133 
9.6.1 Alternatives to prison .................................................................................... 133 
  5 
9.6.2 Other interventions in the criminal justice system ........................................ 135 
9.7 Drug use and problem drug use in prisons ............................................................ 136 
9.8 Responses to drug-related health issues in prisons ................................................ 137 
9.8.1 Drug treatment ............................................................................................... 137 
9.8.2 Prevention and reduction of drug-related harm ............................................. 138 
9.8.3 Prevention, treatment and care of infectious diseases ................................... 138 
9.8.4 Prevention of overdose-risk upon prison release........................................... 138 
9.9 Reintegration of drug users after release from prison ............................................ 138 
10. Drug Markets ............................................................................................... 141 
10.1 Introduction ........................................................................................................... 141 
10.2 Availability and supply .......................................................................................... 142 
10.2.1 Perceived availability of drugs, exposure, access to drugs e.g. in general 
population, specific groups/places/settings, problem drug users ................. 142 
10.2.2 Drugs origin: national production versus imported ....................................... 143 
10.2.3 Trafficking patterns, national and international flows, routes, modi operandi; 
and organisation of domestic drug markets ................................................. 144 
10.3 Seizures .................................................................................................................. 147 
10.3.1 Quantities and numbers of seizures of all illicit drugs .................................. 147 
10.3.2 Quantities and numbers of seizures of precursor chemicals used in the 
manufacture of illicit drugs .......................................................................... 149 
10.3.3 Number of illicit laboratories and other production sites dismantled; and 
precise type of illicit drugs manufactured there ........................................... 149 
10.4 Price/purity ............................................................................................................ 149 
10.4.1 Price of illicit drugs at retail level ................................................................. 149 
10.4.2 Price/potency of illicit drugs ......................................................................... 150 
10.4.3 Composition of illicit drugs and drug tablets ................................................ 150 
Part B ................................................................................................................... 151 
11. Bibliography ................................................................................................ 151 
11.1 List of references ................................................................................................... 151 
11.2 List of relevant databases available on internet ..................................................... 162 
11.3 List of relevant internet addresses ......................................................................... 162 
12.  Annexes ....................................................................................................... 164 
12.1 List of Standard Tables and Structured Questionnaires used in text ..................... 164 
12.2 List of tables .......................................................................................................... 164 
12.3 List of figures ......................................................................................................... 166 
12.4 List of maps ........................................................................................................... 166 
12.5 List of legislation ................................................................................................... 166 
12.6 List of abbreviations .............................................................................................. 167 
 
  
  6 
Summary of each chapter 
This report, written following European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) guidelines,1 is an overview of new developments and trends in the drugs 
area in Ireland between 2011 and 2013. These are covered under the following 
headings: 
1. Drug policy: legislation, strategies and economic analysis 
2. Drug use in the general population and specific targeted-groups 
3. Prevention 
4. Problem drug use 
5. Drug-related treatment: treatment demand and treatment availability 
6. Health correlates and consequences 
7. Responses to health correlates and consequences 
8. Social correlates and social reintegration 
9. Drug-related crime, prevention of drug-related crime and prison 
10. Drug Markets 
 
 
Main points  
1. Drug policy: legislation, strategies and economic analysis 
The Criminal Justice (Search Warrants) Act 2012 was signed into law on 24 July 2012. 
It provides additional safeguards in circumstances of urgency requiring the immediate 
issue of a warrant. The Road Traffic Bill 2013, when enacted, will provide for new 
measures to test for driver intoxication based on nontechnology-based cognitive tests. 
The Spent Convictions Bill 2012 will provide that convicted persons whose sentence is 
below a specific threshold, may withhold details of the conviction, for example when 
seeking employment. Legislative measures are currently being progressed to provide 
for the legal sale of medicinal cannabis and to address the illegal street sale of 
prescription drugs. 
 
The Criminal Justice Act 1999 created a new offence of possessing controlled drugs 
having a value of £10,000 (€13,000) or more for sale or supply, which attracted a 
presumptive sentence of 10 years’ imprisonment. The Law Reform Commission (LRC) 
has recommended that this presumptive sentencing regime be repealed. The LRC 
highlights the apparent injustice inherent in the legislation whereby the same 
presumptive sentencing regime applies to individuals regardless of their position in the 
drug trafficking operation and their consequent level of moral culpability.  
 
Progress continues in implementing the 61 actions in the National Drugs Strategy 
2009–2016, with delays in implementing 16 actions noted owing to the continuing 
economic downturn, the ongoing deliberations on a National Substance Misuse 
Strategy, or the delay in renewing the mandate of the National Advisory Committee on 
Drugs. Only one new policy initiative was undertaken at national level – a review of 
drugs task forces – and not all the recommendations have been implemented. In the 
third sector, community sector groups have been stressing the importance of placing 
the individual at the centre of their work and, as a result, emphasising human rights, 
harm reduction and a focus on the whole person. Civil society organisations have also 
hosted two events on policy issues: ‘Criminalising addiction: is there another way?’ and 
‘Responding to addiction in a time of recession’. 
 
 
 
 
                                               
1
 The EMCDDA guidelines require each Focal Point to write its National Report in a prescribed format using standard 
headings and covering each topic using a check list of items. This helps to ensure comparability of reporting across the 
EU.  www.emcdda.europa.eu/ 
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2. Drug use in the general population and specific sub-groups 
The All-Ireland general population survey 2010/2011 reported detailed information on 
cannabis in 2013: More people than ever before had tried cannabis at least once in 
their lifetime, with the rate at one in four adults, compared to one in six in the 2002/3 
survey.  However, rates for last-year and last-month prevalence have tapered off since 
the 2006/7survey.  Additionally, among those consuming cannabis, age of initial use 
has remained the same, at 18 years, and use declines with age. Among those defined 
as recent users, 17% met the EMCDDA criteria for cannabis abuse, from which it is 
inferred that approximately 39,953 people in Ireland abuse cannabis, and 9% were 
classified as dependent, from which it is inferred that approximately 18,440 people are 
cannabis dependent. 
 
The All-Ireland general population survey 2010/2011 reported detailed information on 
sedatives or tranquillisers in 2012: Prevalence rates were 14% for lifetime use, 7% for 
last-year use and 3% for last-month use. There were statistically significant increases 
in the lifetime rate (up by 32%) and the last-year rate (up by 38%) since the 2006/7 
survey. Prevalence rates increased among the groups traditionally associated with 
these medicines (women and the older population), but the largest increases were in 
the rates of use by men and by young people.  
 
The All-Ireland general population survey 2010/2011 reported detailed information on 
anti-depressants in 2012: In 2010/11 the prevalence rates were 10% for lifetime use, 
5% for last-year use and 4% for last-month use. The rate for last-month use increased 
by 29% since the 2006/7 survey. Prevalence rates for women were higher than those 
for men , but overall, the gap between men and women in terms of lifetime and last-
year rates has narrowed.  Lifetime rates for older adults increased by 21%, from 11% in 
2006/7 to 13% in 2010/11. No statistically significant changes were found over time 
among young adults. 
 
The European School Survey Project on Alcohol and Other Drugs (ESPAD) 2010/2011 
reported that the rate of lifetime use of any illicit drug decreased from 22% in 2007 to 
19% in 2011. As the majority of 15–16-year-olds who have tried any illicit drug have 
used cannabis (marijuana or hashish), the decrease in illicit drug use may be explained 
by the fall in the number of students who have tried cannabis at some point in their 
lives, from 20% in 2007 to 18% in 2011 (just above the European average of 17%).  
The Health behaviour in school children (HBSC) 2010  reported an overall decrease in 
self-reported alcohol and cannabis use among school children in Ireland in 2010 when 
compared to 2006. This may represent a true decrease, possibly owing to children 
having less pocket money in recent years, or it may be the result of sampling variation, 
or a combination of both factors. 
 
 
3. Prevention 
The current direction of school-based universal substance use education and 
prevention, particularly among second-level students, is moving towards an integrated 
hybrid model incorporating a whole-school approach to overall health and social 
education, alongside an emphasis on young people developing their personal and 
social competencies. Owing to particular concerns around the threat of suicide among 
young people, a comprehensive set of guidelines promoting positive mental health and 
well-being among post-primary students have been developed and disseminated.  
 
A recent report estimated that 43% of young people aged between 10 and 24 
participated in youth work activities in 2011. An economic evaluation of youth work 
undertaken by independent consultants estimated that the State would save costs to 
the value of €2 billion for an €992 million investment over the next 10 years. A recent 
study found that young people reported that participating in youth clubs and related 
activities helped them to achieving personal development and happiness, skills and 
experiences needed for life and feeling included in society. 
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4. Problem drug use (PDU) 
Bulletin 3 in the series of reports on the 2010/11 general population survey on drug use 
in Ireland and Northern Ireland reports on cannabis use in the adult population (15–64 
years), on cannabis dependence and cannabis abuse as well as on patterns of 
cannabis use.  The study indicates that the likelihood of a young adult in Ireland using 
daily or almost daily has declined substantially since the 2006/7 survey.  Despite lower 
prevalence, frequency of use is higher among older adults, changing little since the last 
survey.  The number of treatment cases reporting cannabis as their main problem 
substance has increased significantly in Ireland and in 2010 cannabis became the most 
common problem drug reported by new cases. 
 
Merchants Quay Ireland (MQI), a national voluntary agency providing services for 
homeless people and for drug users, reported that in 2011 there were 21,819 visits to 
its Drug Services and 18,951 needle exchanges, with 4,051 individuals using the 
services, 492 of whom were new clients.  The new MQI centre in the Midlands provided 
over 4,000 one-to-one interventions in 2011.   
 
The first nationwide survey on drug and alcohol ‘misuse’ among the adult offender 
population on probation supervision are described includes findings on the nature of 
and engagement with drug and alcohol treatment services by adult offenders on 
probation supervision. 
 
 
5. Drug-related treatment: treatment demand and treatment availability 
The report of the expert group set up to examine the regulatory framework for products 
containing buprenorphine/naloxone and buprenorphine-only was published in 2013. 
The expert group has concluded that methadone is the drug of first choice for treating 
opiate dependency, but buprenorphine/naloxone may be appropriate for some patient 
cohorts in certain circumstances.  It has recommended that the regulations, guidelines 
and protocols governing methadone may also apply to the prescribing and dispensing 
of buprenorphine/ naloxone, or buprenorphine-only products, and that the details of 
patients receiving these products should be recorded on the Central Treatment List.  
The group advised that if buprenorphine/naloxone or buprenorphine-only products 
were to be used in Ireland, changes would have to be made to the misuse of drugs 
legislation and to the regulations for the prescription and supply of methadone. 
 
At mid-2013 there were 144 beds available for detoxification nationally. Only four beds 
are available for adolescent detoxification treatment, and the average waiting time for 
these beds is four to five weeks. 
 
New clinical practice guidelines on safe and effective prescribing of methadone for 
pregnant women in maternity hospitals have been published. Several reports have also 
been published looking at different interventions for problem drug users: brief 
interventions to reduce problem alcohol use in patients on methadone treatment; 
psychotherapeutic interventions by GPs providing treated to methadone patients in 
primary care; and group psychological intervention for psychosis with cannabis 
dependence. 
 
TDI data showed that in 2012, 7,703 cases entered treatment, a decrease of 336 cases 
from 2011. The majority were male (73.0%) and the mean age was 29 years, similar 
trends to 2011.  As in previous years, opiates (mainly heroin) were the most common 
main problem drug reported by cases entering treatment (51.6%).  The reduction in the 
proportion and number of cases treated for cocaine as a main problem substance 
continued, but there was an increase in the number of cases entering treatment for 
cannabis as their main problem substance. There were 9,419 clients registered for 
methadone treatment (including those receiving methadone in prison), only a 2% 
increase on 2011.  Since 2009, the number of clients registered on methadone 
treatment has stabilised 
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6. Health correlates and consequences 
Between 2011 and 2012, the number of new cases of HIV among injecting drug users 
(IDUs) has continued to decline. In 2012, 13 new diagnoses of HIV were IDUs, 
compared to 71 in 2004. In 2012, 69% of IDUs newly diagnosed with HIV infection 
were co‐infected with Hepatitis C. There was a 12% increase in hepatitis B 
notifications in Ireland in 2012 compared to 2011, but no new acute cases of hepatitis 
B infection among IDUs in 2012. While there was a 17.5% increase in hepatitis C 
notifications in Ireland in 2012 compared to 2011, the decreasing hepatitis C 
notifications and increasing median age is indicative of a reduced incidence of hepatitis 
C in the population. Injecting was the predominant risk factor for 484 of the new cases 
and the average age was 37 years. A 2011 study to determine the burden of hepatitis 
C infection in Ireland found that 63% of confirmed cases were men with a median age 
at diagnosis of 28 years; 70% had a history of drug use. Examination of genotype 
found that 53% of drug users had genotype 1 hepatitis C infection and 42% had 
genotype 3 hepatitis C infection.  
 
Various reports are described on including studies of blood-borne virus prevalence and 
testing and treatment status among IDUs; acute and chronic medical consequences 
among IDUs; dental disease among clients attending Irish alcohol and drug use 
treatment centres; overdose cases admitted to Irish hospitals; admissions to Irish 
psychiatric units and hospitals of cases with a drug disorder (ICD-10 Code F11–19, 
F55);  the association of substance use disorders and a history of psychiatric disorder 
or serious mental health problems among Irish adolescents.  
 
Ireland participated in Phase II of the International ADHD in Substance Use Disorders 
Prevalence (IASP) study to estimate the prevalence of ADHD in substance use 
disorder (SUD)-treatment-seeking patients. A total of 21% participants in Ireland 
screened positive for ADHD, none of which had been diagnosed in childhood. They 
were all being treated for problematic drug use, not for problematic alcohol use.  
 
The first study in Ireland to use the Comprehensive Assessment of At-Risk Mental 
States (CAARMS) to identify the prevalence of ultra-high risk (UHR) state for psychosis 
among young offenders has found that substance use problems were reported by 85% 
of those interviewed. 
 
In 2011, there were 220 deaths owing to poisoning recorded in Ireland by the National 
Drug-Related Deaths Index (NDRDI).  This represents a substantial increase compared 
to 2010, when 173 such deaths were recorded. 
 
 
7. Responses to health correlates and consequences 
In September 2012 the National Hepatitis C strategy was published. It contains 
updated epidemiological information on hepatitis C, details of new direct acting 
antivirals, and makes 36 recommendations. Five studies of the hepatitis C virus are 
described; they relate to treatment and management, current screening for HCV in 
pregnant women in Ireland and the related side-effects of treatment.  Other reports 
described include a study of the treatment of patients who are co infected with HIV and 
hepatitis C virus, and an audit of Irish Psycho-Gastroenterology Hepatitis C service.  
 
Three studies from large maternity hospitals are described. Two explore the paradigm 
for target screening versus universal screening for HCV in the routine prenatal care of 
women. A third study looked at methadone maintenance and prescribed medication 
among opioid dependent pregnant women.  
 
Finally, a small study has found that the GP plays an important role in meeting youth 
mental health needs, particularly in economically deprived urban areas. The author 
concluded that GPs and primary care teams need support and education for mental 
health issues for younger patients, particularly on the complexities of comorbidity. 
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8. Social correlates and social reintegration 
A number of studies have highlighted the interplay between drugs/alcohol, socio-
economic marginalisation and co-morbidity – among people attending a needle 
exchange service in Dublin; among 211 children and young people living  in state care; 
among residents in a hostel for the homeless in inner-city Dublin and among clients of 
a voluntary organisation providing shelter and accommodation to homeless people, 
among the adult offender population on probation supervision in Ireland.  
 
The Central Statistics Office published a comprehensive profile of the homeless 
population, as enumerated in the 2011 census of the population of Ireland. A total 
3,808 were either counted in accommodation providing shelter for homeless persons or 
were identified as sleeping rough. The government published a policy statement on 
homelessness in January 2013 making explicit its commitment to ending 
homelessness by the end of 2016 by implementing the housing-led approach. Recent 
research with stakeholders working in the homeless sector and with some homeless 
people suggests that it may not be just a matter of providing ‘bricks and mortar’ to 
tackle homelessness, particularly for people with long histories of homelessness.  
 
At June 2013 there were 895 participants on drug rehabilitation places in the 
Community Employment  scheme which was set up to provide education and 
vocational training to people in recovery from substance use. The most up-to-date data 
on the employment status of people reporting for drug treatment show a steady 
downward trend in terms of their employment prospects. 
 
 
9. Drug-related crime, prevention of drug-related crime and prison 
The number of legal proceedings for the possession of drugs for personal use (simple 
possession) has continued to decline since 2009. Proceedings for drug supply have 
also decreased marginally since 2009. A noteworthy development has been the 
continued increase in the offence of cultivating/ manufacturing controlled drugs, more 
than doubling since 2009. Since 2009, the number of prosecutions for Driving Under 
the Influence of Drugs has decreased significantly. 
 
The Inspector of Prisons, in his annual report for 2012, stated that the availability of 
drugs remains a major issue in a number of Irish prisons The Inspector also identified a 
number of issues of concern throughout the prison system, many of them drug-related. 
At present, for example, approximately 25% of Irish prisoners are in secure 23-hour 
lock-up for their own protection. This is often linked to threats from drug gangs in prison 
or because of drug debts owed to individuals or gangs. 
 
In 2012 the Drug Treatment Clinical Policy document issued by the Irish Prison Service 
(IPS) in 2008 was reviewed to ensure that services provided in prisons were equivalent 
to those provided in the community. It was amended to reflect changes in legislation 
and practice in the community, including the statutory requirements in relation to HIV 
testing and notification, and the development of In Reach services for the treatment of 
Hepatitis C. The IPS has adopted and is introducing the recommendations of the 
Review. 
 
 
10. Drug markets 
The Garda Síochána Commissioner stated that there are approximately 25 Organised 
Crime Groups (OCGs) operating throughout the State, the vast majority of which are 
drug trafficking groups.. In 2012, the Garda National Drugs Unit (GNDU) arrested 125 
persons in connection with drug trafficking offences, 91 of whom were charged and are 
currently before the courts.  
 
The total number of drug seizures increased from 5,299 in 2004 to a peak of 10,444 in 
2007. Between 2008 and 2010, the number almost halved, to 5,477. This decrease can 
be explained primarily by the significant decrease in cannabis-type substances seized. 
  11 
The decrease in cannabis seizures between 2009 and 2010 may also be partly 
explained by a change in the nature of cannabis use, with people moving from resin to 
more potent forms of cannabis, such as herbal cannabis. Herbal cannabis seizures 
almost doubled between 2009 and 2011, from 981 in 2009 to 1,833 in 2011, and then 
levelled off in 2012. There was a significant decline in seizures of cocaine and heroin 
between 2008 and 2011. In 2012, heroin seizures increased slightly, while cocaine 
seizures continued to decrease. Seizures of ecstasy-type substances also decreased 
significantly between 2008 and 2010. However, in 2011, they increased by more than 
900%. This upward pattern has continued, albeit by a small margin, in 2012. 
 
The GNDU carried out eight ‘test purchase’ operations targeted at low-level dealers 
nationwide, which led to 71 people being arrested in respect of 281 criminal offences. 
An Garda Síochána monitors drug markets on a nationwide basis annually and records 
current drug values. From the estimated total values of drug seizures published in the 
2012 Garda annual report, estimated unit prices have been deduced, and following 
further clarification from the GNDU, these data are presented in this National Report for 
the first time. 
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Part A: New Developments and Trends 
1. Drug policy: legislation, strategies and economic analysis 
1.1 Introduction 
The classification of drugs and precursors in Ireland is made in accordance with the 
three United Nations conventions of 1961, 1971 and 1988. Irish legislation defines as 
criminal offences the importation, manufacture, trade in and possession, other than by 
prescription, of most psychoactive substances. The principal criminal legislative 
framework is laid out in the Misuse of Drugs Acts (MDA) 1977 and 1984, and the 
Misuse of Drugs Regulations 1988. The offences of drug possession (s.3 MDA) and 
possession for the purpose of supply (s.15 MDA) are the principal forms of criminal 
charge used in the prosecution of drug offences in Ireland. The Misuse of Drugs 
Regulations 1988 list under five schedules the various substances to which the laws 
apply. 
 
The National Drugs Strategy (interim) 2009–2016 (NDS) provides the 
implementation framework for illicit drugs policy in Ireland (Department of Community 
2009). The Strategy has an overall strategic objective, ‘To continue to tackle the harm 
caused to individuals and society by the misuse of drugs through a concerted focus on 
the five pillars of supply reduction, prevention, treatment, rehabilitation and research’. 
Implementation is based on a ‘partnership’ approach, whereby over 20 statutory 
agencies, multiple service providers and community and voluntary groups work 
together in a nationwide network of regional and local drugs task forces (DTFs) to 
deliver the Strategy, with the statutory agencies critical in terms of core service 
provision. The Minister for Health has overall responsibility for the NDS, and an 
Oversight Forum on Drugs (OFD), chaired by the Minister of State for Primary Care 
within the Department of Health, and comprising senior representatives of the various 
statutory agencies involved in delivering on the Strategy, and representatives from the 
community and voluntary sectors, meets every quarter to monitor progress and 
address any operational issues. A Drugs Advisory Group (DAG), comprising 
representatives from the relevant public, community and voluntary sector 
organisations, including DTFs, advises the Minister of State on operational and policy 
matters relating to the NDS, with a special focus on implementation at local and 
regional level. 
 
Priorities for public expenditure on the drugs issue are set out in the NDS. Public 
funds are allocated by way of the annual parliamentary Estimates process, which 
allocates funds to departmental Votes. Funding for regional or local initiatives may be 
either directly from government agencies and funds such as the Young People’s 
Facilities and Services Fund (YPFSF), administered by the Department of Children and 
Youth Affairs (DCYA), or via the regional and local DTFs. Funding by DTFs proceeds 
from ‘initial’ to ‘mainstreamed’ funding as follows: 
 Initial funding: DTF projects are set up as pilot projects with funding provided 
through the Drugs Initiative, administered by the Department of Health. The relevant 
government department or agency acts as the channel of funding to the project 
during this pilot phase.  
 Mainstreamed funding: after the pilot phase, each project is evaluated and a 
decision taken with regard to mainstreaming it in the appropriate government 
department or agency.  Once mainstreamed, responsibility for funding the project 
transfers to that department or agency and the Department of Health is no longer 
involved. DTFs continue to have a monitoring role in relation to mainstreamed 
projects. 
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1.2 Legal framework 
This update covers drug-related acts and bills of the Oireachtas introduced or 
progressed during the reporting year. It also identifies new substances brought under 
control within the terms of the Misuse of Drugs legislation. Subject to the obligations of 
European Union membership as provided in the Constitution of Ireland, the sole and 
exclusive power of making laws for the State is vested in the Oireachtas. The 
Oireachtas consists of the President and two Houses, Dáil Éireann (House of 
Representatives) and Seanad Éireann (Senate). Bills are proposals for new laws. They 
are usually approved by a Minister or another member of the government. 
Occasionally, a private member’s bill is proposed by a member of the opposition. Such 
bills, because they have not originated in government, are less likely than government-
sponsored bills to become law. To become law, a bill must first be approved by both 
the Dáil and the Seanad, although the Dáil can override a Seanad refusal to pass a bill. 
Joint committees are groups of members of Parliament, including both government 
members and members of the opposition, which discuss proposed legislation and 
make recommendations for amendments to the Minister. Bills can be introduced in 
either the Dáil or Seanad and there are five stages in considering a bill. The second 
and third stages are considered the most important as they offer the fullest 
opportunities to Members to discuss and amend the contents of the bill. Once the bill 
has been passed by the Oireachtas, the Taoiseach (Prime Minister) presents it to the 
President to sign into law, and then it becomes an Act. 
 
Acts do not come into operation until a commencement order is issued in the form of a 
statutory instrument. There are five main types of statutory instrument: orders, 
regulations, rules, bye-laws and schemes. Statutory instruments have a wide variety of 
functions. They are not enacted by the Oireachtas but allow persons or bodies to whom 
legislative power has been delegated by statute to legislate in relation to detailed day-
to-day matters arising from the operation of the relevant primary legislation. Statutory 
instruments are used, for example, to implement European Council Directives and to 
delegate the powers of ministers. Specified government ministers and other agencies 
and bodies are authorised to make statutory instruments and several hundred 
instruments are made annually. Notice of the making of the commencement order is 
published in the Oireachtas newsletter Iris Oifigiúil. 
 
Also considered below where available are relevant debates in the Oireachtas in 
relation drug-related legislation, court decisions where the judiciary have provided 
specific interpretations of legislation, and academic and/or research findings in relation 
to drug-related legislation. 
 
1.2.1 Laws, regulations, directives or guidelines in the field of drug issues 
(demand & supply) 
This update covers drug-related acts and bills of the Oireachtas introduced or 
progressed between July 2011 and July 2012. It also identifies any new substances 
brought under control within the terms of the MDA legislation. 
 
The Europol Act 2012 was signed into law on 26 December 2012. The Act provides for 
the implementation of the decision of 6 April 2009 establishing the European Police 
Office (Europol) and replaces the Europol Convention and Protocols which previously 
provided the basis for Europol. Section 7 of the Act permits Europol to request member 
states to initiate criminal investigations while section 8 provides for the transmission of 
data to the Europol Information System (EIS). The EIS is used to store personal 
information about people who are suspected or convicted of having committed a crime 
for which Europol has competence or where there are reasonable grounds to believe 
that they will commit such an offence. 
 
The Criminal Justice (Search Warrants) Act 2012 was signed into law on 24 July 2012. 
The Act amends, inter alia, the provisions in the Criminal Justice (Drug Trafficking) Act 
1996 relating to the issue of search warrants under section 26 of the Misuse of Drugs 
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Act 1977. The Act amends section 8 of the Criminal Justice (Drug Trafficking) Act 
1996. Section 8(2) permits a superintendent (or above) to issue a warrant under 
section 26 of the Misuse of Drugs Act 1977 in circumstances of urgency requiring the 
immediate issue of a warrant and where it would be impracticable to apply to either a 
District Court judge or a peace commissioner. The amendments insert two additional 
safeguards. New subsection (2A) provides that only a superintendent who is 
independent of the investigation concerned may issue a warrant under section 26. 
‘Independent of’ is defined as not being in charge of, or involved in the investigation 
concerned. New subsection (2B) requires a superintendent who issues a warrant 
under section 26 to record the grounds on which he/she issued the warrant either at 
the time or as soon as reasonably practicable after issuing the warrant.  
 
Current status of relevant Bills before the Dáil is shown in Table 1.2.1.1 
 
Table 1.2.1.1 Status of bills before the Dáil relevant to the drugs issue, July 2013 
Title  Status  
The Fines (Payment and Recovery) Bill 2013 provides for the introduction of 
attachment of earnings as a means of recovering unpaid fines with the intention 
of reducing substantially the numbers of people committed to prison for the non-
payment of fines. Where a person fails to pay a fine by the due date for payment 
(including by instalments where the person has chosen to pay by instalments) the 
court will make either a recovery order or an attachment order. If neither of these 
is considered appropriate (for example, where the person is not in employment 
and has no realisable assets), the court will consider imposing a community 
service order. The court may commit a person to prison if it is not possible to 
make any of the three orders. Community service is also an option, as an 
alternative to imprisonment, where a recovery order or an attachment order has 
been imposed, but where the fine or a portion of the fine remains outstanding 
New Bill 29 July 2013 
The Road Traffic (No.2) Bill 2013 provides, inter alia, new measures to test for 
driver intoxication. Members of An Garda Síochána will be empowered to require 
people driving or attempting to drive a mechanically propelled vehicle in a public 
place, to undertake intoxication impairment testing. This involves nontechnology-
based cognitive tests (i.e. walking a straight line, tipping one’s nose, counting 
while standing on one leg etc.). The results of these tests may be used in 
evidence in support of the Garda forming an opinion that the person is 
intoxicated. Under the new provisions, the Minister will be empowered to 
prescribe in regulations the nature of the tests and their manner of administration, 
as well as a form for recording the observations made during the tests. It will also 
be an offence to fail to comply with a requirement to undergo intoxication 
impairment testing. Section 12 amends the Road Traffic Act 2010 to allow for the 
taking, subject to medical approval, of a specimen of blood from an incapacitated 
(e.g. unconscious) person following a road traffic collision involving death or 
injury. 
New Bill 26 June 
2013 
 
The Spent Convictions Bill 2012 provides that in the case of convicted persons 
whose sentence is below a specific threshold, they may, under certain 
circumstances, withhold details of the conviction, for example, when seeking 
employment. This is intended to apply where a prison sentence not exceeding 12 
months or a fine or penalty have been imposed, and then only after a certain 
number of years have elapsed without a further conviction.  The purpose of the 
bill is to help rehabilitate convicted persons through facilitating their reintegration 
into the workforce and allowing them to build new careers. As many problematic 
drug users whose offence is drug-related receive relatively short prison 
sentences, this legislation could have a positive impact in terms of facilitating 
rehabilitation interventions. 
New Bill June 2012 
 
 
1.2.2 Laws implementation 
The rehabilitation of offenders see also section 9.6.1 
The Irish Penal Reform Trust (IPRT) has been campaigning for spent convictions 
legislation for six years (for an earlier version of this Bill, dated 2007, see (Irish Focal 
Point (Reitox) 2010)) Section One. The IPRT welcomed the publication of the Criminal 
Justice (Spent Convictions) Bill 2012 as a positive step in supporting the rehabilitation 
of offenders (Health Research Board 2012), and made submissions on earlier drafts of 
the current Bill (Irish Penal Reform Trust 2012, 4 May). According to the IPRT, the 
issues identified in its submissions on the earlier drafts of the Bill remain at the centre 
of its position on the present Bill (Irish Penal Reform Trust 2013). These are: 
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 the need for the Bill to apply to a wide range of convictions, 
 the need for the rehabilitation periods to be set at reasonable, proportionate and 
practical levels, and 
 any differential treatment of particular areas of employment should be kept to a 
minimum and must be justified. 
 
Impact of organised crime legislation 
The Criminal Justice Act 2006 and the Criminal Justice (Amendment) Act 2009 
created, for the first time, the offence of participation in a criminal organisation and 
made provision to enable all organised crime offences to be declared scheduled 
offences for the purpose of trial in the Special Criminal Court, which operates with three 
judges and without a jury (Health Research Board 2006).  
 
In a recent presentation to the Joint Oireachtas Committee on Justice, Defence and 
Equality, the Commissioner of An Garda Síochána stated that from  the enactment of 
the Criminal Justice (Amendment) Act 2009 on 23 July 2009 to 30 September 2012 the 
legislation had been used on 179 occasions where arrests were made relating to 
organised crime, with just eight individuals being charged under the legislation –  six 
under section 72 for participating or contributing to certain activities, and two under 
Section 71A  for directing the activities of a criminal organisation (Joint Committee on 
Justice Defence and Equality 2012 ) (p. 3). It is not clear if anyone has yet been 
convicted under the legislation.  
 
Review of mandatory sentencing legislation 
The Law Reform Commission (LRC)2 has recommended that the presumptive3 
sentencing regime for drug offences be repealed (Law Reform Commission 2013). The 
Criminal Justice Act 1999 created a new offence of possessing controlled drugs having 
a value of £10,000 (€13,000) or more for sale or supply, which attracted a presumptive 
sentence of 10 years’ imprisonment, except where there were ‘exceptional and specific 
circumstances’ relating to the offence, or to the person convicted of the offence (Health 
Research Board 2012). In a previous consultation paper, which analysed the operation 
and impact of this legislation, the LRC called for a review of the sentencing regime, 
finding that in effect it had merely led to a ‘bulge in the prison system comprising low-
level drugs offenders’ serving lengthy prison sentences (Law Reform Commission 
2012) (p.189). Following further examination, the LRC has now concluded that the 
legislation has not contributed to any reduction in levels of criminality, which it defines 
as ‘the paramount aim of the criminal justice system’ (Law Reform Commission 2013) 
(p.181). The LRC reviews similar legislation in a number of other common law 
countries, noting that the enactment of presumptive minimum sentencing in Ireland 
was, to some extent, influenced by sentencing reforms in the United States and the 
United Kingdom in particular. In the drugs context, a range of punitive sentencing 
measures have been introduced in other jurisdictions so as to reflect the relative 
seriousness of specific drug-related offences. Aggravating factors can include repeat 
drug offences, dealing drugs to minors or dealing drugs with the aid or conspiring of a 
child under the age of 18 years, drug trafficking while in possession of a firearm, selling 
drugs on a school bus or in the vicinity of a school, college, or  housing project, or 
selling drugs to someone who is pregnant,. Running a drug trafficking enterprise or 
acting as the principal administrator, organiser or leader of a continuing criminal 
enterprise can also lead to more severe punishments. Aggravating factors may also 
relate to the quantity of drugs involved in the offence. 
 
Although such a comparative analysis is of interest, the LRC cautions against relying 
too heavily on examples set by other countries, noting that these provisions ‘are often 
the product of circumstances and cultural factors specific to the jurisdiction in question’ 
                                               
2
 The LRC is an independent statutory body established by the Law Reform Commission Act 1975. Its principal role is to 
keep the law under review and to make proposals for reform, in particular by recommending the enactment of legislation 
to clarify and modernise the law 
3
 The LRC uses the term ‘presumptive’ as distinct from mandatory sentence in that there is a presumption that the 
sentence would apply unless the court deems otherwise in a specific case. The LRC distinguishes such sentences from 
mandatory life sentences for murder treason or capital murder, for example. 
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(Law Reform Commission 2013)  (p. 174). Ultimately, the LRC concludes, presumptive 
sentencing should be evaluated in terms of the extent to which it is consistent with the 
general aims of criminal sanctions which include deterrence, punishment, reform, 
rehabilitation and reparation. In particular, the LRC observes that deterrence and 
punishment feature prominently as aims in respect of those offences that attract 
presumptive sentences as these sentences seek to ‘(i) dissuade by coercive means, 
the offender from committing another drugs…offence and to punish him or her severely 
for the offence…committed, and (ii) dissuade the public at large from committing the 
relevant drugs…offence’ (Law Reform Commission 2013) (p. 175).  
 
With regard to deterrence, the LRC observes that, in practice, ‘high-level (drug) 
offenders…shield themselves from detection and prosecution by means of complex 
and constantly evolving networks of distributors’ (Law Reform Commission 2013) p175. 
Consequently, the LRC concludes, ‘it is unlikely that such offenders would be deterred 
by the prospect of a presumptive…sentence when they are unlikely to be subjected to 
it’ (Law Reform Commission 2013)p175. At the other end of the scale, offenders are 
either ‘low-level drug mules whose involvement in the drugs trade is generally secured 
by means of exploitation and/or coercion’ or, referring to an observation of the Court of 
Criminal Appeal, ‘they are themselves drug addicts struggling to escape from the 
terrors of their addiction’ (Law Reform Commission 2013)p175. Drug mules would be 
unlikely to be deterred by a presumptive sentence because of either their inability to 
assess the legal consequences of their actions or fear of the consequences of refusing 
to carry drugs. Dependent drug users, on the other hand, are prepared to risk 
‘victimisation, overdose, the transmission of diseases, and toxicity and impurities in the 
drug in order to feed their addiction’ and, as a consequence, according to the LRC, 
‘they are unlikely to be deterred by the prospect of lengthy imprisonment’ (Law Reform 
Commission 2013) p175. 
 
With regard to meeting the aims of punishment, from a retributive perspective, the LRC 
highlights the apparent injustice inherent in the legislation whereby the same 
presumptive sentencing regime applies to individuals regardless of their position in the 
drug trafficking operation and their consequent level of moral culpability. This arises 
because ‘the market value of the drugs (€13000 or more)…is prioritised at the expense 
of other factors relevant to culpability, such as role, motive and state of mind of the 
offender’ (Law Reform Commission 2013) p175. 
 
In calling for a repeal of the presumptive sentencing regime, the LRC concludes that 
the objective of reducing drug-related crime is unlikely to be achieved solely through 
criminal law enforcement but that crime-reduction approaches must be informed by a 
deeper understanding of the complexity of the relationship between illicit drug use and 
crime and a focus on measures aimed at addressing drug dependency.4 
 
Medicinal cannabis 
Legislative measures are currently being considered to provide for the legal sale of 
medicinal cannabis. In response to a Parliamentary Question, Alex White TD, Minister 
of State at the Department of Health, stated: 
 
My Department has been informed by the Irish Medicines Board (IMB) that it is 
in receipt of a market authorisation request from a manufacturer under the EU 
Mutual Recognition Procedure for a medicinal product containing Cannabis 
extract. This product is indicated for the relief of symptoms of spasticity for 
people with multiple sclerosis. Under the Misuse of Drugs Act, 1977, the 
manufacture, production, preparation, sale, supply, distribution and possession 
of cannabis or cannabis-based medicinal products are unlawful except for the 
purposes of research. 
                                               
4
 With regards to the drugs-crime linkage, the LRC endorses the analysis provided in an HRB publication Connolly, J. 
(2006). Drugs and crime in Ireland. HRB Overview Series 3. Health Research Board, Dublin. Available at 
http://www.drugsandalcohol.ie/6045/. It also highlights the current focus on recovery from drug dependence by the 
misuse of drugs work sector of the British-Irish Council.  
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My Department is currently examining how authorised cannabis-based 
medicinal products for patients suffering from Multiple Sclerosis may be legally 
prescribed by medical practitioners and used by patients for the treatment of 
MS in Ireland. In that respect, Department officials have been engaging with 
experts to identify how best to legally prescribe authorised cannabis-based 
medicinal products while maintaining existing controls on cannabis and 
cannabis substances. While the legislative amendments required can be made 
by means of statutory instrument, the legal issues are complex. The matter is 
being progressed as quickly as possible in my Department and it is hoped to 
bring forward legislative proposals in mid-2013. (White, A 2013, March 20)  
 
Street sale of prescription drugs 
Under the Medicinal Products (Prescription and Control of Supply) Regulations, it is 
prohibited for a person to supply a prescription medicine except in accordance with a 
prescription, and the supply must be made from a registered pharmacy by or under the 
personal supervision of a registered pharmacist. A person who contravenes these 
regulations is guilty of an offence. However, the illegal street sale of prescription drugs 
has emerged as an important issue in the Irish drug scene in recent years (see 
discussion in (Health Research Board 2012) Section One). In response to a 
Parliamentary Question on the issue, Alex White TD, Minister of State at the 
Department of Health, stated: 
 
Through the framework of the National Drugs Strategy 2009-2016, the 
Department of Health is working in collaboration with the relevant statutory 
agencies to monitor the availability of controlled drugs, including prescription 
medicines, through illicit channels…My Department is reviewing the Misuse of 
Drugs Regulations with a view to introducing additional controls on certain 
prescription drugs being traded illicitly, for example benzodiazepine medicines. 
These additional controls include introducing import and export controls as well 
as an offence of possession, thereby assisting the law enforcement roles of 
Customs and of the Garda Síochána. (White, A 2013, May 8) 
 
1.3  National action plan, strategy, evaluation and co-ordination 
1.3.1 National action plan and/or strategy 
Ireland held the presidency of the EU for the first six months of 2013. Irish officials and 
politicians were occupied with EU-level drug policy issues for much of the reporting 
period covered by this National Report (Pike 2013). Only one new policy initiative was 
completed at national level – the review of drugs task forces – and not all 
recommendations have yet been implemented (see Section 1.3.4 below). 
  
Regarding the adoption of a national substance misuse strategy, which process began 
in 2012 (see (Health Research Board 2012): Section 1.3.1), the government 
considered the proposed action plan in the autumn of 2012 but declined to endorse it.  
While the Minister for Health, James Reilly TD, and the Minister of State at the 
Department of Health with special responsibility for drug and alcohol policy, Alex White 
TD, both favour the public health approach taken in the action plan, other Ministers and 
their officials have questioned the evidence base for the claims that alcohol-related 
advertising and sponsorship of sports events by alcohol firms have an impact on the 
conduct and behaviour of children and young adults (White, A 2013 May 23).  
Notwithstanding this difference of opinion, as at mid-June 2013, work was continuing 
on ‘maximising agreement across all departments and Ministers’: 
 
Proposals are currently being finalised on foot of the recommendations in the 
Steering Group Report on a National Substance Misuse Strategy 2012. These 
proposals cover all of the areas mentioned in the report, including legislation on 
minimum unit pricing; controls on alcohol advertising and sponsorship; labelling 
of alcohol products, and measures on access and availability of alcohol. The 
Cabinet Committee on Social Policy has considered these proposals and it is 
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intended to bring forward a finalised package of proposals for consideration by 
Government shortly. In the meantime, work on developing a framework for the 
necessary Department of Health legislation is continuing. A health impact 
assessment is being commissioned in conjunction with Northern Ireland as part 
of the process of developing a legislative basis for minimum unit pricing. The 
health impact assessment will study the impact of different minimum prices on a 
range of areas such as health, crime and likely economic impact. (White, A 
2013 June 11)  
 
In July 2013 the Joint Oireachtas Committee on Transport and Communications5 
published a report on sponsorship of sports by the alcohol drinks industry (Joint 
Committee on Transport and Communications 2013). In light of the government’s 
proposed policy changes, in March/April the Committee invited representatives of the 
Irish Rugby Football Union, the Gaelic Athletic Association, the Football Association of 
Ireland, Alcohol Action Ireland, the College of Psychiatrists, Horse Racing Ireland, the 
Federation of Irish Sports and the Drinks Industry Group of Ireland to make their cases 
for and against drinks industry sponsorship of sport. Having reflected on these 
presentations, the Joint Committee concluded in its report that, while it appreciated that 
actions must be taken to address the harm caused to individuals in Irish society by the 
misuse of, and over-indulgence in, alcohol, it did not believe that the link between 
sponsorship and consumption had been proved. It recommended, inter alia: 
 
 Sponsorship by the alcohol drinks industry should remain in place until such time 
as it can be replaced by other identifiable streams of comparable funding. 
 A fixed percentage of all sponsorship received by each and every organisation 
(sporting, cultural, arts, music etc) from the alcohol drinks industry should be ring-
fenced and paid into a central fund to be administered by an appropriate body. That 
fund should be used exclusively for alcohol and substance abuse prevention 
programmes. 
 All sporting organisations should be encouraged to support programmes which 
contribute to social inclusion in order to reduce the abuse of alcohol, particularly 
among young people. 
 A prohibition on sponsorship by the alcohol industry should only be considered if it 
is done on a pan-European basis in order to ensure that Irish sports and sporting 
organisations are not operating at a disadvantage relative to their international 
competitors. 
 
Despite the slow progress at policy level, organisational mandates have been 
expanded to include both drugs and alcohol. At national level, the National Advisory 
Committee on Drugs has been reconstituted as the National Advisory Committee on 
Drugs and Alcohol (NACDA). The Committee’s role is to advise government on the 
prevalence, prevention, treatment, rehabilitation and consequences of substance use 
and misuse in Ireland, based on the analysis of research findings and information 
available to it. Catherine Comiskey, professor of Healthcare Statistics at the School of 
Nursing and Midwifery in Trinity College Dublin, chairs the new Committee, which 
comprises representatives from government departments, state agencies and bodies in 
the community and voluntary sectors. The NACDA’s mandate will expire at the end of 
2016, when the current NDS also expires.  At local level, the remit of drugs task forces 
has been expanded to include alcohol, and in future they are to be called ‘drugs and 
alcohol task forces’ (DATFs) (see Section 1.3.4 for more detail).  
 
1.3.2 Implementation and evaluation of national action plan and/or strategy 
Three reports published in the last year relating to the implementation and/or 
evaluation of the NDS are described here. Each was undertaken for different reasons 
and from a distinctive perspective – one from the point of view of government officials, 
one from the point of view of politicians, and one from the viewpoint of civil society.  
                                               
5
 This Joint Oireachtas Committee comprises 20 members drawn from both houses of the Oireachtas (Parliament) and 
is representative all political parties and independents. 
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Department of Health progress report on implementing the NDS, 2012–2013   
In line with Action 59 of the NDS, which calls for the development of ‘an overall 
performance management framework for the NDS across all Departments and 
Agencies to assess and monitor progress’, the Department of Health publishes an 
annual report on the implementation of the 63 actions contained in the NDS 
(Department of Health 2013b). Progress on specific actions in the past year is 
described in the relevant sections elsewhere in this report. Some themes reported on in 
the progress report that cut across two or more pillars are highlighted in the following 
paragraphs (numbers in brackets refer to actions in the NDS).  
 
Legislative and regulatory measures 
Work is proceeding to ensure that the statutory provisions for road-side impairment 
testing for drug-driving are sound (9), and a Bill to update the law in relation to forensic 
evidence, including providing for the establishment of a national DNA database, is due 
to be published this year (11). The Department of Health is engaged on an ongoing 
basis in ensuring comprehensive and effective statutory controls of psychoactive 
substances (14, 15 & 40) and of drug precursors (16). With regard to enhanced data 
gathering, proposals for a health identifier are being developed (52), and legislative 
measures to reduce delays in reporting by the Coroner Service are proceeding (53). 
 
Pilot programmes 
Several pilot programmes are being run, evaluated and/or rolled out across the 
country. They include  piloting of a programmed response to drug-related intimidation 
in the community and to the involvement by adults of young children in illegal activities 
associated with the drug trade (5 & 7); a drugs intervention programme in two Dublin 
Garda districts, which focuses on youth and young adults who come to the attention of 
the Gardaí and the Probation Service owing to behaviour caused by substance misuse 
(38); an integrated model of care in 10 sites, which is currently being evaluated (32); 
and an education and training programme on screening and brief intervention for 
problematic alcohol use for nurses and midwives (36).  
 
Quality and best practice  
Standards and guidelines are being developed in relation to drug prevention and drug 
treatment. Training is being provided to Garda in the use of roadside drug-related 
impairment testing (9). Information, advice and training regarding drug prevention are 
available to teachers and schools through a dedicated web site and a dedicated SPHE 
support service (20 & 21). Both the Youthreach Quality Framework Initiative (QFI) and 
the National Quality Standards Framework of Youth Work (NQSF) include modules 
relating to substance misuse (23 & 24).  
 
A comprehensive set of clinical guidelines for the treatment of opioid dependence are 
due to be published in 2013 (35). As at the end of 2012, 98 organisations were 
involved in the QuADS (Quality in Drugs and Alcohol Services) Support Project 
(45.)The National Addiction Training Programme (NATP) is currently addressing gaps 
identified by a survey conducted in late 2012 of training completed in HSE and drugs 
task force areas. The main gap identified was in advanced level training. Working 
closely with the National Drug Rehabilitation Implementation Committee (NDRIC), the 
NATP is also engaged in rolling out the UK-based DANOS/Skills for Health (47). 
Finally, educational models have been or are being developed for paramedic and nurse 
and midwife training to ensure they are familiar with relevant drug treatment issues and 
alternative care pathways. Comprehensive coverage of problematic substance issues 
is also being included in undergraduate doctor training (48).   
 
Co-operation 
Co-operation at operational level between government departments, state agencies 
and community- and voluntary-sector bodies has proceeded on a number of fronts. The 
criminal justice agencies (An Garda Síochána, the Courts Service, the Irish Prison 
Service and the Probation Service) have embarked on a project to establish linkages 
between their IT systems (6). Under the Prevention pillar, two cross-departmental 
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working groups have been set up. One, comprising representatives from the 
departments of Health (DoH), Children and Youth Affairs (DCYA), and Education and 
Skills (DES), and from the National Educational Psychological Service (NEPS), the 
National Council for Curriculum and Assessment (NCCA) and the SPHE Post-Primary 
Support Service, was tasked with updating drug awareness programmes in second-
level schools (20). With regard to early-school leaving, a working group comprising 
officials from DES and DCYA was established following the transfer of functions under 
the Education (Welfare) Act 2000 in May 2011 from the Minister for Education and 
Skills to the Minister for Children and Youth Affairs. The purpose of this group is to 
ensure that education links are safeguarded and maintained given the range of 
interrelated activities of both Departments (31). Through the Young People’s Facilities 
& Services Fund (YPFSF), DCYA are also developing more links with other agencies 
with the aim of increasing usage of facilities, sharing costs and maximising resources 
(25).  
 
In pursuit of a ‘national drug treatment service’ that integrates treatment and 
rehabilitation and uses an integrated model of care, Action 33 of the NDS calls for the 
maximisation of ‘operational synergies between Drug Addiction Services, Alcohol 
Treatment and Rehabilitation Services, General and Emergency Hospital Services and 
Mental Health Services’. The progress report gives the following update on how the 
NDRIC, which is playing a key role in integrating treatment and rehabilitation services 
and is leading on the 10-site pilot, has maximised operational synergies: 
 
In the last quarter of 2012 a number of gaps and blocks were escalated to 
NDRIC via pilot sites relating to the need for more shared working between 
Mental Health Services & Addiction Services. As a result, NDRIC plans to invite 
mental health services to become involved in the formal rehabilitation 
interagency structures in each area when the rehabilitation framework is rollout 
[sic] beyond the pilot sites in 2013. In addition, NDRIC have also extended an 
invitation to national management in mental health services to take a seat on 
NDRIC to ensure that there is a common approach to shared care planning 
between the services. ((Department of Health 2013b): p. 20)  
 
In June 2012 NDRIC also extended its membership to include the National Family 
Support Network (FSN). Following this the FSN were invited to engage in focus groups 
to scope the research instruments for the evaluation of the implementation of the 
rehabilitation framework in the ten sites piloting the use of an integrated model of care, 
and were interviewed as part of the research process to examine the experience of the 
framework implementation from the perspective of family members (41). At the same 
time, NDRIC also extended its membership to include a representative from SURF 
(Service Users Representative Forum) (42).  
 
A protocol for the seamless transition of treatment services between the Irish Prison 
Service (IPS) and the Health Service Executive (HSE) is in place and is reported to be 
working well ‘in the main’ (43). The progress report comments on the challenges: 
 
… in areas of the country where community treatment places are not available, 
challenges to delivery exist. Notwithstanding this it should be acknowledged 
that through collaboration with community services, effort is made to ensure 
continuity and initiation, where clinically indicated, of Methadone Maintenance 
Treatment. Difficulties remain with the remand population as the IPS is not in a 
position to influence releases directed by the Courts, however communication 
strategies have improved. A cross-sectoral group, chaired by the IPS, meet to 
monitor and review issues regarding implementation of this recommendation. 
((Department of Health 2013b): p. 28) 
 
Information and communication technologies (ICT) 
ICT is being employed in the gathering of data and managing of information in the 
criminal justice area (6) and in the youth affairs area (24). Electronic communication 
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technologies are being used to support drug prevention (27) and to provide education, 
training and professional support to service providers (20, 21, 27 & 36) 
 
At-risk groups 
Children and young people are the focus of a wide number of initiatives – in relation to 
supply reduction (7), drug prevention (10, 20–25 and 29–31), and treatment and 
rehabilitation (34, 37, 38, 41). At-risk groups among the adult population include 
Travellers, new communities, LGBTs, the homeless and sex workers. Members of 
these groups are to have their treatment and rehabilitation needs specifically 
addressed (44), and a sub-group of the Drugs Advisory Group is to monitor progress in 
relation to this action, as well as monitoring services for families trying to cope with 
substance-related problems, the needs of service users and drug treatment services in 
prisons (60). 
 
Alcohol 
Although the National Substance Misuse Strategy and action plan have not been 
agreed, a number of actions in the NDS relate to alcohol use and are being 
implemented. Law enforcement agencies are engaged in addressing alcohol-related 
problems via the Joint Policing Forums (3) and in ensuring compliance with the 
prohibition of the sale of alcohol to persons under 18 years of age (10). In drug 
education and awareness campaigns, alcohol is being addressed alongside illicit drugs 
(27 & 28), and both drugs and alcohol are considered when responding to the needs of 
families and parents facing drug-related problems (29). In the interests of adequately 
treating all the needs of dual diagnosis clients, operational synergies between Drug 
Addiction Services and, inter alia, Alcohol Treatment and Rehabilitation Services are to 
be maximised (33).  Moreover, the HSE Alcohol Screening and Brief Intervention 
Project has been engaged in developing and implementing a guiding framework for 
education and training for nurses and midwives (36). A National Screening and Brief 
Intervention Protocol for alcohol and substance misuse for Tier 1 Services and Tier 2 
interventions is to be developed in 2013 (52). The national clinical and organisational 
governance framework endorsed by the HSE for all treatment and rehabilitation 
services is QuADS (Quality in Drugs and Alcohol Services) (45).  
 
Overall progress 
No actions have been dropped from the NDS apart from the two (57 & 63) already 
reported in last year’s report ((Health Research Board 2012): Section 1.3.2).  Delays or 
constraints in implementing some actions continue. The continuing economic downturn 
is hampering some efforts under the supply reduction, treatment and rehabilitation, and 
research and information pillars (6, 11, 32, 39, 53, 55 & 57). The ongoing deliberations 
regarding the National Substance Misuse Strategy are holding back work on the 
development of integrated drug and alcohol prevention frameworks and integrated 
monitoring systems (19, 22, 26, 28, 30 & 51). The delay in renewing the mandate of the 
National Advisory Committee on Drugs (NACD) has slowed down work on the research 
and information agenda (37,6 49 & 54). The need for appropriate statutory and 
regulatory provisions and compliance has delayed the implementation of roadside 
impairment testing (11) and the establishment of a regulatory framework for the 
provision of counselling within substance misuse services (46).  
 
Assessment/evaluation 
While reporting on implementation and/or evaluation of individual actions, the annual 
report does not report on progress in relation to the key performance indicators and 
objectives set under each pillar in the NDS, or on the achievement of the overall 
                                               
6
 The progress report anticipates that a yet-to-be published implementation report on the National Strategy for Research 
and Data on Children's Lives 2011–2016 will describe progress in developing and implementing a mechanism for early 
identification, and onward referral where appropriate, of substance misuse among under 18 service users. The report 
has now been published Department of Children Youth Affairs (2013). National strategy for research and data on 
children’s lives 2011–2016. Implementation report: action plan update 2012. Department of Children and Youth Affairs, 
Dublin. Available at http://www.drugsandalcohol.ie/20177/. It reveals that the six relevant actions have been held up 
owing to the delay in renewing the mandate of the NACD. 
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strategic aims and objective of the NDS. Moreover, while a review of the previous NDS, 
covering the period 2001–2008, was undertaken at the mid-way point (Department of 
Community 2005), a similar mid-term review of the current NDS, covering the period 
2009–2012, has not been undertaken. 
 
Government report on implementing the Programme for Government, 2012 
While the first annual report on the coalition government’s implementation of its 
programme for government focused on ‘key priorities’ relating to drug treatment, 
rehabilitation and harm reduction, the second report (Government for National 
Recovery 2011-2016 2013) focuses on initiatives in the law enforcement area (see 
Table 1.3.2.1 below).  
 
Table 1.3.2.1 Progress in implementing drug-related ‘key priorities’ in Programme for Government 
2011–2016, March 2013 
Key priorities Update in Programme for Government annual report 2013 Further 
information 
in other 
sections 
Review of the Drug Treatment Court 
programme  
– 9.6.1 
 
Rehabilitation services including 
expansion of places across country, 
provision of services at local level, 
participation in community employment 
schemes, and introduction of compulsory 
as well as voluntary programmes 
– 8.3.2 
8.3.3 
Needle exchange programmes expanded 
across the country where needed most 
– 5.2.2.2 
Roadside drug testing  Government has approved drafting of the Road Traffic Bill, 
which will provide for the introduction of roadside testing for 
drivers suspected to be under the influence of drugs. 
1.2.1, 9.3 
Prison sentences versus non-custodial 
alternatives 
A strategic review of penal policy [including alternatives to 
custody] is underway and the review is due to report in 2013. 
9.6.1 
Mandatory sentencing  The strategic review of penal policy includes mandatory 
sentencing.  
1.2.2 
Supply reduction and criminal assets 
seizures 
– 10.3 
 
 
Reduction of flow of drugs into prisons A range of security initiatives have been introduced in closed 
prisons, including x-ray scanners, tighter control and monitoring 
of prison visits, airport style security screening of all staff and 
visitors, and increased random searches of prisoner 
accommodation. These have proven particularly effective in 
reducing the availability of drugs in the prisons, with drug 
seizures decreasing by 28 per cent between 2010 and 2012.  
9.7 
Customs controls to combat drug supplies 
at source 
– 10.2.3 
Budget transparency and accountability 
  
The Oversight Forum on Drugs meets each quarter with all 
Departments and Agencies to monitor progress on the actions in 
the NDS, and to address any operational difficulties that may 
arise.  
 
 
Prevention measures including drug 
awareness programmes in schools, 
preventing addiction in schools, and 
introducing Education Prevention Units in 
all task forces  
– 3.3.1 
Source: (Government for National Recovery 2011-2016 2013) 
 
Children’s advocacy group rates progress in tackling alcohol, drugs and 
smoking, 2012 
The Children’s Rights Alliance (CRA) has published its fifth annual report assessing the 
government’s performance in honouring its promises to the over one million children 
living in Ireland (Children's Rights Alliance 2013). Having awarded ‘Ds’ for each of the 
first three years, 2008–2010, in its fourth report, for 2011, the CRA gave the 
government a ‘C+’, reflecting its ‘commitment to children’s rights’, as evidenced by the 
appointment of a Minister for Children and Youth Affairs with full cabinet status, the 
creation of a new Department of Children and Youth Affairs, and the commitment to 
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hold a referendum on children’s rights. In the latest report, for 2012, the CRA has given 
an overall ‘C’ grade, reflecting ‘a satisfactory attempt to date, though children remain 
wanting’. 
 
Notwithstanding the improvement in the overall rating, under the subheading ‘Right to 
Health’, the report gives the government a ‘D’ for progress in 2012 in relation to 
alcohol, drugs and smoking. It adjudges progress ‘unsatisfactory’. The report states 
that despite the commitment that every government department, agency or task force 
responsible for implementing elements of the National Addiction Strategy would be 
required to account to the minister for their budget annually and to demonstrate 
progress on achieving targets, a National Addiction Strategy has not been published 
and ‘is not expected until 2016’. The report goes on to comment that ‘there is no 
Government policy on tackling alcohol misuse; no Government decision has been 
made on recommendations of the Steering Group’. It calls for, inter alia, the following 
actions in 2013:  
 
 Urgently adopt a national strategy to tackle alcohol misuse and ensure it is 
coherent with the Interim National Drugs Strategy 2009–2016. The strategy should 
have a clear focus on the impact of alcohol and drugs on children, including 
reducing children’s access to alcohol and drugs; curbing the widespread availability 
of cheap alcohol; restricting the promotion of alcohol; raising awareness of the 
potential harmful effects of alcohol and drugs and developing youth appropriate 
addiction treatment services. It should also address harmful parental drinking and 
its impact on children. The Strategy should be accompanied by a clear plan, with 
targets, timeframes and accountability structures. 
 Sustain investment in non-alcohol and drug free spaces for young people. 
 
 
1.3.3 Other drug policy developments e.g. government declaration, civil society 
initiatives 
 
Government strategy to improve the nation’s health and well-being 
On 28 March 2013 the government launched Healthy Ireland: a framework for 
improved health and wellbeing 2013–2025 (Department of Health 2013a). Healthy 
Ireland sets out a policy framework and actions to improve health and wellbeing and 
reduce the health risks posed to future generations. The government has developed 
the policy in response to rising levels of chronic illness, lifestyle trends that threaten 
health and persistent health inequalities. The report states that the economic 
justification for the policy is clear: in Ireland, the estimated economic cost per year 
associated with obesity, smoking, alcohol use and mental health issues is around €18 
billion. The report notes that the economic cost of the illicit drugs market in Ireland has 
never been calculated. However, it points out that the use of illegal drugs in the last 
year was reported at 7% of adults aged between 15 and 64 years, and drug use was 
the direct or indirect cause of 534 deaths in 2008. 
 
Based on international evidence, which shows that, in order to make a positive change 
in population health and wellbeing, a whole-of-government approach is needed (as well 
as involving local communities and society as a whole), the authors of the policy 
framework have identified 64 broad inter-sectoral actions, with initial partners including 
government departments, statutory agencies, civil society organisations, the 
community and voluntary sector, the private sector, and employee representative 
organisations. The authors also recognise that ensuring effective implementation of the 
policy, making sure it does not get left on a shelf, is the biggest challenge. The 
framework of actions emphasises five activities – leadership, measurement, 
partnership, empowerment, and resource management – designed to ensure the policy 
remains on the front burner. 
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How Healthy Ireland will work in with the NDS remains to be seen. With regard to 
alcohol, citing the 2012 report on a national substance misuse strategy (Steering Group 
on a national substance misuse strategy 2012), Healthy Ireland identifies a decrease in 
alcohol consumption across the population as an indicator and sets a target of reducing 
the amount of alcohol consumed by people over the age of 15 years to an annual per 
capita consumption of 9.2 litres of pure alcohol. No date is set for this target. 
 
Community sector groups stress ‘humanistic’ values 
In their 2011 annual report, the co-ordinator and the chair of the Southern Regional 
Drugs Task Force (SRDTF) set out their vision of how the individual should be at the 
centre of a drugs task force’s responses to the illicit drugs problem (Black 2012). Co-
ordinator Chris Black reported that, as well as focusing on its funded projects, the 
SRDTF has been involved in innovative development work that draws on international 
sources. He suggested this was ‘setting the seeds for a more user friendly, person 
centred and health based approach to drugs policy and drugs support’. In a personal 
introduction to the report, the chair of the SRDTF, Peadar King, contrasted the ‘harsh 
and unsympathetic response to drug producers and consumers’ adopted generally 
around the world following the ratification of the 1961 UN convention and its 
concomitant treaties, with the response of civil society, health activists and field 
workers who foreground citizens’ human rights and promote harm reduction strategies. 
King is concerned that this focus on human rights and the reduction of harm may be 
undermined by the new wave of managerialism, the effects of which he likens to the 
destructive impact of the original UN Convention.  
 
The Ballymun Youth Action Project (BYAP), a community-based response to drug and 
alcohol misuse in north Dublin, works with individuals, supports families and 
communities, and builds capacity through training and research.  In its strategic plan for 
2013–2015 (Ballymun Youth Action Project 2013), BYAP has set out its way of 
working. Its approach is rooted in an ethos of valuing individuality and the capacity of 
individuals, families and communities to change. It commits to respecting where people 
have come from, where they are at now, and where they see they could be; to 
supporting the possibility of change; and to addressing where necessary the bigger 
issues that are presented by the many cross-cutting systems within which each 
individual has to make their way in life, including their family, the education system, the 
justice system, and the health system. The ethos and commitments are reflected in the 
strategic objectives and actions that BYAP has set itself for the next three years. 
 
Civil society organisations focus on two policy issues 
‘Criminalising addiction: is there another way?’ was the title of a conference hosted by 
CityWide Drug Crisis Campaign in Dublin in May 2013.7 The objective was to start an 
evidence-based debate on Ireland’s current drug policies and the alternatives. Some 
120 participants from community drug projects, voluntary projects, youth services, 
drugs task forces, government departments and universities attended the conference 
at which four speakers made presentations. Following the presentations, participants 
took part in table discussions on the barriers to decriminalisation and what the 
international evidence reveals about the issue.  There was general, but not complete, 
agreement that the evidence for decriminalisation is convincing, while the issues 
around legalisation appear to be complicated. It was also noted that the underlying 
issues of poverty and social disadvantage remain crucial to addressing the impact of 
drugs on the lives of people, families and communities. In closing the conference, the 
Chairperson of CityWide, Anna Quigley, stated that the conference was a first step. 
CityWide planned to publish an information leaflet, providing basic information about 
decriminalisation and also listing sources of further information.  CityWide sees this as 
a starting point for discussion in drugs task forces, projects, community groups and 
also for use by local and national public elected representatives.  
                                               
7
 The conference was organised on foot of a commitment made by CityWide in 2012 to hold an open debate on 
decriminalisation Higgins, M. and CityWide (2012). The drugs crisis in Ireland: a new agenda for action. CityWide policy 
statement 2012. CityWide, Dublin. Available at http://www.drugsandalcohol.ie/17145/. A written report on the 2013  
conference and videos of the four presentations are available at www.citywide.ie/news/2013/05/27/watch-the-
conference-presentations/ and accessed on 25 July 2013. 
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‘Responding to addiction in a time of recession’ was the theme of a seminar hosted by 
the Ballymun Youth Action Project (BYAP) in June 2013. The purpose of the seminar 
was to provide an opportunity to step back and think about the impact of funding 
cutbacks.  Róisín Shortall TD described the seminar as providing a ‘critical space’ to 
reflect on what amounts to a slow dismantling of the safety net that has been created 
within local communities, leading to the re-marginalisation of particular areas.   
 
The seminar was attended by over 80 representatives of community and voluntary 
agencies, funders, local people and political representatives. There were two speakers 
– Brian Harvey, an independent social research consultant, and Dr Mary Ellen 
McCann, lecturer in UCD’s School of Applied Social Science and former director of 
Ballymun Youth Action Project.8 
 
Brian Harvey, having outlined the scale of the withdrawal of resources from community-
led responses to poverty and social inclusion, particularly since 2002, echoed the 
sense among those present that no one could have anticipated the wave of destruction 
of our social, community development infrastructure is experiencing, when Ireland was 
previously seen as a European leader in this regard. He outlined what he termed a 
‘strategic turn’ which began in 2002 and which was compounded by the 2008 economic 
and social crisis. Against a baseline figure of a 4.3% cut in government spending 
overall between 2008 and 2013, local and community development programmes have 
been cut by 42% and the Drugs Initiative by 32%. It is estimated that by 2015, there will 
be 31% fewer workers in the voluntary and community sector. Harvey added that no 
other country in Europe, as far as he knows, has experienced such an extraordinary 
decline since 1948.  
 
Dr Mary Ellen McCann illustrated the intimate connection between community issues 
and drug problems, and how policies in either domain have large effects in other 
domains. In the context of conflicting reports from consultants ((Goodbody Economic 
Consultants 2006); (Department of Finance 2009)), the call for ‘evidence’ needs to take 
account of a range of more subtle measures, including case studies which provide rich 
data to increase our understanding, and the use of community indicators that give 
access to measures regarding what is really important for communities affected by 
drug use. She stressed that, in the context of the narrative of the development of 
community responses, the community needs to tell the community story.  
 
Underlying the recognition of the current crisis and its origins, contributors were clearly 
wary of the talk of a straightforward recovery, where ‘all will be well again’. Instead, the 
speakers raised the real concern of ‘cost cutting’ becoming ‘penny pinching’ in the 
name of ‘reform’, and the growing hints of ‘post-austerity austerity’. A clear message 
was given regarding the importance of holding on to the developments within the sector 
that have been achieved over the last 30 years, and the ‘footholds that have been 
gained’ in the creation of community responses and systems. The response within the 
voluntary and community sector must endure and, as Harvey concluded, ‘It behoves us 
to make the case for an enlightened balanced European social model, with a role for 
civil society’. 
 
 
1.3.4 Co-ordination arrangements 
 
An International Drug Issues Group (IDIG) was formed in line with Action 61 in the 
NDS. Comprising representatives of the departments of Health, Foreign Affairs and 
Trade, and Justice and Equality, and of An Garda Síochána, Revenue’s Customs 
Service, the Irish Medicines Board and the Health Research Board, and convened by 
the Drug Policy Unit in the Department of Health, the IDIG meets every quarter to co-
ordinate Ireland’s responses on the international drug policy stage. The Irish EU 
                                               
8
 The following account is based on the report of the seminar posted on www.byap.ie and accessed on 25 July 2013.  
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Presidency Steering Group on Drugs Issues was drawn from this larger grouping and 
drew on the wider expertise represented on the IDIG when necessary (Pike 2013). 
 
In December 2012 the Department of Health’s report on the review of drugs task 
forces, which had been initiated by Minister of State Róisín Shortall TD in late 2011 
(see (Health Research Board 2012): Section 1.3.4), was published (Department of 
Health 2012c). This report dealt with the first term of reference for the review: ‘review 
the role and composition of Drugs Task Forces and the national structures under which 
they operate’.  It made four key recommendations: 
 
1. Rename the drugs task forces ‘drug and alcohol task forces’ (DATFs). Their terms 
of reference are to implement the NDS at regional and local level and to support 
and strengthen community-based responses. As previously, this role includes 
maintaining an overview of regional and local developments, promoting strategies 
and monitoring, evaluating and assessing the impact of funded projects. 
2. Reconstitute the Drugs Advisory Group (DAG) as a National Co-Ordinating 
Committee for Drug and Alcohol Task Forces (NCC–DATF). Its terms of reference 
are to drive implementation of the NDS at local and regional level.   
3. Encourage more public representative involvement in the work of drug and alcohol 
task by giving local members of the Oireachtas and members of relevant local 
authorities ‘automatic entitlement’ to sit on DATFs. 
4. Reduce the number of task forces from 24 to 19 by merging some task forces and 
expanding the boundaries of others. 
 
As measures to address the abuse of alcohol remain under consideration by the 
Government, the NCC-DATF has not yet been established.  In late July 2013, Minister 
of State White stated that he intended ‘to arrange a series of bilateral dialogues in the 
coming weeks with Government departments and agencies, the community and 
voluntary sector and the drugs task forces in order to assess how the inter-agency 
approach to the National Drugs Strategy can be maintained and strengthened (White, 
Alex 2013 ).   
 
With regard to strengthening participation by elected public representatives in the work 
of the task forces, given that some 860 elected representatives would appear to be 
eligible to sit on the 19 DATFs, i.e. an average of 45 public representatives per DATF, 
clarification is needed as to who precisely will have this entitlement and how the 
efficiency and effectiveness of the DATFs will be maintained.  
 
Finally, with regard to redrawing the task force boundaries, when launching the report, 
Minister of State White announced that he intended to consult with the drugs task 
forces on the proposed boundary changes. The outcome of this consultation has yet to 
be announced. 
 
Coordination at operational level, or ‘co-operation’, is described in Section 1.3.2 above, 
when outlining some cross-cutting themes in the Department of Health’s annual 
progress report on implementing the NDS in 2012–2013. 
 
 
1.4 Economic analysis 
 
The second and third terms of reference for the review initiated by Minister of State 
Róisín Shortall TD in September 2011 (see (Health Research Board 2012): Section 
1.3.4) were: 
 
 streamline the funding arrangements for drugs projects supported by Drugs Task 
Forces, and where appropriate, transfer responsibility for funding to relevant 
statutory agencies; and 
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 overhaul the accountability and reporting arrangements for the drugs projects which 
continue to be supported by Drugs Task Forces.  
 
However, these were not dealt with in the December 2012 report on the review, which 
is described in Section 1.3.4 above. Instead, readers of this report were informed that 
Minister of State White had requested officials to bring forward proposals with regard to 
the two matters. He had also invited stakeholders ‘who may have further comments to 
make on this issue to submit their views to his office at the earliest opportunity’. No 
deadline for these submissions was specified. 
 
At the BYAP seminar on ‘Responding to addiction in a time of recession, held in June 
2013, independent social research consultant Brian Harvey described how, against a 
baseline figure of a 4.3% cut in government spending overall between 2008 and 2013, 
local and community development programmes have been cut by 42%, and the Drugs 
Initiative by 32%. See Section 1.3.4 above for more detail. 
 
1.4.1 Public expenditures 
Public expenditure directly on the drugs issue from 2008 to 2012 is reported here 
(Table 1.4.1). There has been an overall 12% decrease in expenditure over the 5-year 
period. 
 
Table 1.4.1 Expenditure and allocations directly attributable to drugs programmes 2008–2012 
Department/Agency 
2008 
Expenditure 
€m 
2009 
Expenditu
re 
€m 
2010 
Expenditu
re 
€m 
2011 
Expenditu
re 
€m 
2012 
Expenditu
re €m 
Department of Health  
(Previously Office of the Minister for 
Drugs) 
65.207 39.377 34.992 32.876 31.475 
Department of Health     
(formerly Dept Health and Children) 
1.033 0.949 0.763 0.704 0.901 
Department of Children and Youth 
Affairs  (Formerly OMCYA) 
0.000 28.501 25.740 25.000 22.669 
Department of Education and Skills 12.386 3.643 2.461 0.411 0.815 
Health Service Executive 101.867 104.867 105.400 91.149 90.752 
Department of Social Protection 
(previously FÁS area)  
18.800 18.800 18.000 14.934 11.859 
Department of Environment, 
Community & Local Government 
0.496 0.461 0.461 0.400 0.200 
Department of Justice & Equality 12.340 14.801 14.478 18.681 18.580 
Irish Prison Service 5.000 5.000 5.200 5.200 5.000 
An Garda Síochána 44.400 45.004 44.500 45.014 45.850 
Revenue’s Customs Service 14.900 15.867 15.797 15.470 14.241 
Total: 276.429 277.240 267.792 249.839 242.342 
Source: Drug Policy Unit in the Department of Health (unpublished data)  
 
 
1.4.2 Budget 
Table 1.4.2.1 shows the annual budget (current and capital) for the Drugs Initiative 
Programmes from 2011 to 2014. Administered by the Drugs Programmes Unit in the 
Department of Health, the programmes funded under the Drugs Initiative are primarily 
drug-related projects and initiatives in drugs task force areas, whose purpose is to 
address the drug problem at local and regional level in pursuance of the National 
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Drugs Strategy 2009–2016. Over the four years, spending will have decreased by 
17%. 
 
Table 1.4.2.1 Estimate of total expenditure on the Drugs Initiative, 2011–2014 
 2011 Estimate (€000) 2012 Estimate (€000) 2013 Estimate (€000) 2013 Estimate (€000) 
Vote Health: Drugs 
Initiative 
33,667 31,375 29,951 27,951 
Sources:   (Department of Finance 2011) and (Department of Finance 2013) 
 
 
1.4.3 Social costs 
The National Youth Council of Ireland (NYCI) have published what they claim to be the 
first national comprehensive and rigorous economic assessment of youth work in 
Ireland (Indecon International Economic Consultants 2012). The economic assessment 
was guided by the question: What would be the likely outcomes for young people 
participating in justice-, health- and welfare-related youth programmes, and the costs to 
the State if these programmes were not available? Indecon estimates that the State will 
benefit by saving costs to the value of €2 billion for an €992 million investment over the 
next 10 years; benefits will exceed projected costs by a factor of 2.2.  
 
In respect of the economic value of health-related youth work programmes which 
include the Young Person’s Facilities and Services Fund (YPFSF) and HSE and local 
drugs task force funding streams, Indecon compared the cost of funding such 
programmes with the estimated cost to the State if these services were unavailable at 
the youth work organisation level. Funding provided through the YPFSF and local 
drugs task forces, with additional health-promotion-related funding provided by the 
HSE, is distributed to organisations whose programme are directed towards young 
people who are at risk of substance abuse and the associated adverse health-related 
impacts. If 2011 funding levels were to be maintained, the estimated cost of health-
related funding to the youth sector over a 10-year period would be €420.5 million. 
Indecon assumes that in the absence of this funding an estimated 4% of beneficiaries 
of these youth-work programmes would have to receive treatment for substance abuse 
in adolescent treatment centres at a cost to the State of €60.6 million annually, or 
€509.9 million in present value terms over a 10-year period; maintaining health-related 
funding at 2011 levels would save the State an estimated €89.5 million over the 
projected 10-year period. See also section 3.3.3 for further discussion of this study 
 
.  
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2. Drug Use in the General Population and Specific targeted-
Groups 
2.1 Introduction 
Drug prevalence surveys of the general and school-child population are important 
sources of information on patterns of drug use, both demographically and 
geographically, and, when repeated, reveal changes over time. In Ireland such surveys 
are conducted every three to four years. These surveys increase understanding of 
drug use, which, in turn, helps in the formulation and evaluation of drug policies. They 
also enable informed international comparisons, provided countries conduct surveys in 
a comparable manner. The four main data collection tools in Ireland are described 
below. 
 
An All Ireland Drug Prevalence Survey was initiated in 2002 by the National Advisory 
Committee on Drugs and Alcohol (NACDA), formerly the National Advisory Committee 
on Drugs, in Ireland and the Public Health Information and Research Branch (PHIRB), 
formerly known as the Drug and Alcohol Information and Research Unit (DAIRU), 
within the Department of Health, Social Services and Public Safety (DHSSPS) in 
Northern Ireland. The main focus of the survey is to obtain prevalence rates for key 
illegal drugs, such as cannabis, ecstasy, cocaine and heroin, on a lifetime (ever used), 
last year (recent use), and last month (current use) basis. Similar prevalence questions 
are also asked of alcohol, tobacco, and other drugs such as sedatives, tranquillisers 
and anti-depressants. Attitudinal and demographic information is also sought from 
respondents.  
 
The questionnaire and methodology for this drug prevalence survey are based on best-
practice guidelines drawn up by the EMCDDA. The questionnaires are administered 
through face-to-face interviews with respondents aged between 15 and 64 normally 
resident in households in Ireland and Northern Ireland. Thus, persons outside these 
age ranges, or who do not normally reside in private households, have not been 
included in the survey. This approach is commonly used throughout the EU and 
because of the exclusion of those living in institutions (for example, prisons, hostels) 
this type of prevalence survey is usually known as a general population survey. 
 
The first iteration of this general population drug prevalence survey was undertaken in 
2002/3 (National Advisory Committee on Drugs and Drug and Alcohol Information and 
Research Unit 2005a), and a second iteration in 2006/7 (National Advisory Committee 
on Drugs and Drug and Alcohol Information and Research Unit 2008). A series of 
bulletins reporting the findings of the 2002/3 and 2006/7 iterations have been 
published. The most recent (third) survey was conducted in 2010/11 and to date, five 
bulletins on the findings have been published.  
 
As with other European surveys, people over the age of 64 are excluded from this 
survey, as they grew up in an era when both the use and availability of illegal drugs 
were very limited. Therefore, surveys with older people have, to date, shown very low 
rates of use even on a lifetime basis. This situation will change over time as the 
younger population grows older: lifetime prevalence rates are likely to increase for a 
considerable period of time. When examining the data and comparing results over 
time, last-year use is the best reflection of changes as it refers to recent use. Last-
month use is valuable insofar as it refers to current use.  
 
The Survey of Lifestyles, Attitudes and Nutrition (SLÁN) is a national survey of the 
lifestyles, attitudes and nutrition of people living in Ireland. To date, three surveys have 
been completed – in 1998 (Friel, et al. 1999), 2002 (Kelleher, et al. 2003) and 2007 
(Morgan, et al. 2008) – and have examined the health and social status, and related 
health service use, of adults aged 18 years and older living in private households. 
SLÁN 1998 and SLÁN 2002 were postal surveys, based on samples from the electoral 
register, and involved 6,539 respondents in 1998 (62% response rate) and 5,992 in 
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2002 (53% response rate). SLÁN 2007 interviewed 10,364 respondents face-to-face in 
their homes, based on samples from the GeoDirectory (62% response rate). The SLÁN 
data are not comparable with the results of the 2002/3, 2006/7 and 2010/11 all-Ireland 
general population drug prevalence survey as the SLÁN survey excludes those aged 
between 15 and 17 years and includes those aged over 65 years. 
 
The Health Behaviour in School-aged Children (HBSC) is a cross-national research 
study conducted in collaboration with the WHO (World Health Organization) Regional 
Office for Europe. The study aims to gain insights into, and increase our understanding 
of, young people's health and well-being, health behaviours and their social context. It 
collects information on the key indicators of health and health-related attitudes and 
behaviours (including alcohol and cannabis use) among young people aged 11, 13 and 
15 years. HBSC was initiated in 1982 and is conducted every 4 years. It is a school-
based survey with data collected through self-completion questionnaires administered 
by teachers in the classroom.  
 
The Health Promotion Research Centre, National University of Ireland, Galway was 
invited to join the HBSC network in 1994 and conducted the first survey of Irish 
schoolchildren in 1998 (Friel, et al. 1999). the survey has been repeated in Ireland in 
2002 (Kelleher, et al. 2003), 2006 (Nic Gabhainn, et al. 2007) and 2010 (Kelly, C, et al. 
2012). 
 
The European School Survey Project on Alcohol and Other Drugs (ESPAD) is a 
collaborative effort of independent research teams in about 40 European countries. 
Data on alcohol and illicit drug use among 15–16-year-olds have been collected every 
four years since 1995, using a standardised method and a common questionnaire. The 
Swedish Council for Information on Alcohol and Other Drugs (CAN) initiated the project 
in 1993. Support has been provided by the Pompidou Group at the Council of Europe, 
the Swedish Ministry of Health and Social Affairs, the Swedish National Institute of 
Public Health and the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). The data collections in the individual countries are funded by national 
sources. The rationale for the ESPAD surveys is that school students are easily 
accessible and are at an age when onset of substance use is likely to occur. Early 
school leavers, a group known to be vulnerable to alcohol and drug use, are not 
represented in this survey, so the results do not indicate the extent of alcohol and other 
drug use among all 15–16-year-old children. ESPAD survey information is valuable in 
planning prevention initiatives.   
 
The fourth iteration of the survey was conducted in 35 European countries, including 
Ireland, in the spring of 2007 and the results were published in March 2009 (Hibell, et 
al. 2009). Data were collected for the fifth iteration of ESPAD in 2010/2011 and the 
survey findings were published in 2012 (Hibell, et al. 2012).   
 
2.2 Drug use in the general population (based on probabilistic sample) 
Extent and patterns of cannabis use in Ireland 
The National Advisory Committee on Drugs and Alcohol (NACDA) recently published 
Bulletin 3 in the series of reports on the 2010/11 survey on drug use in the general 
population in Ireland and Northern Ireland (National Advisory Committee on Drugs and 
Alcohol 2013). The bulletin reports on cannabis use in the adult population (15–64 
years), on cannabis dependence and cannabis abuse as well as on patterns of 
cannabis use in Ireland.  A total of 5,128 people were interviewed, representing a 
response rate of 60%.  This article presents a summary of the main results for Ireland 
reported in the bulletin. 
 
Prevalence of cannabis use, abuse and dependence 
The results from the 2010/11 survey reveal that 25% of the adult population (15–64 
years) reported having used cannabis at some point during their lives (lifetime use); 6% 
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reported use in the year prior to the survey (recent use); 3% reported use in the month 
prior to the survey (current use).   
 
The rates of cannabis use were notably higher among men than women.  Lifetime 
prevalence for men (33%) was almost twice as high as the rate for women (18%); last-
year prevalence was three times as high (men, 9% vs women, 3%); and last-month 
prevalence was five times as high (5% vs 1%).   The lifetime prevalence among men 
increased from 27% in the 2006/7 survey (National Advisory Committee on Drugs and 
Drug and Public Health Information and Research Branch 2008) to 33% in the 2010/11 
survey, a statistically significant increase of 22%.There was a relatively small increase, 
from 17% to 17.5%, in women’s lifetime prevalence rates in the same period. 
 
Rates of cannabis use were substantially higher among young adults (15–34 years) 
than among older adults (35–64 years) in the 2010/11 survey.  Lifetime prevalence 
among young adults (33%) was more than one and a half times that among older 
adults (19%), last-year prevalence was just over three times as high (young adults 10% 
vs older adults 3%) and last-month prevalence was five times as high (5% vs 1%).  
While there were statistically significant increases in lifetime prevalence for younger 
adults, from 29% in 2006/7 to 33% in 2010/11, no statistically significant changes were 
found for older adults over that period (3% in both 2006/7 and 2010/11).   
 
The prevalence of cannabis abuse and of cannabis dependence were measured in 
the NACD Drug Prevalence Survey for the first time in 2010/11 using M-CIDI, as 
advised by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 
Substance abuse and substance dependence are defined in the DSM-IV as a 
maladaptive pattern of substance use leading to clinically significant impairment or 
distress.   
 
Seventeen per cent of recent cannabis users met the criteria for cannabis abuse, with 
rates being higher among males (20%) than females (8%) and among young adults 
(20%) than older adults (9%).  Of the valid responses from the survey sample, 1.3% 
met the criteria for current cannabis abuse. Applying this rate to the 15–64-year-old 
general population (3,073,269 in 2011) it is inferred that approximately 39,953 people 
in Ireland abuse cannabis.  
 
Nine per cent of recent cannabis users were classified as dependent.  Dependence 
was higher among males and among young adults. Of the valid responses from the 
survey sample, 0.6% met the criteria for current cannabis dependence.  Applying this 
rate to the 15–64-year-old general population, it is inferred that approximately 18,440 
people in Ireland are cannabis dependent.   
 
Patterns of cannabis use 
Among lifetime cannabis users, the median age of first use was 18 years.  This was 
unchanged since the last survey.   
 
Almost half (48%) of the current cannabis users had used cannabis on 1–3 days 
(lowest frequency use) in the month prior to the survey, an increase on the 2006/7 
figure of 37%; this frequency was most common among female users (54%) and older 
adult users (55%).  Between the two surveys the proportion of all adults engaging in 
the highest frequency use (20 days or more) in the previous month decreased from 
24% to 14%. 
 
Since 2006/7 the relative share of herb to resin used by current users has reversed.  In 
2010/11 herb was the main type of cannabis used by current users, at 71%, while 
resin, at 60%, was the most common form reported in the 2006/7 survey.  Almost all 
(94%) current cannabis users said that a joint was the main method they used when 
consuming cannabis.  Forty-five per cent did not know where the cannabis they 
consumed was grown; 38% said that the cannabis they used was grown in Ireland, an 
increase on the 2006/7 figure of 16%.  
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Nearly three quarters (73%) of recent users said it would be easy for them to obtain 
cannabis in a given 24-hour period.  Over four fifths (83%) said they sourced cannabis 
from someone they knew relatively well, e.g. either shared by or bought from family 
members and/or friends.    
 
Over one quarter (27%) of lifetime cannabis users said they had used it on a regular 
basis at some point and most (74%) of this group said they had stopped using.  The 
three most common reasons given for stopping cannabis use were:  not wanting to 
take it any more (27%); cannabis being no longer a part of their social life (18%); and 
health concerns (17%). 
 
Acceptability of cannabis use 
Respondents were asked about the acceptability and risk of cannabis use:  
º 66% agreed with cannabis use being permitted for medical reasons;  
º 69% disagreed with cannabis use being permitted for recreational reasons;  
º 73% disapproved of smoking cannabis occasionally;  
º 64% considered smoking cannabis on a regular basis to be very risky. 
 
Profile of cannabis users  
Socio-economic group:   Rates for lifetime cannabis use were highest among those 
classified as Group A (professionals and managers) (35%) and lowest among those in 
Group D (semi-skilled and unskilled) (20%).  Last-year rates were also highest for 
those in Group A (10%) and lowest among those in Group C2 (skilled manual workers) 
(7%). 
 
Housing tenure:  Cannabis prevalence rates were highest among people renting 
accommodation.  Among those renting from a private landlord lifetime prevalence rates 
were 37% while last-year prevalence was 12%.  Rates for last-month use were highest 
among those renting from a local authority/housing agency (7%).   
 
Level of education and age left school:  Results point to cannabis use increasing with 
level of education attained.  On the one hand, rates were highest among students, at 
21% (lifetime), 10% (last-year) and 4% (last-month).  Lifetime rates were also highest 
among those who had left school at 20 years or over (34%) and among those with a 
third-level education (31%).  On the other hand, lowest lifetime rates were found for 
those who left school at 15 years or under and among those with primary-level 
education only (19%).   
 
Marital status:  Last-year prevalence was highest among those who were cohabiting 
(13%), followed by those who were single (12%).  Last-month rates were highest 
among cohabiting and divorced people (at 7%).   
 
Discussion 
The findings of the 2010/11 survey suggest a mixed picture regarding the cannabis 
situation in the general population in Ireland. More people than ever before had tried 
cannabis at least once in their lifetime, with the rate at one in four adults, compared to 
one in six in the 2002/3 survey (National Advisory Committee on Drugs and Drug and 
Alcohol Information and Research Unit 2005b).  The trend is, however, changing and 
rates for last-year and last-month prevalence have tapered off since the last survey.  
This development is in line with that in many European countries which are reporting a 
recent fall or stabilisation in cannabis prevalence rates (European Monitoring Centre for 
Drugs Drug Addiction 2011).  Additionally, among those consuming cannabis, age of 
initial use has remained the same, a welcome finding given the link between early 
initiation and high-risk groups.   
 
The 2010/11 survey data show that age continues to be an important factor in the 
pattern of cannabis use in Ireland and that use declines with age.  Gender is also 
important for several reasons: it interacts with age with the effect that the decline in use 
happens later for men than for women.  Although the extent of use has declined, 
  33 
prevalence rates are still considerably higher among men than women, with no 
indication of any narrowing of the gender gap.  Closer examination of the data is 
needed, however, as these age and gender effects are likely to vary across regions in 
Ireland, reflecting differences in context, particularly social and economic 
circumstances.  These influences, how they vary with context and time are important, 
particularly for targeting areas where patterns of drug use have become entrenched 
and for identifying where action may be needed to prevent this situation.  
 
When compared to the results from the 2006/7 survey, cannabis is now used less 
frequently among current users, an important finding given the increased uptake of 
herbal cannabis use since the last survey.  While the data from the two surveys show 
that high-frequency use has always been more common among men than women, the 
propensity for men to be high-frequency users has fallen sharply since the 2006/7 
survey, with the effect that the gap between men and women has reduced considerably 
between the two time periods.   
 
The likelihood of a young adult in Ireland using cannabis daily or almost daily has 
declined substantially since the survey in 2006/7.  Despite lower prevalence, frequency 
of use is higher among older adults, changing little since the last survey.  Among 
current users, high-frequency use, or intensive use, is reported by 10% of young adults 
and 24% of older adults.   
 
An indication of the public health impact of a drug can be seen in the numbers entering 
treatment.  The number of treatment cases reporting cannabis as their main problem 
substance has increased significantly in Ireland and in 2010 cannabis became the most 
common problem drug reported by new cases (Bellerose, et al. 2011).  
 
Dependence is increasingly recognised as a possible consequence of regular cannabis 
use.  For many people, intensive use and dependence on cannabis are linked. Among 
those defined as recent users, 17% met the EMCDDA criteria for cannabis abuse and 
9% were classified as dependent. 
 
However, in comparison with the available data on tobacco or alcohol use, little is 
known about the extent of cannabis dependence or abuse in Ireland.  This bulletin 
provides a solid baseline for the ongoing monitoring of the prevalence and nature of 
cannabis dependence and abuse in the general population and among recent users.  
Its findings also point to the need for further research on the consequences of 
increased availability of high-potency cannabis, on the experiences of cannabis use in 
the population of long-term users, and on the continuation and discontinuation rates of 
long-term use and factors influencing these rates and how these might be targeted by 
treatment and other services.   
 
Use of sedatives or tranquillisers and anti-depressants  
The National Advisory Committee on Drugs (NACD) recently published Bulletin 6 in the 
series of reports on the 2010/11 general population survey on drug use in Ireland and 
Northern Ireland (National Advisory Committee on Drugs and Public Health Information 
Research Branch 2012). The bulletin reports the prevalence of sedative or tranquilliser 
and anti-depressant use among adults aged 15–64 years.  
 
Sedatives or tranquillisers  
‘Sedatives’ and ‘tranquillisers’ are commonly used terms for a group of medicines 
which depress brain and central nervous system activity. Benzodiazepines are the 
most common type of drug in this group; the ‘Z-drugs’, such as zolpidem and 
zopiclone, are also included in this group and have the same effect. Medically, 
sedatives or tranquillisers are often referred to as hypnotics (which treat insomnia) or 
anxiolytics (which relieve anxiety). The same drug can be used as a hypnotic or as an 
anti-anxiety agent depending on the dosage used and on the time of day that it is 
consumed.  
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º Prevalence rates were 14% for lifetime use, 7% for last-year use and 3% for last-
month use. There were statistically significant increases in the lifetime rate (up by 
32%) and the last-year rate (up by 38%) since the last survey. 
º The prevalence rates for women were somewhat higher than those for men on all 
three measures: lifetime use (16% vs 12%), last-year use (7% vs 6%) and last-
month use (3% vs 2%).   
º The lifetime prevalence rate for men increased by 55% since the last survey, while 
the rate for women increased by 17%. The last-year prevalence rate for men 
increased by 54%, while the rate for women increased by 28%. Overall, the gap 
between men and women in terms of lifetime and last-year rates has narrowed. 
º Prevalence rates were higher among older adults (aged 35–64) than younger 
adults (aged 15–34) on all three measures: lifetime use (17% vs 10%), last-year 
use (8% vs 5%) and last-month use (4% vs 1%). Lifetime and last-year rates 
increased in both age groups since the last survey, but the increases were 
substantially larger for the younger adult group. Lifetime rates for young adults 
increased by 71%, compared to 16% for older adults; last-year rates increased by 
92%, compared to 20% for older adults. As a consequence, the gap between the 
older and younger age groups in terms of lifetime and last-year use has narrowed. 
º The median age at first use was 30 years, and was lower among men (28 years) 
than women (30 years).   
º More than half (53%) of current users of sedatives or tranquillisers had taken them 
on 20 or more of the 30 days prior to the survey. Almost all (95%) said they had got 
the medicines on prescription from a doctor.   
º Rates of use of sedatives or tranquillisers were highest at both ends of the social 
spectrum (among professionals and managers and among those who were 
dependent on long-term social assistance).  
º Prevalence rates were higher among people who were separated, divorced or 
widowed than among married or co-habiting people.   
 
The misuse of certain prescribed medicines, including sedatives or tranquillisers, is of 
increasing concern in Europe (Casati, et al. 2012), and is reported as a growing health 
problem globally (United Nations Office on Drugs and Crime 2011). Such medicines 
can be more easily obtained than illicit drugs, and the potential for their misuse is 
widespread. In Ireland, these medicines are legally and appropriately prescribed to 
patients to treat medical conditions, including some mental health illnesses (such as 
anxiety, depression and other mood disorders). Their use for short periods of time is 
recommended to allow doctors or other health professionals and patients deal with or 
stabilise an underlying condition.  
 
The general population survey in Ireland  is an important source of information to 
establish the extent and nature of use of these prescription medicines and to identify 
which population groups are more likely to be prescribed such drugs. The 2010/11 
NACD survey highlights several issues. 
 
The results show that the proportion of people using sedatives or tranquillisers has 
grown in recent years in Ireland. The reasons for this are not clear. Prevalence rates 
increased among the groups traditionally associated with these medicines (that is, 
women and the older population). However, the largest increases were in the rates of 
use by men and by young people. It is important to continue monitoring use of these 
drugs and to develop a better understanding of the patterns of use in sub-populations 
(McLarnon, et al. 2011). 
 
The survey also raises questions about the safety of the pattern of sedative or 
tranquilliser use in the general population. Clinical guidelines (Department of Health 
and Children 2002) (Health Service Executive and Irish College of General 
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Practitioners 2006) recommend that, particularly with regard to anxiety-related 
conditions, many of these medicines should be prescribed for short-term (2–4 weeks) 
relief and taken for the shortest duration of time, with the least frequency possible, so 
as to avoid tolerance, drug dependence and the adverse effects of long-term use. 
However, the survey shows that over half (53%) of all current users reported daily or 
almost daily use; the proportion rose to 63% in the older adult group. It is important to 
note that current users in Ireland are engaging in this frequency of use for periods of 
longer than one month and many may be at risk of experiencing a range of side effects, 
including dependence. Clinicians can play a critical role in identifying patients who may 
be at risk of overuse. 
 
The NACD surveys show that social class plays a role in sedative or tranquilliser use. 
Key indicators of socio-economic deprivation, such as being unemployed, having low 
educational attainment or fewer years in education, and living in social housing, were 
associated with higher prevalence for sedative use in the 2002/3 and 2006/7 surveys. 
Results from the 2010/11 survey, however, show a departure from this pattern in that 
prevalence rates are now highest among those who are unemployed/without 
employment, followed by those in managerial or professional occupations. An 
explanation offered for this new pattern is that it reflects a response to the stress of 
deteriorating economic conditions in Ireland. However, the fall-out from the recession 
will have impacted all occupational groups and it is difficult to see why managers and 
higher professionals would have resorted to sedatives or tranquillisers more than other 
social groups. 
 
General practitioners everywhere need to be aware that the medicine they prescribe 
may be over used or diverted from the intended patient and fall into the wrong hands 
(United Nations Office on Drugs and Crime 2011). A more considered approach by 
health care professionals to alternative (and complementary) treatments where 
appropriate, as well as efforts to inform the general population on the safe and effective 
use of sedatives or tranquillisers and on the viability of other treatments, may be 
effective in reducing their use in the future.   
 
Alex White TD, Minister of State at the Department of Health with responsibility for 
primary care, is considering imposing additional controls on the main sedatives and 
tranquillisers, such as benzodiazepines and ‘Z-drugs’. The legislative amendments 
being considered include the introduction of an offence of unauthorised possession, as 
well as controls on the import and export, of such drugs (Department of Health 2012a). 
It is also proposed to tighten the prescribing and dispensing rules applying to these 
drugs. One of the main challenges in formulating policy to reduce the misuse or over-
use of these medicines is doing so in a way that does not interfere with appropriate 
use.   
 
Anti-depressants  
An anti-depressant is a prescribed medicine used to alleviate medical conditions known 
as mood disorders (which include major depression, chronic depression and anxiety 
disorders). Two examples of anti-depressants are serotonin re-uptake inhibitors 
(SSRIs) and serotonin and noradrenaline re-uptake inhibitors (SNRIs). The former are 
used as a first-line treatment for depression, while the latter are used to treat patients 
who do not respond to first-line treatment.  
 
º In 2010/11 the prevalence rates among adults (aged 15–64 years) were 10% for 
lifetime use, 5% for last-year use and 4% for last-month use. The rate for last-
month use increased by 29% since the 2006/7 survey. 
º Prevalence rates for women were higher than those for men on all three measures: 
lifetime use (13% vs 8%), last-year use (6% vs 4%) and last-month use (5% vs 
2%). 
º The lifetime rate for men increased by 41% since the last survey, while the rate for 
women was unchanged. The last-year prevalence rate for men increased by 33%, 
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and the rate for women was unchanged. Overall, the gap between men and women 
in terms of lifetime and last-year rates has narrowed.  
º Lifetime rates for older adults increased by 21%, from 11% in 2006/7 to 13% in 
2010/11. No statistically significant changes were found over time among young 
adults.   
º The median age at first use was 30 years, two years younger than the median age 
reported in 2006/7, and was lower for women (30 years) than for men (34 years). 
º The vast majority (92%) of current users reported taking anti-depressants on 20 or 
more days in the month before the survey, and 99% reported getting the medicine 
on prescription from a doctor. 
º Prevalence rates were highest for those who were dependent long-term on social 
assistance, and lowest for professionals and managers. 
º Prevalence rates were higher for people who were separated, divorced or widowed 
than for married or co-habiting people.   
 
2.3 Drug use in the school and youth population (based on 
probabilistic sample) 
European School Survey Project on Alcohol and Other Drugs (ESPAD) 
The European School Survey Project on Alcohol and Other Drugs (ESPAD) has 
conducted surveys of school-going children every four years since 1995, using a 
standardised method and a common questionnaire. The fifth survey was conducted in 
36 European countries during 2010/11 and collected information on alcohol, tobacco 
and illicit drug use among 15–16-year-old students (Hibell, et al. 2012).  
 
The number of students completing valid questionnaires in the 2010/11 survey 
conducted in Ireland was 2,207 from 72 randomly selected schools. Fewer schools and 
students participated in 2010/11 than in 2007 or 2003.  
 
Four-fifths of the students (80% boys and 81% girls) reported that they had consumed 
alcohol at some point in their life, and 73% (72% boys and 73% girls) had drunk alcohol 
in the year prior to the survey. Half (48% boys and 52% girls) had drunk alcohol in the 
30 days prior to the survey, a decrease of six percentage points since the 2007 survey 
(56%). Two-fifths (40%) reported having had five or more drinks on a single occasion in 
the month prior to the survey.  Almost one-quarter (23%) reported that they had had 
one or more episodes of drunkenness in the 30 days prior to the survey, a decrease of 
three percentage points since the 2007 survey (26%). Nine per cent of the girls and 
13% of the boys had had their first episode of drunkenness at or before the age of 13 
years. The 2011 European average for alcohol consumption in the last 30 days was 
57% (7 percentage points higher than Ireland), while the European average for 
drunkenness in the last 30 days was 17% (6 percentage points lower than Ireland).  
 
Beer (40%), spirits (35%) and cider (33%) were the most common types of alcohol 
drunk in the month prior to the survey. Respondents reported drinking an average of 
6.7 centilitres of alcohol on the last alcohol-drinking day prior to the survey, which 
places Ireland joint (along with the UK) fifth highest. Those who drank alcohol at some 
point in their life were asked to rate their level of intoxication during the last alcohol 
drinking day on a scale of one to ten; the average rate for Irish students was 3.8, which 
places Ireland third highest after the UK and the Faroe Islands.  
 
Eighty-four per cent of the students reported that alcohol was easy or fairly easy to 
acquire in Ireland. Over one-quarter (26%) had bought alcohol for their own 
consumption in an off-trade outlet in the 30 days prior to the survey; 37% had done so 
in an on-trade outlet.  Sixty-five per cent reported that they were likely to experience 
positive consequences from alcohol consumption, while 35% were likely to experience 
negative consequences. Some of the negative consequences reported were getting 
into trouble with the police (22%), not being able to stop drinking (20%), and doing 
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something they regretted (48%). Ten per cent of boys and six per cent of girls had 
experienced ‘delinquency problems’ as a result of their alcohol use in the year prior to 
the survey. Delinquency problems included being involved in a physical fight (16% 
boys and 7% girls), being a victim of robbery or theft (4% boys and 3% girls), and being 
in trouble with the police (11% boys and 8% girls).  
 
The lifetime use of alcohol has decreased by 10 percentage points in 15 years, falling 
from 91% in 1995 to 81% in 2011, and alcohol use in the month prior to the survey has 
decreased by 19 percentage points, from 69% in 1995 to 50% in 2011. The proportion 
reporting having had five or more drinks on one occasion during the last 30 days has 
decreased by only four percentage points, from 23% in 1995 to 19% in 2011. The 
consumption of five or more drinks in the one sitting is an indicator of harmful use of 
alcohol.  
 
Over two-fifths (43%) of the students (42% boys and 45% girls) reported that they had 
smoked cigarettes at some point in their life, and 21% (19% boys and 23% girls) had 
smoked cigarettes in the 30 days prior to the survey. Over one-fifth had had their first 
cigarette at or before the age of 13 years. Five per cent were smoking daily at or before 
the age of 13 years. The 2011 European average for smoking cigarettes in the last 30 
days was 28% (7 percentage points higher than Ireland), while the European average 
for smoking cigarettes daily at age 13 or under was 6% (one percentage point higher 
than Ireland). Three-quarters reported that cigarettes were easy or fairly easy to 
acquire in Ireland. Over one-fifth thought that people who smoked cigarettes 
occasionally were at great risk of harming themselves; 67% thought that smoking one 
or more packs a day constituted a great risk.  
 
The reduction in cigarette use is larger than the reduction in alcohol use, and alcohol is 
easier to acquire than cigarettes. The rate of lifetime use of cigarettes decreased by 31 
percentage points, from 74% in 1995 to 43% in 2011, and use in the month prior to the 
survey decreased by 20 percentage points, from 41% in 1995 to 21% in 2011. The 
proportion who reported smoking cigarettes on a daily basis by age 13 years 
decreased by 13 percentage points, from 18% in 1995 to 5% in 2011. 
 
The Irish data show a fall of 3 percentage points in the rate of lifetime use of any illicit 
drug between 2007 (22%) and 2011 (19%) (Table 2.3.1). Boys (23%) were more likely 
than girls (15%) to have used illicit drugs at some point in their life. As the majority of 
15–16-year-olds who have tried any illicit drug have used cannabis (marijuana or 
hashish), the decrease in illicit drug use may be explained by the fall in the number of 
students who have tried cannabis at some point in their lives, from 20% in 2007 to 18% 
in 2011 (just above the European average of 17%). Boys (22%) were more likely than 
girls (15%) to use cannabis at some point in their life. Fourteen per cent of respondents 
had used cannabis in the year prior to the survey (higher than the European average of 
12%). Only two per cent had used ecstasy at some point in their life and the proportion 
was the same in the year prior to the survey, indicating recent introduction to the use of 
this drug. In the case of cocaine powder, 3% had used it in their lifetime, just above the 
European average of 2%. Nine per cent of respondents reported that they had taken 
prescribed tranquillisers or sedatives at some point in their lives, and a further three per 
cent had taken them without a prescription. One in twenty had taken alcohol with pills 
‘in order to get high’. Lifetime use of solvents/inhalants decreased considerably, from 
15% in 2007 to 9% in 2011, and the rate is now the same as the European average 
(9%).  
 
Forty per cent of the students reported that cannabis was easy or fairly easy to acquire 
in Ireland, while lower but considerable proportions reported that amphetamines (14%), 
ecstasy (21%) and sedatives (17%) were easy or fairly easy to acquire. Alcohol and 
cigarettes are easier to acquire than illicit drugs.  
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Table 2.3.1   Proportions of school-going children (15–16 years) in Ireland reporting lifetime use of 
drugs in ESPAD surveys, 1995, 1999, 2003, 2007 and 2011 
 
 
1995 
% 
1999 
% 
2003 
% 
2007 
% 
2011 
% 
Lifetime use      
Any illicit drug* 37 32 40 22 19 
Cannabis 37 32 39 20 18 
Inhalants (solvents) n.a. 22 18 15 9 
Ecstasy 9 5 5 4 2 
Cocaine powder 2 2 3 4 3 
Amphetamines 3 3 1 3 2 
Prescribed tranquilisers or sedatives n.a. 11 10 10 9 
Non-prescribed tranquilisers or sedatives 7 5 2 3 3 
*includes amphetamines, cannabis, cocaine, crack, ecstasy, heroin and LSD or other hallucinogens 
n.a. = not available 
Source: (Hibell, et al. 2012)  
 
Health behaviour in school children: alcohol and cannabis use   
The Health Behaviour in School-aged Children (HBSC) survey 2010 was published on 
16 April 2012 (Kelly, C, et al. 2012). Researchers at the National University of Ireland, 
Galway, did the survey. Previous iterations of the survey had been undertaken in 2006, 
2002 and 1998.  
 
In 2010 43 countries and regions participated in the 4-yearly HBSC survey. In Ireland, 
the HBSC 2010 survey collected data from children aged 9 to 18 years, and the data 
analysed on alcohol and cannabis is for children aged 10 to 17 years.  
 
A nationally representative sample of primary and post-primary schools in Ireland was 
randomly selected and subsequently, within schools, classes were randomly selected. 
The HBSC questionnaire was developed by the international HBSC research network, 
administered by teachers and completed by the selected students themselves. 
Younger children received a shorter questionnaire. Just over two-thirds (67%) of invited 
schools and 85% of students participated in the survey. There was a higher 
representation from social classes 1 and 2 and lower representation from social 
classes 3, 4, 5 and 6 in the 2010 survey than in the 2006 survey. 
 
Overall, 46% of children (aged 10–17) reported that they had consumed an alcoholic 
drink at some point in their life, a fall of seven percentage points on the 2006 figure of 
53%. Girls (43%) were less likely than boys (48%) to report drinking alcohol, and as 
children grew older they were more likely to report drinking alcohol.  
 
The proportion of children (aged 10–17) who had consumed alcohol in the 30 days 
prior to the survey was 21%, a fall of five percentage points on the 2006 figure of 26%. 
Boys (22%) were more likely than girls (19%) to have consumed alcohol in the last 30 
days.  
 
Twenty-eight per cent of children reported having been ‘really drunk’ at some point in 
their life, a fall of four percentage points on the 2006 figure of 32%. More boys (29%) 
than girls (26%) reported this, and the proportion reporting drunkenness increased with 
age: 4% of 10–11-year-olds, 16% of 12–14-year-olds and 52% of 15–17-year-olds. 
Children from lower social class groups were more likely to report having been ‘really 
drunk’ than those from middle and higher social class groups. The proportion who 
reported having been ‘really drunk’ in the 30 days prior to the survey has decreased 
marginally, from 20% in 2006 to 18% in 2010, which may be explained by sampling 
variation or the sample representation by socio-economic group. 
 
Eleven per cent of 15-year-old girls and 15% of 15-year-old boys had their first episode 
of drunkenness at the age of 13 years or under. 
 
Overall, 27% of children (aged 10–17) reported that they had smoked a cigarette at 
some point in their life, a fall of nine percentage points on the 2006 figure of 36%. Girls 
(26%) were less likely than boys (27%) to report smoking cigarettes, and as children 
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grew older they were more likely to report smoking. Overall those from the lowest 
social class were more likely to smoke than those in the middle and higher social 
classes. The proportion of children (aged 10–17) who had smoked in the year prior to 
the survey was 12%, a fall of three percentage points on the 2006 figure of 15%.  
 
Eight per cent of children (aged 10–17) reported having used cannabis in the 12 
months prior to the survey, a halving of the 2006 figure of 16%.  More boys (10%) than 
girls (6%) reported such use. The proportions increased with age, for example, 1% of 
10–11-year-olds compared to 17% of 15–17-year-olds.  
 
Five per cent of children reported having used cannabis in the 30 days prior to the 
survey, a fall of two percentage points on the 2006 figure of 7% which may be 
explained by sampling variation.  More boys (7%) than girls (3%) had used cannabis in 
the month prior to the survey.  
 
Overall, there was a decrease in self-reported alcohol and cannabis use among school 
children in Ireland in 2010 when compared to 2006. This may represent a true 
decrease, possibly owing to children having less pocket money in recent years, or it 
may be the result of sampling variation, or a combination of both factors. 
 
2.4 Drug use among targeted groups/settings at national and local level 
(university students and conscript surveys, migrants, music venues gay 
clubs, gyms) 
For most recent research, on substance use among third-level students in Limerick, 
see (Irish Focal Point (Reitox) 2011). 
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3. Prevention 
3.1 Introduction 
Drug prevention is one of the four pillars in the National Drugs Strategy (interim) 2009–
2016 (NDS) (Department of Community 2009). The NDS states that ‘a tiered or 
graduated approach to prevention and education measures in relation to drugs and 
alcohol should be developed with a view to providing a framework for the future design 
and development of interventions’ (para. 3.56). It identifies three levels in this 
framework: 
 Universal (primary) prevention programmes, aimed at the general population such 
as students in schools, to promote overall health of the population and to prevent 
the onset of drug and alcohol misuse.  Measures often associated with this type of 
programme include awareness campaigns, school drug/alcohol education 
programmes and multi-component community initiatives. 
 Selected (secondary) prevention programmes, aimed at groups at risk, as well as 
subsets of the general population including children of drug users, early school 
leavers and those involved in anti-social behaviour, to reduce the effect of risk 
factors present in these subgroups by building on strengths and developing 
resilience and protective factors. 
 Targeted (tertiary) prevention programmes, for people who have already started 
using drugs/alcohol, or who are likely/vulnerable to engage in problematic 
drug/alcohol use (but may not necessarily be drug/alcohol dependent), or to 
prevent relapse. These programmes are aimed at individuals or small groups and 
address specific needs. 
 
This framework combines universal, selected and targeted with the old classificatory 
framework of primary, secondary and tertiary, which is misleading in that it implies that 
universal prevention is also the primary step in prevention. In Ireland young people and 
their families are the main target groups for drug prevention activities, which consist 
mainly of universal and selected prevention, with little focus on targeted prevention. 
 
The NDS identifies as priorities for Prevention, improving the delivery of SPHE in 
primary and post-primary schools and co-ordinating the activities and funding of youth 
interventions in out-of-school settings to optimise their impacts. Drug prevention 
interventions in schools are delivered through the Walk Tall (primary schools) and the 
Social, Personal and Health Education (SPHE) (post-primary schools) programmes. 
The SPHE programme aims to improve social and personal competencies in students 
so they can understand and counter the many social influences that are seen as 
contributing to their use of drugs and alcohol. In the community, prevention 
programmes are provided in different settings, such as youth clubs and youth cafés, 
and by means of diversion activities provided by the statutory, voluntary and 
community sectors. 
 
The NDS calls for a continued focus on orienting educational and youth services 
towards early interventions for people and communities most at risk. Actions are to be 
developed to further support the families of drugs users, and community development 
is acknowledged as an important step in building the capacity of local communities to 
avoid, or respond to and cope with, drug problems. Early school leavers are targeted 
through measures such as the School Completion Programme and embedding the 
government’s DEIS (Delivering Equality of Opportunity in Schools) Action Plan, which 
tackles disadvantage among the school-going population, in schools in LDTF areas. 
The Department of Education and Skills (DES) has also developed a strategy to tackle 
educational disadvantage and early school leaving in the Traveller community.  
 
Stand-alone mass media awareness and information campaigns are regarded as less 
effective than multi-component, multi-level interventions that reflect the complex nature 
of drug prevention and harm reduction. The NDS proposes that preference be given to 
the development of timely awareness campaigns targeted in a way that takes individual 
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social and environmental conditions into account key areas such as third-level 
institutions, workplaces, sports and other community and voluntary organisations. 
 
3.2 Environmental prevention 
3.2.1 Alcohol and tobacco policies 
 
Alcohol taxation 
Table 3.2.1.1 includes data on the amount of excise duty that was paid on different 
alcohol beverages in 2011; these are the most recent data available. Excise duties on 
beer, wine and cider are paid per hectolitre of volume (1 hectolitre = 100 litres). Excise 
duty on spirits is paid per litre.  
 
Table 3.2.1.1: Excise duty on alcohol beverages, 2011 
Alcohol beverage Excise paid in € 
Beer Excise paid per hectolitre of beer containing >2.8% alcohol (ethanol) €15.71 
Wine Excise paid per hectolitre of wine containing 5.5%–15% alcohol (ethanol) 
€262.24 
Cider Excise paid per hectolitre of cider containing 2.8%–6% alcohol (ethanol) €65.86 
Spirits Excise paid per litre of alcohol €31.13 
Source: (Revenue Commissioners 2011) 
 
Blood alcohol concentration allowed for drivers 
 
See National Report 2012 (Health Research Board 2012), Section 3.2.1, for the most 
recent information.  
 
Age limits for purchasing (or consuming) alcohol 
 
The minimum age limit for on- and off-premises sales for beer, wine and spirits is 18 
years.  
See National Report 2012 (Health Research Board 2012), Section 3.2.1, for the most 
recent information.  
 
Distribution of alcohol 
 
See National Report 2012 (Health Research Board 2012), Section 3.2.1, for the most 
recent information.  
 
Public policy with regard to alcohol-related nuisance  
 
See National Report 2012 (Health Research Board 2012), Section 3.2.1, for the most 
recent information.  
 
Price of cigarettes and other tobacco products (taxation) 
Table 3.2.1.2 includes data on the amount of excise duty that was paid on different 
tobacco products in 2011; these are the most recent data available.  
 
Table 3.2.1.2: Excise duty on tobacco products, 2011 
Tobacco product Excise paid in € 
Cigarettes (specific duty per 1,000 cigarettes) €183.42 
Cigarettes (Ad Valorem duty as per cent of retail 
price)  
18.25% 
Cigars (per kilogram) €261.066 
Fine cut tobacco for rolling cigarettes (per kilogram) €220.301 
Other smoking tobacco (per kilogram) €181.117 
Source: (Revenue Commissioners 2011) 
 
Smoke-free work and other public places 
As part of the National Tobacco Control Framework, the Health Service Executive 
(HSE) has committed to making all its workplaces and campuses smoke-free by 2015.  
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According to recent information made available by the HSE, 17 hospitals are now 
tobacco free. (Health Service Executive n.d).  
 
See National Report 2012 (Health Research Board 2012), Section 3.2.1, for more 
detailed information on legislation banning smoking in the workplace.  
 
Age limits for purchasing (or consuming) tobacco products 
 
See National Report 2012 (Health Research Board 2012), Section 3.2.1, for the most 
recent information.  
 
Advertising and promotion of cigarettes and other tobacco products 
 
See National Report 2012 (Health Research Board 2012), Section 3.2.1, for the most 
recent information.  
 
Treatment to help dependent smokers stop 
The health education website www.QUIT.ie is operated by the HSE with the principal 
aim of encouraging dependent smokers to quit. The website includes information on 
the health impacts of smoking, benefits of quitting, useful tips on how to measure level 
of addiction and a cost calculator. There is also an option to sign up to a QUIT plan and 
receive on-going email support during the first six weeks.  
 
The National Smokers’ Quitline (1850 201 203), operated by the HSE, offers a 
confidential counselling service to people seeking support or information about quitting 
smoking. The service is available 8 am – 10 pm, Monday to Saturday. 
 
The Smoking Cessation Services operated by the HSE provide specialist support to 
people in community or health service settings. Services include one-to-one, group or 
telephone support. Services are available free of charge. 
 
3.2.2 Other social and normative changes 
See National Report 2012 (Health Research Board 2012), Section 3.2.1, for the most 
recent information.  
 
 
3.3 Universal prevention 
3.3.1 School 
 
Substance use prevention and education in schools 
It would appear that the current, and perhaps future, direction of school-based 
universal substance use education and prevention, particularly among second-level 
students, is moving towards an integrated hybrid model incorporating a whole-school 
approach to overall health and social education, alongside an emphasis on young 
people developing their personal and social competencies. For example, actions 20 
and 21 of the NDS relate specifically to improving the implementation of Social, 
Personal and Health Education (SPHE) as the universal mechanism to prevent 
substance misuse in students attending both primary and post-primary schools. 
However, it is not clear how much time will be given to specific substance use 
components such as the Social Norms approach, whereby young people’s perceptions 
about substance use among their peers are challenged with empirical evidence.  
 
An update on the implementation of actions in the NDS in 2012 has recently been 
published (Department of Health 2013b). It refers to proposed changes to the 
implementation of SPHE within the Junior Cycle (12–15 years). These proposals are 
part of a new overall framework governing the curriculum for the Junior Cycle with the 
focus on promoting innovation within the school and developing a sense of identity 
  43 
within the student (National Council for Curriculum and Assessment 2011). The Junior 
Cycle framework is based on eight core principles, one of which is ‘Wellbeing’, whereby 
‘the curriculum contributes directly to the physical, mental, and social wellbeing of 
students’ (p. 10). The framework also includes five priority learning units (PLUs) 
including one on ‘looking after myself’, and eight skills that students should master 
including ‘staying well’ and ‘managing myself’. SPHE, within this new framework, will 
become a short course of 100 hours (60–70 hours at present). However, it would 
appear that the 100 hours may be spread across the three-year period of the Junior 
Cycle. SPHE is one of 24 subjects listed on the curriculum and will be assessed at 
school level.  
 
The new learning curriculum in the Junior Cycle will be evaluated as follows: ‘the extent 
to which a school’s programme supports students in developing key skills, improving 
literacy and numeracy, and in learning relevant to all the statements of learning will be 
evaluated in the first instance by the school itself through an on-going process of self-
evaluation…’ (p. 23). These processes will be supplemented by an evaluation 
undertaken by the Department of Education and Skills through its schools inspectorate. 
It is not clear to what extent, changes in knowledge, attitudes and behaviours around 
substance use will be measured as part of the evaluation of this broad curriculum 
framework. 
 
The progress report on implementing the NDS in 2012 (Department of Health 2013b) 
also contains information on how teachers are being supported to implement SPHE in 
schools. For example, at post-primary level a dedicated SPHE Support Service, 
comprising six members of staff, is in place. This service provides training, advice and 
support to schools to assist in implementing SPHE. In the school year 2011/12, 3,949 
teachers and other staff attended school-based events and 1,581 teachers attended 
cluster in-service training organised by the SPHE Support Service. The Professional 
Development Services for Teachers (PDST) provides professional development and 
support for teachers and schools. The website of the PDST now includes specific 
material on substance use. The following extract has been taken from the website to 
illustrate the philosophy underpinning the delivery of substance use education in 
schools:  
Substance Misuse Prevention Education should not be treated differently to 
other areas of the curriculum or taught in isolation. Such approaches could 
have the effect of sensationalising it as a topic rather than treating it as an 
integral part of the holistic development and education of the pupil in the context 
of the primary curriculum. The teacher is the best placed person to deliver 
substance misuse prevention education in the school setting. …Substance 
Misuse Prevention Education involves developing social and personal skills, 
fostering health promoting values and attitudes and giving age appropriate 
information, in that context on medicines and drugs, both legal and illegal…’ 
(Downloaded from http://www.pdst.ie/node/812 )  
Guidelines to promote positive mental health among school-going students 
A comprehensive set of guidelines promoting positive mental health and well-being 
among post-primary students was recently published (Department of Education Skills, 
et al. 2013). The overall aim in designing and publishing these guidelines is to promote 
a whole-school approach to positive mental health and suicide prevention. The 
guidelines were developed by an inter-departmental group in three phases: (1) a 
national consultation process with key stakeholders from health, education and other 
relevant sectors; (2) a review of national and international literature on good practice in 
health promotion and suicide prevention; and (3) developing the guidelines using 
information gathered from the consultation process and the literature review through 
on-going discussion with key partners.  
 
The guidelines are based on the theoretical assumption that developing positive mental 
health and well-being, linked to a sense of attachment and bonding to school, will foster 
  44 
improved resilience and social skills among students. Schools are encouraged to 
promote positive mental health and well-being through adopting a whole-school 
approach, permeating all aspects of school-life, from the curriculum to relations 
between staff and students and via the school environment. The guidelines also state 
that ‘the full implementation of Social, Personal and Health Education (SPHE) and 
Relationships and Sexuality Education (RSE) provides a framework for educating 
young people about their health and well-being in a planned and structured way’ (p. 
21). The guidelines recommend that schools adopt the three-tiered continuum of 
support model for promoting mental health:  
 
 support for all (universal) by providing early identification and intervention for young 
people showing mild or transient signs of difficulty,  
 support for some (selective) by identifying young people who are at risk of 
developing unhealthy patterns of behaviour or who are already showing early signs 
of mental health difficulties, and  
 support for a few (indicated) by supporting young people with complex or enduring 
needs relating to their mental and emotional well-being. 
 
The guidelines are conceptually rich in identifying the key risk factors that may 
compromise a young person’s mental health and the protective factors that can be 
fostered to develop resilience, which will counteract pressures on the young person’s 
mental health. Situating potential responses within the universal, selective and 
indicated prevention framework gives ample scope for schools to develop responses 
that tackle issues affecting the whole school population, while also putting in place 
measures to support young people who may have a higher risk profile around their 
mental health.   
 
The report states that ‘it is vital that school management and staff review and build on 
existing good practice and implement the processes described in these guidelines to 
support the emotional health of young people’ (p. 51). 
 
3.3.2 Family 
 
Action 29 of the NDS aims to develop a series of prevention measures that focus on 
the family under the following programme headings: 
 supports for families experiencing difficulties due to drug/alcohol use, 
 parenting skills, and 
 targeted measures focusing on the children of problem drug and/or alcohol users 
aimed at breaking the cycle and safeguarding the next generation.  
 
The progress report on implementing the NDS in 2012 (Department of Health 2013b) 
reports in relation to Action 29 that a broad mix of measures are being provided to 
support families, including individual counselling, family therapy and, in some regions, 
the Strengthening Families programme and the Community Reinforcement Approach. 
However, there is no specific data presented as to the profile of families using these 
services or the outcomes for families and their children.  
 
3.3.3 Community 
 
A large number of young people living in Ireland participate in youth work activities. 
Two recent reports – one an economic assessment of youth work (Indecon 
International Economic Consultants 2012) and the other a systematic mapping of youth 
work research (Dickson, et al. 2013) – have provided a very useful evidence base for 
policymakers and practitioners seeking to understand the value of youth work and to 
make decisions on the design and expected outcomes of youth work interventions. 
Both reports are seminal pieces of work and have been undertaken in a rigorous 
fashion, covering substantive areas that are pertinent to youth work.  
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The first comprehensive and rigorous economic assessment of youth work in Ireland 
was undertaken on behalf of the National Youth Council of Ireland (Indecon 
International Economic Consultants 2012). The report includes a useful insight into the 
nature and extent of youth work. For example, the vast majority (80%) of youth work 
organisations provides recreational, arts and sports-related activities; over half provide 
activities focused on the welfare and well-being of young people, including measures 
that address substance misuse and early school-leaving; some provide activities to 
divert young people from crime and anti-social behaviours.  
 
An estimated 312,615 young people aged between 10 and 24 participated in youth 
work activities  during 2011; this figure represents 43.3% of this age cohort nationally; 
54% of participants were female and 53.3% were believed to be socially or 
economically disadvantaged. There are over 40 national youth work organisations in 
the sector responsible for providing services through local community-based projects 
and groups. It is estimated that 40,145 individuals work in a voluntary capacity in the 
sector and 1,397 full-time equivalents are employed in management, service delivery 
and training and support for volunteers. The youth work sector received almost €79 
million in public funding during 2011: the Department of Children and Youth Affairs 
(DCYA) provided €61.5 million, the Irish Youth Justice Service (IYJS) €8.8 million and 
the Health Service Executive (HSE) €8.3 million. This represented an investment by 
the State of €206 per young person participating in youth work activities in 2011.  
 
An economic assessment of youth work 
The economic assessment (Indecon International Economic Consultants 2012) was 
guided by the following question: What would be the likely outcomes for young people 
participating in justice, health, and welfare-related youth programmes, and the costs to 
the State if these programmes were not available? The assessment was undertaken on 
the assumption that annual funding to these programmes remains constant over the 
next 10 years. Indecon estimated that the State would benefit by saving costs to the 
value of €2 billion for an €992 million investment over the next 10 years; benefits would 
exceed projected costs by a factor of 2.2. The projected €992 million investment was 
based on the assumption that the 2011 funding streams (total receipts of almost €79 
million) would be maintained and considering the relevant adjustments when 
undertaking such an assessment.  
 
In respect of the economic value of health-related youth work programmes, which 
include the Young People’s Facilities and Services Fund (YPFSF) and HSE and local 
drugs task force (LDTF) funding streams, Indecon compared the cost of funding such 
programmes with the estimated cost to the State if these services were unavailable at 
the youth work organisation level. Funding provided through the YPFSF and LDTFs, 
with additional health-promotion-related funding provided by the HSE, is distributed to 
organisations whose programmes are directed towards young people who are at risk of 
substance abuse and the associated adverse health-related impacts. If 2011 funding 
levels were to be maintained, the estimated cost of health-related funding to the youth 
sector over a 10-year period would be €420.5 million. Indecon assumed that in the 
absence of this funding, an estimated 4% of beneficiaries of these youth-work 
programmes would have to receive treatment for substance abuse in adolescent 
treatment centres at a cost to the State of €60.6 million annually, or €509.9 million in 
present value terms over a 10-year period; maintaining health-related funding at 2011 
levels would save the State an estimated €89.5 million over the projected 10-year 
period.  
 
The results of this cost-benefit analysis suggest that the public funding provided by the 
State for youth work services represents value for money. This reflects in particular the 
benefits of targeted programmes in the areas of justice, health and welfare, which 
address the needs of young people in a pre-emptive and holistic manner, compared to 
a scenario where the absence of these supports is likely to mean that the State would 
face substantially greater costs over the longer term.  
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Qualitative evidence on the impacts of youth work in Ireland  
The views of over 40 organisations working in the youth sector were sought in relation 
to the levels of significance they attach to their work with youth (Indecon International 
Economic Consultants 2012). A large majority of organisations in the sector attach very 
significant or significant levels of importance to the following aspects of youth work in 
helping:  
 
 young people to gain practical skills, 
 young people to gain education and training qualifications, 
 to reduce costs associated with crime and anti-social behaviour, 
 to reduce health and social care costs associated with substance misuse, 
 to expand labour market and other economic opportunities for young people, and 
 to promote equal economic opportunity between women and men.  
 
The relative significance of these particular aspects of youth work reflects to a large 
degree the findings of the review using a systematic mapping approach undertaken on 
behalf of the Department of Children and Youth Affairs (DCYA) (Dickson, et al. 2013). 
The authors claimed this work represented the first systematic international map of 
youth work research; the work was commissioned by the DCYA to inform the 
development of a youth policy framework for Ireland. The authors defined a systematic 
map as ‘a classification and description that aims primarily to illustrate the kinds of 
studies that exist [in a specific area]’ (p. 4). The purpose of such mapping studies is to 
identify the scope, nature and content of empirical research that has been undertaken 
on a particular topic and to present the findings in the form of a descriptive analysis of 
the relevant research, without critically appraising the included studies. Comparing key 
components in the design and evaluation of youth work reported in international 
research and in the practice of youth work in Ireland, the review showed that there 
were many similarities between youth work in Ireland and elsewhere. For example, the 
personal and social development of young people was reported as the primary aim in 
over twice as many included studies as any other aim; in Ireland, the definition of youth 
work in the Youth Work Act 2001 gives prominence to the personal and social 
development of youth as the main outcome of youth work:  
 
A planned programme of education designed for the purpose of aiding and 
enhancing the personal and social development of young people through their 
voluntary involvement, and which is complementary to their formal, academic or 
vocational education and training and provided primarily by voluntary youth 
work organisations. (Youth Work Act 2001, Part 1, Section 2)  
 
Leisure, recreation and arts activities were reported by most studies included in the 
review. Similarly, the work by Indecon (Indecon International Economic Consultants 
2012) reported that the vast majority (80%) of youth work organisations in Ireland 
provided recreational, arts and sports-related activities. Sports and recreation are 
clearly popular pursuits among children and young people as the findings from a recent 
national consultation show (Department of Children and Youth Affairs 2012). The 
researchers undertaking this survey posted questionnaires to primary and second-level 
schools, which were completed by 66,705 children and young people; 81% (n=54,163) 
of responses were from primary school students and 19% (n=12,542) from students at 
second-level. The majority of respondents (52%, n=34,714) were female. In response 
to the question ‘what’s the best thing about being a child in Ireland?’ 16% (n=8,411) 
said they liked sports, including both individual and team sports. In response to the 
question ‘what do you think is good about being a young person living in Ireland?’ 16% 
(1,966) in post-primary schools said they liked sports, including having sport as an 
outlet from school and work.  
 
The report by Indecon (Indecon International Economic Consultants 2012) spelt out the 
economic and socially disadvantaged conditions in which over half of all young people 
attending youth work services lived (based on 2011 figures). This indicated that the 
rationale for targeting funding to the most at-risk communities, which underpinned the 
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establishment of the YPFSF and the LDTFs, remains relevant today. However, further 
work is needed to evaluate the outcomes of youth work in Ireland against international 
benchmarks and to assess the effectiveness of using generic youth work models, i.e. 
personal and social development, to target the most at-risk young people. 
 
Views of young people on the value of youth work 
What has been described as consultations with young people were undertaken recently 
by the DCYA and the National Youth Council of Ireland (Department of Children and 
Youth Affairs 2013b). Three regional consultations were undertaken with 239 young 
people in Sligo, Cork and Dublin; 57% were female and 73% were aged under 18 
years. The consultations were undertaken as part of a European programme called 
‘Structured Dialogue’, a process established by the Council of the European Union in 
its resolution for a renewed framework for co-operation in the youth field (2010–2018).  
 
The report (Department of Children and Youth Affairs 2013b) documents a large 
number of achievements that young people claim they secured through participation in 
youth-related clubs and activities. These are listed under three broad categories: (1) 
personal development and happiness, (2) skills and experiences needed for life, and 
(3) feeling more included. Young people talked about how participating in youth-related 
clubs and activities helped them: 
 
 … to discover who they are, ‘what they want from life’, and to accept 
themselves for who they are by building self-confidence and self-esteem. In 
addition, young people feel that clubs ‘give you an opportunity to talk to people 
you wouldn’t talk to otherwise’, resulting in respect, tolerance and acceptance of 
others and their differences.  (p. 9) 
 
When young people were asked for their views on how the existing activities could be 
improved, and new ideas for clubs and activities, the responses mainly centred on 
young people having a more active say in running clubs and activities, more interaction 
with similar groups outside the clubs, greater diversity of activities in clubs, an 
emphasis on providing a welcome to new members, and a safe space in clubs to 
address specific issues, such as disability, sexual health and sexual orientation. 
 
 
3.4 Selective prevention in at-risk groups and settings 
3.4.1 At-risk groups  
Action 24 of the NDS is to co-ordinate the activities and funding of youth interventions 
in out-of-school settings (including the non-formal youth sector) to optimise their impact 
through targeting risk factors, while developing protective factors for youth at risk. The 
agency with primary responsibility for this action is the DCYA. Progress in 2012 on this 
action has recently been reported (Department of Health 2013b). Progress has 
included revised reporting forms and procedures for funding of youth interventions in 
out-of-school settings, work on an on-line reporting system to be introduced in 2014 to 
provide data on participant numbers and service provision, a start on implementing the 
National Quality Standards Framework for Youth Work (NQSF), and work on 
developing a Children and Youth Strategy to be followed by a Youth Policy Framework.  
 
A new set of standards, to complement the NQSF and to support volunteer-led youth 
groups in creating and providing quality, developmental/educational programmes and 
activities for young people in safe and supportive environments, was recently published 
(Department of Children and Youth Affairs 2013a). The standards aim to:  
 
 improve the quality of the programmes and activities provided, 
 improve the way programmes and activities are planned and delivered, and  
 provide young people with the opportunity to have a say in the development and 
review of the group and its activities. 
  48 
The standards will be implemented with youth groups on a phased and incremental 
basis throughout 2013 with a view to all youth groups in receipt of funding from the 
DCYA being engaged in the process from January 2014. It is expected that many of 
the groups funded by the DCYA will already be in a position to adhere to them and 
confirm that they have achieved each of the indicators of achievement. The standards 
are based around three core principles from which the standards and indicators derive 
(see Table 3.4.1.1).  
 
Table 3.4.1.1: Core principles, standards and indicators to structure and guide youth groups and 
their activities 
Principles Standards Indicators 
Young-person centred Programmes (activities), 
practices (how you work and 
how the group operates) and 
people (young people, 
volunteer leaders) ensure and 
promote the voluntary 
participation, inclusion and 
voice of young people. 
1) Young people are actively involved 
in the running of the group. 
2)  Young people are actively involved 
in the design and delivery of 
activities. 
3) Young people are actively involved 
in the planning and evaluation of 
activities. 
4) Activities are accessible and 
inclusive. 
Safety and well-being Programmes (activities), 
practices (how you work and 
how the group operates) and 
people (young people, 
volunteer leaders) ensure and 
promote the safety, support 
and well-being of young 
people. 
1) Appropriate insurance cover in 
place. 
2) Health and safety procedures in 
place. 
3) Child protection policy and 
procedures in place. 
Developmental/educational  Programmes (activities), 
practices (how you work and 
how the group operates) and 
people (young people, 
volunteer leaders) ensure and 
promote the development, 
achievement and progression 
of young people. 
1) Young people’s needs and 
interests are recognised and 
responded to. 
2) Young people’s abilities and 
potential are developed. 
3) Young people’s participation and 
achievement are recognised. 
4) Support and training is provided 
for volunteer leaders. 
Source: (Department of Children and Youth Affairs 2013a) 
 
Action 25 of the NDS aims to develop facilities for both the general youth population 
and those most at risk through increased access to community, sports and school 
facilities in out-of-school hours; and the development of youth cafés. Progress on this 
action in 2012 has been reported (Department of Health 2013b). The YPFSF allocated 
€21.332 million to assist in the development of youth facilities and services 
 
3.4.2 At-risk families 
 
The Teen Counselling service operated by Crosscare, a voluntary organisation, aims to 
provide a professional counselling service for teenagers and their families who are 
experiencing emotional, behavioural and functional difficulties. The service works in 
teams of two, usually a psychologist and a social worker, who initially assess the 
nature and severity of problems with the parents and teenagers who present. 
Subsequently, parents and teenagers are provided with individual counselling 
sessions, and when appropriate, combined sessions are scheduled; a consultant 
psychiatrist attends on a sessional basis. According to the annual report of the Teen 
Counselling service for 2011, ‘one of the founding principles of the service has been 
prevention of more serious difficulties, particularly in the area of substance abuse…’ 
(Crosscare Teen Counselling 2011), p. 35).  
 
The annual report records that in 2011, 437 families attended the service; 281 new, 
and 156 continuing from 2010. The profile of the 281 new teenage client’s shows that 
56% were aged under 16 years, 52% were female and 89% were attending second-
level school. Among the 281 new teenage clients, 19% (n=52) reported using drugs, 
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with hash used by 90%, cocaine by 10%, ecstasy by 8%, solvents by  6%, and 
pills/medicines by 17%. Twice as many males were using drugs and over a fifth (22%) 
of all young people using drugs were under 16.  
 
Almost half (48%) of all new teenage clients reported drinking alcohol; 20% of these 
were under 16 and there were no notable gender differences in overall alcohol 
consumption. Twenty-four per cent (n=68) of new teenage clients smoked cigarettes 
and the report notes the percentage of smokers under 16 had doubled from 2010; 
overall there were slightly more girls smoking than boys.  
 
Behavioural problems in the home, school and the community were the main reason 
for the majority (59%) of new teenage clients being referred to the service, 37% were 
referred owing to family problems such as conflict or parental separation, and 36% for 
emotional problems, e.g. anxiety. Relationship and communication problems were 
noted in 83% of families of new teenage clients. The percentage of new teenage clients 
reporting self-harm doubled from 11% in 2010 to 22% in 2011 and 21% of new clients 
reported suicidal ideation.  
 
The main objective of the service is to support the ‘normal systems’ that provide 
teenagers with stability, attachment and positive development, i.e. the home, the family 
and the school. Teenagers are invited to evaluate the extent of their main problems as 
they experience them at home, in school, with friends and with self, before and after 
counselling. In 2011, 25% (n=69) of all teenagers completed this evaluation. There was 
improvement reported in all four domains: 89% reported improvement in the home, 
74% in school, 54% among friends and 88% with self. Among parents who completed 
the evaluation process before and after counselling (n=88, 32%), 90% reported 
improvements in the severity of their problems and 93% reported improvement in their 
ability to cope with their problems. Improvements were also reported by counsellors 
around the main problems families presented with and their underlying problems; 
counsellors also noted improvements in some teenagers and in some of the families 
who appeared to function better. 
 
Communities that have experienced higher than average socio-economic disadvantage 
have been characterized as being the communities most at risk of experiencing acute 
problematic drug use among residents. For example, a number of communities have 
been designated as local and regional drug and alcohol task force areas in order to 
receive specific funding to support the reduction of the risks. In most of these areas, 
the community and voluntary sectors have often been to the fore in developing 
innovative responses to tackle substance use and associated problems. However, 
recent austerity measures have seen a reduction in funding to these at risk 
communities which have had a corresponding impact on the nature and extent of 
services being provided. For example, Harvey estimated an overall reduction in 
government supports for the community and voluntary sector of 48 per cent (Harvey 
2012).  He pointed to reductions in supports for community development and key 
community projects such as those funded through the drugs task forces. As a result, 
Harvey reports that community and voluntary organisations have taken a number of 
actions to ‘downsize’, including reducing expenses, laying off non-permanent staff and 
taking a reduction in pay and conditions. These changes are taking place alongside an 
increased demand for their services and a reduction in the number of state agencies 
who would have supported the community and voluntary sector as part of their 
statutory remit. For further information, see also Section 1.3.3, and (Health Research 
Board 2012), Section 1.4.1.)  
 
3.4.3 Recreational settings (incl. reduction of drug and alcohol related harm) 
See National Report 2008 (Alcohol and Drug Research Unit 2008), Section 3.4.3, for 
most recent information. 
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3.5 Indicated prevention 
3.5.1 Children at risk with individually attributable risk factors (e.g. children with 
Attention Deficit (Hyperactivity) Disorder, ,children with externalising or internalising 
disorders) Externalising : sensation seeking, conduct disorders; Internalising : extreme 
shyness, depression. 
The Child and Adolescent Mental Health Service (CAMHS) teams are the first line of 
specialist mental health services for children and young people affected by poor mental 
health. The multi-disciplinary teams include psychiatrists, psychologists, nurses, social 
workers, speech and language therapists and occupational therapists.  Data extracted 
from the latest annual report of CAMHS shows that in 2012, there were 63 teams 
operating the service (Health Service Executive 2012a).   
 
The annual report shows that from October 2011 to September 2012 the number of 
referrals to the CAMHS teams increased by 17%. A total of 9,843 new cases were 
offered an appointment, 8,671 were seen and 1,172 did not attend. Of the 8,671 cases 
seen, a total of 2,685 had been re-referred to the service. This number of re-referrals 
represents 31% of the new cases seen and is reported as part of an increasing trend in 
re-referrals since 2008, which coincided with the onset of the economic recession and 
the implementation of fiscal austerity measures. Over the 12-month period from 
October 2011 to September 2012, 45% of new cases were seen within one month of 
referral and 66% were seen within three months. According to the report, young people 
whose need was deemed urgent were seen as a priority while routine cases were 
placed on a waiting list. There were 2,056 young people waiting to be seen at the end 
of September 2012; this represented an increase of 8% over the number waiting a year 
earlier. The majority of referrals (64.6%) in 2011 were from GPs.  
 
During November 2011, a clinical audit was undertaken by 58 CAMHS teams, who 
collected data on 8,479 cases seen during the month. Of the cases seen, 41.6% were 
aged 10–14 years, 28.4% were aged 5–9 years , 16.5% were aged 16–17 years, 12% 
were aged 15, and 1.4% were aged 0–4. Males accounted for 64.9% of all children 
seen in November 2011 and were the majority gender in each of the age bands. The 
primary presentation of each of the cases is summarised out in Table 3.5.1.1  Males 
made up the majority in all primary presentations apart from those for eating disorders, 
deliberate self-harm depression and emotional disorders, where females were in the 
majority. The male to female ratio for ADHD and other attention disorders was 4:1. 
Twenty per cent (n=1,684) of children seen by the service in November 2011 were in 
contact with social services. 
 
Table 3.5.1.1: Primary presentations of 8,479 cases seen by 58 CAMHS teams, November 2011 
Primary presentation Examples of disorders Number % 
Hyperkinetic disorders  ADHD and other 
attention disorders 
3,025 35.7 
Anxiety disorders Phobias, OCD, Post-
traumatic stress 
disorder 
1,588 18.7 
Autistic spectrum disorders Autistic disorder 947 11.2 
Depressive disorders Depression 798 9.4 
Conduct disorders Oppositional defiant 
disorder, aggression, 
arson 
580 6.8 
Deliberate self-harm Lacerations, substance 
overdose 
285 3.4 
Developmental disorders Deficits in speech and 
social skills 
217 2.6 
Eating disorders Pre-school eating 
problems, anorexia 
nervosa, bulimia 
nervosa 
207 2.4 
Psychotic disorders Schizophrenia, manic 
depression, drug-
induced psychosis 
108 1.4 
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Primary presentation Examples of disorders Number % 
Habit disorders Sleeping problems, 
bed-soiling 
84 1.0 
Substance abuse Drug and alcohol 
misuse 
30 0.4 
Gender role identity Problems with gender 
identity 
16 0.2 
Source: (Health Service Executive 2012a) 
 
 
3.6 National and local media campaigns 
Action 27 of the NDS focuses on developing a national website to provide information 
and access to a national helpline, and Action 28 on developing a range of awareness 
campaigns. Some progress was achieved in delivering on these actions in 2012 
(Department of Health 2013b). For example, it is reported that during 2012, 
developments to the drugs.ie website, which is the main national forum for 
disseminating information and awareness campaigns included: 
 
 launch of an online outreach campaign to link in with other relevant websites and 
social media pages;  
 continued development of drug and alcohol related video content; 
 an online alcohol self-assessment and brief intervention tool based on the AUDIT 
screening tool;  
 to complement the online alcohol self-assessment tool an online drug self-
assessment and brief intervention tool is under development;   
 redesign of the Facebook page and an extensive Facebook ads campaign;  
 the use of drugs.ie Facebook page to publicise two HSE emergency alerts (i) 
suspected contamination batch of heroin and (ii) a brown substance passed off 
as MDMA and linked to two deaths in the south-east; 
 re-development of the National Directory of Services; 
 a virtual advisory group comprising HSE addiction services staff, drug task force 
personnel, and representatives from youth websites; and  
 continued production and dissemination of the drugs.ie eBulletin. 
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4. Problem Drug Use (PDU)  
4.1 Introduction 
A PDU is defined as an ‘injecting drug user or long duration/regular user of opiates, 
cocaine and/or amphetamines’ (EMCDDA 2004). 
 
It is not possible to estimate the number of injecting drug users or PDUs, apart from 
opiate users, in Ireland as the National Drug Treatment Reporting System (NDTRS) 
does not use a unique identifier. This issue has been raised in strategy submissions 
and it is hoped that it will be addressed in a forthcoming health information bill.  
 
A national 3-source capture-recapture (CRC) study, to provide statistically valid 
estimates of the prevalence of opiate drug use in the national population during 2006, 
was commissioned by the National Advisory Committee on Drugs (NACD) and 
undertaken in 2001 and 2006.  The second study (Kelly, Alan, et al. 2009) indicated 
that use had increased since the previous survey (Kelly, Alan, et al. 2003). There were 
11,807 known opiate users in 2006. The major expansion of the national methadone 
treatment programme between 2001 and 2006 is the main reason for the inflation of 
the figures. There is some doubt over the estimate produced of a possible further 8,983 
opiate users who have not come into contact with any of the drug treatment services, 
hospital in-patient services or the Gardaí. 
The following are among the trends (2001–2006) seen in the study results: 
 
 the rate of opiate use among females and males aged 15–24 decreased, indicating 
a significant reduction in the number of young people commencing opiate use,  
 an increase in opiate use outside of Dublin, and 
 a higher proportion of opiate users in treatment in Dublin than elsewhere, reflecting 
the more recent spread of opiate use outside Dublin and the later development of 
treatment services.  
The NACD are able to estimate the number of people dependent on cannabis in the 
year prior to the survey using data from the general population survey on drug use 
2010/11. The questionnaire has two measures of cannabis dependency, the MCIDI 
based of clinical diagnosis and the SDS used in a number of studies on treatment. The 
MCIDI results are reported here. 
4.2 Prevalence and incidence estimates of PDUs 
4.2.1 Indirect estimates of problem drug use 
Extent and patterns of cannabis use in Ireland 
The National Advisory Committee on Drugs and Alcohol (NACDA) recently published 
Bulletin 3 in the series of reports on the 2010/11 survey on drug use in the general 
population in Ireland and Northern Ireland (National Advisory Committee on Drugs and 
Alcohol 2013). The bulletin reports on cannabis use in the adult population (15–64 
years), on cannabis dependence and cannabis abuse as well as on patterns of 
cannabis use in Ireland.  A total of 5,128 people were interviewed, representing a 
response rate of 60%.  This article presents a summary of the main results reported in 
the NACDA bulletin. 
 
The prevalence of cannabis abuse and cannabis dependence were measured in the 
NACD Drug Prevalence Survey the first time in 2010/11 using M-CIDI9. Substance 
                                               
9
 The Composite International Diagnostic Interview (CIDI, World Health Organization, 1990) contains the DSM-IV 
diagnostic criteria for substance abuse and dependence and is a validated method to assess the seriousness of a 
person’s cannabis use. Advised by the EMCDDA, the abbreviated version, the Munich Composite International 
Diagnostic Interview (M-CIDI), a 19 item instrument reflecting the four cannabis abuse and seven cannabis dependence 
criteria, was used for the NACD 2010/11 Drug Prevalence Survey. 
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abuse and substance dependence are defined by the DSM-IV as a maladaptive 
pattern of substance use leading to a clinically significant distress or impairment.   
 
The application of the EMCDDA accepted classification system for cannabis abuse 
shows that among recent cannabis users 17% met criteria for cannabis abuse.  Rates 
of cannabis abuse were higher among recent male users (20%) than female users 
(8%) and among young adult users (20%) compared to older adults (9%).  Among all 
adults in the survey (15-64 yrs) just over 1% met the criteria for current cannabis 
abuse. The population of Ireland was 4,470,700 in 2010 which implies that 
approximately 44,707 people abuse cannabis in Ireland.  
 
Applying the classification system used by the EMCDDA, the results show that 9% of 
recent cannabis users were classified as dependent.  Dependence was higher among 
male and among young adult recent users. Among all adults in the general population 
(15-64 yrs) the proportion classified as currently cannabis dependent was 0.6%. Given 
the population of Ireland in 2010 this implies that approximately 26,824 people meet 
cannabis dependence criteria in Ireland.   
 
The likelihood of a young adult in Ireland using daily or almost daily has declined 
substantially since the survey in 2006/7.  Despite lower prevalence, frequency of use is 
higher among older adults, changing little since the last survey.  Among current users 
high frequency use, or intensive use, is reported by 46% of young adults and 55% of 
older adults.   
 
An indication of the public health impact of a drug can be seen in the numbers entering 
treatment.  The number of treatment cases reporting cannabis as their main problem 
substance has increased significantly in Ireland and in 2010 cannabis became the 
most common problem drug reported by new cases (Bellerose, et al. 2011). 
 
 
4.2.2 Estimates of incidence of problem drug use 
There are no estimates of the incidence of problem drug use in Ireland. 
 
 
4.3 Data on PDUs from non-treatment sources (police, emergency, 
needle exchange etc) 
Merchants Quay Ireland Review 2011  
Merchants Quay Ireland (MQI) is a national voluntary agency providing services for 
homeless people and for drug users. Its needle exchange health promotion unit 
provides drug users with information about risks associated with drug use and the 
means to minimise such risks and it also offers drug users a pathway into treatment 
and the possibility of living without drugs. In September 2012 MQI published its annual 
review for 2011 (Merchants Quay Ireland 2012). 
 
In 2011, there were 21,819 visits to Drug Services and 18,951 needle exchanges, with 
4,051 individuals using the services, of whom 492 were new clients. A heroin drought 
in the winter of 2010/2011 saw the number of clients drop in January 2011 to 810 and 
then rise again to 2,043 by November 2011. A total of 1,220 safer injecting workshops 
were undertaken with injecting drug users during the year.  
 
In 2011 MQI opened the Athlone Open Door Centre in the Midlands. Providing a range 
of needle exchange/harm reduction services for drug users, in its first year this Centre 
provided over 4,000 one-to-one interventions.   
 
 
4.3.1 PDUs in data sources other than TDI 
 
Drug and alcohol use among adult offenders on probation supervision in Ireland 
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In May 2012 the findings of the first nationwide survey on drug and alcohol ‘misuse’ 
among the adult offender population on probation supervision were published 
(Probation Service 2012b). ‘Misuse’ was defined in the report as drug-taking which 
causes harm to the individual, their significant others or the wider community. It 
included illicit drug taking or alcohol consumption that leads a person to experience 
social, psychological, physical or legal problems related to intoxication or regular 
excessive consumption and/or dependence. The objectives of the survey were to (1) 
ascertain the number of adult offenders on probation supervision who ‘misused’ drugs 
and or alcohol, (2) examine the nature and frequency of the ‘misuse’, (3) establish 
correlations if any between drug and/or alcohol  ‘misuse’ and offending, and (4) identify 
the level and nature of engagement with drug and alcohol treatment services. The data 
are intended to inform service provision within the Probation Service and also to inform 
the work of other relevant agencies.  
 
The case records of all adult offenders as of 1 April 2011 were reviewed by Probation 
Officers who completed a specifically developed questionnaire. A total of 2,963 valid 
questionnaires were returned, giving a response rate of 96.7%. While the survey 
captured a large representative cohort of young offenders on the caseloads of 
Probation Officers, limitations with the method used were acknowledged. One was the 
questions regarding the nature and frequency of drug and alcohol use as Probation 
Officers indicated that there was uncertainty with regard to some clients’ current 
alcohol and drug using status and in some cases they could not confirm current alcohol 
or drug using status as urinalysis had not been undertaken.  
 
Section 1 of the questionnaire collected data on the prevalence of drug and alcohol 
‘misuse’ among the adult offender population on probation supervision and on trends 
by age, gender and probation region. The authors defined prevalence as ‘the 
proportion of the offender population who misused drugs/alcohol, current use referring 
to last 12 months or part of the last 12 months and past use referring to beyond the last 
12 months’.  
 
The majority of those on probation supervision were male (2,576) and only 387 were 
female. The number using drugs or alcohol was 2,636 (89%), with similar proportions 
among both among men and women (Table 4.3.1.1). Drug and/or alcohol use was 
more prevalent among younger offenders, both female and male (Table 4.3.1.2). Use 
of drugs and/or alcohol by women peaked later than males, at 39.3% between the ages 
of 25 and 34, while drug and/or alcohol use among male offenders peaked in the 18–-
24-year age category. Use levels declined among older offenders, coinciding, 
according to the authors, with a decrease in the number of offenders in these age 
categories.  
 
Table 4.3.1.1   Prevalence of drug/alcohol use among the adult offender population on probation 
supervision, by gender, 2011  
Gender Users Non-users Total  
Male 2304 (89.4%) 272 ( 10.6) 2576 (87%)  
Female 
Total 
332 (85.8%) 
2636 (89%) 
55 (14.2%) 
327 (11%) 
387 (13%) 
2963 (100%) 
 
Source: (Probation Service 2012b) 
 
 
Table 4.3.1.2   Prevalence of drug/alcohol use among the adult offender population on probation 
supervision, by age and gender, 2011  
Gender 18–24 years 25–34 years 35–44 years 45–54 years 55+ years 
Female 35% 39.3% 18.1% 4.8% 2.0% 
Male 41.5% 35.1% 15.8% 5.5% 2.7% 
Source: (Probation Service 2012b) 
 
Among those reporting drug and/or alcohol use (n=2,636), 42.3% had used drugs and 
alcohol, 26.5% drugs only, and 20.2% alcohol only (Table 4.3.1.3). Larger numbers of 
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offenders in the younger age groups had used drugs only (36.3% in the 25–34-year 
age category). Use of alcohol only was higher among the older adult offender 
population (49.2% in the 45–54-year age category). Combined drug and alcohol use 
was higher among younger offenders (90.7% in the 18–24 age category, and 92.8% in 
the 25–34 age category). The decline in the prevalence of combined drug and alcohol 
use by those in the older age categories coincided, according to the authors, with a 
decrease in the number of offenders in these age categories. 
 
Table 4.3.1.3   Prevalence of drug and/or alcohol use among the adult offender population on 
probation supervision, by age and substance, 2011  
Substance 
used 
18–24 years 25–34 years 35–44 years 45–54 years 55+ years Total 
Drug only 23.8% 36.3% 24.8% 8.1% 3.0% 26.5% 
Alcohol only 15.3% 14.4% 28.4% 49.2% 44.6% 20.2% 
Drug and 
alcohol 
combined 
90.7% 92.8% 89.4% 77.3% 54.5% 42.3% 
Source: (Probation Service 2012b) 
 
When the data were analysed by Probation Service region (of which there are 10), it 
was found that the Dublin South and Wicklow regions had the highest levels of both 
combined drug and alcohol use among the adult offender population on probation 
supervision (91.2%) and ‘drug misuse only’ (34.1%), followed by the Dublin North and 
North East regions, which had a similar level of combined drug and alcohol misuse 
among the adult offender population (91.1%) and a slightly lower level of drug use only 
(27.2%). Alcohol use only was highest among the adult offender populations in the 
South West region at 27.9%, followed by the West, North West and Westmeath regions 
at 27.7%.  
 
Section 2 of the questionnaire explored the nature and frequency of drug and alcohol 
use among the adult offender population on probation supervision and identified 
current multiple drug use (inclusive of alcohol). The author stated that the levels of 
‘current’ (defined in this section of the report as ‘weekly, monthly, and occasional’) use 
were more than likely an under-estimation because of uncertainty about clients’ alcohol 
and/or drug using status. Alcohol was identified as the most commonly used substance 
both currently (36.4%) and previously (37.6%), and cannabis the most commonly used 
illicit substance both currently (21.8%) and previously (31.6%) (Table 4.3.1.4). 
 
Table 4.3.1.4   Number and percentage of the adult offender population on probation supervision 
(n=2,963) who were current and/or past users of drugs and/or alcohol, by substance, 2011 
 Current Previous 
Substance used   n % n % 
Alcohol 1078 36.4 1113 37.6 
Cannabis 645 21.8 937 31.6 
Opiates 265 8.9 766 25.9 
Stimulants 190 6.4 1002 33.8 
Misused prescribed drugs 219 7.4 568 19.2 
Miscellaneous* 55 1.9 256 8.6 
Source:  (Probation Service 2012b) 
*Miscellaneous includes steroids, hallucinogens, headshop products and other substances 
 
The data on current use showed the following:  
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 The majority of current alcohol users (66.8%) were male between 18 and 34 
years of age. The majority of current cannabis users (90.7%) and current opiate 
users (75.5%) were males aged between 18 and 44 years, with the highest 
proportion of them located in the Dublin North and North East regions, followed 
by the Dublin South and Wicklow regions (23.2%).  
 8.9% of survey participants were currently using opiates and were from the 
Dublin North and North East regions (12.5%) and Dublin South and Wicklow 
regions (11.4%).  
 Over one fifth of current opiate users were female (22.2%) and 16% were 
‘current’ prescribed drug users. 
 Previous use of opiates was higher in the female population (34.1%) compared 
to males (24.6%).  
 
Table 4.3.1.5 shows weekly drug use among the adult offender population on probation 
supervision.  
 The drug most frequently used on a weekly basis by both men (18.5%) and 
women (12.4%) was alcohol, with the South West region showing the highest 
percentage (44.1%) of ‘current’ alcohol use. (Conversely, monthly use of 
alcohol was proportionally higher among women (5.2%) than among men 
(3.8%)). 
 Cannabis was the illicit drug most frequently used by adult males on a weekly 
basis (14.4%). 
 Proportionally more women (9%) used opiates on a weekly basis than men 
(4.2%). (Monthly use of opiates was also proportionally higher among women 
(1.0%) than among men (0.8%)). The author commented that while opiate use 
was historically confined to Dublin, the results of the survey showed that the 
proportion of opiate misusers is emerging as a significant problem in the 
Midlands and South East region.  
 The level of weekly use of prescribed drugs was high among the female 
population (8.5%), twice that among males (4.5%).  
 
Table 4.3.1.5   Weekly drug use among the adult offender population on probation supervision, by 
gender, 2011 
 Males 
(n=2,576) 
Females 
(n=387) 
 n % n % 
Alcohol 476 18.5 48 12.4 
Cannabis  372 14.4 31 8.0 
Opiates 108 4.2 35 9.0 
Stimulants  70 2.7 10 2.6 
Prescribed drugs  116 4.5 33 8.5 
Source: (Probation Service 2012b) 
 
As shown in Table 4.3.1.6, 20.8% (n=616) of offenders were noted by Probation 
Officers to be currently using two or more drugs (alcohol inclusive). The number of 
adult offenders perceived as currently using more than one drug inclusive of alcohol 
was examined based upon Probation Officers’ professional judgement and perceptions 
and what was known about the clients’ current misusing behaviour and may not be fully 
representative of the true level outlines these results.  
 
Table 4.3.1.6 Number and percentage of adult offenders (n=2,963) currently using more than one 
drug inclusive of alcohol, 2011 
Currently using n % 
2 drugs 347 11.7 
3 drugs 138 4.7 
4 drugs 69 2.3 
5 drugs 36 1.2 
6 drugs 26 0.9 
Source:  (Probation Service 2012b) 
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Section 3 of the questionnaire collected data on the relationship between drug/alcohol 
use and crime. See Section 9.4 for a report on this data. 
 
Section 4 of the questionnaire collected data on the nature and engagement with drug 
and alcohol treatment services by adult offenders on probation supervision. Findings 
included:  
 
 41.7% of the total drug-using offender population on probation supervision were 
currently engaged in drug treatment, with 30.2% of drug users undertaking 
urinalysis. 
 5.8% of drug users were currently in residential treatment.  
 72.2% of opiate users were currently in receipt of methadone maintenance. 
 32.5% of the total number of drug users were currently attending counselling 
services. 
 9.3% of those who used drugs were currently attending Narcotics Anonymous. 
 33.7% of alcohol users were described as current ‘problematic alcohol misusers’, 
and 79.8% were described as ‘problematic alcohol misusers’ in the past.  
 
 
4.4 Intensive, frequent, long-term and other problematic forms of use 
 
 
4.4.1 Description of the forms of use falling outside the EMCDDA’s PDU 
definition (in vulnerable groups) 
See Section 4.4.1 of the 2012 National Report (Health Research Board 2012) for the 
most recent information 
 
 
4.4.2 Prevalence estimates of intensive, frequent, long term and other 
problematic forms of use, not included in the PDU definition 
See Section 4.4.2 of the 2012 National Report (Health Research Board 2012) for the 
most recent information 
  58 
5. Drug-related treatment: treatment demand and treatment 
availability  
5.1 Introduction 
Two broad philosophies underlie the approaches to drug-related treatment in Ireland: 
medication-free therapy and medication-assisted treatment. Medication-free therapy 
uses models such as therapeutic communities and the Minnesota Model, though some 
services have adapted these models to suit their particular clients’ needs. Medication-
assisted treatment includes opiate detoxification and substitution therapies, alcohol and 
benzodiazepine detoxification, and psychiatric treatment. Various types of counselling 
are provided through both philosophies of treatment and independent of either type of 
treatment. Alternative therapies, such as acupuncture, are provided through some 
community projects.  
 
Data on drug treatment in Ireland are collected through two national data collection 
tools – the Central Treatment List and the National Drug Treatment Reporting System. 
 
The Central Treatment List (CTL) was established under Statutory Instrument No 225 
following the Report of the Methadone Treatment Services Review Group 1998 
(Methadone Treatment Services Review Group 1998). This list is administered by the 
Drug Treatment Centre Board on behalf of the HSE and is a complete register of all 
patients receiving methadone (for treatment of opiate misuse) in Ireland and provides 
all data on methadone treatment nationally. 
 
The National Drug Treatment Reporting System (NDTRS) is a national 
epidemiological database which provides data on treated drug and alcohol misuse in 
Ireland. The NDTRS collects data from both public and private outpatient services, 
inpatient specialised residential centres and low-threshold services.  For the purposes 
of the NDTRS, treatment is broadly defined as ‘any activity which aims to ameliorate 
the psychological, medical or social state of individuals who seek help for their 
substance misuse problems’.  The NDTRS is a case-based, anonymised database. 
The NDTRS is co-ordinated by staff at the Health Research Board (HRB) on behalf of 
the Department of Health and Children. The number of drug treatment services 
participating in the NDTRS continues to increase (Standard Table TDI 34).  Although 
treatment is provided within the Irish Prison Service, it was only in 2009 that 
counsellors working in the prison service began to return information to the NDTRS.   
 
Other entities mentioned in this chapter are as follows: 
 
The Aislinn Adolescent Addiction Centre in County Kilkenny is a non-profit-making 
organisation that provides quality treatment for persons between the ages of 15 and 21 
years and assists families by offering an Addiction Awareness Programme. 
  
The Ana Liffey Drug Project (ALDP) is a ‘low threshold - harm reduction’ service, 
based in north inner city Dublin. The project works with people, experiencing addiction, 
to minimise the harm that problematic drug use causes them, their families and the 
wider community.   
 
Drug Treatment Centre Board (DTCB) see National Drug Treatment Centre. 
 
The Health Service Executive (HSE), which manages Ireland’s public health sector, 
provides an addiction service, including both illicit drugs and alcohol, delivered through 
Social Inclusion Services, which is part of its Integrated Services Directorate.  Addiction 
treatment services are provided through a network of statutory and non-statutory 
agencies. Some of the principal non-statutory agencies include: 
 
The Institute of Obstetricians and Gynaecologists is the professional and training 
body for obstetrics and gynaecology in Ireland. The Institute was established in 1976 
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and is one of six faculties and institutes within the Royal College of Physicians of 
Ireland (RCPI). 
 
Merchants Quay Ireland (MQI) is a voluntary organisation, based in South Inner City 
Dublin, which provides a wide range of services to homeless people and drug users. 
 
In 1998 a Methadone Treatment Protocol (MTP) was introduced, to ensure that 
treatment for opiate misuse could be provided wherever the demand exists. New 
regulations pertaining to the prescribing and dispensing of methadone were introduced, 
and a joint Health Board/Irish College of General Practitioners (ICGP) committee was 
formed to provide training, ongoing education and regular audit for general practitioners 
(GPs) taking part in the programme. Under this protocol, any GP wishing to take part in 
the provision of treatment services to drug users, must undertake training as provided 
by the ICGP.  Under the MTP, GPs are contracted to provide methadone treatment at 
one of two levels – Level 1 or Level 2.   Level 1 GPs are permitted to maintain 
methadone treatment for misusers who have already been stabilised on a methadone 
maintenance programme. Each GP qualified at this level is permitted to treat up to 15 
stabilised misusers. Level 2 GPs are allowed to both initiate and maintain methadone 
treatment. Each GP qualified at this level may treat up to 35 misusers. Practices where 
two Level 2 GPs are practising are permitted to treat up to 50 misusers. Locally-based 
methadone treatment for opiate misusers is now provided through drug treatment 
clinics, satellite clinics or through GPs in the community.  
 
The National Addiction Training Programme (NATP) was developed on foot of 
Action 47 in the National Substance Misuse (interim) Strategy 2009–2016. The HSE 
has responsibility for the NATP, developing national training standards for all involved 
in the provision of substance misuse services, and for the coordination o0f training 
provision within a single national substance misuse framework.  
 
The National Centre of Pharmacoecomomics (NCPE) conducts the health 
technology assessment of pharmaceutical products for the HSE in Ireland in 
collaboration with the HSE Corporate Pharmaceutical Unit (HSE-CPU).  The aim is to 
promote expertise in Ireland for the advancement of the discipline of 
pharmacoeconomics through practice, research and education. 
 
The National Drug Rehabilitation Implementation Committee (NDRIC) is 
responsible for overseeing and monitoring the implementation of the recommendations 
contained in the report of the Working Group on Drugs Rehabilitation, the development 
of protocols, service level agreements and a quality standards framework, and 
ensuring appropriate training is instigated. Chaired by the HSE, the NDRIC comprises 
representatives of the HSE, government departments, agencies and community and 
voluntary sector organisations, the National Advisory Committee on Drugs, service 
professionals, problem drug users and families of problem drug users.  
 
The National Drug Treatment Centre (NDTC) was formerly the Drug Treatment 
Centre Board (DTCB). Under the Health (Miscellaneous Provisions) Act 2010 the 
DTCB was dissolved and its assets and liabilities transferred to the HSE on 1 January 
2013. Originally located at the 'Charitable Infirmary', Jervis Street Hospital, Dublin 1, it 
was known as the National Drug Advisory and Treatment Centre and later as the Drug 
Treatment Centre Board. The first treatment service in the country, it provides effective, 
high-quality and client-focused treatment. It offers guidance and training to other 
professionals working in the area of substance misuse and contributes to policy 
development in drug and addiction management. 
 
The Research Outcome Study in Ireland (ROSIE) was the first prospective study of 
treatment outcomes for opiate users to be conducted in Ireland. The objective was to 
evaluate the effectiveness of treatment and other intervention strategies for opiate use. 
The study recruited 404 opiate users entering treatment between September 2003 and 
June 2004. Three treatment modalities, provided through both inpatient and outpatient 
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settings, were the focus of attention – methadone maintenance, structured 
detoxification, and abstinence-based treatment programmes. In addition, a sub-sample 
of individuals was recruited from needle exchange interventions. Participants were 
interviewed at treatment intake, or as soon as possible thereafter, and again at 6 
months, 12 months and 3 years after the baseline interview. Data were collected by 
means of a structured interview. The interview instrument contained a comprehensive 
set of outcome measures detailing the social and psychological characteristics of the 
cohort, and a range of treatment process factors in relation to treatment outcomes. 
Between September 2006 and October 2008 seven papers in the ROSIE Findings 
series, concentrating on particular aspects of the study, were published; in June 2009 a 
report on outcomes at 1-year and 3 years for the whole population and the ‘per 
protocol’ population, i.e. participants who completed all three interviews, was published 
(Comiskey, et al. 2009). In 2010 six further papers reporting on the data were 
published including analyses of the effects of treatment settings, treatment pathways 
and use of additional drugs on treatment outcomes for opiate users. 
 
 
5.2 General description, availability and quality assurance 
 
5.2.1 Strategy/policy 
 
HSE targets for drug-related services in 2013  
Each year the HSE publishes a ‘national service plan’ (NSP). The plan sets out the 
type and volume of services to be delivered during the year. In 2013, according to the 
most recent NSP (Health Service Executive 2013),  service activity volumes in relation 
to drug-related treatment are expected to be similar to last year’s targets (Table 
5.2.1.1).  
 
Table 5.2.1.1 HSE service activity volumes in relation to drug-related treatment, 2012–2013 
 Expected 
activity 2012 
Projected 
outturn 2012 
Expected 
activity 2013 
Methadone treatment 
Number of clients in methadone treatment (outside 
prisons) (monthly target) 
8,640 
 
8,855  
 
8,650 
 
Substance misuse 
Number of substance misusers (aged over 18 years) for 
whom treatment has commenced within one calendar 
month following assessment. 
1,260 
 
1,025  
 
1,260 
 
Source :(Health Service Executive 2013), p. 24 
 
NSP 2013 is a much shorter document than previous years’ plans (Health Service 
Executive 2012b). Deliverables, including priorities, key actions and measures, are not 
included. Moreover, there is no discussion of the past year’s performance vis-à-vis that 
expected in the coming year, for instance, how the reported 19% shortfall in the 
delivery of treatment to substance misusers over the age of 18 within one month of 
assessment in 2012 will be corrected in 2013. 
 
The HSE’s drug-related services may be expected to be influenced by the two broader 
challenges outlined in NSP 2013. First, in November 2012 the Minister for Health 
published Future health, the framework for ‘the most radical reform of our health 
services in the history of the state’ (Department of Health 2012b). The core of this 
reform is a single-tier health service, supported by universal health insurance (UHI). 
The government is seeking innovative ways to deliver care and in particular integrated 
care pathways, to be achieved under the most stringent fiscal constraints experienced 
for decades.  
 
Thus, the HSE will proceed with ‘business-as-usual’ in 2013, while also implementing 
structural reforms including changes in the way hospital services are funded and 
managed, disaggregating childcare services from the HSE and establishing a child and 
family support agency, setting up a new directorate structure, establishing a patient 
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safety agency, and ensuring that social care services including mental health, disability 
and primary care are fit for purpose.  
 
A second key priority for drug-related treatment services will be to ensure that financial 
and service performance is reported on and managed in a timely and proactive 
manner. Building on the work of recent years, the 2013 accountability framework is 
intended to ensure that performance is measured against agreed plans that specify 
targets for access, service quality and volumes. These plans will be monitored through 
a range of scorecard metrics. Service managers will be held to account and under-
performance will be addressed. 
 
The financial framework is intended to ensure that all areas of the health care system 
have budgets that are achievable, while also delivering the savings necessary. For the 
first time, the allocations outlined in the plan are based on the projected spend rather 
than on historic budgets, with a view to ensuring sustainable budgets.  
 
Proposed regulatory framework for buprenorphine/naloxone products in Ireland 
The drug suboxone, a combination of buprenorphine and naloxone, was licensed for 
use in 2006 in Ireland as an alternative to methadone for opiate dependency.  In 2007 
the then Department of Health and Children set up an expert group to examine the 
regulatory framework for products containing buprenorphine/naloxone and 
buprenorphine-only. The expert group considered a number of relevant documents, 
including an evaluation of a feasibility study on the use of suboxone in Ireland 
(Fitzgerald 2011) (for more detail, see Section 5.2.2). The report containing the expert 
group’s recommendations was made available this year (Expert Group on the 
Regulatory Framework 2011).  The terms of reference of the group are outlined below, 
with a summary of its deliberations and associated recommendations. 
 
1. In the context of the product authorisation for suboxone issued by the European 
Medicines Agency, to consider and make a recommendation as to whether the general 
regulation of relevant professions provides a sufficient regulatory framework for the 
prescription and dispensing of buprenorphine/ naloxone, or buprenorphine-only 
products in Ireland. 
 
The group concluded that the regulations and guidelines for the prescribing and 
dispensing of methadone can also apply to buprenorphine/naloxone, or buprenorphine-
only products. 
 
2. To consider and make recommendations if appropriate as to which if any elements 
of the methadone protocol should apply to suboxone, and if so how they could apply in 
practical terms.   
 
The group concluded that the Methadone Protocol Scheme could also apply to the 
prescribing and dispensing of buprenorphine/naloxone or buprenorphine-only products, 
and that the details of patients receiving these products should be recorded on the 
CTL.  Other general recommendations included having consistent and uniform 
guidelines for prescribing and dispensing these products and that the current 
methadone prescription form should be adapted for them, the need for co-ordinated 
multi-disciplinary training, and a system of clinical governance and audit for GPs and 
pharmacies.   
 
3. To consider and make recommendations if appropriate as to whether and if so how 
suboxone should be made available to particular client groups and/or settings in an 
Irish context, taking into account the work done by the National Advisory Committee on 
Drugs (NACD)  and taking into account the cost of this treatment.  
 
The group concluded that methadone is the drug of first choice for treating opiate 
dependency, but that buprenorphine/naloxone may be appropriate for some patient 
cohorts in certain circumstances, as follows: 
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 patients already receiving treatment with buprenorphine/naloxone; 
 patients with a specific medical condition where methadone is contraindicated, for 
example prolonged QT interval; 
 patients who have never been prescribed methadone before, especially young 
patients, where detoxification is a primary goal of treatment; 
 patients whose main problem drug is codeine or another pharmaceutical opioid; or 
 patients whom the prescriber believes to be stable for at least six months, 
particularly in regard to employment or education, and committed to compliance 
with the treatment. 
 
After individual patient risk assessment, less-than-daily dosing can be considered, with 
frequency down to every second day or even to three times per week after a 
satisfactory level of stabilisation. The total amount of suboxone given on any one day 
must not exceed the maximum of 24 mg authorised by the European Medicines 
Agency.   
 
The group stated that economic factors involved were outside the scope of their 
deliberations but were relevant to the establishment of a buprenorphine/naloxone 
treatment protocol and should be considered.  These factors include: 
 findings of the economic evaluation done by the National Centre of 
Pharmacoeconomics in 2007,  which found that suboxone and buprenorphine-only 
could not be considered cost effective when compared to methadone in clinics or in 
the community (National Centre for Pharmacoeconomics 2007); 
 generic pricing discussions between the HSE and the manufacturer; 
 HSE clinics which have their own budgets and consistency of treatment; and 
 contractual implications in relation to prescribing and dispensing for both GPs and 
pharmacists. 
 
The group advised that the recommendations be reviewed within two years of the date 
on which they were given to the Minister, to allow for new research and evidence to be 
taken into account. 
 
4. To consider and make recommendations if appropriate as to whether and if so in 
what way buprenorphine-only products should be available in Ireland.   
 
The group was not aware of any buprenorphine-only products being marketed in 
Ireland to treat opiate dependence. They acknowledged that, while not authorised in 
Ireland, buprenorphine-only products may be prescribed for pregnant women in certain 
circumstances, and with appropriate advice and warning. They advised that if a 
buprenorphine-only product were to be prescribed and dispensed in Ireland, it should 
be done with extreme caution owing to the high risk of diversion and potential for use 
by injection.    
 
5. To consider any legal advices received in relation to the above matters. 
 
After taking legal advice, the group decided that if buprenorphine/naloxone or 
buprenorphine-only products are to be used in Ireland then the appropriate changes 
will have to be made to the misuse of drugs legislation and the regulations for the 
prescription and supply of methadone.   
 
 
5.2.2 Treatment systems 
Suboxone feasibility study evaluated 
In June 2013 the Department of Health released the results of an evaluation of the 
suboxone feasibility study which started in June 2009 (Fitzgerald 2011). The evaluation 
was carried out between October 2010 and February 2011.  The objectives of the 
evaluation were to: 
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 evaluate how patients were selected for participation and how they progressed 
through the study, 
 examine how the prescribing and dispensing of suboxone operated in an Irish 
context, 
 consider the practical operation of the feasibility study, and 
 identify the core elements of the regulatory framework needed for the safe use of 
suboxone in Ireland. 
 
A variety of methods were used to evaluate the feasibility study: analysis of quantitative 
and clinical records, semi-structured interviews, and surveys.  Not all patients who had 
started on suboxone could be contacted for consent to be included in the evaluation 
and not all patient records were available to be audited.  Other stakeholder involvement 
consisted of eight semi-structured interviews with prescribers; 13 semi-structured 
telephone interviews with pharmacists/dispensers; 36 responses to a semi-structured 
survey of patients (completed either on-line, on paper or over the telephone); two face-
to-face interviews with patients; and two written submissions from patients.  The clinical 
notes and dispensing records for 41 patients were reviewed.  There were five key 
informant interviews.  
 
A total of 139 patients registered as having received suboxone between 2006 and 2011 
were eligible to be included in the evaluation. Also included were 11 prescribers based 
in the then Drug Treatment Centre Board (DTCB), seven prescribing GPs based in 
other clinics or practices, and 50 dispensers, the majority (78%) of which were 
community pharmacies. Table 5.2.2.1 outlines the characteristics of those included in 
the evaluation and the reason for exit from treatment. 
 
Table 5.2.2.1   Characteristics and treatment statistics of patients included in suboxone database, 
2006–2011 
Total number of eligible patients N = 139 
Males 91 (66%) 
Females 48 (34%) 
  
Patients previously treated with methadone  76 (55%) 
  
Total number of treatment episodes N = 149* 
Age in years of patients starting each treatment episode  
Under 18 6 (4%) 
18 to 25 31 (21%) 
26 to 35 60 (40%) 
36 to 45  39 (26%) 
46 and over 13 (9%) 
  
Type of treatment at start of episode  
Detoxification 27 (18%) 
Opiate maintenance 122 (82%) 
  
Patient outcomes†  
Still in suboxone treatment on 31 Jan 2011 63 (42%) 
Exits from treatment (or from treatment episode) 86 (58%) 
  
Reason for exit N = 86 
No contact 29 (34%) 
Transfer to other opioid substitute 23 (27%) 
Treatment successfully completed 19 (22%) 
Treatment failure 7 (8%) 
Gone abroad  5 (6%) 
Deceased‡  1 (1%) 
Other 2 (2%) 
Source: Adapted from (Fitzgerald 2011), pp. 9, 11 and 13 
* 10 patients were in suboxone treatment on two separate occasions, which accounts for the 149 treatment episodes. 
† Based on review of 41 charts/records. 
‡ The death was unrelated to suboxone treatment. 
 
Process and limitations of the study 
The author noted several issues that may have influenced the results and 
generalisability of the evaluation.  She was unable to contact a number of patients who 
  64 
had received suboxone but who were no longer in contact with the treatment services.  
Not all who consented to be included in the evaluation could be contacted 
subsequently. Also, the evaluation only included the opinions of those who had been 
involved in the original feasibility study, who therefore might already have been 
positively disposed to the use of suboxone.   
 
Rationale for commencing suboxone 
The main reasons for prescribing suboxone, as recorded in the clinical notes or 
dispensing records for 41 patients, were that the patient had a low level of heroin 
dependence, either having never injected,   rarely injected or only a short history of 
heroin use (16, 39%), or that the patient had requested suboxone, or did not want 
methadone (10, 24%) (Table 5.2.2.2). The survey of patients showed that the majority 
(79%) felt that suboxone was the best option for them after discussions with their 
doctor. Of 22 patients previously prescribed methadone, 45% had experienced side-
effects. Of 11 who had never been prescribed methadone, 55% wanted detoxification 
(i.e. to be substance free) rather than to stay on opiate substitution treatment.  
 
Table 5.2.2.2   Reasons for suboxone prescription recorded in clinical notes or reported by 
prescriber, 2006–2011 
Records reviewed N = 41 
Main drug of dependence  
Heroin (injected) 24 (58%) 
Heroin (smoked) 10 (24%) 
Codeine 4 (10%) 
  
Selection of patients / reason for suboxone prescription  
Low level of heroin dependence  16 
Patient requested it, or did not want methadone 10 
Treatment for detoxification  6 
Previous failed methadone treatment or particular difficulties 
with methadone 5 
Stable 5 
Medical need 4 
Codeine dependent / oxycodone dependent 4 / 1 
Previous buprenorphine treatment 3 
Unclear 2 
Source: Adapted from (Fitzgerald 2011), pp. 9, 11 and 13 
 
Patient experience of suboxone 
The majority of the 36 patients who participated in the evaluation were very positive 
about their experience of suboxone, and many were still on the treatment.  They 
reported benefits such as ‘feeling like themselves again, reduced cravings’ and 
returning to a more normal life.  On the downside, several commented on the 
difficulties of having to be in withdrawal in the early stages of suboxone treatment, 
which may be a barrier for some individuals.  
 
Prescribing and dispensing 
The evaluation found that there were three different protocols on the use of suboxone 
in circulation at the time of the feasibility study. There was an informal system of 
training and support for doctors who participated in the study.  The dosage and 
initiation regimes used ranged from 2 mg to 26 mg daily. It was noted that suboxone is 
licensed only for provision of doses up to 24 mg in any one day, and that the possibility 
of less-than-daily dosing was mentioned in only one of the protocols, underlining the 
need for clinicians to share their experience in this area. 
 
Issues were highlighted with regard to the prescription form for suboxone, in particular 
when the prescription did not comply with the requirements of the Misuse of Drugs Act.  
Problems reported regarding the availability of 2 mg suboxone tablets caused some 
difficulties for pharmacists.  Patients were supplied with a variety of information 
documents and/or verbal advice on starting suboxone. However, some of the patients 
reported that they had forgotten what they had been told when first prescribed 
suboxone, highlighting the need for standardised and accessible written information. 
 
  65 
Costs 
The evaluation discussed the 2007 report undertaken by the National Centre for 
Pharmacoeconomics (NCPE) for the expert group (National Centre for 
Pharmacoeconomics 2007).The NCPE report concluded that on current evidence 
suboxone could not be considered cost effective for patients attending HSE clinics 
unless opiate abstention rates were at least 10% higher with suboxone than with 
methadone. The evaluation noted that the low cost of methadone made comparing 
costs with any other treatment difficult.  It was felt that societal costs had not been 
factored into the NCPE report and that, although more expensive than methadone, 
providing suboxone to certain patients for whom there is a clear rationale would have 
economic and societal benefits. 
 
Regulating provision 
The regulatory mechanisms discussed were: 
 having a cap on the number of patients who can be prescribed suboxone, 
 having a fixed budget cap (rather than a cap on patients), 
 restricting prescribing to certain groups of prescribers and/or patients, and 
 negotiation with the relevant pharmaceutical company on price. 
 
There was no clear consensus among prescribers or key informants as to what was the 
most appropriate mechanism to regulate provision, as each mechanism had both 
positive and negative aspects.   
 
Conclusions and recommendations 
The evaluation concluded that ‘suboxone has been used in this feasibility study with a 
wide range of patient groups, for whom it has the potential to be beneficial and it 
appears to offer a number of advantages over methadone’ (p.44). In considering future 
safe provision of suboxone in Ireland, the author made a number of recommendations, 
which are summarised below:  
 
1. The Suboxone Expert Group should discuss and agree interim criteria determining 
eligibility for suboxone treatment.  
2. If suboxone prescribing is restricted to certain groups/subjected to certain criteria in 
future, audit and reporting processes should be established to add weight to the 
criteria and enable any prescribing patterns that are unusual or fall outside the 
criteria to be identified and explored. 
3. National guidelines on the use of suboxone across all prescribing and dispensing 
settings should be developed.  
4. Standard patient information resources should be used across all settings. 
5. Prescriptions for suboxone should be clear and unambiguous.   
6. The system of remuneration for suboxone in future should be incorporated into 
remuneration systems for opioid treatment services and should be clearly 
communicated to prescribers and dispensers (including any future prescribers and 
dispensers). 
7. Clarification of the ethical and legal position of pharmacists and clinics in relation to 
the various options for coping with stock shortages should be provided.  
Professional guidance should be prepared in relation to the appropriate 
management of such situations. 
8. Arrangements should be made for the appropriate management of suboxone stock 
which may be left in pharmacies when they no longer have any patients on the 
drug. 
9. Suboxone should be made available through more than one wholesaler to reduce 
the likelihood of stock shortages. 
10. Suboxone initiation and prescribing should only be undertaken by those with 
suitable expertise and training.   
11. Suboxone dispensing should be restricted to those with suitable expertise and 
training.  
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12. A mechanism is needed that allows prescribers to share and discuss their 
experiences with suboxone (and in the management of opioid dependence in 
general, including methadone).   
13. Engagement should take place with the pharmaceutical company marketing 
suboxone in order to consider price, budget projections and shared-risk 
arrangements for any future use of suboxone. 
14. Any future consideration of the cost-effectiveness of suboxone should take into 
account the full range of potential benefits from successful treatment of opioid 
dependence, including reduced social costs. 
 
Availability of detoxification beds 
As reported by the Department of Health in July 2013 (Department of Health 2013b), 
144 beds are available nationally for detoxification.  They are distributed across a 
range of services. There are 23 beds in two medical detoxification units, with an 
average waiting time of between one and two months. There are 117 beds available for 
community-based residential treatment, and the average waiting time varies – six 
centres have average waiting times of zero to less than seven days, while waiting lists 
in the others vary from two to four weeks. Only four beds are available for adolescent 
detoxification treatment, at the Aislinn Addiction Centre. The average waiting time for 
these beds is four to five weeks. 
 
 
5.2.2.1 Organisation and quality assurance 
 
Development of clinical guidelines for opiate treatment 
The most recent update on the implementation of the National Drugs Strategy (interim) 
2009–2016 (Department of Community 2009) from the Department of Health states 
that the new national clinical guidelines for opioid treatment are expected to be 
finalised in 2013 (Department of Health 2013b) (Health Research Board 2012).  They 
will be the first national guidelines for both HSE clinics and general practice and will 
replace the current ICGP guidelines (Irish College of General Practitioners 2008).  The 
guidelines are expected to cover the following areas:  
 clinical governance, 
 essential elements of treatment provision, 
 psychosocial components of treatment, 
 pharmacological interventions, 
 health considerations, and 
 specific treatment situations and populations. 
 
Guidelines for prescribing methadone in pregnancy 
New clinical practice guidelines on safe and effective prescribing of methadone for 
pregnant women in maternity hospitals were jointly published in April 2013 by the 
Institute of Obstetricians and Gynaecologists and the HSE (Institute of Obstetricians 
and Gynaecologists  and Health Service Executive 2013). Based on an earlier 
document used by the three Dublin maternity hospitals, these new guidelines were 
developed after a wide-ranging review of the literature and consultation with key 
stakeholders.   
 
The document recommends that all pregnant women who are problem opiate users 
should attend a specialist or high-risk antenatal clinic.  If this is not possible, these 
women should attend the same clinic throughout their pregnancy to ensure continuity 
of care. The guidelines work through various common clinical scenarios and issues 
around admission and discharge. They are designed to guide clinical judgment, not to 
replace it.   
 
Clinical Scenario 1: Pregnant women admitted and known from medical record or 
verbal history to be on prescribed methadone 
 Their methadone provider should be contacted to confirm details.  The hospital 
medical team should ensure that methadone is prescribed in a timely manner. 
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Clinical Scenario 2: Pregnant women admitted with a take–away methadone supply 
 Women should be advised not to bring supplies of take-away methadone into 
hospital. If they do, the methadone must be sent to the pharmacy to be destroyed. 
 
Clinical Scenario 3: Pregnant women admitted to hospital self-reporting heroin use but 
not registered with the addiction services or a prescribing GP 
 These women need to be assessed and treated in a timely manner, given that 
opiate withdrawal carries the risk of pre-term delivery and foetal death.  It is 
advisable to seek guidance from the local addiction services and also to confirm 
that the woman is opiate dependent.  The management of initiation of any 
methadone treatment should be closely monitored. 
Clinical Scenario 4: Pregnant women admitted looking for a prescribed dose of 
methadone out of hours and known to be on prescribed methadone from medical 
record or verbal history 
 As methadone cannot be administered on an out-patient basis, the woman must be 
admitted, and then up to half her current dose prescribed. 
 
Intoxicated pregnant women  
 Because of the risk of overdose, methadone must not be dispensed to a woman 
who may be intoxicated until she has been medically assessed. 
 
Vomiting in pregnant women on methadone-maintenance treatment 
 Vomiting may not be related to the methadone, so other possible causes should be 
investigated, e.g. hyperemesis gravidarum.  Depending on the timelines and 
amount vomited, a proportion of, or the entire dose, may be re-administered. 
 
Discharge of methadone-maintained women 
 All details of the woman’s methadone prescription should be sent to the prescriber 
in the community (either clinic or GP).  Women should not be discharged with 
supplies of methadone from hospital stock or with a prescription for methadone or 
benzodiazepines.  
 
Peripartum pain management 
 Women on methadone treatment should be offered, if required, the same pain relief 
options as other women for labour or post-partum pain, as maintenance doses of 
methadone do not provide adequate pain relief.  They should be reassured that 
there is no evidence that the administration of opiates for pain relief leads to 
relapse, but they may require higher doses to provide effective relief. 
 
Breastfeeding 
 Women who are stable on methadone and have no contra-indications should be 
encouraged to breastfeed if they wish.  However, if the woman is on other 
medication, e.g. benzodiazepines, advice should be sought. 
 
Methadone dosing in pregnancy 
 This can be a difficult area to manage, particularly because of the complexities of 
pregnancy-associated pharmacokinetic changes, which have been shown to 
reduce the concentration of methadone in the blood. Some women may wish to 
reduce their dose in order to reduce the risk of neonatal abstinence syndrome in 
their infant. However, there is no evidence to support this theory.  Each woman’s 
dose, her tolerance and its effectiveness should be monitored and titrated closely 
during the pregnancy.  Because of the risk of relapse and the subsequent risk to 
the foetus, detoxification from methadone is not recommended during pregnancy. 
 
The guidelines also make eight general recommendations: 
1. Methadone maintenance treatment is the treatment of choice for opioid-dependent 
pregnant women. In adequate doses, methadone provides stability for the woman 
during pregnancy, avoiding repeated cycles of intoxication and withdrawal that may 
adversely affect the foetus.  
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2. Withdrawal from opioids can cause foetal death and preterm delivery. It is important 
that women who report illicit opiate use are assessed and treated in a timely 
manner.  
3. Clear communication between maternity hospitals and local addiction services is 
required, particularly in relation to methadone doses and admission/discharge of 
methadone-maintained women.  
4. Initiation of methadone may be required in a maternity hospital to avoid obstetric 
complications of opioid withdrawal. Careful initiation is required, as the highest risk 
of overdose mortality is in the first two weeks on methadone treatment.  
5. A validated scoring tool should be used to assess signs of opioid withdrawal in 
opioid-dependent pregnant women.  
6. Opioid-dependent pregnant women are at risk of under-treatment of peripartum pain.  
7. Breastfeeding should be encouraged in women who are stable on methadone 
maintenance treatment unless there are other medical contraindications.  
8. The maternal methadone dose should be individually adjusted to control maternal 
craving or withdrawal symptoms.  
 
For a more in-depth analysis of methadone prescribing and dosing for pregnant women 
in Ireland, see a study (Cleary, et al. 2013) described in Section 7.4 of this National 
Report.  
 
QuADS Support Project 
The Quality in Drugs and Alcohol Services (QuADS) Support Project, run by the Ana 
Liffey Drug Project and supported by the HSE, now has 98 organisations enrolled 
(Department of Health 2013b).  The project provides support related to capacity 
building, information sharing and other issues.  Services involved in this project have 
access to 78 different policies, tools and templates for quality standards in, for 
example, governance, human resources, service provision, service user involvement 
and care and case management (Ana Liffey Drug Project 2012). A pilot system has 
also recently been developed to enable services to peer review how consistent they 
are with the QuADS system.  
 
Training standards for the addiction services 
Action 47 of the National Drugs Strategy (interim) 2009–2016 (Department of 
Community 2009)   calls for the development of national training standards for the 
addiction services. This year the Department of Health issued an update on progress in 
implementing the NDS, including this action (Department of Health 2013b).  It was 
reported that a survey was carried out which showed the different types of training 
being delivered in this sector: 
 national drugs rehabilitation framework training, 
 children and family interventions, 
 specific drug awareness, 
 psychosocial interventions, and 
 specific high risk areas related to addiction. 
 
Most of the training provided is aimed at a foundation or intermediate level and a gap 
has been highlighted in the provision of more advanced training requirements.   The 
National Addiction Training 
Programme (NATP) is consulting with various third-level educational institutions in 
order to develop new, accredited programmes to fill this requirement. 
 
Going forward, the NATP will work with the National Drug Rehabilitation 
Implementation Committee (NDRIC) to develop national competencies, and then the 
standards for training modules for those competencies.  The HSE is adopting the UK 
system, the DANOS/Skills for Health, as the standard for training. 
 
Experience of methadone treatment 
Two recent qualitative studies in Ireland looked at the experience of (i) services users 
in methadone treatment and (ii) methadone prescribers.  Overall, service users 
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reported that they were satisfied with receiving methadone treatment in general 
practice; many of the respondents had been attending the same doctor for more than 
five years (Latham 2012).  The study found that they valued being treated with respect 
and being listened to. In the second study (Van Hout and Bingham 2013), participating 
doctors prescribing methadone (in both clinics and general practice) felt that 
methadone treatment had helped to reduce harm for their clients, especially in relation 
to injecting drug use, risk of infection, and overdose. It also helped to improve other 
aspects of a client’s life such as relationships and employment. Despite this, it was 
reported that respondents noted some problem areas such as the restrictive nature of 
daily doses on clients’ freedom, reducing doses and detoxification.  The study 
recommendations included expansion of referrals to primary care, improving 
interagency community psychological and detoxification supports, consideration of 
other substitution medication and appropriate treatment for poly-substance use.    
 
5.2.2.2 Availability and diversification of treatment 
 
Brief interventions to reduce problem alcohol use in patients on methadone 
treatment 
The Alcohol Use Disorders Identification Test (AUDIT) is a tool developed by the World 
Health Organization (WHO) to screen for harmful or hazardous drinking.  The AUDIT–
C is a modified version of this tool.  The scores range from zero to 20, a higher score 
indicating more problem use.  WHO also developed brief interventions (BI) to be used 
in tandem with the AUDIT.  In Ireland, it was estimated that 35% of patients attending 
primary care for methadone treatment had problem alcohol use. 
 
An Irish study (Darker, et al. 2012a) was designed as an implementation study in order 
to assess whether BIs were effective in reducing harmful or hazardous alcohol use by 
patients on methadone treatment. It addressed two specific questions:  
 
1. Was it feasible for professionals working in the Dublin methadone clinics to screen 
patients and deliver BIs to patients on methadone treatment? 
2. Was it feasible for professionals working in the Dublin methadone clinics to 
incorporate screening patients and delivering BIs to patients on methadone 
treatment in their typical clinical workload? 
 
Three of the largest methadone clinics in Dublin were chosen and all patients (N=863) 
were eligible to participate in the study. However, those patients who were 
experiencing an acute psychotic episode, those not attending at the time of the 
screening or those who had an AUDIT score indicating alcohol dependence, were 
excluded from the study.  In all, 48 clinical staff (nurses, GPs, counsellors, social 
workers and outreach workers) were trained in using the WHO BI protocols.   
 
A total of 710 patients were screened at baseline with the AUDIT, and those whose 
scores indicated hazardous or harmful drinking (160, 23%) recieved a BI immediately 
after screening. There was good follow-up for re-screening and 91% of these 160 
patients were re-screened three months later (by a different professional) using the 
AUDIT–C.  The study ran from January to November 2009. 
 
The authors found that there was a statistically signficant reduction in AUDIT–C scores 
between the first screening (and BI) and the re-screening.  Of note, there was a 
statistically significant decrease in the proporpotion of men who had a positive AUDIT–
C score  at the re-screening but this decrease was not observed for women.  The 
authors stated that this could be the result of the study being under-powered as only 46 
women received a BI at the baseline screening.   
 
The only factors to predict alcohol consumption at baseline screening were gender and 
length of time of treatment.  The only factor to predict AUDIT–C scores at re-screening 
was AUDIT–C scores at baseline screening.   
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The authors concluded that this study was the first evidence that a BI delivered by a 
clinician can be incorporated into the workload of methadone clinics and can reduce 
alcohol consumption in patients receiving methadone treatment.  This is important 
given the high proportion of methadone patients (23%) who reported hazardous or 
harmful drinking in this study, and considering the high prevalance of hepatitis C 
among problem drug users in Ireland.   
 
Psychotherapeutic interventions by GPs providing methadone treatment to 
patients in primary care 
A study was carried out, using a grounded theory approach, to examine how GPs 
provided psychotherapeutic interventions10 to their patients who receive methadone 
treatment in primary care in Ireland (Kenny and O'Carroll 2012). 
 
The researchers used a theoretical sampling strategy where initially three GPs known 
to have a lot of experience in providing methadone treatment were selected for 
interview.  Further participants were selected to address the emerging themes arising 
from those initial interviews.  In all, 13 participants were interviewed: seven GPs who 
prescribed methadone in primary care, four non-prescribing professionals (practice 
nurses and counsellors) and two GPs who did not prescribe methadone but who used 
psychotherapeutic interventions. 
 
Seven main themes were identified in the research.  There was a lack of standard 
assessment procedures or protocols for providing this care, and some GPs had 
developed their own individual approaches to such treatment options.  There was a 
wide variation in belief in and knowledge of the value of psychotherapeutic 
interventions, ranging from the belief that it was essential to the view that it was 
optional.  GPs had difficulties accessing high-quality psychotherapeutic services as 
they had doubts about the standards and quality of some of these services.  Unlike 
other medical services, in general GPs did not follow up on the referral outcomes of 
psychotherapeutic services their patients had attended.  Participants experienced 
difficulties accessing psychotherapeutic resources provided through formal structures 
once the patient was discharged to the community.  GPs adopted a continuous care 
model and holistic approach to their patients on methadone. There was evidence that 
the GPs who participated in the study sought to subtly move their patients towards 
abstinence where appropriate. 
 
The authors noted that while the grounded theory method is well established, the study 
focused on one particular area of GP care, which only a minority of GPs provided and 
many of those were based in the greater Dublin area, and so urged caution about the 
generalisability of the study. 
 
The authors stated that while there is much research into the use of psychotherapeutic 
interventions with methadone treatment, unfortunately the evidence regarding its 
usefulness with this client group is not conclusive.  They believed that the lack of 
structured approaches to these methods, including the lack of a guiding framework, 
hinders the development of an evidence base in Ireland to inform and improve practice. 
 
Counselling therapy in cocaine-using methadone-maintained patients 
A study was designed to examine why cocaine-using methadone-maintained patients 
did not attend cognitive behavioural coping skills (CBCS) therapy that was provided for 
them (Darker, et al. 2012b).  The authors undertook this study because they had 
previously had to abandon a randomised controlled trial looking at the effectiveness of 
CBCS therapy among cocaine-using methadone-maintained patients owing to lack of 
attendance (Darker, et al. 2012a).     
 
                                               
10
 Psychotherapeutic interventions refer to psychological techniques designed to establish a therapeutic relationship 
with the patient and to encourage communication of conflicts and self-insight. The goal is to bring relief to symptoms, 
changes in behaviour leading to improved social and vocational functioning, and personal growth. 
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All 45 participants in the original study were contacted and 37 agreed to be interviewed 
and reasons for attending and not attending were explored.  Motivational 
inconsistencies (e.g. ‘loss of hope to change right now’, ‘no good reason to stop using 
cocaine’, ‘not motivated’) were the main reasons for non-attendance.  Conflict with staff 
did not emerge as a major issue for non-attendance.  However, a good relationship 
with staff was among the main reasons for attending cognitive behaviour therapy 
(CBT).   
 
The authors concluded that it is still undetermined as to whether CBCS therapy is 
useful in reducing  cocaine use by those in methadone treatment if they themselves are 
not motivated to stop using cocaine.  They suggested that it may require a more 
stepped approach, including such interventions as motivational interviewing, in order to 
address this issue. 
 
Group psychological intervention (GPI) for psychosis with cannabis dependence 
There are few proven effective interventions for psychotic patients who also have a 
substance dependency. Among those diagnosed with schizophrenia, cannabis is the 
most common substance misused. Research points to the fact that cannabis use can 
be a causal factor in both the development of psychotic illness and the severity and 
duration of symptoms. Few studies have identified interventions that reduce cannabis 
use and improve clinical outcomes in this population.  
 
In light of the limited evidence on effective interventions, researchers in Ireland carried 
out a randomised controlled trial (RCT) comparing a group-based psychological 
intervention (GPI) with standard care among patients in the early course of psychotic 
illness who were also cannabis dependent (Madigan, et al. 2013). The primary 
outcome measure was the extent of cannabis misuse and the secondary outcome 
measures were positive and negative symptoms, depressive symptoms, global 
functioning, insight, attitude to treatment and quality of life.  
 
Participants were recruited from three different sites in Ireland: the DETECT service in 
South County Dublin/North Wicklow, the then Drug Treatment Centre Board in Dublin 
city centre, and the Cavan–Monaghan Mental Health Service.  Participants had either 
experienced their first psychotic episode or were within three years of onset of non-
affective or affective psychosis.  
 
Participants were randomly assigned (by computer) to one of two groups.  One group 
received a GPI that integrated cognitive behavioural therapy with motivational 
interviewing, in addition to standard care.  The other group, the treatment as usual 
(TAU) group, received standard care but not the additional GPI.  A clinical nurse 
specialist used a range of standardised measures and questionnaires to rate the 
outcome measures at follow-up. Participants were followed up at three months and at 
one year.   
 
Of the 88 participants recruited, 59 were randomly allocated to the GPI group and 29 
were randomly allocated to the TAU group.  Data were analysed on an intention-to-
treat basis.  Mean lifetime use of cannabis was 9.6 years in the GPI group and 7.5 
years in the TAU group.  Other baseline demographic characteristics are shown in 
Table 5.2.2.2.1.  
 
 
 
 
 
 
 
 
 
 
  72 
Table 5.2.2.2.1   Baseline demographic characteristics of participants in RCT of group 
psychological intervention (GPI) for psychosis with comorbid cannabis dependence 
 GPI TAU 
Mean age (years)  27.6 28.2 
Mean duration of untreated psychosis 
(months) 
14.4 12.2 
 n (%) n (%) 
Gender     
Male 46 (78) 23 (79) 
Female 13 (22) 6 (21) 
     
Education     
Primary 3 (5) 0 (0) 
Secondary 26 (44) 11 (38) 
Third level 24 (41) 15 (52) 
Masters/professional 6 (10) 3 (10) 
Employed 17 (29) 10 (35) 
     
Diagnosis     
Schizophrenia 25 (42) 13 (44) 
Schizophreniform disorder 6 (10) 3 (10) 
Bipolar disorder 10 (19) 4 (16) 
Schizoaffective disorder 1 (2) 0 (0) 
Delusional disorder 2 (3) 3 (10) 
Brief psychotic disorder 3 (5) 3 (10) 
Major depressive disorder 5 (9) 1 (3) 
Substance-induced disorder 3 (5) 2 (7) 
Psychosis not otherwise specified 4 (7) 0 (0) 
Source: Adapted from (Madigan, et al. 2013) 
 
At three months and one year no differences were found between the two groups in the 
primary outcome measure – frequency of cannabis misuse. There were no differences 
between the two groups in any of the secondary outcome measures, with the exception 
of subjective quality of life scores, which were significantly higher in the GPI group at 
both three months and one year. This is noteworthy as research shows that a reduction 
in negative outlook is an important outcome of treatment for people with schizophrenia.    
 
The authors stated that this was the first RCT to look at GPIs to reduce cannabis use 
among those in the early stages of a psychotic illness. The study found that the 
intervention had no effect on reducing cannabis use. The authors suggested that the 
intervention may have been given for too short a period (18 weeks) to have sufficient 
impact on the outcome measures. They also pointed out that they recruited only 88 
participants from 230 patients referred and that they did not compare relapse rates 
between the two groups because of variations in admission procedures in the 
participating centres. The authors recommended that more trials involving 
psychological interventions be carried out with this client group.   
 
MQI annual review 2011  
The Merchants Quay Ireland (MQI) annual review for 2011 highlighted some important 
new initiatives at MQI including the Athlone Open Door Centre, the new 10-bed unit at 
St Francis Farm Detox facility, and the start of renovation works at the Riverbank 
Centre (Merchants Quay Ireland 2012). 
 
The outreach worker for the New Communities Support Service provided one-to-one 
support to 112 service users, 53% of whom were from Poland. The Easy Access 
Education for Homeless People programme engaged with 45 clients during 2011: 34 
male and 11 female. 
 
MQI’s needle-exchange service recorded approximately 21,819 client visits in 2011. 
The report highlighted a continuing high level of demand for homeless services: 58,858 
meals were provided, with an additional 29,000 meals provided by the Extended Day 
Service in association with Focus Ireland. The Primary Health Care Services provided 
3,331 interventions in 2011. 
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MQI continued to provide the national prison-based addiction counselling service to 12 
prisons in 2011: 10,293 individual counselling sessions and 2,830 group attendances 
were recorded during the year. This service was provided by 26 counsellors. The 
service also co-ordinated an eight-week inter-agency programme at the medical unit in 
Mountjoy Prison for groups of nine clients at a time. Seven groups, totalling 63 clients, 
participated in 2011, of whom only four did not complete the programme.   
 
MQI in association with the Midland Regional Drugs Task Force and the HSE 
administered the Midlands Family Support and Community Harm Reduction Service, 
providing outreach and working with families of those actively using drugs in that task 
force region. The family support service provided 140 group sessions and 505 
individual sessions, in addition to 723 supportive phone calls. The harm reduction 
service provided needle-exchange services and engaged in 4,000 one-to-one client 
interventions during 2011. The Midlands Traveller-Specific Drugs Project worked with 
38 clients and engaged in 1,187 support sessions. Athlone Open Door Centre, for 
which MQI assumed operational responsibility in January 2011, recorded 1,415 visits 
and provided 400 meals, with an average of 44 clients per month. 
 
The services offered by MQI and the numbers of people accessing them in 2011 are 
shown below in Table 5.2.2.2.2. 
 
Table 5.2.2.2.2   Services offered by Merchants Quay Ireland in 2011 
Service Type of intervention Activity in 2011 
Needle-exchange and 
health-promotion 
services 
Promotes safer injecting techniques  
HIV and hepatitis prevention 
Safe sex advice 
Information on overdose 
Early referral to drug treatment services 
4,051 used needle-exchange services, of whom 492 
were new clients 
1,220 safer injecting workshops 
Stabilisation services Methadone substitution 
Gateway programme 
18 service users 
795 service visits  
Integration 
programmes 
Access to transitional accommodation 
in Ballymount House 
Leixlip House with Respond Housing 
Association 
3 residents (annual average) 
 
9 admissions, with an average of 5 clients in the house 
for an average tenancy of 5 months  
Training and work 
programmes 
FÁS Community Employment scheme
11
 86 participants 
Of the 35 who completed FÁS placements at MQI, 2 
secured permanent employment, 7 moved to further 
education 
High Park 17-week, drug-free residential 
programme including individual 
counselling, group therapy, educational 
groups, work assignments and 
recreational activities 
50 participants (of whom 4 were admitted for 
detoxification) 
3 clients completed detox  
24 clients completed the full programme 
St Francis Farm Residential programme – reduced from 
a 6-month to a 14-week  programme in 
October 2011, in conjunction with a 
new 4–6-week detox facility on site 
40 participants 
15 clients completed three months or more 
23 clients part-completed the programme 
Source: (Merchants Quay Ireland 2012) 
 
 
5.3 Access to treatment 
 
5.3.1 Characteristics of treated clients (TDI data included) 
A national study of retention in methadone treatment 
The Central Treatment List (CTL) records all patients who enter and exit methadone 
treatment in Ireland in real time.  Basic demographic details, date of entry, date of exit 
and reason for exit are collected.  As retention in methadone treatment is believed to 
be a key indicator of success, a retrospective study was conducted using CTL data in 
order to determine retention rates in methadone maintenance in Ireland (Mullen, et al. 
2012).  
 
                                               
11
 Responsibility for administering the Community Employment Scheme has transferred from FÁS to the Department of 
Social Protection.  
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A retrospective random sample of 1,875 new entries to treatment for 1999, 2001 and 
2003 was requested from the CTL.12  In all, 606 cases had to be excluded as they did 
not meet the criteria (e.g. not new entrants to treatment, incomplete exit details, 
attending a methadone detoxification programme), so 398 cases were included for 
1999, 419 cases for 2001 and 452 cases for 2003, a total of 1,269.  Using a data 
collection instrument which included key factors for retention in treatment, data were 
extracted from the clinical records of those included in the study.  The length of stay in 
treatment at 12 months was calculated and retention at 12 months was calculated 
using logistic regression.   
 
The majority of cases included were male (69%) and the mean age was 26 years. 
Almost a third (29%) had never been in methadone treatment before. Most had a 
history of injecting drug use (74%).  The average daily dose was 58 mg (20.9 SD) and 
there was a significant mean difference in average daily dose by time in treatment.  Six 
out of ten (61%) of those who started treatment were still in continuous treatment at 12 
months. Of those who left treatment before 12 months (n=499), the reasons were 
known for only 40%.  The main reason recorded was treatment failure defined as, for 
example, returning to opiate use, no contact for one month and being asked to leave 
treatment.  Other reasons included cases moving on to a detoxification programme. 
Five people died.   
 
Logistic regression was used to discover what factors may predict retention in 
treatment at 12 months (Table 5.3.1.1).  This showed that being male and also 
attending specialist drug treatment were factors significantly related to leaving drug 
treatment before 12 months.  However, methadone dose was found to be the strongest 
predictor of retention in treatment as those who received less than 60 mg daily were 
three times more likely to leave treatment before 12 months. 
 
Table 5.3.1.1 Factors associated with retention in methadone treatment at 12 months using a 
logistic regression model 
Factor Total* Adjusted odds ratio (95% CI) p-value 
Gender    
Male 870 1.4 (1.0-2.0) 0.03 
Female 399 1  
    
Facility type    
Specialist drug treatment 153 2.0 (1.2-3.5) 0.01 
Community drug treatment 858 1.2 (0.8-1.7) 0.4 
Primary care setting 258 1  
    
Average methadone dose    
59 mg or less 484 3.0 (2.2-4.0) 0.0001 
60 mg or more 489 1  
Source: (Mullen, et al. 2012) 
Initial model included age, injecting drug use. Significant factors were retained in the final model 
* Numbers do not always add up to total because of missing data 
 
The authors stated that the retention rate in treatment of 61% found in this study was 
high and compared well with other research done in Ireland.  Gender, type of treatment 
facility and higher dosage were found to be factors in predicting retention.  In Ireland 
there has been a move towards providing addiction treatment in primary care, the 
effectiveness of which is borne out by this study.  However, one of the limitations of the 
study was that it could not control for certain potential confounders such as 
homelessness or co-morbidities.  Also, clients who are more chaotic tend to be treated 
in specialist drug treatment centres rather than in primary care. Further research is 
needed to determine any additional factors which may influence retention in 
methadone maintenance treatment in Ireland.   
 
Relapse following residential detoxification treatment 
                                               
12
 A minimum sample size of 1,152 was calculated, based on an expected 50% of cases to be retained in treatment, 
95% confidence intervals and an absolute precision of 5 percentage points. 
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Detoxification is the term given to a process whereby an individual is medically weaned 
from a drug, including opiates.  Studies have shown that completion rates for this 
treatment are higher when conducted in a residential service.  Unfortunately there is a 
risk of relapse after detoxification treatment, as with any drug treatment.  The authors 
of this study wished to better understand factors which may be associated with relapse 
following opiate detoxification treatment, especially in the context of relatively little work 
done in Ireland on this issue (Ducray, et al. 2012).   
 
The aim of the study was to identify and describe the context and factors involved in 
relapse after discharge from an inpatient opiate detoxification programme in Ireland. 
The characteristics of the original 144 participants have already been described in a 
previous study (Smyth, B.P., et al. 2005).  Of these, 109 were interviewed 18 to 36 
months after discharge for this current study using the Maudsley Addiction Profile and 
also a modified structured questionnaire based on factors associated with relapse.  Of 
these, 102 reported an episode of relapse into drug use after discharge. 
 
Almost two thirds (71%) relapsed within one week of discharge, most using heroin 
alone on this occasion (87%) and just over half (51%) reporting injecting.  Of those who 
were alone at the time of relapse into heroin use, 65% reported injecting. The different 
factors were categorised as main, major or minor. The main precipitation factors for 
relapse were difficulties with cravings (30%) and low or bad mood (27%).  Ease of 
access to heroin and missing the support of the inpatient service were identified as the 
major precipitation factors. However, most participants (86%) reported two or more 
factors contributing to their relapse. 
 
The authors identified a number of limitations to the study, particularly the retrospective 
assessment of the factors and the associated risk of recall bias, and the use of a static 
model of assessment. The data were collected over ten years ago, before the 
development of more dynamic models of relapse, which include the synergy between 
many different factors including social and environmental. 
 
The authors stated that this study had identified specific identifiable high-risk factors 
associated with relapse in the Irish context, which may assist treatment in Ireland that 
provides detoxification, particularly if there is a move to provide more of this type of 
treatment in the future.  
 
Outcomes of methadone treatment 
A retrospective study was conducted in one of the main methadone clinics in Dublin, 
focusing on patient outcomes (Somers and O'Connor 2012).  One hundred and 
seventeen patients were enrolled in the study: they were first admissions for the year in 
question (2008); were not on anti-retroviral treatment; and were not pregnant. The 
primary outcome measure was the presence of heroin in urine specimens.  Data were 
recorded at baseline, and at three, nine and 15 months after admission.  At three 
months, 37 patients had dropped out, leaving 80.  A higher proportion of those who 
dropped out, as opposed to those who remained at the end of three months, were 
repeat attenders and were homeless (Table 5.3.1.2).  
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Table 5.3.1.2 Comparison of characteristics of patients remaining at, and dropping out before, end 
of month 3 of methadone treatment   
Characteristic Remained at end of month 
3 
Dropped out before end of month 
3 
 N = 80 N = 37 
Mean Age (years) 34.1  31.5 
Methadone dose on day of 
admission  
43.8 mg (SD 26.9) 39.9 mg (SD 29.3) 
Male 63.8% 67.9% 
Dual diagnosis 16.2% 10.8% 
Repeat admission 12.5% 37.8% 
Homeless 21.2% 37.8% 
Heroin positive urine 73.1% 66.7% 
Cocaine positive urine 10.3% 6.1% 
Benzodiazepine positive urine 73.0% 63.6% 
Alcohol positive urine 9.1% 15.2% 
Cannabis positive urine 47.7% 38.9% 
Source: (Somers and O'Connor 2012)   
 
Sixty-six patients remained in the study at the nine-month follow-up. This number 
dropped to 56 at the 15-month follow-up. 
 
The study examined the relationship between heroin and other substances found in 
urinalysis and methadone dose over the time points, looking at the outcomes  
‘abstinent’ (urine negative for substances), ‘intermittent’ (less than 20% of urines 
positive for substances) and ‘regular’ (more than 20% of urines positive for substances) 
during a defined period.  Poorer outcomes were associated with cocaine positive urines 
(OR 0.69, CI 0.59 to 0.81) and benzodiazepine positive urines (OR 0.7, CI 0.53 to 
0.93).  At 15 months, methadone dose was significantly associated with improved 
outcome (OR 1.67, CI 1.16 to 2.41).   
 
Prescription of take-away doses of methadone was significantly associated (OR 1.34, 
CI 1.1 to 1.6) with an improved outcome (defined as negative urine specimen or less 
than 20% heroin positive urine specimens during a specified period of time).  A poorer 
outcome was significantly associated with heroin positive urine on day of admission 
(OR 0.74, CI 0.56 to 0.97), prescription of low dose methadone (OR 0.65, CI 0.48 to 
0.87), and behavioural sanctions (OR 0.8, CI 0.65 to 0.98).  Only a low dose of 
methadone (OR 0.07, CI 0.01 to 0.33) remained a significant factor on multiple 
regression analysis.  
 
The authors found that a methadone dose of more than 60 mg was associated with 
improved outcomes. Poorer outcomes were associated with those who used cocaine 
and benzodiazepines, lower dose methadone and behavioural sanctions. The authors 
recommended that a prospective study be undertaken at the clinic looking at the effects 
of different methadone dosages and the effect of co-morbid psychiatric illness on 
heroin use and client behaviour.  
 
Client groups with poorer outcomes in methadone treatment 
Data from the ROSIE study were reanalysed in a recent study using Chi-squared 
Automatic Interaction Detection (CHAID) (Murphy and Comiskey 2013). The authors 
stated that ‘CHAID is an alternative approach to multiple linear and logistic regression 
models of treatment outcomes and is especially useful when the data set is not well 
suited to regression analysis due to perhaps violation of normality assumptions’.   
 
The authors believed that the CHAID modelling process worked well with the ROSIE 
dataset, despite certain limitations including the lack of a control group, participants not 
randomly selected and re-grouping of dependent variables owing to small numbers.  
They modelled the interactions between outcome, heroin use in the past 90 days (at 
one-year follow-up) and four different medico-psychosocial domains.  The only 
significant association with poorer outcomes was for males older than 22 years and 
heroin use at one year.   
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The authors concluded that it is important to be able to identify sub-groups in order to 
plan effective treatment but further research is necessary to examine the way different 
patient groups respond to methadone treatment.  CHAID modelling could be a useful 
tool in this process. 
 
Adolescents in treatment 
The prevalence of psychiatric disorders in a cohort of adolescents attending substance 
misuse treatment (James, et al. 2013) is described in Section 6.3.2 of this National 
Report.   
 
5.3.2 Trends in treated population and treatment provision (incl. numbers) 
 
Treatment Demand Indicator data 
A summary of the Treatment Demand Indicator (TDI) (also see TDI data), as provided 
by the NDTRS, shows that 7,703 cases entered treatment in 2012, a decrease of 336 
cases since 2011.13 The decrease may reflect a genuine decrease in the numbers of 
cases entering treatment in 2012.  However, it may also reflect in part the difficult 
economic circumstances experienced by Ireland over the past five or so years and a 
reduction in resources both in the NDTRS and among service providers.  In 2012, 
3,270 (42.5%) cases were new entrants, similar to 2011. In 2012, as in previous years, 
the majority of cases attended outpatient services (5,062, 65.7%).  The majority were 
male (73.0%, 5,621) and the mean age was 29 years, similar trends to 2011. 
 
As in previous years, opiates (mainly heroin) were the most common main problem 
drug reported by cases entering treatment in 2012 (3,971, 51.6%).  This represents a 
decrease compared to 2011, when 4,351 cases entered treatment for problem opiate 
use.  This decrease is also seen in the data from the CTL (see below and also 
Standard Table 24).  The reduction in the proportion and number of cases treated for 
cocaine as a main problem substance continued in 2012, with a decrease to 654 
(8.5%) from 760 (9.5%).  
 
However, there was an increase in the number of cases entering treatment for 
cannabis as their main problem substance in 2012.  In 2012, 2,216 (28.8%) cases 
entered treatment for problem cannabis use compared to 2,086 cases in 2011.  This is 
not surprising as the most recent general population survey showed a significant 
increase in the proportion of adults in Ireland who have ever used cannabis (National 
Advisory Committee on Drugs and Alcohol 2013) (see Section 2.2 for more detail). 
However, it may reflect participation of services in the NDTRS or availability of 
treatment in the country. 
 
Clients registered on methadone treatment  
The number of clients registered for methadone treatment on 31 December each year 
are reported by the Central Treatment List (CTL)  (see Standard Table 24). As at 31 
December 2012, 9,419 clients were registered for methadone treatment (including 
those receiving methadone in prison) (personal communication, Caroline Comar, CTL).  
This is only a 2% increase on the previous year.  Since 2009, the number of clients 
registered on methadone treatment has stabilised.  This may reflect a change in 
patterns of drug use, but analysis of other sources, including treatment data and 
numbers of problem drug users, is necessary to explore this further.  Of the 9,419 
clients, the majority were male (69%) and the largest proportion (28%) were aged 
between 35 and 39 years.  
 
Methadone treatment is provided by specialised clinics, specialist GPs and in prison.  
In 2012, 57% of patients were receiving treatment in specialist outpatient clinics, 38% 
from GPs and 5% in prison.  The proportion of clients receiving treatment in specialist 
outpatient clients and from GPs has remained relatively stable over the past 10 years.  
                                               
13
 It should be noted that the selection of NDTRS data for national analysis differs slightly to the selection of data for 
TDI. Therefore there are some differences between what is reported in TDI and what is published in HRB Trend papers 
and web updates. 
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6. Health Correlates and Consequences 
6.1 Introduction 
 
Problematic drug use can be associated with a number of other health conditions or 
lead to a range of health consequences, including drug-related infectious diseases, 
drug-related overdoses, a range of chronic illnesses and acute conditions, and 
psychiatric comorbidity. Information on these various health correlates and 
consequences is collected in a variety of information systems, which are described 
below. 
 
Computerised Infectious Disease Reporting (CIDR) is a new information system 
developed to manage the surveillance and control of infectious diseases in Ireland. It 
also monitors organisms' ability to resist antibiotic drugs (antimicrobial resistance). 
CIDR is a shared national information system for the CIDR partners – the HSE, the 
Health Protection Surveillance Centre, the Food Safety Authority of Ireland, the Food 
Safety Promotion Board and the Department of Health.  
 
The Health Protection Surveillance Centre (HPSC) is Ireland’s specialist agency for 
the surveillance of communicable diseases.  Part of the Health Service Executive 
(HSE), and originally known as the National Disease Surveillance Centre, the HPSC 
endeavours to protect and improve the health of the Irish population by collating, 
interpreting and disseminating data to provide the best possible information on 
infectious disease. The HPSC has recorded new cases among injecting drug users of 
HIV since 1982, hepatitis B since 2004, and hepatitis C since 2006.  
 
The HIPE (Hospital In-Patient Enquiry) is a computer-based health information 
system, managed by the Economic and Social Research Institute (ESRI) in association 
with the Department of Health and the HSE. It collects demographic, medical and 
administrative data on all admissions, discharges and deaths from acute general 
hospitals in Ireland. It was started on a pilot basis in 1969 and then expanded and 
developed as a national database of coded discharge summaries from the 1970s 
onwards. Each HIPE discharge record represents one episode of care; each discharge 
of a patient, whether from the same or a different hospital, or with the same or a 
different diagnosis, gives rise to a separate HIPE record.  The scheme, therefore, 
facilitates analyses of hospital activity rather than of the incidence of disease. HIPE 
does not record information on individuals who attend accident and emergency units 
but are not admitted as inpatients.  
 
The National Office for Suicide Prevention (NOSP) was established in 2005 after 
publication of Reach Out National Strategy for Action on Suicide Prevention 2005–
2014 (National Suicide Review Group, et al. 2005). The NOSP’s core aim is to oversee 
the implementation, monitoring and evaluation of Reach Out. The NOSP is an office 
within the HSE and is linked in that structure to the Office of the Assistant National 
Director, Mental Health. 
 
The National Poisons Information Centre (NPIC), located in Beaumont Hospital, 
Dublin, provides a national telephone information service on the toxicity, features and 
management of cases of poisoning. This 24-hour service is offered mainly to doctors 
and other health care professionals. Queries are dealt with by poisons information 
officers at the Centre between 8 am and 10 pm daily, while out-of-hours calls are 
automatically diverted to the UK National Poisons Information Service (NPIS). Data 
from this source provide indications of the pattern of human cases of poisoning, 
including age, gender and agent. 
 
The National Psychiatric In-Patient Reporting System (NPIRS), administered by the 
Health Research Board (HRB), is a national psychiatric database that provides detailed 
information on all admissions to and discharges from 56 inpatient psychiatric services 
in Ireland. It records data on cases receiving inpatient treatment for problem drug and 
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alcohol use. NPIRS does not collect data on the prevalence of psychiatric comorbidity 
in Ireland. The HRB publishes an annual report on the data collected in NPIRS, entitled 
Activities of Irish psychiatric units and hospitals. 
 
The National Registry of Deliberate Self-Harm is a national system of population 
monitoring for the occurrence of deliberate self-harm, established at the request of the 
Department of Health and Children by the National Suicide Research Foundation 
(National Parasuicide Registry Ireland 2004). Since 2006/07 the Registry has achieved 
complete national coverage of hospital-treated deliberate self-harm. The Registry 
defines deliberate self-harm as ‘an act with non-fatal outcome in which an individual 
deliberately initiates a non-habitual behaviour, that without intervention from others will 
cause self-harm, or deliberately ingests a substance in excess of the prescribed or 
generally recognised therapeutic dosage, and which is aimed at realising changes that 
the person desires via the actual or expected physical consequences’. All methods of 
deliberate self-harm are recorded in the Registry, including drug overdoses and alcohol 
overdoses, where it is clear that the self-harm was intentionally inflicted. All individuals 
who are alive on admission to hospital following a deliberate act of self-harm are 
included. Not considered deliberate self-harm are accidental overdoses, e.g. an 
individual who takes additional medication in the case of illness, without any intention 
to self-harm; alcohol overdoses alone, where the intention was not to self-harm; 
accidental overdoses of street drugs (drugs used for recreational purposes), without 
the intention to self-harm; and individuals who are dead on arrival at hospital as a result 
of suicide. 
 
The National Suicide Research Foundation (NSRF) is an independent, multi-
disciplinary research unit which investigates the causes of suicide and deliberate self-
harm in Ireland. 
 
The National Virus Reference Laboratory (NVRL) provides a diagnostic and 
reference service for clinicians investigating viral infections throughout Ireland. The 
laboratory is affiliated to the University College Dublin (UCD) School of Medicine and 
Medical Science. The NVRL currently performs over 700,000 tests annually, involving 
some 120 tests for 40 different pathogens and provides specialist reference services. 
 
The data collected by the Primary Care Re-imbursement Service (PCRS), previously 
called the General Medical Services (GMS) Payments Board, are another source of 
information on the health correlates and consequences of problematic drug use among 
those who have medical cards, which are means-tested.  Medical-card holders 
received certain health services, including approved prescribed drugs and medicines, 
free of charge up to December 2009 and since January 2010 for a minimal charge. 
Operated by the HSE, the PCRS administers payments to doctors, pharmacists and 
dentists who provide services under the PCRS scheme.  
 
The Suicide Support and Information System (SSIS) was established by the NSRF, 
in line with Action 25.2 of the Reach Out National Strategy for Action on Suicide 
Prevention 2005–2014 (National Suicide Review Group, et al. 2005). It was developed 
to prevent suicide by facilitating access to support for the bereaved while at the same 
time obtaining information on risk factors associated with suicide and deaths classified 
as open verdicts. The NOSP provided funding for a pilot-study in the Cork region, 
which ran from September 2008 to March 2011. 
 
Problematic drug use can also lead to premature death. Death can occur as a result of 
overdose (either intentional or unintentional), actions taken under the influence of 
drugs, medical consequences or incidental causes. Although illicit drugs are involved in 
many cases of drug-related death, licit (including prescribed) drugs are also frequently 
involved, either alone or in conjunction with an illicit drug. Alcohol has been reported as 
the third greatest risk factor for ill health and premature death in Europe. Established in 
2005, the National Drug-Related Death Index (NDRDI), which is maintained by the 
HRB, is an epidemiological database which records cases of death by drugs poisoning, 
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and deaths among drug users in Ireland, extending back to 1998. The NDRDI also 
records data on alcohol-related poisoning deaths, deaths among those who are alcohol 
dependent, extending back to 2004. 
 
The Central Statistics Office (CSO), acting on behalf of the Department of Health, 
compiles quarterly and annual statistical reports on deaths in the Irish population. 
These reports are based on administrative data supplied by the General Register 
Office. The principal variables collected include date of death, address of residence of 
deceased, place of death, underlying cause of death, occupation, age, sex, and marital 
status. Since 1 January 2007 the underlying cause of death has been coded according 
to ICD10. 
 
6.2 Drug-related infectious diseases 
6.2.1 HIV/AIDS and viral hepatitis 
HIV surveillance, 2012 
Voluntary linked testing for antibodies to HIV has been available in Ireland since 1982. 
Figure 6.2.1.1 presents the number of new cases of HIV among injecting drug users 
(IDUs) reported in Ireland, by year of diagnosis; data from 1982 to 1985 are excluded 
as these four years were combined in the source records. According to the most recent 
report of the HPSC, at the end of 2012, 341 people were newly diagnosed with HIV in 
Ireland (crude notification rate of 7.4 per 100,000 per population) and the figure has 
been declining since 2004.  
 
In 2012, 13 (3.8%) newly-diagnosed HIV cases were IDUs (Standard Table 09-1). The 
number of diagnoses among IDUs has been steadily decreasing, from 71 in 2004 to 13 
in 2012 (a decline of 82%). Of the 13 newly-diagnosed cases who were IDUs, ten were 
men and the median age was 34 years (range 22 to 50 years). Five cases were born in 
Ireland, three in Central and Eastern Europe and two in Western Europe. Where CD4 
count was reported, 63% of injectors in 2012 were diagnosed late, including 38% who 
were severely immuno‐compromised. Two of the 13 IDUs were also diagnosed with an 
AIDS-defining illness at the time of their HIV diagnosis, and four had had a previous 
negative HIV test. Among the IDUs newly diagnosed with HIV infection, 69% were co‐
infected with hepatitis C (Donnell, et al. 2013). 
 
 
Figure 6.2.1.1 Number and rolling average number of new cases of HIV among IDUs, by year of 
diagnosis, reported in Ireland, 1986–2012  
Source: Unpublished data reported to Department of Health by National Disease Surveillance Centre and HPSC, 2013  
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There were 581 notifications of hepatitis B in 2012 compared to 525 in 2011, a 12% 
increase (Table 6.2.1.1). The number of acute cases in 2012 remained low at 37, 
showing a small decrease from 2011 when there were 45 acute cases. Among acute 
cases in 2012, 27 (73%) were aged between 20 and 44 years and 29 (78%) were 
male. There were no new acute cases of hepatitis B infection among IDUs in 2012. 
 
Table 6.2.1.1   Acute and chronic hepatitis B cases reported to the HPSC, by risk factor status, 
2011–2012 
 2011 2012 
Hepatitis B status Acute Chronic Unknown Acute Chronic Unknown 
 No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Total number of cases 45 460 20 37 521 23 
% of cases by status (8.6) (87.6) (3.8) (6.4) (89.6) (4) 
Cases with reported risk factor data 44 183 5 36 243 5 
% of cases with risk factor data 
 of which  
(97.7) (39.8) (25) (97) (47) (22) 
       Injecting drug users 0 (0%)  1 (0.6)  0 (0%)  5 (1%) 0 (0%)  
Cases without reported risk factor data 1 277 15 1 278 18 
% of cases without risk factor data (2.3) (60.2) (75) (3) (53) (78) 
Total 525 581 
Source: Unpublished data reported to Department of Health by National Disease Surveillance Centre and HPSC, 2013 
 
Hepatitis C notifications, 2012 
There were 1,036 hepatitis C notifications in 2012, (Table 6.2.1.2), a 17.5% decrease 
on 2011, when there were 1,257 notifications. Previous annual numbers have included 
cases diagnosed in the past, which were not previously notified. Decreasing hepatitis C 
notifications and increasing median age is indicative of a reduced incidence of hepatitis 
C in the population. Demographic data in 2012 were similar to previous years, with 
66% of 689 cases (66%) being male, the median age at notification being 37 years, 
and 67% of cases being aged between 25 and 44 years.   
 
Table 6.2.1.2 Hepatitis C cases and notification rates per 100,000 population, 2004–2012 
   Year n Notification rate 
2004 1119 26.4 
2005 1403 33.1 
2006 1210 28.6 
2007 1541 36.5 
2008 1511 35.8 
2009 1240 29.3 
2010 1236 29.2 
2011 1257 29.6 
2012 1036 24.4 
Source: Unpublished data from HPSC, 2013  
 
Risk factor data were available for 637 (61%) of the 2012 cases. For 484 (76%) of 
these cases, injecting was the predominant risk factor (Table 6.2.1.3); of these cases, 
348 (72%) were men, and the average age was 37 years (Standard Table 09-4). 
Among the 484 cases where injecting was the predominant risk factor, 399 (82%) lived 
in Dublin and the adjoining counties of Kildare and Wicklow (Health Protection 
Surveillance Centre 2012a). 
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Table 6.2.1.3   Demographic data on IDUs with hepatitis C notified to HPSC, 2012 
  n (%) 
Total number of known injector cases 484 
Gender 
 Male 348 (72) 
Female 136 
Gender not known 0 
Age 
 Mean age 36.9 
Median age 36 
Under 25 years 23 (4.8) 
25-34 years 178 (36.8) 
Over 34 years 282 (58.2) 
Age not known 1 (0.2) 
Place of residence 
 Dublin, Kildare or Wicklow 399 (82.4) 
Elsewhere in Ireland 85 (17.6) 
Source: Unpublished data from HPSC, 2013  
 
Hepatitis C co‐infections  
Co‐infection with hepatitis C and HIV complicates both diseases. Untreated HIV 
infection increases the risk of liver damage and can accelerate cirrhosis compared with 
those infected with hepatitis C alone. Provisional data from HPSC/CIDR found that 
during 2012, there were 14 co‐infections with hepatitis C and HIV. Of these cases, nine 
were male and the median age at notification was 34 years. Country of birth was 
known for ten of these cases – five were born in Ireland, four in central and eastern 
Europe and one in Asia. Risk factor was known for seven cases, and two of these were 
IDUs.  
 
Co-infection with hepatitis C and hepatitis B can also lead to more severe liver disease 
and an increased risk of liver cancer. There were seven cases of co‐infection with 
hepatitis C and B in 2012. Of these cases, six were male and the median age at 
notification was 34 years. Two cases were co‐infected with hepatitis C and B and HIV. 
Risk factor data were available for two cases, one of whom was an IDU (Health 
Protection Surveillance Centre 2012a). 
 
Determination of the burden of hepatitis C virus infection in Ireland  
Testing for anti-hepatitis C virus began in Ireland in 1989 and over the next 15 years 
about 95% of confirmatory investigations, both serological and molecular, were 
performed in the National Virus Reference Laboratory (NVRL). The NVRL has a 
laboratory information management system (LIMS) which is specimen-based rather 
than person-based. There is no unique personal health identification number system in 
use in Ireland and it is possible that many persons infected with the hepatitis C virus 
(HCV) have had repeated tests performed, making total counts of positive cases 
impossible.  
Thornton and colleagues completed a study to estimate prevalence of chronic HCV 
infection in Ireland between 1989 and 2004. The study was completed to inform future 
health services planning for those with chronic HCV infection and also to contribute to 
understanding of the increasing scale of HCV infections in Europe (Thornton, Lelia, et 
al. 2011).  
The results confirmed that between 1989 and 2004, 10,384 individuals were infected 
with the hepatitis C virus and that it was not possible to determine the definitive HCV 
status of a further 2,637 individuals. In 75.6% (n=7,853) of confirmed cases, it was 
possible to assign a risk factor, including current or former drug use (79.7%, n=6,255), 
receipt of blood or blood products (16.4%, n=1,285), accidental exposure to blood/body 
fluids including by assault (1.3%, n=102), sexual exposure (1.2%, n=98), vertical 
exposure (1.0%, n=79) and contact with a case or an at-risk individual (0.4%, n=34) 
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(Figure 6.2.1.2). Unfortunately, available information did not allow for specification of 
whether drug use was injecting or non-injecting.  
The majority of the 10,176 confirmed cases (for those where age and gender were 
known) were men (63%) with a median age at diagnosis of 28 years, and 70% of these 
men had a history of drug use. The median age at diagnosis for those infected through 
drug use was 25 years for men, and 23 years for women. This has increased since 
2001 and the median age for all identified drug-use-related new diagnoses in 2004 was 
28 years. 
Genotype was available for 60.8% (n=6,314) of all confirmed positive individuals. Of 
these, 55.3% (n=3,493) were genotype 1, 38.6% (n=2,444) were genotype 3, 3.6% 
(n=227) were genotype 2, 1.0% (n=62) were genotype 4 and 0.1% (n=6) were 
genotype 5. A small number of individuals were infected with more than one genotype, 
most commonly genotypes 1 and 3 (1.2%, n=73). The genotype distribution differed 
between people infected through drug use and those infected through blood/blood 
products; 53% of drug users had genotype 1 HCV infection and 42% had genotype 3 
HCV infection. This information is important when planning treatment services and in 
determining the efficacy of antiviral treatment. 
The 10,384 chronic HCV cases obtained from the LIMS data were adjusted using five 
assumptions to provide an estimate of those who acquired chronic HCV infection 
between 1989 and 2004 and living with it in 2009. Following adjustments for testing at 
other laboratories (5% increase), for diagnosis between 2004 and 2009 (additional 
4,262 cases), and for a chronicity rate of 75% (reduction by 25%), and allowing for a 
mortality rate of 13% and an under-diagnosis rate of 50%, 67% and 80%, it was 
estimated that there were at least 19,826 individuals living with chronic HCV infection in 
2009, but the number could be as high as 29,739 or 49,565. 
 
 
Figure 6.2.1.2   Number of NVRL-confirmed HCV cases by year of diagnosis and reported risk 
factor, 1989–2004  
Source: (Thornton, Lelia, et al. 2011) 
 
Profile of clients attending the Health Promotion Unit–Needle Exchange, MQI 
Merchants Quay Ireland (MQI) carried out a study in 2012 to gain an up-to-date profile 
of the clients accessing its Health Promotion Unit–Needle Exchange (HPU) service, in 
order to inform service planning and provision (Jennings 2013). A self-report research 
instrument was developed and titled the Merchants Quay Health Promotion Unit 
Questionnaire. It had four sections looking at socio-demographic characteristics, 
substance use, injecting risk-behaviour and blood-borne viruses (BBVs). Having 
explained the purpose of the questionnaire and having obtained consent, MQI-trained 
staff collected the data on a one-to-one basis from clients aged over 18 years. Ethical 
considerations were given particular attention in view of the vulnerability of the 
respondents. The limitations of self-reporting and recall bias were recognised, 
particularly with relation to BBVs, which are not a measure of true prevalence, and the 
fact that respondents were current injectors with a myriad of affective symptoms.  
 
The researchers interviewed 338 current drug users, 290 (86%) men and 48 (14%) 
women. The average age of respondents was 34 years, with 49% aged between 25 
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and 34 years. The respondents included 19 different nationalities but the majority were 
Irish (88%); 91% resided in the Dublin area; 47% lived in their own or rented 
accommodation, and 31% were categorised as homeless.  
 
Of the 338 respondents, 329 (97%) were currently injecting drugs. Of the 329 current 
injectors, 163 (50%) reported injecting up to six times or more in the week prior to the 
study. Approximately three-quarters of the sample reported use of only one main 
injection site with 98 (30%) reporting injecting into either the groin or the neck.  Sharing 
injecting equipment and paraphernalia in the last month was reported by 97 (29%) of 
participating injectors, 33 (10%) sharing syringes, 32 (10%) sharing cookers, 22 (7%) 
sharing   needles, 43 (13%) sharing  water, 39 (12%) sharing tourniquets, 24 (8%) 
sharing  frontloading, 17 (5%) back-loading and 28 (9%) sharing  filters. Table 6.2.1.4 
summarises the responses given by participants regarding their BBV test results and 
whether they were receiving treatment at the time of the study. 
 
Table 6.2.1.4   Reported BBV status, and treatment status, clients of MQI Health Promotion Unit–
Needle Exchange (n=338), 2012  
Blood-
borne 
virus 
status  
(BBV) 
Participants 
reported 
ever-tested 
status 
Positive 
test results 
among 
participants 
who  
reported 
ever-tested 
status  
Negative 
test results 
among 
participants 
who 
reported 
ever-tested 
status  
Unknown 
test results 
among 
participants 
who  
reported 
ever-tested 
status  
Participants 
declined to 
answer any 
questions 
relating to 
infection 
with BBV 
Participants 
who reported 
testing 
positive who 
were 
receiving 
treatment  
 n % n % n % n % n % n % 
HIV 264 78 22 8 234 89 8 3 3 1 10 45 
Hepatitis 
B 
263 78 12 5 241 92 9 3 3 1 2 17 
Hepatitis 
C 
278 82 125 45 140 50 13 5 3 1 18 14 
Hepatitis 
C + HIV  
262 78 15 6         
Hepatitis 
B + 
Hepatitis 
C  
262 78 8 3         
Hepatitis 
B + C + 
HIV  
258 76 1 <1         
Source: (Jennings 2013) 
 
Two hundred and sixty-four (78%) respondents reported having been tested for HIV at 
some point. Of those who reported being tested, 22 (8%) tested positive and 234 (89%) 
tested negative. Of those who reported testing negative and for whom data were 
available as to when they were last tested, the author stated that 45% (89/198) had not 
been retested within the past year despite being at risk of infection through injecting 
drug use. Only 10 (45%) of those who reported testing positive for HIV were receiving 
treatment.  
 
Testing for hepatitis B at some point was reported by 263 (78%) respondents. Of those 
who reported being tested, 12 (5%) tested positive and 241 (92%) tested negative, nine 
(3%) did not know whether they had been ever tested or not and three (1%) declined to 
answer the question. Of those who reported testing negative and who could provide an 
estimate of when they were last tested for hepatitis B, 98/204 (48%) had not been 
retested within the past year despite being at risk of infection through injecting drug 
use.  Only two (17%) of those who reported testing positive for Hepatitis B were 
receiving treatment.  
 
Two hundred and seventy-eight (82%) respondents reported having been tested for 
hepatitis C. Of those who reported that they had been tested, 125 (45%) reported 
having tested positive, 140 (50%) reported testing negative, and 13 (5%) did not know 
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their hepatitis C status. Of those who reported testing negative for hepatitis C and for 
whom data were available as to when they were last tested, the author stated that 37% 
(42/112) had not been retested in the last year despite being at risk of infection through 
injecting drug use. 
 
 
 
6.2.2 STI’s and tuberculosis 
 
The 2012 HPSC HIV Report data found that one (7.7%) of the 13 newly-diagnosed HIV 
cases among IDUs was co-infected with syphilis (Donnell, et al. 2013).  
 
 
6.2.3 Other infectious morbidity (e.g. abscesses, sepses, endocarditis, wound 
botulism) 
 
Characteristics, healthcare usage, morbidity and mortality of IDUs attending an inner 
city emergency department 
A 2010 survey undertaken at an inner-city Dublin hospital’s Accident & Emergency 
department with a high community prevalence of intravenous drug use concluded that 
injecting drug use had resulted in the emergence of a sub-group of people with a 
unique set of medical issues (O'Connor, et al. 2013). This prospective observational 
study over a three-month period (1 January 2010 to 31 March 2010) collected data on 
the characteristics of patients with a history of active injecting drug use presenting at 
the Accident & Emergency department. One hundred and forty-six patients with a 
history of injecting drugs were identified, contributing to 222 acute or emergency 
presentations.  These patients were predominantly male, of Irish nationality, and 
displayed high levels of homelessness, unemployment and lack of stable family or 
intimate partner relationships. Forty-five per cent of these presentations occurred as a 
result of infection (95%, CI 38.5% to 51.5%). Trauma, pure toxicological issues, 
thromboembolic phenomena and psychiatric issues comprised the other common 
acute diagnoses.  
 
The study found Gram-positive infection rates of 20% for Methicillin-sensitive 
Staphylococcus aureus (MSSA), 5% for Methicillin-resistant Staphylococcus aureus 
(MRSA), 7% for CN staphylococcus aureus, 7% for pneumococcus, 4% for beta-
haemolytic streptococcus and 4% for enterococcus. Gram-negative infections included 
candida (13%), E. coli/coliforms (11%) and pseudomonas (4%). The percentage of 
virulent Gram-positive organisms predominated over Gram-negative species in 
abscesses (44% to 32%) and in blood-stream infections (44% to 29%). The authors 
pointed to the need for more Gram-negative antibiotic prescribing in some current 
clinical practice.  
 
The burden of co-morbid medical illness in the study cohort was substantial with high 
rates of hepatitis C infection (74%) and HIV infection (13.8%). Healthcare utilisation 
indices for this study cohort were found to be extremely high on multiple measures. 
The cohort had an attendance rate to the Accident and Emergency department of 445 
visits per 100 patient-years, an admission rate to hospital of 69 per 100 patient-years 
and mortality rate of 4.9 per 100 patient-years. The study concluded that active IDUs 
presented with considerable acute and chronic medical consequences and high 
healthcare utilisation associated with their injecting drug use and its complications. 
 
6.2.4 Behavioural data 
There is no routine collection of behavioural data in Ireland. For the most recent 
information, see study presented in Section 6.2.3 and Table 6.2.3.2 of the 2011 
National Report (Irish Focal Point (Reitox) 2011). 
 
Dental health of residents in alcohol/drug abuse treatment centres  
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A cross-sectional observational study examined dental health among clients of Irish 
alcohol and drug use treatment centres (O'Sullivan, EM 2012a). The study examined 
the independent and combined impact of ‘alcohol only’ and ‘alcohol plus drug’ use on 
the dental health of the residents in the treatment centres and provided baseline data 
on dental health of individuals undergoing treatment for alcohol/drug use. Clients were 
visited monthly or bimonthly over 12 months between October 2006 and September 
2007. A short semi-¬structured interview was followed by a comprehensive oral health 
examination.  
Table 6.3.1 presents the participants’ demographic and behavioural characteristics and 
dental status. Of the 203 participants, over half (111) used alcohol plus drugs, and 92 
used alcohol only. The participants comprised 142 men and 61 women, and their ages 
ranged from 18 to 73 years, with 124 (59%) being under 40 years old. A statistically 
significant age difference was found between the ‘alcohol only’ users and the ‘alcohol 
plus drugs’ users,  with the mean age of ‘alcohol only’ users being 47 years, and the 
mean age of ‘alcohol plus drugs’ users being 30 years. A statistically significant age 
difference was found between the ‘alcohol only’ users and the ‘alcohol plus drugs’ 
users. 
 
Among the ‘alcohol only’ users, 81 (88%) self-reported their weekly alcohol 
consumption prior to admission as being either over 60 units per week, or described 
their habit as ‘binge drinking’. Tobacco was used by 177 (87%) of participants but 
‘alcohol only’ users were less likely to smoke tobacco than the ‘alcohol plus drugs’ 
users. 
 
Table 6.3.1    Demographic and behavioural characteristics and dental status of treatment centre 
clients (n=203), by substance, 2006/2007 
Variable  Alcohol only 
Users = 92 
N (% of alcohol only  users) 
Alcohol + drugs 
Users = 111 
N (% of alcohol + 
drugs users) 
Male  59 (64) 83 (75) 
Female  33 (36) 28 (25)  
Mean age in years 47.2  30.2  
Current smoker 71 (77) 106 (96) 
Mean number of years of alcohol drinking  20.5  13.9 
Alcohol preference    
Beer 65 (71) 96 (87) 
Spirits  9 (10) 4 (4) 
Wine  20 (21) 15 (14) 
Regular mouthwash user  33 (36) 30 (27) 
Regular dental attendee 33 (36) 35 (32) 
Mean number of teeth present  22  27  
Mean number of DMFT*    
       Decayed teeth  2  2  
       Missing teeth  10  5  
       Filled teeth  6 4  
Source: (O'Sullivan, EM 2012a) 
* DMFT=Decayed/Missing/Filled Teeth 
 
One hundred and nineteen (58%) participants had evidence of overt periodontal 
disease, the prevalence increasing with age from 22% among teenage participants to 
74% among those aged 50–¬59 years; prevalence was not influenced by whether the 
participants used alcohol only or alcohol and drugs. Those with periodontal disease 
had poorer oral hygiene, fewer teeth and more decayed teeth. One hundred and 
twenty-three (87%) men and 42 (69%) women were in need of urgent dental treatment 
and extractions. More extractions were needed among infrequent dental attendees, 
heroin users and those with dental infection. The level of tooth loss among Irish alcohol 
and drug users was nearly five times that recorded for the general Irish population 
(Whelton, et al. 2007). 
 
Higher levels of tooth decay were found among the alcohol and drug user group than 
among the alcohol-only user group, particularly men. The study found a high rate of 
dental disease among those suffering from alcohol and alcohol/drug use, suggesting a 
lack of meaningful engagement between alcohol/drug users and their dentists. The 
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multi-factorial nature of dental disease coupled with multiple substance use and high 
tobacco consumption makes research in this area challenging. Oral hygiene and tooth 
loss have an impact on overall health and well-being, and neglect will impact on 
population health, particularly in view of the growing problem with alcohol and drug use 
nationally. The authors concluded that the introduction of a state-funded scheme to 
provide basic dental treatment in residential centres should be considered from a public 
health perspective and in the interests of ultimately reducing overall healthcare costs. 
 
6.3 Other drug-related health correlates and consequences 
6.3.1 Non-fatal overdoses and drug related emergencies 
 
Data extracted from the Hospital In-Patient Enquiry (HIPE) scheme were analysed to 
determine trends in non-fatal overdoses discharged from Irish hospitals in 2011. There 
were 4,254 overdose cases in that year, of which 34 died in hospital.  The 4,220 
discharged cases are included in this analysis. The number of overdose cases 
decreased by 6% between 2010 and 2011. Trends over time indicate a decrease in 
overdose cases admitted to Irish hospitals every year, falling from 5,012 cases in 2005 
to 4,254 cases in 2011, 758 fewer cases over the seven years of data collection 
(Figure 6.3.1.1). 
 
 
Figure 6.3.1.1   Overdose cases admitted to Irish hospitals, 2005–2011 (N=32,490) 
Source: Unpublished HIPE data 
 
Gender 
Between 2005 and 2011 there were more overdose cases among women than among 
men, with women accounting for 2,305 (54%) of all overdose cases in 2011 (Figure 
6.3.1.2). 
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Figure 6.3.1.2   Overdose cases admitted to Irish hospitals, by gender, 2005–2011 (N=32,490) 
Source: Unpublished HIPE data 
 
Age group 
There were 117 fewer overdoses in 2011 compared to 2010 among those aged 15–24 
years, and 140 fewer overdose cases among those aged under 25 years in 2011 than 
in 2010, with the incidence of overdose decreasing with age. However, in 2011 the 
incidence increased by 14 in age groups 45–54 and 55–64 years in 2011 compared to 
2010. Trends over time show that in 2005, 40% of cases were aged less than 25 years, 
compared to 33% in 2011, and overdose cases admitted to Irish hospitals decreased 
by 15%, falling from 5,012 in 2005 to 4,254 in 2011. 
 
 
Figure 6.3.1.3   Overdose cases admitted to Irish hospitals, by age group, 2005–2011 (N=32,490) 
Source: Unpublished HIPE data 
 
Area of residence 
In 2011, 1,059 (25%) of overdose cases occurred among persons resident in Dublin 
(city and county), 3,177 (75%) among persons resident outside Dublin, and 27 (0.6%) 
among persons recorded as of ‘no fixed abode’ or resident outside Ireland.  
 
Drugs involved 
Table 6.3.1.1 presents the positive findings per category of drugs and other substances 
involved in all cases of overdose in 2011. Non-opioid analgesics were present in 1,336 
(31%) cases. Paracetamol is included in this drug category and was present in 806 
(19%) of cases. Psychotropic agents were taken in 973 (23%) and benzodiazepines in 
960 (22%) cases. There was evidence of alcohol consumption in 518 (12%) cases. 
Cases involving alcohol are included in this analysis only when the alcohol was used in 
conjunction with another substance. 
 
Table 6.3.1.1   Categories of drugs involved in overdose cases admitted to Irish hospitals, 2011 
(N=4,254)* 
Drug category 
Positive findings per drug 
category* 
 n % 
Non-opioid analgesics 1336 31.4 
Benzodiazepines 960 22.6 
Psychotropic agents 973 22.9 
Antiepilepic / Sedative / Antiparkinson agents 540 12.7 
Narcotics and hallucinogens 539 12.7 
Alcohol 518 12.2 
Systemic and haematological agents 149 3.5 
Cardiovascular agents 137 3.2 
Autonomic nervous system 55 1.3 
Anaesthetics 65 1.5 
0-14 15-24 25-34 35-44 45-54 55-64 65-74 75-84 85+
2005 740 1275 1017 882 581 282 140 70 25
2006 701 1269 942 835 575 273 126 98 21
2007 550 1287 995 893 624 312 136 99 22
2008 560 1233 1026 867 543 274 148 90 31
2009 353 975 887 845 576 281 140 85 30
2010 490 1053 922 863 642 294 143 90 25
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Drug category 
Positive findings per drug 
category* 
Hormones 54 1.3 
Systemic antibiotics 79 1.9 
Gastrointestinal agents 71 1.7 
Other chemicals and noxious substance 259 6.1 
Diuretics  53 1.2 
Muscle and respiratory agents 27 0.6 
Topical agents 31 0.7 
Anti-infectives / Anti-parasitics 19 0.4 
Other gases and vapours 45 1.1 
Other and unspecified drugs 924 21.7 
*The sum of positive findings is greater than the total number of cases because some cases involved more than one 
drug or substance.  
Source: Unpublished data from HIPE 
 
Overdoses involving narcotics or hallucinogens 
Narcotic or hallucinogenic drugs were involved in 580 (14%) of overdose cases in 
2011. Figure 6.3.1.4 shows the number of positive findings of narcotics or 
hallucinogens drugs among the 580 cases. The sum of positive findings is greater than 
the total number of cases because some cases involved more than one drug from this 
category.  Opiates were used in 445 (80%) cases, cocaine in 82 (15%) and cannabis in 
46 (8.5%) cases. 
 
Figure 6.3.1.4   Narcotics and hallucinogens involved in overdose cases admitted to Irish hospitals, 
2011 (N=580) 
Source: Unpublished data from HIPE 
 
Overdoses classified by intent 
In 2,773 (66%) cases the overdose was classified as intentional (Figure 6.3.1.5). For 
56 cases, there was no classification of intent recorded and for 24 cases two intent 
classifications were recorded. These 80 cases were not included in the analysis. 
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Figure 6.3.1.5   Number of overdose cases admitted to Irish hospitals, by classification, 2011 (N= 
4,174) 
Source: Unpublished data from HIPE 
 
Table 6.3.1.2 presents the positive findings per category of drugs and other substances 
involved in the 2,773 cases of intentional overdose in 2011. Non-opioid analgesics 
were involved in 1,053 (38%) cases, benzodiazepines in 717 (26%) and psychotropic 
agents in 783 (28%) cases. 
 
Table 6.3.1.2   Categories of drugs involved in intentional overdose cases admitted to Irish 
hospitals (n = 2,773), 2011 
Drug category Number % 
Nonopioid analgesics 1053 38.0 
Benzodiazepines 717 25.9 
Psychotropic 783 28.2 
Antiepilepic/Sedative/Antiparkinson 450 16.2 
Alcohol 343 12.4 
Narcotics and hallucinogens 288 10.3 
Cardiovascular 89 3.2 
Systemic and haematological 91 3.3 
Other chemicals and noxious 
substance 
87 3.1 
Hormones 37 1.3 
Autonomic nervous system 33 1.2 
Systemic antibiotics 60 2.2 
Gastrointestinal 53 1.9 
Anaesthetics 18 .6 
Diuretics  28 1.0 
Muscle and respiratory 7 .3 
Antiinfectives/antiparasitics 11 .4 
Topical agents 7 .3 
Other gases and vapours 0 .0 
Other and Unspecified Drugs 235 8.5 
Total cases 4390 100 
*The sum of positive findings is greater than the total number of cases because some cases involved more than one 
drug or substance.  
Source: Unpublished data from HIPE 
 
 
6.3.2 Other topics of interest e.g. psychiatric and somatic co-morbidity, traffic 
accidents, pregnancies and children born to drug users 
 
Antidepressant use and suicide in Europe 
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An ecological, naturalistic multi-national (29 European countries) study analysed the 
trends over a 14-year period, from 1996 to 2009, in the use of antidepressants and 
rates of suicide, adjusting for gross domestic product, alcohol consumption, 
unemployment and divorce. It also examined whether any reduction in the rate of 
suicide preceded any trend towards increased use of antidepressants (Gusmao, et al. 
2013). 
 
Data on the defined daily dosage (DDD) for adults for antidepressants were analysed, 
giving an estimate of use of these drugs and the proportion of the population receiving 
treatment with a particular antidepressant on a daily basis. The DDD of a drug for 
adults is determined by an independent scientific committee making use of the WHO 
Collaborating Centre for Drug Statistics Methodology. Data on the DDD per thousand 
individuals per day (DDD/1000/day) for antidepressants were used in the analysis. 
These data provide a rough estimate of use of these drugs and the proportion of the 
population receiving treatment with a particular antidepressant on a daily basis. In 
order to maximise time series data on antidepressant use in each country between 
1996 and 2009, other data sources were used: IMS Health (www.imshealth.com), 
Organisation for Economic Co-operation and Development (OECD) pharmacy sales, 
national statistical offices and published literature. The quantities of antidepressants 
sold, as recorded in the IMS database, were converted into kilograms of active 
ingredient in order to establish the total quantity of defined daily dosage (DDD) sold. 
This figure was then divided by the country mid-year resident population in order to 
obtain a global DDD/1000/day. Ireland’s DDD/1000/day for antidepressants, calculated 
using IMS data available for the 14-year period, was found to have almost trebled 
between 1996 (17.96) and 2009 (55.51). Annual suicide standard death rate (SDR) 
data were available for 30 years (1980–¬2009) and showed that the suicide SDR in 
Ireland in 1980 was 7.69 and 11.61 in 2009, a difference of 3.92. The SDR was highest 
between 1985 and 1990 at 21.   
 
An inverse correlation (as antidepressant use increased, suicide rates decreased) was 
observed in all but one country between the antidepressant DDD/1000/day and the 
recorded SDR for suicide.  Portugal was the country where there was a positive 
correlation between anti-depressant DDD/1000/day and suicide SDR. This might be 
explained by the lack of precision of Portugal’s suicide register and over-estimation of 
undetermined violent deaths concealing suicides. There was also an inverse 
correlation with GDP, with the exception of Ireland, Poland and Spain. There was a 
consistent direction and magnitude of correlation between antidepressant 
DDD/1000/day and GDP in all of the 29 countries. No strong patterns were seen in 
respect of the suicide SDR and alcohol consumption, unemployment or divorce.   
 
In Ireland, the sharp increase in antidepressant DDD/1000/day was not associated with 
a similar decrease in the suicide SDR as in other countries.  The authors suggested 
that this might be explained by the fact that in Ireland suicide is more frequent among 
young and middle-aged men who typically present an unfavourable help-seeking 
behaviour (Moller-Leimkuhler 2000). The authors (Gusmao, et al. 2013) stated that, 
while the study could not depict causal links and results should be interpreted with 
caution, the effectiveness and potential cost-effectiveness of antidepressants as an 
intervention for suicide prevention should be considered.  The findings underline the 
importance of the appropriate use of antidepressants as part of routine care for people 
diagnosed with depression.  
 
Drug admissions to psychiatric facilities, 2011 
Activities of Irish psychiatric units and hospitals 2011, the annual report published by 
the Mental Health Information Systems Unit of the Health Research Board (Daly and 
Walsh 2012), shows that there were 839 admissions to Irish psychiatric units and 
hospitals in 2011 of cases with a drug disorder (ICD-10 Code F11–19, F55), of whom 
352 (42%) were treated for the first time. This represents a reduction of 127 first-ever 
admissions for drug disorders since 2010, which is a rate of 7.7 per 100,000 total 
population, down from 9.7 per 100,000 in 2010 (Figure 6.3.2.1). It should be borne in 
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mind that admissions and discharges represent episodes or events rather than 
persons. 
 
 
Figure 6.3.2.1 Rate of first admission of psychiatric cases with a diagnosis of drug disorder (using 
ICD-10 three character categories) per 100,000 of the population in Ireland, NPIRS, 1990–2011 
Source: Annual reports from the National Psychiatric In patient Reporting System (NPIRS), 1990–2011 
 
Two hundred and three (58%) first-ever admissions of cases with a drug disorder were 
to psychiatric units in general hospitals, followed by 98 (28%) admissions to psychiatric 
hospitals, and 51 admissions (14%) to private hospitals and charitable centres. There 
were 15 child and adolescent admissions for drug disorders, of which eight were first-
ever admissions. Of these first-ever admissions, seven were voluntary and one was 
involuntary.  
 
Five hundred and eighty-two (69%) cases hospitalised for a drug disorder were 
discharged within two weeks. 
 
Substance use and psychiatric disorders in Irish adolescents 
In line with the Mental Health Act 2001, Ireland’s substance use treatment services are 
established separately from mental health services as mental illness is not considered 
to include substance use disorder (SUD). Substance use disorder and psychiatric 
disorders often co-exist and are regarded as dual diagnosis, co-morbidity or co-
occurring disorders (CODs). International research suggests that the high level of 
psychiatric co-morbidity among adolescents with SUD is the rule rather than the 
exception (Deas 2006). 
 
In light of research findings, early intervention and prevention of CODs are emphasised 
in international research. However, there is a paucity of Irish research on CODs. The 
Youth Drug and Alcohol Service (YoDA), located in Tallaght in west Dublin, provides 
assistance and expert treatment to under-18s living in Dublin South-West and Dublin 
South City, who are having problems related to their drug or alcohol use. It is the 
largest outpatient adolescent substance use treatment programme in Dublin. A recent 
cross-sectional retrospective review of admissions to the service examined patterns of 
psychiatric disorders among SUDs and explored possible gender differences (James, 
et al. 2013). The researcher reviewed 144 admission assessments of adolescents 
made during an 18-month period from January 2010 to June 2011. The review found 
that118 (82%) of those attending were male, with a median age of 16 years (range 13–
19 years) (Table 6.3.2.4). 
 
Table 6.3.2.4: Profile of clients of Youth Drug and Alcohol Service (YoDA), West Dublin, (N = 144), 
January 2010–June 2011 
 n % 
Gender   
  male 118 81.9 
  female 26 18.1 
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 n % 
Living Arrangements   
  parent(s) 111 77.1 
  other relatives 5 3.5 
  In-care 24 16.7 
  others 4 2.8 
Education/Employment status   
  paid employment 5 3.5 
  unemployed 55 38.2 
  alternative education 22 15.3 
  mainstream education 61 42.4 
  unknown 1 0.7 
Main substance of abuse   
  alcohol 33 22.9 
  cannabis 89 61.8 
  cocaine 4 2.8 
  heroin 3 2.1 
  ecstasy/speed 1 0.7 
  anxiolytics/hypnotics 11 7.6 
  legal highs 3 2.1 
Referral source   
  self 4 2.8 
  family 55 38.2 
  addiction services 2 1.4 
  general practice 1 0.7 
  emergency units 4 2.8 
  social work department 35 24.3 
  criminal justice department 24 16.7 
  youth outreach services 2 1.4 
  schools 7 4.9 
  mental health services 8 5.6 
Criminal history   
  none 30 20.8 
  cautions 10 6.9 
 has  juvenile liaison officers 52 36.1 
  charges 51 35.4 
  unknown 1 0.7 
Source: (James, et al. 2013) 
 
The number with a pre-existing psychiatric diagnosis was 55 (38%). Nineteen (13%) 
received a psychiatric diagnosis following entry to YoDA and 70 (49%) had received a 
psychiatric diagnosis at some point in their lives. The most common psychiatric 
diagnosis was deliberate self-harm (DSH) (39, 27%), followed by Attention Deficit 
Hyperactivity Disorder (ADHD) (30, 21%) (Table 6.3.2.5).  
 
Only one in 25 participants had a diagnosis of conduct disorder (CD) but the authors 
noted that CD is probably under-diagnosed among Irish substance-using adolescents. 
While the study examined lifetime psychiatric diagnoses using a retrospective review of 
clinical data, it is possible that mental health problems below the threshold of clinical 
diagnoses may have been under-estimated.  
 
The conclusion was that one in every two Irish adolescents with SUD had a history of 
psychiatric disorder or serious mental health problems during their lifetime and girls 
were more likely to have psychiatric disorders than boys. The authors stated that 
adolescent substance treatment services should have staff equipped with the skills to 
access and manage co-¬occurring psychiatric problem 
 
Table 6.3.2.5: Psychiatric disorders among YoDA clients, by gender, (N = 144), January 2010–June 
2011 
  
Boys 
N 
(%) 
Girls 
N  
(%)  
Total 
Sample 
N 
(%)  
Odds Ratio  
(95%CI) 
 
p value 
Psychiatric 
disorders 
(incl. DSH) 
51 
(43.2) 
19  
(73.1) 
70 
 (48.6) 
0.3 (0.1-0.7) 0.006 
 Pre-existing 42 13  55  
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Boys 
N 
(%) 
Girls 
N  
(%)  
Total 
Sample 
N 
(%)  
Odds Ratio  
(95%CI) 
 
p value 
(35.6) (50.0) (38.2) 
  YoDA-
diagnosed 
13 
(11.0) 
6 
 (23.1) 
19  
(13.2)   
      
Psychiatric 
diagnoses 
(excl. DSH) 
43 
(36.4) 
13  
(50.0) 
56  
(38.9) 
0.6 (0.2-1.3) 0.19 
  Pre-
existing 
38 
(32.2) 
12  
(46.2) 
50  
(34.7)   
  YoDA-
diagnosed 
7 (5.9) 
1  
(3.8) 
8 
 (5.6)   
      
ADHD 
26 
(22.0) 
4  
(15.4) 
30  
(20.8) 
1.6 (0.5-4.9) 0.45 
  Pre-
existing 
23 
(19.5) 
4  
(15.4) 
27  
(18.8)   
  YoDA-
diagnosed 
3 
 (2.5) 
0  
(0) 
3  
(2.1)   
      
Depression 
8  
(6.8) 
7  
(26.9) 
15 
 (10.4) 
0.2 (0.1-0.6) 0.002 
  Pre-
existing 
7  
(5.9) 
6  
(23.1) 
13  
(9.0)   
  YoDA-
diagnosed 
1 
 (0.8) 
1  
(3.8) 
2 
 (1.4)   
      
Psychosis 
6  
(5.1) 
1  
(3.8) 
7 
 (4.9) 
1.3 (0.2-
11.6) 
0.79 
  Pre-
existing 
5  
(4.2) 
1 
 (3.8) 
6 
 (4.2)   
  YoDA-
diagnosed 
1 
 (0.8) 
0  
(0) 
1  
(0.7)   
      Conduct 
Disorder 
4  
(3.4) 
1  
(3.8) 
5  
(3.5) 
0.9 (0.1-8.2) 0.91 
  Pre-
existing 
3 
 (2.5) 
1  
(3.8) 
4 
 (2.8)   
  YoDA-
diagnosed 
1 
 (0.8) 
0 
 (0) 
1  
(0.7)   
      
Oppositional 
Defiant 
Disorder 
5 (4.2) 1 (3.8) 6 (4.2) 1.1 (0.1-9.8) 0.93 
  Pre-
existing 
5 (4.2) 1 (3.8) 6 (4.2) 
  
  YoDA-
diagnosed 
0 (0) 0 (0) 0 (0) 
  
      
Asperger's 
Syndrome 
3 (2.5) 0 (0) 3 (2.1) n/a 
 
  Pre-
existing 
3 (2.5) 0 (0) 3 (2.1) 
  
  YoDA-
diagnosed 
0 (0) 0 (0) 0 (0) 
  
      Anxiety 
Disorder 
5 (4.2) 3 (11.5) 8 (5.6) 0.3 (0.1-1.5) 0.14 
  Pre-
existing 
5 (4.2) 3 (11.5) 8 (5.6) 
  
  YoDA-
diagnosed 
0 (0) 0 (0) 0 (0) 
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Boys 
N 
(%) 
Girls 
N  
(%)  
Total 
Sample 
N 
(%)  
Odds Ratio  
(95%CI) 
 
p value 
      
Attachment 
Disorder 
2 (1.7) 0 (0) 2 (1.4) n/a 
 
  Pre-
existing 
2 (1.7) 0 (0) 2 (1.4) 
  
  YoDA-
diagnosed 
0 (0) 0 (0) 0 (0) 
  
      Tourette's 
Syndrome 
1 (0.8) 0 (0) 1 (0.7) n/a 
 
  Pre-
existing 
1 (0.8) 0 (0) 1 (0.7) 
  
  YoDA-
diagnosed 
0 (0) 0 (0) 0 (0) 
  
      Eating 
Disorder 
0 (0) 1 (3.8) 1 (0.7) n/a 
 
  Pre-
existing 
0 (0) 1 (3.8) 1 (0.7) 
  
  YoDA-
diagnosed 
0 (0) 0 (0) 0 (0) 
  
      
Adjustment 
Disorder 
1 (0.8) 1 (3.8) 2 (1.4) 0.2 (0.1-3.5) 0.23 
  Pre-
existing 
0 (0) 1 (3.8) 1 (0.7) 
  
  YoDA-
diagnosed 
1 (0.8) 0 (0) 1 (0.7) 
  
      Deliberate 
Self-Harm 
(DSH) 
24 
(20.3) 
15 (57.7) 39 (27.1) 0.2 (0.1-0.5) 0.001 
  Pre-
existing 
17 
(14.4) 
9 (34.6) 26 (18.1) 
  
  YoDA-
diagnosed 
7 (5.9) 6 (23.1) 13 (9.0)     
n/a – odd ratios not calculable 
 
Attention-deficit hyperactivity disorder (ADHD) in adults attending addiction 
treatment 
The International ADHD in Substance Use Disorders Prevalence (IASP) study is 
directed by the International Collaboration on ADHD and Substance Abuse (ICASA) 
network and is a multi-site study.  Eight European countries (Norway, Sweden, the 
Netherlands, Belgium, France, Spain, Switzerland and Hungary), the USA and 
Australia participated in Phase I of the study, which closed in September 2011. Over 
2,500 substance use disorder (SUD) patients were sampled, with approximately 38% 
scoring positive on the ADHD Symptoms Rating Scale (ASRS). Of these 2,500 
patients, over 1,000 were evaluated for ADHD, depression, bipolar disorder, anti-social 
personality and borderline personality disorder. A preliminary estimate of the 
prevalence of ADHD in SUD-treatment-seeking patients was recorded at 20% (Van 
den Brink 2012). 
 
Phase II of the IASP study started in September 2011 in Ireland, South Africa, Egypt 
and Brazil. A research team based in the School of Health Sciences at Waterford 
Institute of Technology undertook the Irish part of the study (Van Hout and Foley 2013). 
Following in-depth IASP protocol training, the researchers invited 47 new treatment 
cases presenting to four treatment settings in the south-east region of Ireland to 
participate in the IASP study.  
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There were 34 males and 13 females and the median age was 36 years. Seventeen 
were engaged in treatment for problematic poly-substance use, 14 for problematic 
alcohol use, 14 for problematic drug use and two were undefined.  A total of 10 (21%) 
participants screened positive for ADHD using the Adult ADHD Symptoms Rating 
Scale (ASRS–v1.1) at time one (1st screening),  and this reduced to six (12.7%) at time 
two (2nd screening). These six were all young men, with a median age of 23 years. 
None of the 10 participants identified at time one screening had been diagnosed in 
childhood. They were all being treated for problematic drug use, not for problematic 
alcohol use. These findings support the usefulness and cost-effectiveness of ASRS to 
detect ADHD co-¬morbidity in SUD patients in addiction treatment settings. The 
authors stated that the prevalence of ADHD in SUD patients in Ireland remains 
unknown but the economic and public health burden of SUDs is compounded by the 
presence of ADHD.  
 
Echoing the recommendations of the report on a retrospective study of admissions to 
the Youth Drug and Alcohol Service (YoDA), described just above (James, et al. 2013), 
the authors (Van Hout and Foley 2013) suggested that a timely diagnosis would impact 
on treatment outcomes and that combined pharmacological and psychosocial 
interventions coupled with specialist mental health teams are central to the treatment 
success for co-morbid adults with ADHD and SUD.  
 
Ultra-high risk (UHR) of psychosis on committal to a young offender prison  
In 2012, the first Irish study to report on rates of psychosis in the ultra-high risk (UHR) l 
state for psychosis in a young offender population was published (Flynn, et al. 2012) 
The aim of the study was to provide evidence to enable the efficient allocation of a 
limited mental health resource in identifying and treating the most serious mental 
disorders carrying the highest healthcare burden.  
 
It was a cross-sectional study of young male offenders only, using the Comprehensive 
Assessment of At-Risk Mental States (CAARMS), the Social and Occupational 
Functioning Scale (SOFAS) and the Developmental Understanding of Drug Misuse and 
Dependence (DUNDRUM-DS), which assesses the severity of use of a range of 
intoxicants on four levels. It was the first study to use the CAARMS to identify the 
prevalence of UHR psychosis among young offenders.  
 
Data were collected over a 52-week period (June 2011–¬May 2012) in St Patrick’s 
Institution in Dublin, which is a young offender institution with 217 beds. At the time of 
the study it was the only prison accepting males aged 16 to 20 in the state (population 
4.6 million). Every third person committed was interviewed and the final number of 
participants interviewed was 171. Individuals were excluded if they had a previous 
committal.  All those selected were seen within seven  days of reception, screened by a 
prison nurse within six hours of reception and seen by a GP within 24 hours and then 
had a detailed assessment by visiting psychiatrists.  
 
The results showed that the average age of the study participants was 18.2 years and 
all were under 20 years old (Table 6.3.2.6). The mean time from reception to interview 
by the psychiatrists was 4.1 days. Of the 171 interviewed, 39 (23%) met the criteria for 
UHR, five (3.5%) met the criteria for vulnerability only, nine (5%) met the criteria for 
vulnerability and attenuated psychosis, 19 (11%) met the criteria for attenuated 
psychosis only, and one (0.6%) met the criteria for attenuated psychosis and brief 
limited intermittent psychosis (BLIPS). Two (1.2%) met the criteria for BLIPS and one 
(0.6%) met the criteria for both vulnerability and psychosis.  UHR was not evenly 
distributed according to age, with the highest rate among 18-year-olds. This was not 
related to legal status as it occurred in 23.2% of those on remand and 22.5% of those 
committed. 
 
Table 6.3.2.6 Ultra-high risk of psychosis among those on committal to a young offender prison, by 
age, 2011/2012 
Age (years) 16 17 18 19 20 All 
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Source: (Flynn, et al. 2012) 
 
Substance use problems were reported by 146 of those interviewed (85%) and 
associated with progressively lower SOFAS scores. The number of new committals to 
the young offender institution who met the criteria for UHR of psychosis was 39 (23%) 
and was associated with an increasing number of substance use problems and lower 
SOFAS scores, suggesting that the UHR state identified in this study was associated 
with meaningful impairments. There was a significant relationship between UHR status 
and number of substance use problems (range 0 to 7, x=32.6,df=7, p< 0.001; linear by 
linear association =22.9, df=1, p, 0.001).  Table 6.3.2.7 outlines the number of 
substance use problems and UHR status. 
 
 
Table 6.3.2. 7  Number of substance use problems and UHR status  among those on committal to a 
young offender prison, 2011/2012 
Number of substance 
use problems 
CAARMS status Total 
 Negative Positive Total 
 N (% of row ) N (% of row ) N 
0 23 (89%)  3 (11%) 26  
1 36 (84%) 7 (16%) 43 
2 29 (91%) 3 (9%) 32 
3 18 (86%) 3 (19%) 21 
4 17 (71%) 7 (29%) 24 
5 6 (40%) 6 (60%) 15 
6 2 (40%) 3 (60%) 5 
7 1 (20%) 4 (80%) 5 
Total  132 39 171 
Source: (Flynn, et al. 2012) 
 
6.4 Drug-related deaths and mortality of drug users 
6.4.1 Drug-induced deaths (overdoses/poisonings) 
 
The National Drug-Related Death Index (NDRDI) publishes national figures on drug-
related deaths (Health Research Board 2013). This comprises all deaths owing to 
poisonings, including both illicit drugs covered by Section D, and also other drugs such 
as alcohol and prescription medication not reported in Standard Table 6. 
 
In 2011, there were 220 deaths owing to poisoning recorded in Ireland by the National 
Drug-Related Deaths Index (NDRDI) as per Selection D.  This represents a substantial 
increase compared to 2010, when 173 such deaths were recorded (Table 6.4.1.1; see 
also Standard Tables 5 and 6). It should be noted that annual data previously reported 
have been changed as the database has been updated as new information has 
become available. 
 
Table 6.4.1.1 Poisonings (Selection D) by year, NDRDI, 2002–2011 
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
Selection D 127 108 128 171 189 208 215 217 173 220 
Source: Unpublished data, NDRDI 
 
Overall, the mean age of those who died owing to poisoning remained stable compared 
to previous years at 35.6 years (see Standard Table 6).   
 
Two factors appear to have been influencing the increase in deaths, although more  in-
depth analysis is required to fully understand and explain the increase.  Firstly, while 
opiates continue to be associated with most poisoning deaths (87.3%), almost three 
quarters of deaths owing to poisoning (74.5%) involved more than one drug, a higher 
proportion than reported in all previous years.  Secondly, a  rise has been observed in 
Number on 
committal 
22  40 28 50 31 171 
CAARMS 
positive  
1 (4.5%) 10 (25%) 10 (35.7%) 11 (22%) 7 (22.6%) 39 (22.8%) 
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the number of deaths where methadone was implicated (either alone or with another 
drug).  In 2011, there were 113 deaths where methadone was implicated (either alone 
or with another drug) compared to 60 in 2010.   
 
The reason for the increase in the number of deaths where methadone was implicated 
(alone or in conjunction with another drug) is not yet clear.  The methodology of data 
collection for the NDRDI did not change during that time period.  However, the same 
trend was seen in Scotland in 2010/2011, with a big jump being recorded in the number 
of deaths related to methadone (General Register Office for Scotland 2013, National 
records of Scotland 2013). Further investigation and analysis is needed to try to 
ascertain the reasons behind this finding.  
 
In contrast, the number of deaths where heroin was implicated (alone or with another 
drug or substance) dropped for the third consecutive year, from a peak of 115 in 2009 
to 61 in 2011.  In 2010, heroin or unspecified opiates alone accounted for 23.7% of all 
deaths owing to poisoning but in 2011 this category only accounted for 9.1% of all 
deaths.   
In late December 2010 there was a well-documented heroin drought, which continued 
until early 2011 (Health Research Board 2012).  Data from the NDRDI show that there 
was a reduction in the number of heroin-related deaths in December 2010 and January 
2011 compared to the same months in previous years. However, after January 2011 
the number of heroin-related deaths fluctuated, with no discernible monthly trend apart 
from an overall decrease in the annual number of deaths.  A reduction in the number of 
heroin seizures was recorded again in 2011, but it cannot be ascertained if it is this that 
is influencing the downward trend in heroin-related deaths (Health Research Board 
2012).  The reduction in seizures may be owing to a number of inter-related complex 
factors including a reduction in heroin use, a change in law enforcement activities or 
other factors as yet unknown.  This trend was also seen in the Scottish data for 
2010/2011 (General Register Office for Scotland 2013) (National records of Scotland 
2013).   
 
The decrease in the number of deaths where cocaine was implicated (either alone or 
with another drug or substance) was sustained in 2011, at 23 compared to 21 in 2010.   
 
There was an increase in the number of deaths owing to poisoning which involved 
more than one drug, a higher proportion than reported in all previous years.  
Benzodiazepines, alcohol, antidepressants, and other over-the-counter medications 
were among the main drugs implicated in poly-substance poisonings. The biggest 
increases were among benzodiazepine drugs. For example, the number of deaths 
where diazepam was implicated (along with another drugs) increased to 109 in 2011 
compared to 54 in 2010. 
 
In the seven-year period 2004–2010, a total of 3,972 deaths by drug poisoning and 
deaths among drug users met the criteria for inclusion in the NDRDI database. Of 
these deaths, 2,364 were due to poisoning and 1,608 were due to traumatic or medical 
causes (non-poisoning) (Table 6.4.1.2).  The annual number of poisoning deaths 
increased from 267 in 2004 to 388 in 2007, but decreased in subsequent years, to a 
total of 323 in 2010.  This appears to reflect a downward trend in the number of drug-
related deaths in Europe in 2009 and 2010.  As in all previous years, males accounted 
for the majority of deaths (74% in 2010). The majority were aged between 20 and 44 
years; the median age was 40 years. 
 
Table 6.4.1.2   Number of deaths, by year, NDRDI 2004–2010 (N=3,972) 
 
2004 2005 2006 2007 2008 2009 2010 
All deaths 
 
431 501 561 628 624 652 575 
Poisoning (n=2,364) 267 300 326 388 386 374 323 
Non-poisoning (n=1,608) 164 201 235 240 238 278 252 
Source: (Health Research Board 2013) 
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Just over half (52%) of all poisoning deaths involved more than one substance (poly-
substance cases) (Table 6.4.1.3).  Alcohol alone was responsible for 24% of all deaths 
in 2010. 
 
Table 6.4.1.3   Combinations of drugs involved in poisoning deaths, NDRDI 2004–2010 (N=2,364) 
  2004 2005 2006 2007 2008 2009 2010 
All poisoning deaths 267 300 326 388 386 374 323 
        
Single substances 
       
Alcohol alone 61 51 54 86 81 61 76 
Opiates alone 33 34 53 54 54 60 46 
Analgesic (including an 
analgesic containing an opiate 
compound) 22 24 16 6 10 10 7 
All other specified single 
substances 36 58 67 65 51 57 38 
  
       
Poly-substances 
       Poly-substances (including 
opiates such as heroin, 
methadone) 41 64 80 91 120 121 91 
Poly-substances (including 
analgesics containing an opiate 
compound) 28 31 15 16 11 14 20 
Poly-substances (excluding 
opiates) 35 29 26 58 50 34 32 
Psychoactive medication with 
alcohol 11 9 15 12 9 17 13 
Source :(Health Research Board 2013) 
 
In 2010 the number of deaths in which heroin was implicated decreased by 39%, to 70 
compared to 115 in 2009 (Table 6.4.1.4).  The well-documented heroin drought in 
Ireland in December 2010 and the early part of 2011 may well have been a factor in 
this reduction (Stokes 2012), (Health Research Board 2012). However, further analysis 
of the data and trends in 2011 deaths needs to be undertaken before the full impact of 
that event can be understood.  
 
Since 2007 there has been a 70% decrease in the number of deaths where cocaine 
was implicated, with 20 deaths in 2010 compared to 66 in 2007. This again reflects a 
downward trend in the number of cocaine-related deaths in some European countries.  
Alcohol was involved in 46% of all poisoning deaths in 2010, more than any other drug. 
Benzodiazepines, which include diazepam and flurazepam, were the second most 
common drug group implicated in poisoning deaths. 
 
Table 6.4.1.4   All drugs involved in poisoning deaths, NDRDI 2004¬–2010 (N=2,364) 
 
2004 2005 2006 2007 2008 2009 2010 % Total 
All deaths* 267 300 326 388 386 374 323 100 
         
Alcohol 125 116 111 173 155 142 147 41.0 
        
 
Heroin 29 47 68 80 91 115 70 21.2 
Methadone 40 43 61 55 80 69 56 17.1 
Other opiate
†
 62 69 55 54 47 52 51 16.5 
Cocaine 19 36 53 66 60 53 20 13.0 
MDMA 13 10 7 19 7 ~ ~ 2.5 
        
 
Diazepam 31 41 64 61 66 80 60 17.0 
  100 
 
2004 2005 2006 2007 2008 2009 2010 % Total 
Other benzodiazepine 28 25 29 42 38 30 31 9.4 
Flurazepam 18 13 23 21 20 24 22 6.0 
         
Other prescription medication
§
 42 37 39 61 62 59 71 15.7 
Antidepressant 54 53 43 48 85 67 62 17.4 
Non-opiate analgesic 13 23 12 19 18 16 14 4.9 
        
 
Other
‡
 9 22 21 25 31 50 36 8.2 
Source :(Health Research Board 2013) 
*This is a multi-response table taking account of illicit use of up to six drugs. Therefore numbers and percentages in 
columns may not add  
  up to totals shown, as individual cases may use more than one drug or substance. 
† Includes morphine, codeine, unspecified opiate-type drug, other opiate analgesic. 
§ Includes non-benzodiazepine sedatives, anti-psychotics, cardiac and all other types of over-the-counter medication. 
‡ includes solvents, insecticides, herbicides, other amphetamines, hallucinogens, head shop drugs and other chemicals.   
~ Less than five cases. 
 
 
6.4.2 Mortality and causes of deaths among drug users (mortality cohort studies) 
Currently there are no mortality cohort studies under way. For the most recent research 
on mortality among drug users, a 25-year longitudinal study of a cohort of injecting drug 
users in inner-city Dublin, see Section 6.2.1 of the 2012 National Report  (Health 
Research Board 2012). 
 
6.4.3 Specific causes of mortality indirectly related to drug use (e.g. HIV/AIDS 
and HCV related to IDU, suicides, accidents) 
Deaths among drug users, 2004–2010 
In the seven-year period 2004–2010 a total of 1,608 non-poisoning deaths among drug 
users met the criteria for inclusion in the NDRDI database (Table 6.4.1.1). The number 
of non-poisoning deaths decreased slightly to 252 in 2010, compared to 278 in 2009.  It 
was possible to categorise 243 of the non-poisoning deaths in 2010 as being due to 
either trauma or medical causes (Figure 6.4.3.1).   
 
 
 
Figure 6.4.1.1   Non-poisoning deaths among drug users, NDRDI 2004–2010 (N=1,523) 
Source: (Health Research Board 2013) 
 
The number of deaths owing to trauma decreased to 112 in 2010, down from 132 in 
2009 (Figure 6.4.1.1). The majority (68%) of those who died were aged under 39 years. 
The median age was 33 years.  As in previous years, the majority were male (78% in 
2010) (Health Research Board 2012).  The most common causes of death due to 
trauma were hanging (44%) and drowning (12%). 
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The number of deaths owing to medical causes remained stable in 2010.  However, the 
numbers have risen steadily over the reporting period, increasing from 55 in 2004 to 
131 in both 2009 and 2010 (Figure 6.4.1.1). The majority (63%) of those who died from 
medical causes were aged between 30 and 49 years. The median age was 43 years. 
Males accounted for 76% of those who died. The most common medical causes of 
death were cardiac events (26%) and respiratory problems (12%). 
 
Mortality among injecting drug users 
A study carried out in a large Accident & Emergency department in Dublin found a 
mortality rate of 4.86 per 100 patient-years among a cohort 146 patients with a history 
of injecting drug use who attended in 2010 (O'Connor, et al. 2013).  For more details, 
see Section 6.2.3.   
 
Drug driving and fatal road traffic collisions 
In a recent report on roadside drug testing and equipment and other related matters 
(Cusack, et al. 2012), the NDRDI provided a complete census of fatal road traffic 
collisions where the deceased had a positive toxicology for an illicit substance.  This is 
described in more detail in Section 9.3. 
 
Case studies on drug-related deaths 
The verdict of death by misadventure was given at an inquest of a 37-year-old man 
(Tormey, WP 2012).  The primary cause of his sudden death was recorded as coronary 
thrombosis with secondary cause of death being recorded as cannabis use. The 
deceased was known to smoke 20 cigarettes a day and also to have smoked cannabis. 
Tetrahydrocannabinol was found in the urine but no cannabinoids were detected in the 
deceased’s blood.  According to the author, the role of legal drugs such as nicotine in 
cardiac deaths might be ignored, while the role of cannabinoids might be 
misinterpreted owing to the, at most, two-hour time-limit on their role as triggers for 
myocardial infarction.  The author suggested that ‘Cotinine, the biochemical marker of 
tobacco smoke, should be added to the standard toxicological screen in the guidelines 
on autopsy practice of the Royal College of Pathologists’.  
 
Another case study looked at the death of a 37-year-old woman who died from acute 
haemorrhagic necrotising pancreatitis (Tormey, William P, et al. 2013b).  She had been 
on a methadone programme and at post mortem, toxic levels of codeine with 
potentially lethal levels of methadone were found in blood samples.  The author stated 
that toxicology may not always be able to provide an answer.  In this death it was not 
possible to distinguish whether this was a codeine and methadone poisoning in a case 
of acute pancreatitis (perhaps as a result of overmedication because of pain), or 
pancreatitis caused by opiates, which is a rare occurrence but has been well described. 
 
Biochemical toxicology and suicide in Ireland 
In the event of an unexplained or unnatural death, the pathologist, in conjunction with 
the coroner will ask for a range of toxicological tests. The Department of Chemical 
Pathology in Beaumount Hospital, Dublin, carried out a study to ‘confirm that the 
reliance on the results of immunoassay screen for drugs of abuse and common 
analgesics in order to select samples for compound confirmation by gas 
chromatography-mass spectrometry is likely to understate the potential role of drugs in 
suicide’ (Tormey, WP, et al. 2013a).  Toxicology results for 132 deaths where the 
clinical information provided with the sample from the pathologist indicated that the 
death was due hanging, suicide or drug overdose from March 2006 to April 2008 were 
reviewed retrospectively.  All the deaths originated from the Coroner Service.  The 
results were from broad-based drug screening of blood and urine samples. 
 
Of the 132 deaths, the clinical information provided indicated that most (101) were due 
to hanging, 21 were definite or suspected overdoses, and for 10 deaths the clinical 
information only mentioned suicide (no cause defined). Overall, alcohol (57%), 
benzodiazepines (26%), antidepressants (22%), opioids (20%), cannabinoids (11%), 
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antipsychotics (10%), sympathomimetics (7.5%), hypnotics (5%), cocaine (4.5%) and 
antihistamines (4%) were found in the various laboratory tests.  The authors 
recommended that toxicology screening in the case of death by hanging and other 
suicides should be extended. 
 
National Registry of Deliberate Self Harm Annual Report 2012  
The eleventh annual report from the National Registry of Deliberate Self Harm was 
published in September 2013 (Griffin, et al. 2013). The report contained information 
relating to every recorded presentation of deliberate self-harm to acute hospital 
emergency departments in 2012, giving complete national coverage of cases treated. 
 
There were 12,010 recorded presentations of deliberate self-harm, involving 9,483 
individuals, in 2012. This implies that one in five (2,527, 21%) of the presentations were 
repeat episodes. The rate of presentations decreased from 215/100,000 of the 
population in 2011 to 211/100,000 in 2012, a 2% decrease.  
 
Forty-six per cent of self-harm presentations in 2012 were men and 44% were aged 
under 30 years. Four hundred and sixty-nine (4%) self-harm presentations were living 
in hostels for the homeless or had no fixed abode. Presentations peaked in the hours 
around midnight and were highest on Sundays and Mondays; 32% of episodes 
occurred on these two days. There was evidence of alcohol consumption in 4,610 
(38%) presentations and this was more common among men (42%) than women 
(36%). 
 
Drug overdose was the most common form of deliberate self-harm reported in 2012, 
occurring in 8,284 (69%) such episodes. Overdose rates were higher among women 
(75%) than among men (62%). In 70% of cases the total number of tablets taken was 
known; an average of 30 tablets was taken in these cases. The average among men 
was 32 tablets and among women 28 tablets.  
 
Forty-one per cent of all drug overdoses involved a minor tranquilliser (most commonly 
benzodiazepines), 28% involved paracetamol-containing medicines, 22% involved anti-
depressants or mood stabilisers (anti-depressant drugs known as Selective Serotonin 
Reuptake Inhibitors [SSRIs]) and 10% involved a major tranquilliser. Compared to 
2011, a significant reduction was observed in the involvement of street drugs in 
intentional drug overdose acts, with a fall of 10% in 2012, which followed a 27% 
reduction in 2011. This reduction is likely to have been associated with the ban on 
head shop drugs from August 2010 onwards. 
 
The next steps, or referral outcomes, for the deliberate overdose cases were: 48% 
discharged home; 28% admitted to an acute general hospital; 10% admitted to 
psychiatric in-patient care; a small proportion (3%) refused admission to hospital; and 
12% discharged themselves before receiving referral advice. 
 
The report provided information on what was being or can be done to reduce the 
number of self-harm cases. In January 2012, the National Office for Suicide Prevention 
(NOSP) established a National Working Group to continue to address access to minor 
tranquillisers. The authors recommended that this working group also review the 
implementation of the paracetamol legislation and prescribing patterns of SSRIs. 
 
The authors reported that alcohol continued to be one of the factors associated with the 
higher rate of self-harm presentations on Sundays, Mondays and public holidays, 
around the hours of midnight. These findings underlined the need for on-going efforts 
to: 
o enhance health service capacity at specific times and increase awareness of the 
negative effects of alcohol misuse and abuse such as increased depressive 
feelings and reduced self-control; 
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o intensify national strategies to increase awareness of the risks involved in the use 
and misuse of alcohol, starting at pre-adolescent age, and intensify national 
strategies to reduce access to alcohol and drugs; 
o educate self-harm patients and their families about the importance of reduced use 
of and access to alcohol; and 
o arrange active consultation and collaboration between the mental health services 
and addiction treatment services in the best interest of patients who present with 
dual diagnosis (psychiatric disorder and alcohol/drug abuse). 
 
The authors reported that there was variation in the next care recommended to 
deliberate self-harm patients, and in the proportion of patients who left hospital before a 
recommendation, from 6% in the Southern Hospitals Group to 19% in the Dublin North 
East Hospitals Group. In 2012, a sub-group of the National Mental Health Clinical 
Programme Steering Group produced ‘National guidelines for the assessment and 
management of patients presenting to Irish emergency departments following self-
harm’. The authors of the guidelines recommended ‘that these guidelines be 
implemented nationally as a matter of priority’. In addition, the NOSP has funded pilot 
projects to implement and evaluate suicide and self-harm awareness training for all 
emergency department staff, and to improve assessment procedures for self-harm 
patients in Cork and Kerry, which is a collaborative initiative between Cork University 
Hospital and the National Suicide Research Foundation. 
 
Second Report of the Suicide Support and Information System (SSIS) 
The second report of the SSIS (Arensman, et al. 2013) focuses on two questions:  (1) 
investigating whether there are different subgroups among people who die by suicide, 
and (2) early identification of emerging suicide clusters using advanced geo-spatial 
techniques. The research team identified 275 cases of suicide and 32 deaths with open 
verdicts in County Cork between September 2008 and March 2012. Coroner checklists 
were completed for all 307 cases. 
 
The vast majority (220, 80%) of those who had died with a verdict of suicide were men. 
The average age was 41 years and men were significantly younger at the time of death 
(39 years) than women (46 years). The majority were Irish (93%), single (51%), and 
living in a house or flat (95%). Thirty-three per cent were unemployed, 22% were living 
alone and 2% were living in a supervised hostel. In terms of occupation, 41% had been 
working in the construction sector. 
 
The majority (63%) of the 275 suicide cases died by hanging, 12% by drowning and 
10% by intentional drug overdose. Legal drugs used in the overdose cases included 
both prescribed (53%) and non-prescribed (46%) medication. Illegal drugs used 
included cocaine, ecstasy and heroin.   
 
For those with drugs in their toxicology, just over one quarter (26%) had drugs above 
the therapeutic range, and 21% had multiple drugs in their toxicology. In addition, 39% 
had antidepressants in their toxicology, 54% had benzodiazepines, 39% had opiates 
and 29% had other drugs in their toxicology. Seventeen per cent of the total number of 
cases had taken medication and/or drugs in combination with other methods, such as 
hanging and drowning. A minority (14%) had used other methods, including cutting or 
stabbing, carbon-monoxide poisoning, firearms and jumping from a height or in front of 
a train. Close to one third (31%) of cases had left a note, in the form of a letter, e-mail 
or text message. 
 
Sixty-one per cent of the suicide cases had a family history of mental disorder and the 
same proportion had a personal or family history of substance abuse. Over 39% of 
cases had either a personal experience of significant physical, sexual or emotional 
abuse or a family history of such abuse. Ten per cent of fatalities had a parent or 
sibling who had a non-natural death, such as suicide, homicide or accident.  
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A history of self-harm was known for 132 cases, of which 86 (65%) had engaged in at 
least one act of deliberate self-harm. Of these, 33% had engaged in one act, 14% in 
two acts and 10% in three acts. Twenty-seven per cent had engaged in deliberate self-
harm in the 12 months prior to ending their lives, 14% less than a week before and 
10% less than a day before. 
 
Sixty-two (20%) cases were known to have experienced suicidal behaviour (fatal 
and/or non-fatal) by family members or friends at some point in their lives. Of these 62, 
85% had a relative or close friend who had died by suicide and the remaining 15% had 
engaged in non-fatal self-harm. In eleven cases (18%), the deceased had lost three 
relatives or close friends by suicide. 
 
A psychiatric assessment was known to have taken place in 123 cases. In the majority 
(69%) of these cases, mood disorder (such as depression) was the primary diagnosis, 
followed by anxiety disorder (6%), schizophrenia (5%) and alcohol, drug or alcohol and 
drug dependence/misuse (6%). 
 
In the year prior to death, 173 of the cases had abused alcohol and/or other drugs. Of 
these cases, 49% had abused alcohol only, 28% had abused both alcohol and other 
drugs and 21% had abused other drugs only. 
 
Suicide clusters 
A total of nine statistically significant clusters were observed between August 2010 and 
June 2012. There was much overlap and nestling within these clusters, with two groups 
of clusters emerging.  
 
Group 1 involved 13 cases (12 men and one woman) of suicide in County Cork over a 
three-month period, from April to June 2011. Nearly half the people (46%) had died by 
hanging and 38% had taken an overdose intentionally. At the time of death, 31% had 
used drugs, 23% had used alcohol and drugs, and 38% had a clear toxicology. More 
than one third (38%) had been diagnosed with a psychiatric illness and nearly two 
thirds (61%) had been diagnosed with a physical illness. 
 
Group 2 involved seven cases of suicide (three men and four women) in County Cork 
over a two-month period, from September to October 2011. The majority of the people 
involved had died by hanging, and the next largest number had died by jumping from a 
height. At the time of death, the majority had drugs only in their toxicology results. 
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7. Responses to Health Correlates and Consequences 
7.1 Introduction 
This chapter presents new data on the prevention of drug-related mortality, the 
management of blood-borne viral infections, and responses to co-morbidity. The public, 
voluntary and community sector institutions that have been engaged in the various 
initiatives reported in the following sections are briefly described here.  
 
The Health Service Executive (HSE) is responsible for managing and delivering 
health and personal social services in Ireland. It supports numerous responses to the 
health correlates and consequences of problematic drug use.  
 
The Irish Psycho-Gastroenterology Hepatitis C service is located in Beaumont 
Hospital, Dublin, a 660-bed university teaching hospital with a specialised 
gastroenterology service for assessing and treating patients with chronic hepatitis C 
virus infection. The psychiatry liaison team is part of a multidisciplinary service where 
medical and psychiatric care is offered to all patients who are diagnosed with hepatitis 
C infection and are considered suitable candidates for combined interferon and 
ribavirin therapy.  
 
 
7.2 Prevention of drug-related emergencies and reduction of drug-
related deaths 
 
Withdrawal of distalgesic from the Irish market  
In January 2006, distalgesic was withdrawn from the Irish market. The withdrawal 
resulted in an immediate reduction in sales to retail pharmacies from 40 million tablets 
in 2005 to 500,000 tablets in 2006 while there was a 48% increase in sales of other 
prescription compound analgesics. A study examining the impact of the withdrawal in 
terms of intentional drug overdose (IDO) presentations to hospital emergency 
departments nationally found a positive effect, with an 84% (10 per 100,000)  reduction 
over a three-year period (2006–2008) in the rate of IDO presentations involving the 
drug distalgesic (Corcoran, et al. 2010). There was a 44% increase in the rate of IDO 
presentations involving other prescription compound analgesics but the magnitude of 
this rate was five times smaller than the magnitude of the decrease in distalgesic-
related IDO presentations. The smaller increase in IDO presentations involving other 
prescription compound analgesics indicated evidence of some substitution. The 
authors concluded that the withdrawal of distalgesic in Ireland had been a positive 
measure in preventing non-fatal suicidal behaviour, which is likely also to have an 
effect on suicide.  
 
DUMP (Dispose of Unused Medications Properly) project  
A review of the Dispose of Unused Medications Properly (DUMP) project, set up in 
2002 in the South-Western Heath Board Area (SWHBA) to encourage people to return 
their unused medicines to their local community pharmacies, found that between 2004 
and 2010 the use of minor tranquillisers in drug intentional overdose (DIO) in the area 
remained stable, with a slight decrease in the numbers in 2010 (National Suicide 
Research Foundation 2012). This was in contrast to the rest of the country where an 
upward trend in the use of minor tranquillisers in DIOs was observed since 2007. The 
authors concluded that initiatives such as the DUMP project, aimed at restricting 
access to frequently-used means of self-harm and suicide, were effective in reducing 
DIO involving minor tranquillisers. They strongly recommended implementing the 
campaign nationwide. 
 
Different-sized packs of paracetamol  
Legislation introduced in the UK in 1998 restricted the size of paracetamol packs 
available for sale in pharmacies to a maximum of 32 tablets, and in non-pharmacy 
outlets to a maximum of 16 tablets. In Ireland, similar legislation was introduced in 
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2001, albeit with smaller pack sizes: a maximum of 24 tablets may be sold in 
pharmacies in Ireland, and a maximum of 12 tablets in non-pharmacy outlets.  
A study was undertaken, comparing the number of paracetamol tablets used in 
overdoses in the two countries between 2002 and 2007, and correlating this with 
information on the size of packets of paracetamol (Hawton, et al. 2011). Data on 
general hospital presentations for non-fatal self-harm obtained from the Multicentre 
Study of Self-harm in England and from the National Registry of Deliberate Self-Harm 
in Ireland formed the basis for the study.  
 
The author reported a clear association in both countries between peaks in the number 
of non-fatal overdoses and the use of maximum number of paracetamol packs 
obtained in pharmacy and non-pharmacy outlets. People who overdosed on 
paracetamol tended to consume a quantity of tablets related to available pack sizes. 
However, the number of tablets consumed did not differ significantly between the two 
jurisdictions. In Ireland, people tended more often than in England to take numbers of 
tablets equivalent to multiple packs, raising the question as to whether this difference is 
due to patients’ characteristics, access to care, or greater ease of purchasing multiple 
packs in Ireland compared to England. There were no differences between age groups 
or gender, with the exception of women in Ireland aged 35 years and over, among 
whom there may have been an association between smaller pack size and smaller 
overdoses.  
 
 
7.3 Prevention and treatment of drug-related infectious diseases 
 
National Hepatitis C Strategy  
The HSE published the hepatitis C strategy in September 2012 (HSE National Hepatitis 
C Strategy Working Group 2012). The strategy contains updated epidemiological 
information on hepatitis C and details of new direct-acting antivirals.  The HSE National 
Hepatitis C Strategy Working Group summarised the epidemiology of hepatitis C, 
which is a disease of the liver caused by a virus identified in 1989. This viral disease is 
spread from person to person through contact with infected blood or other body fluids. 
Unsterile injection equipment and infected blood or blood products are the major risk 
factors for the transmission of the virus. There are usually no symptoms associated 
with the acute and early chronic stages of hepatitis C disease. Chronic infection occurs 
in 70%–80% of adults who are infected with the virus. Symptoms of chronic infection 
may include on-going flu-like symptoms, joint pains, abdominal pain, loss of appetite, 
altered bowel habit, mood swings and/or an inability to sleep. Complications of chronic 
hepatitis C include liver cirrhosis, liver failure and liver cancer. There are six genotypes 
for hepatitis C; treatment outcomes are dependent on genotype and other factors. In 
Ireland injecting drug users (IDUs) are likely to have genotypes 1 or 3 (Conroy, et al. 
2003).  
 
Certain factors have been identified as increasing the severity of the disease: these 
include alcohol intake, co-infection with HIV or hepatitis B, super-infection with hepatitis 
A and older age at infection.  The working group reviewed the effectiveness of 
treatment and reported that hepatitis C can be treated with a combination of two or 
three anti-viral agents. The medication used to treat this disease includes pegylated 
interferon, ribavirin and, more recently (in the USA), telaprevir or boceprevir. The 
addition of either telaprevir or boceprevir to the existing treatment (pegylated interferon 
and ribavirin) increases the success of the treatment for those with genotype 1. When 
treated with a combination of the three anti-viral agents, 80% of the hepatitis C 
genotype 1 patients are likely to experience sustained viral clearance, compared to 
50% when only the two drugs (pegylated interferon and ribavirin) are used. There are 
contra-indications to hepatitis C treatment, including pregnancy, severe depression or 
other mental illness, renal disease, autoimmune disease and end-stage liver cirrhosis.  
 
The working group reported that the prevalence of hepatitis C among those infected 
through injecting drug use or the administration of blood and blood products was high. 
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In one study, the proportion of IDUs attending a drug treatment clinic in Dublin who 
tested positive for antibody to hepatitis C virus was 62% (Smyth, Bobby P, et al. 1998), 
and a national study on committal prisoners found that 81% (414) of the IDUs tested 
positive for hepatitis C antibodies (Long, et al. 2001).  
 
The prevalence in the general population is unknown but between 1997 and 2010 the 
prevalence among blood donors was 0.02% and was 1% or less among attendees at 
antenatal clinics (Health Protection Surveillance Centre 2012b). 
 
There have only been two historical studies examining the incidence of hepatitis C 
among IDUs. One study estimated the incidence of hepatitis C among 100 IDUs 
attending treatment in Dublin between 1992 and 1998 who had an initial negative test 
and a repeat test within nine months (Smyth, Bobby P, et al. 2003). The authors 
reported that the incidence of hepatitis C was 66 per 100 person years. A later study 
reported an incidence of 24.5 per 100 person years among a sample (358) of opiate 
users (including some non-injectors) attending treatment in the former South Western 
Area Health Board in 2001/2002 (Grogan, et al. 2005). Comparisons between these 
studies are difficult as it is not possible to ascertain the proportion of non-injectors in 
the sample surveyed in the later study. Studies in Ireland identify homeless people, 
prisoners and asylum seekers as being high-risk populations for hepatitis C, largely 
because a high proportion of prisoners and homeless people inject drugs. The working 
group reported that asylum seekers often come from countries where hepatitis C is 
endemic.  
 
There were 2,800 discharges from acute hospitals with a principal diagnosis of chronic 
viral hepatitis C between 2005 and 2010 and there were 1,193 discharges with a 
principal diagnosis of primary liver cancer. There were 703 cases of hepatocellular 
carcinoma registered by the National Cancer Register Ireland between 1994 and 2010. 
The National Cancer Register Ireland (NCRI) estimates that 30% of hepatocellular 
carcinoma cases were hepatitis C positive. The liver transplant unit at St Vincent’s 
University Hospital reported that 42 (13.5%) of 311 liver transplant cases between 
2000 and 2006 had hepatitis C. 
 
The new national hepatitis C strategy makes 36 recommendations: eight covering 
surveillance; 14 on education, prevention and communication (through six overarching 
themes); six on screening and testing; and eight on treatment (through seven 
overarching themes). The recommendations for ensuring accurate surveillance include: 
 
o ensure laboratory requests for hepatitis C serology contain patient identifiers and 
clinician details;  
o encourage clinicians to notify newly diagnosed cases of hepatitis C and provide 
relevant information where possible; 
o commence enhanced surveillance (including the collection of risk factors) for newly 
diagnosed cases of hepatitis C;  
o establish a national register of patients diagnosed with hepatitis C;  
o commence appropriate public health follow-up on newly notified cases of hepatitis 
C;  
o estimate the prevalence of hepatitis C and identify risk factors among the general 
population; 
o complete a modelling exercise to estimate future disease burden and aid service 
planning; and 
o conduct follow-up studies amongst injecting drug users to identify sero converters 
so as to measure incidence rate.  
 
The recommendations for maximising prevention and ensuring clear and accurate 
information are: 
 
o treat existing drug addiction among IDUs; 
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o prevent transition from smoking heroin to injecting heroin and encourage current 
injectors to move to treatment or harm-reduction approaches; 
o improve provision of harm-reduction materials through nationwide access to and 
uptake of comprehensive set of materials and appropriate communications with 
respect to language, literacy and accuracy; 
o ensure staff and peer-educators are recruited to pre-agreed standards and have 
appropriate training and materials to provide accessible and accurate information;  
o plan and implement a campaign to raise awareness among those who may 
previously have been diagnosed with hepatitis C or who may have been at risk of 
infection in order that they consider accessing new treatment options; and 
o regulate services that provide body-piercing, tattooing and permanent make-up. 
 
The recommendations for ensuring screening and diagnosis are available to the 
appropriate at-risk populations in a timely manner are: 
 
o improve availability of and access to facilities for screening, testing and diagnosis 
available in primary and community care services with adequate and timely 
laboratory facilities; 
o enhance prison-based services with respect to risk assessment, screening and 
follow-up; 
o offer and promote screening for hepatitis C and other blood-borne diseases to 
those who attend services such as needle-exchange programmes and other harm-
reduction services; 
o continue targeted antenatal screening for those with risk factors for hepatitis C 
infection and consider the evidence for introducing universal screening at regular 
intervals; 
o ensure the National Viral Reference Laboratory (NVRL)  provides previous tests 
results to medical practitioners who have ascertained the patient’s consent; and 
o establish guidelines on hepatitis C screening for individuals from endemic countries 
or new entrants to the Irish healthcare system. 
 
The recommendations for ensuring that evidence-based hepatitis C treatment and 
other supports are available to patients in a timely manner are: 
 
o ensure governance, evidence-based protocols and review are available to 
diagnose people with hepatitis C and treat if required; 
o develop, implement and evaluate a treatment model appropriate to the prison 
setting on a national basis 
o establish a postgraduate diploma in hepatitis C management for physicians and 
nursing staff; 
o undertake a formal assessment of the needs of individuals infected with hepatitis C, 
other than through contaminated blood and blood products, through an increased 
number of clinical nurse specialist posts and subsequent needs assessments; 
o develop a role for GPs (with special qualifications) to monitor hepatitis C treatment 
in primary and community care in consultation with other appropriate medical 
specialists; 
o provide patients, particularly those with chaotic lifestyles and other social problems, 
with practical supports to enable them to attend for and adhere to treatment; and 
provide interventions to assess and if necessary reduce alcohol intake in patients with 
hepatitis C. 
 
Hepatitis C: Is there a case for universal screening in pregnancy?  
Hepatitis C is not routinely screened for at antenatal clinics in maternity hospitals in 
Ireland. Most hospitals adopt a policy of targeted or selective screening based on 
criteria such as ever injected illicit drugs or tattooing.  
 
Up until 2007, the policy at the Coombe Women and Infants University Hospital in 
Dublin was a targeted hepatitis C screening programme.  The criteria for inclusion were 
the presence of tattoos or body piercing, a history of intravenous drug use (IDU), 
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receiving blood products or having jaundice, sexual contact potential with an infected 
partner, or being a migrant from a country with a known high prevalence rate of 
hepatitis C. In 2006, 67 women were screened, with 37 (55%) cases identified as HCV-
RNA. Those who tested positive had an average age of 28.5 years .A positive test 
result indicates exposure to the hepatitis C virus and antibodies are thus present. The 
proportion testing positive for hepatitis C viral antibodies (exposed) in the hospital’s 
antenatal population was thus 0.79% for 2006 (37/4,666). . Having a tattoo or a history 
of IDU were the two biggest risk factors for infection. In the group infected with hepatitis 
C, 27% had a C section delivery. Three women were co-infected with HIV and had C 
section deliveries. 
 
In 2007 the policy in the Coombe Women and Infants University Hospital in Dublin 
changed from targeted screening to universal screening. This decision was taken 
following a retrospective analysis of charts of hepatitis C positive mothers who 
attended the hospital for antenatal care between 2006 and 2007. This analysis was 
carried out to determine if there was a case for introducing universal hepatitis C 
screening in pregnancy (Martyn, et al. 2011).  
 
When universal screening was applied in 2007, the proportion of women testing 
positive for hepatitis C viral antibodies in the hospital’s antenatal population was 0.71% 
(66/9,222). Those who tested positive had an average age was 29 years. Having a 
tattoo or a history of IDU were again the two biggest risk factors for infection. In the 
group infected with hepatitis C, 14% had a C section delivery. One woman’s hepatitis C 
status in 2007 would not have been detected by targeted screening as she had none of 
the identified risk factors. Four women were co-infected with HIV in 2007 and had C 
section deliveries. The proportion infected with hepatitis C virus among those on a 
methadone maintenance programme (many of whom had a history of IDU) was 34.7%. 
 
There were similar detection rates for hepatitis C in 2006 using selective screening 
compared with the result in 2007 using universal screening. As 55% (37/67) of women 
tested in 2006 were HCV-RNA positive (targeted screening) and 57.5% (38/66) were 
positive in 2007 (universal screening), the authors concluded that targeted screening 
for hepatitis C did not meet WHO criteria for universal screening but that targeted 
screening based on risk factors works well: few cases will go undetected providing that 
inclusive criteria for selective screening are used.  
 
Universal antenatal screening for hepatitis C 
A large single-centre pilot study to determine the true sero prevalence of hepatitis C in 
an unselected antenatal population and to pilot universal antenatal hepatitis C 
screening was carried out at the Rotunda maternity hospital, Dublin (Lambert, et al. 
2013). At present the Rotunda hospital, like many other maternity hospitals, operates a 
selective screening policy based on disclosed risk factors. Previous studies at the 
Rotunda hospital had revealed a vertical transmission rate of approximately 6.4% 
(Healy, C. M., et al. 2001) 
 
The 9,121 women who were booked for antenatal care over a one-year period from 
June 2007 to June 2008 were offered a hepatitis C antibody test as part of their routine 
antenatal screening. The number who agreed to take part in the study was 8,976, an 
uptake of 98.4%. They were asked to sign a consent form and to complete a risk 
assessment questionnaire for hepatitis C infection. 
 
Seventy-eight women in the cohort tested positive for anti-HCV antibodies giving a 
seroprevalence rate of 0.9%. RT-PCR analysis was carried out on 67 of the 78 positive 
samples. Of these, 43 (64%) were positive for HCV-RNA. Viral loads were available for 
23/78 cases and six (26%) had viral loads greater that 1x106 copies/mL. Genotype 
was available for 18% (14/78) of samples only. The most prevalent genotype was 1B 
(6/14) followed by 1A (4/14).   
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Most (73%) of the 78 anti-hepatitis C positive women reported one or more known risk 
factor –  tattooing (37, 47.4%), a history of IDU (29, 37.2%), other drug use such as 
cocaine or cannabis (30, 38.5%); multiple body piercing (13, 16.7%), current or ex 
partner drug use (16, 20.5%), current or ex partner HCV positive (19, 24.4%). The 
majority (47, 60%) were Irish and over half (44, 57%) were from Eastern Europe.  
 
Among the 78 anti-hepatitis C positive women, one woman was co-infected with 
hepatitis B and two with HIV, 21 (27%) reported no epidemiological risk factors at the 
time of booking into the clinic, and 44 (57%) were from Eastern European countries 
where available information on the risk factors for infection indicates nosocomial 
transmission plays a major role in infection.  Transmission of hepatitis C between 
heterosexuals remains controversial. In this cohort, 24% of anti-hepatitis C positive 
women revealed a current/ex-partner was positive for hepatitis C. In all but one case, 
additional risk factors were disclosed, making conclusions about the role of sexual 
transmission difficult. The authors stated that relying on self-reported risk behaviours 
and the under-estimation of the importance of other risk factors such as heterosexual 
transmission and nosocomial transmission in high prevalence countries means a 
significant proportion of cases will remain undiagnosed under the current guidelines 
(selected screening based on disclosed risk factors). While pregnancy management for 
anti-hepatitis C positive women is the same as for non-infected women (except if HIV 
co-infected), reports on the risks of obstetrical complications owing to maternal 
hepatitis C status are varied. 
 
The authors stated that early referral of mothers to treatment programmes could 
potentially eradicate their hepatitis C, thus ensuring that future unborn children are not 
at risk of this infection. Although there are currently no treatment options available in 
pregnancy to minimise the risk of vertical transmission, timely identification of infection 
would permit interventions to limit/reduce the risk of progression of liver disease. 
Diagnosis would also enable active immunisation against other types of infective 
hepatitides.  Identification of these women as a result of universal screening provides 
evidence that hepatitis C testing should be included with routine antenatal screening.  
 
Hepatitis C treatment in HIV/hepatitis C co-infected patients 
Between October 2008 and January 2009,a retrospective chart review of patients co-
infected with HIV and hepatitis C who attended a genito-urinary medicine and 
infectious disease clinic in a large Dublin hospital was undertaken to identify patient 
demographics, HIV and hepatitis C status and treatment outcomes. (Kieran, et al. 
2011).  
 
Between January 1987 and December 2008, 3,360 HIV-infected patients attended the 
clinical services. Of these, 441 were identified as having a positive hepatitis C antibody 
result, and 55 (12%) of these were excluded from the analysis because 42 had cleared 
their hepatitis C infection spontaneously, while the other 13 patients’ records could not 
be found. Of the remaining 386 patients, 327 (85%) were IDUs.  
 
Of the 327 IDUs, 67 (20%) had initiated hepatitis C treatment, but 260 (79%) had 
received no hepatitis C treatment. Analysis of factors associated with HIV positive 
patients found that active IDU was a barrier to referral to the hepatitis C clinic, as only 
21 of the active IDUs were referred for treatment.  The authors stated that the patients 
not referred to the hepatitis C co-infection clinic were more likely to default from 
appointments, to engage in IDU, to have advanced untreated HIV and not to have had 
hepatitis C treatment offered to them.  
 
Co-infected patients attending the HIV and hepatitis C clinic were more likely to have 
been screened for hepatocellular carcinoma than those attending the general HIV 
service. The authors suggested that the challenges of increasing the uptake of hepatitis 
C care among IDUs are similar to caring for HIV patients and that significant barriers to 
hepatitis C care remain particularly related to substance abuse and outpatient 
attendance. The author’s conclusions were that significant barriers to hepatitis C care 
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remain especially related to substance abuse and outpatient attendance. They 
recommended an integrated HIV/HCV co-infection clinic which could result in 
favourable outcomes for many patients and improved monitoring of liver disease even 
in the absence of a definitive cure for hepatitis C infection.  
 
 
7.4 Responses to other health correlates among drug users 
 
Audit of Irish Psycho-Gastroenterology Hepatitis C service   
Hepatitis C treatment is associated with a number of side effects including 
neuropsychiatric symptoms such as fatigue, irritability, anxiety, depression, psychosis, 
mania, suicidal ideation, cognitive impairment and delirium (Onyike, et al. 2004). A 
recent audit of the Irish Psycho-Gastroenterology  Hepatitis C service  determined the 
number of patients with psychiatric illness prior to and during combined interferon 
treatment and also assessed patient progress during treatment, particularly in relation 
to the development of mental illness and whether therapy needed to be stopped 
(Whitty, et al. 2011). Data were collected prospectively over one year on 50 patients, 
29 (58%) males and 21 (42% females). The mean age of patients was 39 years. During 
the period studied, 46 (92%) patients were undergoing or had completed combination 
therapy. Of the remainder, treatment was discontinued for one (2%) patient owing to 
medical complications arising from the interferon therapy, one patient (2%) was non-
compliant and two (4%) patients had therapy deferred. No patient had their treatment 
deferred owing to psychiatric side effects following commencement of therapy.  
 
There were high rates of psychiatric illness and substance abuse in this group of 
patients. Twenty patients (40%) had a past history of depression, two (4%) had a 
history of psychosis and one (2%) had a history of anxiety disorder. In addition, 42 
(84%) patients had a past history of harmful poly-substance abuse or drug 
dependence. There was no past history of mental illness in the other 27 (54%) patients. 
Thirty-three patients (66%) were treated with psychotropic medication prior to or during 
combination therapy, including those with a past history of depression along with those 
who had current stressors or who had evidenced mild depressive symptoms in the 
month prior to commencing combination therapy. A significant number of patients (17, 
34%) developed a depressive disorder during combination therapy, one developing a 
depressive disorder with psychotic features.  
 
It is known that psychiatric morbidity, in particular depression, is common in patients 
with hepatitis C who are receiving combination therapy. This study found that over one 
third of the patients developed a depressive disorder while on the combined therapy 
but, despite this, completed the treatment course. The authors stated that, in view of 
the high rate of psychiatric disorder development, successful completion requires an 
integrated multidisciplinary approach.  
 
Methadone maintenance and prescribed medication among opioid dependent 
pregnant women 
A 2012 prospective cohort study at two Irish tertiary care maternity hospitals examined 
methadone maintenance and prescribed medication among opioid dependent pregnant 
women (Cleary, et al. 2013). The objective was to compare the incidence of neonatal 
abstinence syndrome (NAS) among the women attending each of the two hospitals.  
 
Data from electronic dispensing records of methadone maintenance doses in the year 
preceding and the month following delivery were available for 89 women. These data 
were examined and NAS was determined using the Finnegan score. The study found 
that 40% (36) of women had their methadone doses decreased during pregnancy and 
35% (31) had their doses increased but the number of new-borns treated for NAS did 
not differ between the two groups.  
 
The authors stated that reducing methadone dose during pregnancy did not appear to 
have an effect on the incidence of NAS and was a common practice in the Irish health 
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service. The authors recommended that clinicians should be guided by maternal 
symptoms with the objective of preventing or minimising concomitant illicit drug use by 
effective dosing and that co-existing maternal mental illness should be assessed and 
managed appropriately in this population.  
 
Youth mental health  
A small study was conducted in the HSE Mid-West region (counties Limerick, Clare, 
North Tipperary), examining the role of the GP in addressing youth mental health 
needs and documenting the spectrum of youth mental health challenges encountered 
by GPs (Healy, Deirdre, et al. 2013). This study complemented similar work in an inner-
city Dublin practice   (Connolly, D, et al. 2012). A self-administered questionnaire was 
sent to 128 GPs in the Mid-West region seeking data on physician and practice 
demographics, case management and barriers to care relating to youth mental health. 
Thirty-nine (30%) GPs responded. The majority of respondents had substantial contact 
with young people, and when asked how many young people attended their practice in 
the previous year, the most frequent answer was ‘more than 250’ (20 practices), 
followed by ‘50–100’ (7 practices), ‘100–250’ (5 practices), and ’10–50’ (3 practices).  
 
They reported that two out of the last ten young people who had consulted them had 
mental health or substance use issues. The three most common reasons cited as to 
why young people attended their practice were for contraception (18, 20%), mental 
health (15, 17%) and respiratory tract infections (11, 12.5%). Of those with mental 
health issues, nine (10%) were referred to dedicated services while three (4%) were 
referred to other non-specialist services. The remainder of patients were not referred to 
secondary care. 
 
The study identified substance abuse issues as the fourth commonest complaint or 
reason why young people attended their GP, and problem alcohol use and problem 
drug use as the sixth and seventh (respectively) most commonly encountered by GPs 
when treating young people.  
 
The authors suggested that these data plus international best practice relating to the 
prevention and treatment of mental and substance use disorders among young people 
should inform future research and service development in the HSE Mid-West. They 
commented that the GP plays an important role in meeting youth mental health needs, 
particularly in economically deprived urban areas. They also suggested that GPs and 
primary care teams need support and education for mental health issues for younger 
patients and particularly on the complexities of comorbidity.  
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8. Social Correlates and Social Reintegration 
8.1  Introduction 
The links between social exclusion and drug use in Ireland have been well established 
(Keane 2007). Problem drug users in treatment tend to be young and male, have low 
levels of education and are unlikely to be employed. For a small proportion, around 
10%, homelessness and insecure accommodation are persistent problems.  
 
The aim of social reintegration is to empower individuals to plan and pursue alternative 
activities to those they engaged in when using drugs. This is achieved through 
providing accommodation, education, and training and employment opportunities for 
recovering drug users.  
 
This chapter presents new data on the social correlates of drug use in Ireland, and 
describes policy and programmes initiated in the past year to support the social 
reintegration of recovering drug users. The broad policy approach and funding to 
support social reintegration are briefly outlined in this section. 
 
The National Drugs Strategy 2009–2016 (Department of Community 2009) lists as a 
priority the implementation of the recommendations contained in the report of the 
working group on drugs rehabilitation (Working Group on drugs rehabilitation 2007). It 
proposes that the recommendations be incorporated in a comprehensive integrated 
national treatment and rehabilitation service, using a four-tier model approach.  
 
The Homeless Agency was formally replaced by the Dublin Region Homeless 
Executive in July 2011. The executive is responsible for providing support and services 
to the Dublin Joint Homelessness Consultative Forum and the Statutory Management 
Group. The Housing (Miscellaneous Provisions) Act 2009 provides a statutory structure 
to address the needs of people who are experiencing homelessness in Ireland. The Act 
outlines a statutory obligation to have an action plan in place and the formation of a 
Homelessness Consultative Forum and a Statutory Management Group.  
 
The Community Employment (CE) scheme, is now operated from the Department of 
Social Protection, includes 1,000 places ring-fenced for recovering drug users. The 
scheme operates through local projects primarily in LDTF areas, where community and 
voluntary groups are required to sign service agreements that outline the work 
programme and the target outcomes for the individuals placed on the CE schemes. 
The objective is to prepare participants for entry into the labour force, but the outcomes 
outlined by most projects tend to refer to personal development, improved literacy skills 
and education capital, and support progression to more specialised training and 
education, rather than help the individual to find employment.  
 
Acknowledging the CE scheme for helping recovering drug users to develop their 
personal and employment skills and find a pathway back to work, the NDS suggests 
that implementation of the Individual Learner Plan (ILP) would help to identify 
participants’ needs and design progression routes towards labour market reintegration.  
The development of targeted programmes is seen as essential and should be an 
integral part of the NDS in the future.  
 
 
8.2 Social exclusion and drug use 
 
8.2.1 Social exclusion among drug users 
 
Merchants Quay Ireland (MQI) has published the profile of a cohort of people attending 
its Health Promotion Unit (HPU) needle exchange (Jennings 2013). Data were 
collected in 2012 from 338 attendees using an instrument developed specifically to 
meet the information needs of the HPU in MQI and included items from internationally 
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validated survey instruments and items fashioned specifically for the present study. 
Staff in the HPU collected data on socio-demographic characteristics, substance use, 
injecting risk behaviour and blood-borne virus (BBV) status and treatment.  
 
Socio-demographic characteristics 
 
A total of 338 participants took part in the study, including 290 males (85.8%). 
Participants ranged in age from 20 to 59 years; the majority were in the 20–34-year 
age group. Participants comprised 19 different nationalities; the vast majority 297 
(88%) were Irish nationals. Approximately one third of the cohort reported living in 
conditions which may be categorised as homeless (Table 8.2.2.1). 
 
Table 8.2.2.1   Attendees at MQI needle exchange, accommodation status during last seven days, 
2012 
Accommodation status n % 
Own/rented home 160 47 
Staying with friends/family 73 22 
Emergency accommodation 67 20 
Sleeping rough 15 4 
Supported temporary 
accommodation 
12 4 
Long-term supported housing 11 3 
Source: (Jennings 2013) 
 
Substance use 
Participants who used heroin were found to consume an average of 2.35 bags per day, 
and to spend an average of €45.72 per day on the drug. Route of administration for the 
vast majority of heroin users was injecting 245 (84.4%); 34 (11.7%) reported both 
injecting and/or smoking heroin and only six (2.7%) reported smoking only.  
 
There were no differences between the genders for most substances used. Where 
differences did occur, proportionately more females than males reported using 
prescribed methadone (73% v. 46%), illicit benzodiazepines (25% v. 17%), and 
prescribed benzodiazepines (23% v. 14%).  
 
Seventy-five per cent (n=272) reported using two or more substances in the last month 
(current use). Thirty per cent (102) reported using two substances in the past month, 
the most frequent combination being heroin and methadone, used by 49 (48%) of the 
sub-sample. Almost 9 out of 10 users who were prescribed methadone reported using 
heroin. Heroin users who did not report using methadone were reported to consume 
higher average amounts of heroin per day, to spend more money on heroin per day 
and to use heroin on the greatest number of days in the past month.  
 
Table 8.2.2.2   Attendees at MQI needle exchange, current use of substances by all participants 
(n=338), 2012  
Substance used in past month n % 
Heroin 290 86 
Prescribed methadone 167 49 
Cannabis 82 24 
Alcohol 74 22 
Illicit benzodiazepines 60 18 
Prescribed benzodiazepines 53 16 
Cocaine 21 6 
Steroids 25 7 
Mephedrone 21 6 
Crack cocaine 20 6 
Illicit methadone 8 2 
Amphetamines 4 1 
Other 13 4 
Source: (Jennings 2013) 
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8.2.2 Drug use among socially excluded groups 
Children being looked after by the state 
The Department of Children and Youth Affairs (DCYA) recently published a report 
detailing a consultation process with 211 children and young people in state care; 
participants ranged in age from 8 to 23 years (Department of Children and Youth 
Affairs 2011). Fifteen consultations were undertaken in Cork, Dublin, Galway and Sligo. 
The young participants came from the following state care settings: prison and 
detention centres (43), residential disability care (10), foster care (58), aftercare (17), 
residential care (48), separated children seeking asylum (34) and young people under 
Section 5 of the  Child Care Act 1991 (1). The report provides a useful insight into the 
main issues that concern young people in care, the difficulties they experience in 
expressing these concerns through current structures and their ideas on how such 
concerns might be articulated in the future.  
 
According to the DCYA, the role played by alcohol and drugs in the lives of some of the 
participants was a recurring theme throughout the consultations. This theme emerged 
primarily from consultations with participants in St Patrick’s Institution (36) and in 
detention centres (7). Many of the participants spoke about using alcohol and/or drugs 
as a means of ‘escaping’ from the traumatic experiences in their lives and few indicated 
any intention to stop using substances in the future. Many also recalled the adverse 
role that alcohol and drugs played in the lives of their parents, which had contributed 
largely to their being placed in state care in the first instance. The adverse experience 
of parental alcohol and drug use was also highlighted by the 58 children aged 8–12 
who were in foster care. The report also contained the views young people on their 
experiences of being looked after by specific state institutions charged with doing this 
work.  
 
From the views expressed by the young participants, a general consensus emerged 
that young people in care would like more meaningful consultation on key decisions 
that impact on their lives; few believed that the current structures of the care plan 
review process or the input of social workers were adequate forums for such 
meaningful consultation. The report recommends that both the care plan review system 
and aspects of the social worker service for young people in care be re-examined. 
Support mechanisms, including a dedicated telephone line, a ‘mentor’ system and 
counselling services for young people in care, are also recommended. These 
recommendations are grounded in the concerns and experiences of young people in 
care as articulated in the consultations reported on above. In this regard, the report 
recommends that ‘the agencies responsible for children in the care of the state must 
listen to the voices of the consultation participants and, more importantly, heed their 
recommendations’ (p. 3).  
 
Homeless people with poor mental health and substance abuse issues 
Recently published research sought to determine the prevalence of mental illness 
among residents of a homeless hostel in inner-city Dublin (Prinsloo, et al. 2012). The 
Structured Clinical Interview for DSM-IV Axis 1 Disorders (SCID-1) Clinical Version was 
used to collect data from study participants over an eight-week period in June–August 
2010. Of 97 men considered as ‘residents’ for the purpose of the study, 38 agreed to 
be interviewed, representing a response rate of 39.2%. Of the 38 participants:  
 
 47.4% were in the 40–54-year age group, 31.6% in the 26–39-year age group and 
21% were aged 55 or over; 
 over half (57.9%) had never married; 
 68.4% had children; 
 73.7% reached secondary level education without graduating; and 
 92% were unemployed. 
 
A total of 81.6% had a current (last 30 days) Axis 1 diagnosis; the rate increased to 
89.5% for lifetime prevalence, when current and past Axis 1 diagnoses were combined. 
  116 
Regarding lifetime diagnoses, the rates were as follows: 42% depressive disorder, 
78.9% substance use disorder, 18.4% anxiety/adjustment disorder and 5.3% psychotic 
disorder. The most common current and past diagnosis was alcohol dependence, with 
52.6% of participants meeting the criteria for dependence. The most common disorders 
during the past 30 days were alcohol dependence 23.7%, opioid dependence and 
major depressive disorder both 18.4% and opioid abuse and alcohol-induced 
depression both 7.9%. According to the authors ‘there was considerable comorbidity 
between disorders, with a significant number of residents experiencing both mental 
illness and substance use problems’ (p. 25).  
Of those interviewed, 31.6% had been admitted to a psychiatric hospital at least once 
during their lifetime and only 23.7% were currently attending an outpatient psychiatric 
or addiction service. The authors note that ‘the low number of residents attending 
services is cause for concern’ (p. 25).  
 
The authors acknowledged the relatively low response rate to the study, and reported 
that information provided to the research team by the specialist support worker at the 
hostel suggested that some of the 59 men who did not agree to be interviewed may 
have had experience of mental illness. They also acknowledged the possibility of 
selection bias, given that the specialist mental health worker at the hostel encouraged 
the men who had mental health problems to be interviewed for the study. However, the 
authors also noted that, to the best of their knowledge, this was the first study 
undertaken in Ireland to assess the complete spectrum of Axis 1 disorders. 
 
Unemployment, homelessness and substance addiction 
The Cork Simon Community, a voluntary organisation providing shelter and 
accommodation to homeless people, undertook a survey in June–July 2012 with 91 
residents to identify the main barriers to employment (Cork Simon Community 2012). 
The respondents were drawn from residents in emergency accommodation and both 
high- and low-support housing. The main barriers to employment were poor mental and 
physical health, substance addiction, early school-leaving, poor literacy, numeracy and 
IT skills, lack of formal qualifications and relevant work skills, low levels of confidence 
and high perception of being discriminated against and histories of long-term 
unemployment and criminal records.  
 
Almost a quarter of valid responses (n=78) cited poor mental and physical health as 
the main reason for losing/leaving their last job. The vast majority, 90% of all survey 
participants (n=91), had worked at some point, with almost half working all or most of 
their lives prior to becoming unemployed. Of those who did work for most of their lives, 
most were employed in unskilled work. When surveyed, 88% of the total 91 were 
unemployed and 92% had been unemployed for one year or more; 45% were receiving 
disability allowance/illness benefit and 26% unemployment benefit/assistance; 17% 
were affected by the Habitual Residence Condition criteria that prevent some foreign 
nationals from receiving social welfare benefits; 8% were in receipt of a state pension 
and 4% were in part-time employment. Poor health was cited by the majority as the 
main barrier to securing and retaining employment.  
 
Alcohol and/or drug addiction and dependence was cited by 22% of valid responses 
(n=78) as the main reason for losing/leaving their last job. Fifty-eight per agreed that 
addiction was adversely affecting their motivation to return to work. Addiction is a major 
worry for those aged under 45 regarding their capacity to find and retain a new job. 
Sixty-five per cent left school prior to completing the Leaving Certificate, more than 
twice the national average. Two-thirds of early school-leavers left school at an average 
age of 14 without completing any state examination.  
 
Substance abuse among offenders on probation supervision 
A report by the Probation Service presents the findings of the first large-scale, 
nationwide survey undertaken by the service on drug and alcohol misuse among the 
adult offender population on probation supervision (Probation Service 2012b). The 
survey involved a representative sample of 2,963 adult offenders on probation officers’ 
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caseloads on 1 April 2011. Questionnaires, developed specifically for the study, were 
completed by the supervising probation officers, based on their case records and 
knowledge of the offenders on their casebooks. The main findings reported suggest 
that:  
 
 89% of the adult offender population on probation supervision had misused drugs 
or alcohol either ‘currently’ (at the time of the survey) or in the ‘past’;  
 of those who misused either alcohol or drugs, 27% misused drugs only, 20% 
misused alcohol only and 42% misused both drugs and alcohol;  
 while females comprised only 12% of the adult offender population, both male and 
female adult offenders exhibited similar drug and alcohol misuse levels;  
 the Dublin probation regions exhibited the highest levels of overall misuse among 
their offender populations, at 91%;  
 almost 21% of offenders were currently misusing two or more substances and over 
9% were misusing at least three substances. This included misuse of alcohol.  
 
The study found that, based on the probation officers’ professional judgment, ‘there 
were a substantial number of cases where drug misuse (74%) and alcohol misuse 
(71.3%) were linked to the offence committed’ (p.38). However, the author added the 
important caveat that the complexity of the issue meant that a ‘strong association’ 
between the drug use and the offence should not be interpreted as meaning that one 
necessarily caused the other.  
 
The study found that drug misuse among female offenders was marginally more likely 
to be linked to the offence than among male offenders; the opposite was the case in 
relation to the link between alcohol and the offence committed. The link between drug 
misuse and offending was more pronounced among younger age groups. In terms of 
the offence type, of those whose drug misuse and offence were linked, 31% of 
offences were drug law offences (such as drug possession), while 36.8% were linked 
to acquisitive crimes (theft, burglary, robbery, property offences). The study also 
highlighted the link between alcohol and crime, particularly violent and public-order-
related crime: the alcohol misuse of 71% of alcohol-misusing offenders was linked to 
the current offence committed, and the majority of alcohol-related offences were crimes 
against the person and public order offences, at almost 40%. The report found that ‘of 
those who misused drugs, 48.4% appeared to be not currently engaging with any drug 
treatment service’ (p. 42). It is unclear why this is the case as the views of offenders 
were not included in the study, one of the acknowledged limitations of the research.  
 
8.3 Social reintegration 
 
8.3.1 Housing 
 
Finding and maintaining sustainable housing remains a problem for many drug users, 
particularly those who are among the homeless population. We now have a more 
reliable picture of the extent and nature of homelessness in Ireland, and this picture 
has been primarily illuminated by the findings and evidence from good quality research. 
Our knowledge base of what contributes to and constructs homelessness has grown. 
We now know more about the conditions of life experienced by the homeless when 
they were growing up, and we know that their very first experience of homelessness 
was caused by lengthy and recurrent episodes of family conflict leading to family 
breakdown. We also know that most of our adult homeless population experienced 
homelessness following family breakdown: they were either taken into care or found 
refuge in an adult hostel accompanied by the mother. With recent changes in the 4-
year national population census, we can now more closely predict the numbers of 
homeless people.  We also know that young women may be more likely to exit 
homelessness and secure sustaining housing than men. Does this finding mean that 
society may be expecting more from its young men, particularly those who are most 
vulnerable?  
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Counting the homeless 
The Central Statistics Office (CSO) has published for the first time a comprehensive 
profile of the homeless population, as enumerated in the 2011 census of the population 
of Ireland (Central Statistics Office 2012). A comprehensive approach to measuring 
homelessness was adopted as part of the census undertaken on 10 April 2011. 
Homeless persons were identified based on where they were located on census night. 
Of the 4,588,252 persons counted in the state, 3,808 were either counted in 
accommodation providing shelter for homeless persons or were identified sleeping 
rough (8.3.1.1).  
 
Table 8.3.1.1   Persons counted in accommodation for the homeless and sleeping rough, by 
gender, Census night, 2011 
Category Male Female Total 
Persons in accommodation 2,481 1,263 3,744 
Persons sleeping rough 58 6 64 
Total 2,539 1,269 3,808 
Source: (Central Statistics Office 2012)  
 
Accommodation types 
 43.2% (n=1,648) of homeless persons were counted in emergency 
accommodation: 1,117 males and 531 females.  
 14.5% (n=555) in transitional accommodation: 397 males and 158 females.  
 24.2% (n=992) in long-term accommodation: 578 males and 414 females.  
 9.0% (n=344) in mixed accommodation: 250 males and 94 females.  
 5.4% (n=206) in what was reported as ‘unknown’ accommodation: 139 males 
and 66 females.  
The Dublin Regional Homeless Executive (DRHE) on behalf of the CSO undertook a 
count of persons sleeping rough in the Dublin area on Census night. The count took 
place between 3.30 am and 6.00 am through a process of ‘discovery’, that is, direct 
observation of the number of persons physically present and sleeping rough in Dublin 
on that night. Of the 64 persons counted sleeping rough, 58 were male and 59 were 
counted in Dublin.  
 
Age profile 
Almost three quarters of homeless persons counted in the Census (n=2,781) were in 
the 20–59-year age group; 641 were in the 0–19-year age group, including 457 
children aged 0–14.  
 
Marital status and the family unit 
Among the 3,351 homeless persons aged 15 or over, two thirds were single, compared 
to 42% in the general population.  Just under 6 % (n=189) were married or re-married, 
compared to 48% in the general population. Almost 17% (n=561) were separated or 
divorced, compared to 6% in the general population. The family unit was defined as a 
couple with or without children or a lone parent with at least one child. There were 296 
family units comprising 905 persons, of whom 498 were children.  
 
Economic and education status 
Of the 3,351 homeless persons aged 15 or over, 1,287 were unemployed and 99 were 
looking for their first job. Twenty-two per cent (n=752) were unable to work due to 
permanent sickness or disability, compared to 4% in the general population.  274 
homeless persons were in work, 218 were students, and 186 were retired.  Forty-nine 
per cent (n=1,439) of homeless persons aged 15 to 59 did not have an educational 
qualification beyond lower second-level, compared to 25% in the general population.  
 
General health and disabilities 
Just over 60% (n=2,298) of the homeless population indicated that their general health 
was ‘good’ or ‘very good’, compared to 89% in the general population. Almost 70% of 
homeless females indicated that their health was ‘good’ or ‘very good’, compared to 
56% of homeless males.  Almost a third (n=1,179) of the homeless population 
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indicated that their general health was ‘fair’, ‘bad’ or ‘very bad’, compared to 10% in the 
general population. Forty-two per cent (n= 1,581) of homeless persons had a disability, 
compared to 13% in the general population. The most common disability was a 
psychological or emotional condition (n=740).  
 
Current government policy on the homeless 
On 21 February 2013 Jan O’Sullivan TD, Minister for Housing and Planning, launched 
a policy statement on homelessness (Department of the Environment 2013). The policy 
statement followed a review of government policy on homelessness (O'Sullivan, Eoin 
2012b). In the review, O’Sullivan is critical of the value for money obtained from state 
expenditure on tackling homelessness. He argues that ‘it is now clear that the 
historically high levels of statutory funding for homelessness services are not delivering 
satisfactory outcomes for homeless households…’ (p. 24). State funding has 
traditionally being channelled into the provision of emergency-type shelter or resource-
intensive interventions with various forms of ancillary support to prepare individuals to 
become ‘housing ready’. In the case of individuals with alcohol and drug problems, this 
has meant that evidence of abstinence or sustained stabilisation was often required 
prior to their being considered for more sustainable accommodation.  
 
In seeking to promote an alternative to the inefficient and ineffective models that make 
up the housing-ready approach, O’Sullivan reviewed a number of studies that reported 
outcomes from both the broad church of the housing-ready / treatment-first approach 
and the housing-first (or housing-led) approach. The latter does not require people to 
demonstrate abstinence or provide evidence that they are ready to be housed. The 
housing-led approach seeks to place homeless people in sustainable rented 
accommodation first, and provides ‘floating supports’ at the request of the person being 
housed. Such supports may include assistance with social welfare enquiries, 
developing independent living skills or seeking help for addiction problems. O’Sullivan 
concludes that ‘the overwhelming evidence points to the effectiveness of a Housing 
Led approach rather than one that seeks to promote Treatment First’ (p. 35).  
 
The policy statement on homelessness launched in January 2013 by Minister of State 
O’Sullivan endorses this view of the evidence base and declares that the policy’s 
primary purpose is to make explicit the government’s commitment to ending 
homelessness by implementing the housing-led approach. The policy statement 
asserts the government’s aim to end long-term homelessness by the end of 2016 and 
encapsulates the government’s response to homelessness to include the following 
components:  
 
1. Preventing homelessness 
2. Eliminating the need to sleep rough 
3. Eliminating long-term occupation of emergency accommodation 
4. Providing long-term housing solutions 
5. Ensuring effective services 
6. Better co-ordinated funding arrangements. 
 
An oversight group has been established to monitor and review the housing-led 
approach advocated in the policy statement. To assist the oversight group, a set of 
seven indicators will be used to ‘demonstrate the dynamics’ of homelessness as it is 
addressed:  
 
1. Number of new homeless presentations on a daily basis 
2. Number of persons in emergency accommodation for longer than six months 
3. Number of persons leaving emergency accommodation 
4. Occupancy rate in emergency accommodation 
5. Number of persons moving on into independent living with support 
6. Number of persons moving on into independent living without support 
7. Number of persons sleeping rough voluntarily and involuntarily. 
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However, if the model is to be applied successfully and if the government is to meet its 
target of ending long-term homelessness by 2016, then sufficient numbers of housing 
units must be made available. In the current climate of austerity and fiscal restraints, 
these outputs may be compromised. In a recent article Mary Regan, political 
correspondent for the Irish Examiner, reports Minster of State O’Sullivan’s 
acknowledgement that ‘her department is “struggling” with ensuring it has enough 
accommodation to meet demand…[But]…her department hopes to secure 3,000’ 
(Regan 2013, ).   
 
Will housing-led services improve service provision to homeless people in 
Ireland? 
Recent research with stakeholders working in the homeless sector and with some 
homeless people suggests that it may not be just a matter of providing ‘bricks and 
mortar’ to tackle homelessness, particularly for people with long histories of 
homelessness. The Simon Community commissioned exploratory research to assess 
whether housing-led services would represent an improvement on existing practice in 
delivering services to homeless people in Ireland (Pleace, et al. 2013). Fieldwork and 
data collection for this research included nine focus groups with 27 participants (21 
males) who were or had recently been homeless, including 19 people who were or had 
been entrenched rough sleepers, i.e. people with high and multiple support needs who 
had sustained experience of sleeping rough. In addition, data were collected from 17 
service providers working with the Simon Communities. In addition, seven 
organisations working in the homeless sector responded to a detailed questionnaire. 
Findings from all fieldwork and collated data were discussed with participants from 
across government and the homeless sector prior to publication of the report.  
 
Awareness of what the housing-led approach means was reported as high among 
service providers. Service users were not as aware of what the approach entailed, but, 
when it was explained, the idea of having their own ‘home’ was popular. There was 
consensus among service providers that simply providing housing to people with long 
histories of homelessness who might have high support needs, such as mental health 
or addiction issues, was unlikely to result in positive outcomes. Appropriate types and 
levels of support with housing were deemed a more effective response. The main 
concern expressed by all participants was the insufficient supply of adequate and 
affordable housing to ensure housing-led services work effectively. Difficulty in 
accessing social housing due to a lack of new supply and barriers in the process of 
allocating the existing supply were cited as particular limitations.  
 
Concerns were also expressed by all participants about the affordability of housing in 
the private rented sector. Restrictions on the amount paid to social welfare claimants 
through rent supplement meant that people were unable to meet the relatively high 
rents being charged in the private sector without having to ‘top-up’ from the remaining 
portion of their welfare payments. Also, the poor standard of some of the affordable 
private rented accommodation was cited as a concern. It was reported that some 
private landlords were reluctant to accommodate people with a history of 
homelessness as these people were perceived to be ‘risky’ tenants. In addition, in a 
social context where the need for private rented accommodation is growing among the 
general population, people with experience of homelessness are often the least 
preferred tenants by some private landlords.  
 
People with experience of homelessness expressed a preference to be housed in 
social housing, which they believed provided more flexibility and stability in the longer 
term and was more suitable to their needs; this view was shared by service providers. 
These views are pertinent given that the housing-led approach is dependent for the 
most part on the immediate provision of a settled home in the community.  
 
Some attractive features of the housing-led approach are that it offers people 
independence, choice and control to a greater extent than alternative models. 
Participants felt that while most people who become homeless in Ireland might wish to 
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live independently in their own home with modest support, housing-led services were 
not the answer for people with high-support needs. Factors cited to elaborate on this 
view included a belief that some people who had experiences of long-term 
homelessness were also affected by their experiences in industrial schools, which in 
some cases led to them experiencing institutionalisation. Those with experience of 
homelessness, that living independently without the appropriate level of support and 
access to meaningful daytime activities such as employment, training and education 
could lead to mental illness and/or relapse into problematic use of alcohol and drugs.  
 
Joint working through case management to offer a package of supports is often seen 
as an integral part of delivering an effective housing-led model. The views expressed 
by service providers suggest that access to welfare benefits and to health and social 
services, as well as to specialist addiction and mental health services, is currently 
restricted for people experiencing homeless. These restrictions have arisen due to 
changes to the levels and eligibility rules for welfare benefits. Restricted access to 
health and other social services, primarily due to cuts in service provision, is seen to 
compromise efforts by the homeless sector to resettle homeless people; people with 
experience of homelessness and who are trying to live independently in the community 
are also adversely affected by these restrictions. Service providers also reported 
problems around mental health services not working with people with drug and alcohol 
problems and alcohol and drug services not working with people with mental health 
problems. These concerns regarding the fragmented nature of service provision may 
have implications for the inclusion of an integrated package of services for homeless 
people as part of the current Housing First Demonstration Project (HFDP) being 
operated in Dublin as, ‘all forms of housing-led services are reliant to at least some 
degree on joint working with the welfare systems and health, social care and mental 
health services’ (p. 27).  
 
Service providers were sceptical of what they perceived to be the official policy view, 
that housing-led services could be delivered as low-cost, low-intensity and short-term 
interventions to assist homeless people. On the contrary, they emphasised that the 
homeless population was not an homogenous group; rather, homelessness was 
experienced by different people for different reasons and with different types and levels 
of support needs. There was consensus among service providers and homeless 
people that the sector needed to retain a broad mix of options to cater for the diverse 
needs of homeless people.  
 
While the idea of housing-led services was generally welcomed and endorsed by 
participants, it is clear that from both standpoints, housing-led services are not currently 
seen as a panacea for the problem of homelessness and its associated issues. The 
reservations expressed by participants centre around the view that responses to 
homelessness need more than just providing housing in the form of ‘bricks and mortar’. 
Effective responses need to include housing alongside appropriate support, especially 
for people with high support needs. In addition, participants cautioned against providing 
housing as an individual unit of residence for some homeless people; instead it was 
suggested that communal residential housing with appropriate support might be more 
suitable for people with personal biographies that include sustained periods of time 
spent in institutions and homelessness.  
 
The divergent views expressed by participants in this exploratory study are not wholly 
different from the academic perspective. According to the authors, ‘the consensus of 
the academic research is broadly similar – housing-led services are very effective at 
ending homelessness among people with high needs and sustained experience of 
homelessness, but that while some other gains in well-being are being achieved, these 
services are not necessarily fully meeting all associated support needs or successful 
with everyone they try to work with’ (p. 31).  
 
Success in exiting homelessness 
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Findings from the only qualitative longitudinal study of youth homelessness undertaken 
in Ireland were published recently (Mayock and Corr 2013). The study covered a six-
year period and included three phases of data collection with young people 
experiencing homelessness in Dublin.  
 
Phase 1: Baseline profile and characteristics (September 2004 – January 2005) 
 
Forty young people, 23 males and 17 females, aged between 14 and 22 years, were 
interviewed during the first phase of data collection (baseline profile). They reported an 
early childhood characterised by poverty, traumatic life events and household conflict 
and instability. They also reported deteriorating relationships with their parents during 
their early to mid-teenage years. Eighteen of the 23 young men left school at or before 
the age of 15; the young women remained longer in education, with 11 of the 17 
attending school at baseline interview.  
 
Twenty-five of the young people were living in under-18s emergency or short-term 
hostel accommodation, and most of the others were accommodated in other short- or 
medium-term accommodation; three were in prison and two were sleeping rough. 
Eleven reported being homeless for 2–4 years and eight for five years or more.  
 
Those with longer homeless histories reported problematic and dependent patterns of 
alcohol and/or drug abuse, with half (13 males and 7 females) reporting use of heroin. 
‘Drug use escalated for practically all young people as their “careers” in homelessness 
progressed and this pattern of consumption was especially apparent among those who 
moved constantly between hostels targeting the under-18s’ (p. 22).   
 
Twenty of the young men and eight of the young women had been charged with at 
least one criminal offence.  According to the authors, ‘their accounts demonstrate the 
interconnectedness of homeless, drug and criminal “careers”. … However, few of the 
young people were heavily involved in drug use and even fewer had records of 
offending at the time they first left home’ (pp. 22–23).  
 
Almost half the 40 young people (9 males and 10 females) first experienced 
homelessness at age 14 or younger, and 12 (9 males and 3 females) at age 15. 
Although most recalled their own unique account of becoming homelessness, the 
authors identified three broad, and overlapping, pathways into homelessness:  
 
 a history of state care, 
 family instability and family conflict, or 
 problem behaviour and negative peer associations.  
 
Sixteen of the young people had experience of the state care system, mainly through 
foster care, with many reporting multiple placements leading to instability and 
disruption in their young lives. Although many experienced a traumatic childhood in the 
family home, this did not prevent them from carrying feelings of resentment about their 
separation from their parents and siblings.  
 
For the majority of the young people, parental conflict and/or marital breakdown 
featured prominently in the events leading to their first homeless experience. Parental 
drug or alcohol abuse was reported by 16, and physical abuse by an adult in the home 
was experienced by 18 young people.  
 
They also reported how their own behaviour, including using alcohol and drugs and 
staying out late with friends, often led to disagreement with their parents. Most of them 
admitted having been ‘rebellious’ in their early teens; however, for many the adverse 
circumstances of the family home contributed to their vulnerability. According to the 
authors:  
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Furthermore, by the time young people found themselves out of 
home for the first time, their experiences of a number of key 
institutions (including the family, school or State care) had been 
overwhelmingly negative. Consequently, at a relatively early age, a 
large number were living outside, or marginal to, the structures that 
play a critical role in preparing young people for the transition to 
adulthood. (p. 24)  
 
Phase 2: Exits from homelessness and continued homelessness (September 2005 – 
August 2006) 
 
Thirty of the young people (16 males and 14 females) were re-interviewed at phase 2 
of data collection. Seventeen (5 males and 12 females) had secured greater stability in 
their accommodation by this juncture, approximately 12–18 months since the baseline 
data collection. Seven were in transitional/supported housing, six were living at home, 
three were in foster or residential state care and one was in private rented 
accommodation. Thirteen (11 male and 2 female) remained homeless; five were in 
prison, four in adult hostels, two were sleeping rough, one was in a residential drug 
treatment programme and one was in temporary accommodation and awaiting 
sentencing in the criminal justice system. As these figures illustrate, a far greater 
number of female participants had exited homelessness by phase 2 of the study.  
 
Phase 3: Sustained exits and prolonged homelessness (September 2009 – August 
2010)  
 
Twenty-eight of the young people (15 males and 13 females) were re-interviewed at 
phase 3 of data collection. Fifteen (3 males and 12 females) had exited or sustained an 
exit from homelessness, of whom nine (including eight females) were living in the 
private rented sector, one male was in local authority housing, one female was living in 
an independent flat, one female was living in their partner’s home, one female was in a 
residential aftercare facility and one female and one male were in the family home. As 
the authors point out: ‘Consistent with the patterns identified at phase 2, far more 
females than males had exited or sustained an exit from homelessness. Gender 
therefore remains significant in the exiting patterns of young people…’ (p. 25). 
 
This study has generated an in-depth and rich understanding of young people’s routes 
into, through and out of homelessness. It is clear that the key institutions of 
socialisation that bring security, development and identity to our young people –  the 
family, the education system and the state care apparatus – can fail miserably at times. 
When these institutions fail and young people end up homeless and vulnerable, 
measures to disrupt this experience and facilitate their quick exit from homelessness 
are key to their regaining stability. In this regard, the successful work done to ensure 
the exit from homelessness of all but one of the young women in this study is 
acknowledged. However, policy and practice also need to acknowledge that it appears 
to be much harder for young men to exit homelessness and the longer they remain in 
this condition the more hazardous their lives become, i.e. criminal convictions and the 
more marginal they remain from society.  
 
 
8.3.2 Education, training 
Information provided in response to questions posed in Dáil Éireann (Ireland’s national 
parliament) reveal the current numbers of recovering drug users that are availing of 
education and training. The Community Employment (CE) scheme provides education 
and training for up to 1,000 people in recovery from substance addiction. The vast 
majority of places on this scheme are taken up by people on methadone, and the 
scheme is shown to stabilise these people’s desire for street drugs and also to free 
some time for them to pursue alternative experiences.  According to Joan Burton TD, 
Minister for Social Protection, at June 2013 there were 895 participants on drug 
rehabilitation places in the CE scheme. Seventy -four per cent (n=664) were located in 
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the Dublin region and 14% (n=125) in Cork Central. The remainder were spread 
throughout other regions. The 664 participants in the Dublin region represent an 
increase of 12% compared with the number for June 2012, when there were 595 
participants in drug rehabilitation projects in the Dublin region (Burton, J 2013 June 9).  
 
In a response to an earlier Parliamentary Question, Minister Burton described the 
process of applying for a place on the CE scheme: ‘The entry age is already set at 18 
years of age for these programmes. The Community Employment (CE) Operating 
Procedures state that CE Drugs Rehabilitation Places (DRP's) are available to persons 
aged 18 years or over who are in recovery and referred for a rehabilitation place on 
CE. Application for a drugs rehabilitation place is based on evidence of an appropriate 
referral following an assessment of the applicant attending a recognised addiction 
support service within the last year within the context of the National Rehabilitation 
Framework of care and case management. This includes HSE addiction services and 
treatment centres, GPs and other relevant statutory, community and voluntary support 
services.’ (Burton, Joan 2012, 12 June) 
 
8.3.3 Employment 
The Report of the Working Group on Drugs Rehabilitation (Working Group on drugs 
rehabilitation 2007) recommends that measures to improve the employability of current, 
former and recovering drug users should form a key part of rehabilitation care plans, 
with the overall aim ‘to maximise the quality of life, re-engagement in independent living 
and employability of the recovering problem drug user, in line with their aspirations’ (p. 
21). Action 32 of the NDS calls for the implementation of the recommendations of the 
rehabilitation report, and the current Programme for Government includes proposals to 
progress some of the recommendations including ‘to assist drug users in rehabilitation 
through participation in suitable local community employment schemes’ (Fine Gael and 
the Labour Party 2011) (p. 50). 
 
However, the most up-to-date data on the employment status of people reporting for 
drug treatment show a steady downward trend in terms of employment prospects for 
these people. There was a drop in the proportion of all cases in employment, from 22% 
in 2005 to 9% in 2010 (see Table 8.3.3.1). ‘…This [drop] is most likely a reflection of 
the current economic climate, and highlights the continued importance of social and 
occupational reintegration interventions as part of the drug treatment process’ 
((Bellerose, et al. 2011), p. 2).  
 
Table 8.3.3.1 Number and percentage of treatment population all cases in employment, NDTRS 
2005–2010 
 2005 2006 2007 2008 2009 2010 
 N           % N           % N           % N           % N           % N           % 
All cases 1025   (21.8) 1071   (21.0) 1059   (18.9) 921     (15.0) 689     (10.9) 670     (9.1) 
Source: (Bellerose, et al. 2011)  
 
There was an even greater drop in the proportion of new cases reporting for treatment 
who were in employment, from 29.7% in 2005 to 11.7% in 2010 (see Table 8.3.3.2). 
New cases are individuals that have never been treated for problem drug use.  
 
Table 8.3.3.2 Number and percentage of treatment population new cases in employment, NDTRS 
2005–2010 
 2005 2006 2007 2008 2009 2010 
 N            % N            % N            % N            % N            % N            % 
New cases 542     (29.7) 590     (28.0) 592     (25.6) 524     (20.8) 386     (13.9) 357     (11.7) 
Source: (Bellerose, et al. 2011) 
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9. Drug-related crime, prevention of drug-related crime and 
prison 
9.1 Introduction 
This chapter presents the most recent statistical data on drug-related crime in Ireland, 
including drug law offences and offences committed as a consequence of a drug 
addiction. It also describes policies and programmes initiated in the past year to 
prevent drug-related crime both in the community and in prisons as well as research 
studies on drug-related crime, prevention and prison. In this section the data sources 
and types of drug-related crimes in Ireland are described, and the approaches to 
preventing drug-related crime, both in the community and in prisons, are also briefly 
outlined. 
 
Since 2006 reporting crime statistics has been the responsibility of the Central 
Statistics Office (CSO). The CSO data are derived from the Garda Síochána 
computerised PULSE system (Police Using Leading Systems Effectively). The vast 
majority of drug offences reported come under one of three sections in the Misuse of 
Drugs Act (MDA) 1977: section 3 – possession of any controlled drug without due 
authorisation (simple possession); section 15 – possession of a controlled drug for the 
purpose of unlawful sale or supply (possession for sale or supply); and section 21 – 
obstructing the lawful exercise of a power conferred by the Act (obstruction). Other 
MDA offences regularly recorded relate to the importation of drugs (section 5), 
cultivation of cannabis plants (section 17) and the use of forged prescriptions (section 
18). 
 
Driving under the influence of drugs (DUID) has been a statutory offence in Ireland 
since the introduction of the 1961 Road Traffic Act. The principal legislation in this area 
is contained in the Road Traffic Acts 1961 to 2002. Section 10 of the Road Traffic Act 
1994 prohibits driving in a public place while a person is under the influence of an 
intoxicant to such an extent as to be incapable of having proper control of the vehicle. 
Intoxicants are defined as alcohol or drugs and any combination of drugs or of drugs 
and alcohol. Although penalties for driving under the influence of alcohol are graded 
according to the concentration of alcohol detected, the law does not set prohibited 
concentrations for drugs. Neither does it distinguish between legal and illegal drugs. 
Tests to identify the level of impairment can only take place where there is a 
reasonable suspicion that an offence is being committed. In reading the tables in this 
chapter, please note that ‘relevant proceedings’ refer to the legal proceedings, such as 
prosecution, taken in relation to an offence as it was originally recorded in the Garda 
Síochána IT system, PULSE (Police Using Leading Systems Effectively). 
 
Over and above the ‘inherent’ drug crimes, that is crimes under the Misuse of Drugs 
Acts or the Road Traffic Acts, ‘non-inherent’ drug crimes are also recorded in Ireland, 
for example acquisitive crime to pay for drugs, crimes of intimidation and violence 
inflicted by drug gangs, money laundering, smuggling or other finance-related crimes, 
or public nuisance. Official crime statistics do not allow one to identify where offences 
were drug-related. These connections can only be made through specific research in 
the area. This is reported in this chapter when available. 
 
Crime prevention in Ireland proceeds on several fronts. Tackling community 
disadvantage is one important approach. Disadvantage in communities is recognised 
as a risk factor in contributing to, among other things, the spread of drug-related crime. 
A wide range of national initiatives exist to tackle disadvantage and its consequences, 
including community and local development programmes, the RAPID and CLAR 
programmes, and targeted urban regeneration projects. These initiatives all contain 
components relating specifically to illicit drugs. In relation to the drug problem, in 1998 
local drugs task forces (LDTFs) were established in areas identified as having the 
highest concentrations of drug misuse; without exception, these areas were all also 
experiencing high levels of socio-economic disadvantage. The purpose of the LDTFs is 
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to co-ordinate local action plans in relation to curbing local supply as well as treatment, 
rehabilitation, education and prevention.  A central feature of the LDTFs is that as well 
as co-ordinating the provision of services locally, they also allow local communities and 
voluntary organisations to participate in the planning, design and delivery of services.  
 
Diversion is another important means of seeking to prevent crime including drug-
related crime – both before, and after, a crime has been committed. Garda Youth 
Diversion Projects are local community activities which work with children. These 
projects aim to help children move away from behaving in a way that might get them or 
their friends into trouble with the law.  In 2005 the Irish Youth Justice Service (IYJS) 
was established to develop a co-ordinated partnership approach among agencies 
working in the youth justice system, to improve service delivery in the system through 
diversion, restorative justice, rehabilitation and detention as a last resort. Garda (Irish 
police force) statistics show that the types of offence committed by children under the 
age of 18 years are primarily theft, alcohol-related offences, criminal damage, assault, 
traffic offences, drugs possession, public order offences and burglary. In addition to the 
Garda Youth Diversion Projects, the Garda Juvenile Diversion Programme (GJDP) 
provides an opportunity to divert juvenile offenders from criminal activity. It operates on 
a nationwide basis under the supervision and direction of the Garda National Juvenile 
Office. The GJDP provides that, in certain circumstances, a young person under 18 
years of age who freely accepts responsibility for a criminal incident be cautioned as an 
alternative to prosecution. The GJDP employs such strategies and initiatives as formal 
and informal cautioning, supervision, restorative cautioning and conferencing, 
community policing and referral to the Garda Youth Diversion Projects (which operate 
outside the GJDP but in concert with it). First established on a pilot basis in 2001 the 
Drug Treatment Court is a specialised District Court, which offers long-term court-
monitored treatment, including career and education support, to offenders with drug 
addictions as an alternative to a prison sentence. The idea is that by dealing with the 
addiction, the need to offend is no longer present.  
 
Finally, individuals and communities are encouraged to participate in helping to prevent 
and/or detect crime. For example, the Customs Drugs Watch Programme, first 
launched in 1994, encourages those living in coastal communities, maritime personnel 
and people living near airfields to report unusual occurrences to Customs. Under the 
Garda Síochána Act 2005, Joint Policing Committees (JPCs) have been established in 
local authority areas to bring together public representatives, representatives of local 
authorities, the Garda Síochána and representatives of the voluntary and community 
sectors to assess levels of crime and anti-social behaviour, including that related to 
alcohol use and illicit drug use, and to make recommendations as to how to prevent 
and address such problems. The JPCs are empowered to establish local policing fora 
(LPF), to deal specifically with drugs and associated issues such as estate 
management and anti-social behaviour. In September 2008 a Dial-to-Stop Dealing 
campaign was launched and operates nationwide; individuals and communities 
affected by drug dealing are urged to pass information by dialling a confidential 
number. 
 
The presence of drugs in prisons led the Irish Prison Service (IPS) to develop a policy 
based on three underlying principles (Irish Prison Service 2006): 
 the presence of drugs in prison will not be tolerated; 
 prisoners will be encouraged and supported to develop a responsible attitude to 
drugs, both while in prison and following release, through a range of measures 
including education and counselling; and 
 prisoners who are addicted to drugs or have other medical problems caused by the 
misuse of drugs will be offered every reasonable care and assistance. 
 
In the accompanying strategy the IPS lists two aims in relation to illicit drugs in prisons: 
(1) to eliminate the supply of drugs into prisons, and (2) to provide prisoners with a 
range of opportunities which encourage them to adopt a drug-free lifestyle, before and 
after release, thereby reducing demand for drugs. 
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The Probation Service works in partnership with communities, local services and 
voluntary organisations to reduce offending and to make communities safer. It funds 
and supports organisations and projects providing drug treatment to offenders, as well 
as other important services such as employment placement, accommodation, 
education and training, restorative justice initiatives. Probation Service staff in the 
community and in prisons may refer clients to these community-based projects, to 
enhance their re-integration and resettlement as positive, contributing members of their 
communities. 
 
 
9.2 Drug-related crime 
 
The link between drugs and crime in Ireland exists simply by virtue of prevailing 
legislation which defines as criminal offences the importation, manufacture, trade in 
and possession, other than by prescription, of most psychoactive substances. Along 
with such official statistical indicators, research and analysis has also been conducted 
in Ireland on the connection between illicit drugs and other types of crime such as theft 
from the person, burglary, larceny and prostitution (Connolly, Johnny 2006). Data on 
drug law offences is presented in section 9.3 and information on other drug-related 
crime is presented in section 9.4. 
 
 
9.3 Drug law offenses 
 
It should be noted that drug offence data are primarily a reflection of law enforcement 
activity. Consequently, they are affected in any given period by such factors as law 
enforcement resources, strategies and priorities, and by the vulnerability of drug users 
and drug traffickers to law enforcement activities. Having said that, when compared 
with other data sources such as drug treatment for example, drug offence data can 
provide a useful indicator of overall drug trends. Alternatively, where law enforcement 
trends differ from those indicated by other data sources in a given period they may 
reveal something about specific law enforcement strategies or activities at that time, 
something that can be further investigated through research. 
 
Figures 9.3.1 and 9.3.2 show trends in proceedings for drug offences from 2004 to 
2011. As can be seen from Figure 9.3.1, the number of legal proceedings for the 
possession of drugs for personal use (simple possession) decreased in 2009 for the 
first time since 2004. The number continued to fall in the following two years. Simple 
possession offences accounted for almost 69% of total drug offence proceedings in 
2011. Proceedings for drug supply have also decreased marginally since 2009. 
 
 
2004 2005 2006 2007 2008 2009 2010 2011
Total drug offences 5800 8279 8948 11721 14513 13668 12119 11250
Drug possession for
personal use
3760 5844 6093 8333 10740 10093 8304 7731
Drug possession for
supply
1653 1989 2322 2735 3104 2835 2980 2783
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Figure 9.3.1   Trends in relevant legal proceedings for total drug offences, and for possession for 
personal use and for supply, 2004–2011 
Source: (Central Statistics Office 2013) 
 
Obstruction offences often involve an alleged offender resisting a drug search or an 
arrest or attempting to dispose of drugs to evade detection. As shown in Figure 9.3.2, 
such offences have generally accounted for the largest number of prosecutions, 
although numbers declined from a high of 415 in 2007 to 245 in 2011, approaching the 
2004 figure of 242. Proceedings for the offence of forged/altered prescriptions have 
also remained fairly constant since 2004.  
 
 
Figure 9.3.2   Trends in relevant legal proceedings for selected drug offences, 2004–2011  
Source: (Central Statistics Office 2013) 
 
Another noteworthy development has been the continued increase in the offence of 
cultivating/manufacturing controlled drugs. Proceedings for this offence have continued 
to increase since 2005, when there were 29 related proceedings, reaching 167 in 2009 
and then more than doubling to 355 in 2011, when they bypassed obstruction offences. 
It is unclear whether this increase reflects a genuine growth in the commission of such 
offences or a sustained concentration of law enforcement on their detection. For 
example, in 2010, the Garda Síochána conducted Operation Nitrogen, a nationwide 
investigation into cannabis cultivation sites by district and divisional drug units (Health 
Research Board 2012). Although the specific focus of this operation may have had an 
impact on the data presented here, a recent report jointly published by the EMCDDA 
and Europol highlighted the increased involvement of organised crime groups in 
cannabis cultivation in many European countries, including Ireland (European 
Monitoring Centre for Drugs and Drug Addiction and Europol 2013). 
 
Courts Service Annual Report 2011 
 
The Courts Service Annual Report for 2012 provides statistics on the outcomes of 
prosecutions for drug offences between January and December 2012 (Courts Service 
2013). Table 9.3.1 shows the outcomes of trials for 15,858 drug offence cases, 
involving 10,643 defendants, prosecuted in the District Court, the lowest court in the 
system where most drug offences are dealt with. This total represents a 10.5% 
decrease on the number of cases prosecuted in 2011 (n=17,715). The most common 
outcome was for cases to be struck out (n=3,366). There were 2,767 offences that 
resulted in fines. Just under 8% (n=1,262) cases resulted in imprisonment or detention, 
a decrease of about 1% on the previous year in terms of the proportion of offences 
resulting in imprisonment. 
 
 
2004 2005 2006 2007 2008 2009 2010 2011
Obstruction 242 291 354 415 348 390 372 245
Forged/altered
prescriptions
86 97 93 94 122 142 124 101
Cultivation or
manufacture
32 29 54 109 142 167 315 355
Importation 27 29 32 35 57 41 24 35
0
50
100
150
200
250
300
350
400
450
N
u
m
b
e
r 
  129 
Table 9.3.1 Sentences for drug offences in the District Court, 2012 
Sentences Imprisonment Fines Community 
service/ 
probation 
Struck 
out 
Dismiss Taken into 
consideration* 
Other Peace 
bond 
Total 
Number of 
offences 
1262 2767 2074 3366 344 2549 3496 186 15858 
* Taken into consideration: The Criminal Justice Act, 1951, s8, provides that where a person, on being convicted of an 
offence, admits him- or herself guilty of any other offence and asks to have it taken into consideration in awarding 
punishment, the Court may take it into consideration accordingly. If the Court takes an offence into consideration, a note 
of that fact is made and filed with the record of the sentence, and the accused cannot be prosecuted for that offence, 
unless her/ his conviction is reversed on appeal. 
Source: (Courts Service 2013) 
 
The Courts Service reports that 1,925 drug offences/offenders were tried in the Circuit 
Criminal Court (Dublin circuit court offences = 1,306; Provincial courts offenders = 
619). The Circuit Court has a higher jurisdiction than the District Court and can thus 
impose a more severe sentence (Courts Service 2013) (pp.35–36).14 Of the 
prosecutions in the Dublin Circuit Criminal Court, 492 led to guilty pleas. Of the 15 
cases that went to trial, two resulted in convictions and 13 in acquittals.  In relation to 
the penalties imposed on conviction by offence, it is reported that four led to community 
service; 162,  suspended sentences; 222, imprisonment; 943, other (including taken 
into consideration, struck out, forfeiture of goods/money/drugs/weapons, destruction of 
drugs/weapons, disqualification from driving)  
((Courts Service 2013) p36).15 
 
Drug driving offences 
Figure 9.3.3 shows the trend in prosecutions for driving or being in charge of a vehicle 
while under the influence of drugs (DUID) between 2003 and 2011. Between 2006 and 
2009 the number of prosecutions for DUID increased from 74 to 703, an increase of 
850%. It is unclear why this increase occurred. It could be due to an increase in the 
incidence of DUID or, the more likely possibility, to an increase in targeted police 
activity in this area. Since 2009, the number of such offences has decreased 
significantly, with 337 reported prosecutions in 2011. 
 
 
Figure 9.3.4   Trend in relevant legal proceedings for driving in charge of a vehicle while under the 
influence of drugs, 2003–2011 
Source: (Central Statistics Office 2013) 
 
                                               
14
 In 2012 the Courts Service began to revise its method of recording and collating statistical data for the Circuit Criminal 
Court. Prior to 2012 outcomes of cases were reported by reference to defendants. From 2012 the Service will report 
outcomes by reference to offences, commencing with the Dublin District Court. The data presented here relate only  to 
the Dublin Circuit court. 
15
 It appears from the data that the number of penalties imposed by offence (n=1331) is greater than the number of 
offences reported (1306). It is unclear why this is the case. However, it is possible that the reported penalties were 
imposed for offences that happened in the previous year (p36).  
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In relation to drug driving offences, the Medical Bureau of Road Safety (MBRS)16 
published a Report on roadside drug testing and equipment and related matters in 
October 2012 (Cusack, et al. 2012). Speaking at the launch, Professor Denis Cusack, 
director of the MBRS, said ‘this report provides a detailed analysis of all aspects of 
roadside drug testing’. Professor Cusack further explained that unlike the situation in 
relation to alcohol, ‘there is no legal limit for drugs. Under current road traffic law, the 
Gardaí must be satisfied that a driver is under the influence to such an extent as to be 
incapable of having proper control of a vehicle. This means that the Garda has to prove 
the driver impairment to the satisfaction of the Court and this can cause difficulties in 
successfully prosecuting such offences’. This report will inform the Road Traffic Bill 
(see Section 1.2). This Bill provides for roadside impairment testing for drug use by 
motorists. Research is currently under way to identify a suitable device for detecting 
drugs during a roadside test, similar to that used for detecting alcohol. 
 
The National Drug-Related Deaths Index (NDRDI) at the Health Research Board made 
a substantial contribution to the MBRS report by providing a complete census of fatal 
road traffic collisions (RTCs) where the deceased person was the driver of the vehicle 
and had a positive toxicology report for an illicit substance. Currently the NDRDI is the 
only data source able to provide comprehensive data on the presence of illicit drugs in 
post-mortem toxicology. In the future, the NDRDI will be able to monitor trends in drug-
related deaths and evaluate the effects the new Road Safety Strategy will have on 
preventing these deaths. Figure 9.3.5 presents NDRDI data for the period 2004 to 2009 
on RTC deaths among vehicle drivers in Ireland where the driver had a positive 
toxicology for one or more illicit drugs at the time of death.  
 
 
Figure 9.3.5    Drugs recorded in post-mortem toxicology reports, vehicle drivers, NDRDI 2004–2009 
(n=93) 
Source: (Cusack, et al. 2012) 
 
In the six-year period 2004 to 2009 there were 93 RTC deaths recorded by the NDRDI. 
Cannabis (38.7%) was the most common illicit drug found in the toxicology reports on 
these 93 individuals, followed by cocaine (23.7%) and MDMA (18.3%). 
 
 
9.4 Other drug-related crime 
Probation Service study on drug and alcohol use among male offenders 
The Probation Service is an agency within the Department of Justice and Equality. The 
Service works closely with the Courts Service, the Irish Prison Service (IPS), An Garda 
Síochána, the Irish Youth Justice Service (IYJS), the Parole Board and many 
                                               
16
 The responsibility for chemical testing of intoxicants in driving in Ireland rests with the Medical Bureau for Road 
Safety, which is a corporate body established in November 1968 by the Minister for Local Government under Part V of 
the Road Traffic Act, 1968. See www.UCD.ie/mbrs  
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organisations in the community. The Probation Service generally becomes involved in 
the criminal justice process between the trial and sanction phases, often in cases 
where a court requires a pre-sanction assessment to assist in deciding on an 
appropriate sanction. The Service manages community sanctions and measures. In 
2012, the Service dealt with 15,080 offenders in the community, a slight increase on 
the 14,845 offenders dealt with the previous year (Probation Service 2013). The 
statistical data provided in the annual report does not provide a breakdown of offenders 
or interventions by offence type.  
 
However, a research report by the Probation Service presents the findings of the first 
large-scale, nationwide survey conducted by the Service on drug and alcohol misuse 
among the adult offender population on probation supervision (Probation Service 
2012b). Although earlier research in Ireland highlighted a link between substance 
misuse and offending behaviour (Keogh 1997), the identification of the precise causal 
connection between drugs and crime remains a complex and much-debated area of 
criminological research (Connolly, Johnny 2006). A better understanding of the nature 
of the connection between drug use and offending has implications for drug and crime 
prevention and for treatment and criminal justice interventions. A major impediment to 
research in this area in Ireland is the absence of data from within the criminal justice 
system. For example, as shown in Section 9.7 below, it is clear from prison drug 
seizures and prison drug testing data, that a significant proportion of Irish prisoners are 
problematic drug users. We also know from data provided in the annual reports of the 
Irish Prison Service the number of people imprisoned for drug offences under the 
Misuse of Drugs Acts, such as drug possession or supply (Irish Prison Service 2013). 
However, most problematic drug users are imprisoned not for breaches of the drug 
laws but for drug-related offences, that is, offences such as theft committed as a 
consequence of their addiction to fund their drug habit. It is in highlighting this particular 
aspect of the drugs–crime nexus that the Probation Service report is particularly 
important. 
 
The survey involved a representative sample of 2,963 adult offenders from probation 
officers’ caseloads on 1 April 2011. Questionnaires, developed specifically for the 
purpose of the study, were completed by the supervising probation officers, based on 
the case records and knowledge of the offenders on the casebooks.  
 
The main objectives of the study were to:  
1. ascertain the number of adult offenders on probation supervision who misuse drugs 
and/or alcohol, 
2. examine the nature and frequency of drug and alcohol misuse, 
3. establish if there is a correlation between drug and/or alcohol misuse and offending 
behaviour, and 
4. identify the level and nature of engagement with drug and alcohol treatment 
services.  
 
Included among the key findings in relation to the first two aims were the following: 
 
 89% of the adult offender population on probation supervision had misused drugs 
or alcohol either ‘currently’ (at the time of the survey) or in the ‘past’.  
 Of those who misused alcohol/drugs, 27% misused drugs only, 20% misused 
alcohol only and 42% misused both drugs and alcohol.  
 While females comprised only 12% of the adult offender population, both male and 
female adult offender’s exhibit similar drug and alcohol misuse levels.  
 The Dublin probation regions exhibited the highest levels of overall misuse among 
their offender populations, at 91%.  
 Almost 21% of offenders were currently misusing two or more substances and over 
9% were misusing at least three substances. This includes misuse of alcohol.  
 
With regard to the third aim, the relationship between drug/alcohol misuse and crime 
among the adult offender population on probation, the study found that, based on the 
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probation officers’ professional judgement, ‘there were a substantial number of cases 
where drug misuse (74%) and alcohol misuse (71.3%) were linked to the offence 
committed’, although the author adds the important caveat that the complexity of the 
issue meant that a ‘strong association’ between the drug use and the offence should 
not be interpreted as meaning that one necessarily caused the other (p.38). In this 
respect, and consistent with other research in this area, the study found that many 
other factors associated with offending behaviour, such as ‘the offender’s 
anger…mental health and mild learning difficulties…disrupted family background, lack 
of parental control, low education, child abuse and domestic violence were also stated 
as risk factors in offending behaviour’ (p.38).  
 
With regard to gender issues, the study found that drug misuse among female 
offenders was marginally more likely to be linked to the offence than that among male 
offenders; the opposite was the case in relation to the link between alcohol and the 
offence committed. The study also found that the link between drug misuse and 
offending was more pronounced among younger age groups. In terms of the offence 
type, of those whose drug misuse and offence were linked, 31% of offences were drug 
law offences (such as drug possession), while 36.8% were linked to acquisitive crimes 
(theft, burglary, robbery, property offences). The study also highlighted the link 
between alcohol and crime, particularly violent and public-order-related crime: the 
alcohol misuse of 71% of alcohol-misusing offenders was linked to the current offence 
committed, and the majority of alcohol-related offences were crimes against the person 
and public order offences, at almost 40% (p.37). 
 
The final aim of the study was to consider treatment uptake among the offender 
population. The study found that ‘of those who misused drugs, 48.4% appeared to be 
not currently engaging with any drug treatment service’ (p. 42). It is unclear why this is 
the case as the views of offenders were not incorporated into the study, one of the 
acknowledged limitations of the research. Nevertheless, this study is an important 
contribution towards the development of evidence-based criminal justice interventions 
in response to crime related to drug and alcohol misuse.  
 
 
9.5 Prevention of drug-related crime 
 
The National Youth Justice Strategy was launched in March 2008 (Irish Youth Justice 
Service 2008). The first strategy, covering the period up to 2010, provided the 
framework for co-ordinated implementation of the Children Act, 200117. 
 
The strategy focuses on five high-level goals: 
 
 to provide leadership and build public confidence in the youth justice system, 
 to work to reduce offending by diverting young people from offending behaviour, 
 to promote the greater use of community sanctions and initiatives to deal with 
young people who offend, 
 to provide a safe and secure environment for detained children that will assist their 
early reintegration into the community, and 
 to strengthen and develop information and data sources in the youth justice system 
to support more effective policies and services. 
 
The second of these high-level goals focuses on Garda Youth Diversion Projects 
(GYDPs), the Garda Diversion Programme, community sanctions and restorative 
justice. GYDPs are funded by the Irish Youth Justice Service (IYJS) and administered 
by the Garda Office for Children and Youth Affairs (formerly Garda Community 
Relations).18 The first two GYDPs were established in 1991. In 2008, 100 projects were 
                                               
17
 A successor to the strategy is due to be published in 2013. See http://www.iyjs.ie/en/IYJS/Pages/WP08000093 
18
 For further information about the GYDPs see Ryan, L., Warren, A., Cadwell, L. and Bowden, M. (2003). Garda Youth 
Diversion Project Guidelines. Department of Justice, Equality & Law Reform, Dublin. Available at 
http://www.drugsandalcohol.ie/20381/ and Redmond, S. (2009). A baseline analysis of Garda youth diversion projects: 
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operating in local communities across Ireland, providing services to some 3,600 young 
people. 
 
The GYDPs are community-based, multi-agency youth crime prevention initiatives 
which seek to divert young people who have been involved in anti-social or criminal 
behaviour into suitable activities to facilitate personal development. The projects may 
also work with young people who are at significant risk of becoming involved in anti-
social behaviour or crime. The GYDPs work primarily with people aged between 12 
and 18.  
 
The director of the Diversion Programme is a Garda Superintendent appointed by the 
Commissioner of An Garda Síochána. The Director must consider all cases and decide 
on the suitability or otherwise of the child for inclusion in the Programme. Published in 
2013, the 2011 annual report on the effectiveness of the Diversion Programme 
(Committee appointed to Monitor the Effectiveness of the Diversion Programme 2013) 
reported the following outputs: 
 
 The total number of incidents referred to the Diversion Programme during 2011 
was 27,384. 
 The total number of individual children referred to the Programme was 12,809. 
 9,721 (76%) of the children referred were admitted to the Diversion Programme. 
 6,944 (54% ) children had their cases dealt with by way of an informal caution. 
 2,777 (22%) children had their cases dealt with by way of a formal caution. 
 25% of children who were referred to the Programme were female while 75% were 
male. 
 Public order (28.86%), theft and related offences (23.69%) and damage to property 
and to the environment (11.31%) constituted the three main categories of offences 
for which children were referred. 
 Controlled drug offences accounted for 1,290 or just under 5% of the total number 
of referrals. Of these offences, 1,046 involved possession for personal use while 
196 involved drug supply offences.  
 
According to the report, the GYDPs work with the child and set ‘an individual plan of 
intervention for him/her which seeks to assist the child to examine their decision 
making process focusing on the decision that led them to offend…motivational 
interviewing techniques are used…to facilitate change and pro-social modelling is used 
to challenge individual participant’s attitudes and behaviours’ (p. 23). Assistance is also 
provided to the family so that changed attitudes can be ‘positively re-enforced at home, 
in school, within peer groups and in the community’ (p. 23). 
 
 
9.6 Interventions in the criminal justice system 
 
9.6.1 Alternatives to prison 
 
Report of the Joint Oireachtas Committee on Justice on Penal Reform 
A report on penal reform by the Joint Oireachtas Committee on Justice, Defence and 
Equality (Joint Committee) has made a number of recommendations aimed at reducing 
overcrowding in Irish prisons and promoting the development of effective alternatives to 
imprisonment (Houses of the Oireachtas Joint Committee on Justice Defence and 
Equality 2013). In October 2011, the Joint Committee established a sub-committee on 
penal reform, following publication of a report by the Thornton Hall Group (Thornton 
Hall Project Review Group 2011).  
The Thornton Hall Group considered the application of alternatives to custody from 
both a front-door and back-door perspective. Front-door strategies involve reducing the 
                                                                                                                                         
considering complexities in understanding youth crime in local communities in Ireland. Irish Probation Journal, 6, 137-
152. Available at http://www.drugsandalcohol.ie/16531/. 
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numbers sent to prison while back-door strategies involved some form of early release. 
The Group identified three forms of early release in Ireland: 
 
 the government power to commute or remit any sentence under Article 13.6 of the 
Constitution, 
 remission under the Prison Rules, which provide that prisoners can earn remission 
of up to 25% of their sentence, and 
 temporary release, provided for under the Criminal Justice Act 1960 as amended 
by the Criminal Justice (Temporary Release of Prisoners) Act 2003. 
 
The recommendations of the Joint Oireachtas Committee are aimed at enhancing 
these measures. Concerned about the ‘significant increase over recent years in the 
number of prisoners in Ireland, the Joint Committee called, in an overarching 
recommendation, for the introduction of a ‘decarceration strategy’ to be introduced, 
involving a ‘declared intention by the Government to reduce the prison population by 
one-third over a ten-year period’ (Houses of the Oireachtas Joint Committee on Justice 
Defence and Equality 2013) (p. 9). The Joint Committee also recommended that all 
sentences of less than six months’ imprisonment imposed in respect of non-violent 
offences should be commuted and replaced with community service orders and that 
standard remission should be increased from one-quarter to one-third of all sentences 
over one month in length. 
 
The Joint Committee also endorsed a recommendation made by the Irish Penal 
Reform Trust in its submission to the committee when it called for ‘a single piece of 
legislation which would set out the basis for a structured release system; to include 
proposed changes to remission…temporary release and parole…for an expanded 
community return scheme… [and to] underpin the strategies currently used by groups 
working with offenders post-release, and with potential offenders’ (p. 9).19 Finally, the 
Joint Committee highlighted the need to address poor prison conditions and prison 
overcrowding and it called for an increase in the number of open prisons. 
 
Drug treatment court 
In relation to the ongoing operation and future of the Drug Treatment Court, which is a 
specific alternative to prison for offenders whose offence is deemed to be drug-related, 
the Minister for Justice and Equality, Alan Shatter TD, stated in response to a 
Parliamentary Question: 
 
The Support and Advisory Committee for the Drug Treatment Court has over 
the course of 2012 undertaken a detailed evaluation of the court's operation 
and is in the process of completing some final enquiries which are due to be 
submitted to my Department in the near future. I will consider this issue further 
when all of the information is to hand. (Shatter 2013, February 12) 
 
An academic article about the drug treatment court, based on qualitative interviews 
with six experienced professionals and bureaucrats involved in the management of 
drug-using offenders in Ireland, looks at the Dublin pilot drug court as an example of 
policy transfer between countries (Butler 2013). Those interviewed were generally 
unconvinced that the American drug court model was technically more effective than 
more traditional methods of diverting offenders from custodial sentencing into 
treatment, and tended to see political support for the initiative in terms of the symbolic 
value of this liberal, humanistic alternative to imprisonment. They also agreed, 
however, that the Dublin drug court was not true to the American model in that it did not 
embody the philosophy of therapeutic jurisprudence, which is central to American drug 
court practice. According to Butler, ‘the role of the judge in a system of therapeutic 
jurisprudence is more activist, more involved and, above all, one of problem solving’ (p. 
6). 
 
                                               
19
 For IPRT submission see Irish Penal Reform Trust (2012). Reform of remission, temporary release and parole. Irish 
Penal Reform Trust,  Available at http://www.drugsandalcohol.ie/18656/ 
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One of the challenges currently facing the drug treatment court is the difficulty in 
attracting suitable participants. This has contributed to a low level of court graduates 
(Department of Justice 2010). In order to address the low number of entrants to the 
court, as of mid-July 2013, it has now been decided to extend the catchment of the 
Drug Treatment Court to the south side of the river Liffey in Dublin (Personal 
communication: Tom Ward, Chief Clerk, Dublin Circuit and District Courts, 31 July 
2013). 
 
9.6.2 Other interventions in the criminal justice system 
Community policing 
A report published by the National Economic and Social Council (NESC) as part of its 
quality and standards in human services in Ireland series reviews the various police 
oversight and consultative bodies established by the Garda Síochána Act 2005 
(National Economic and Social Council 2012). The new regulatory institutions 
established by the Act include the Garda Síochána Ombudsman Commission, the 
Garda Síochána Inspectorate, Joint Policing Committees and Local Policing Fora. The 
NESC report explains that many of these oversight bodies emerged as a response to 
‘revelations about abuse of powers by individual officers’ (p. 2), with the net result 
being a much greater oversight of police activity. However, the report queries their 
overall impact, on both the level and quality of policing and ‘the potentially egregious 
abuses of power’ (p. 2). The report suggests that ‘these bodies have yet to 
institutionalise procedures that would embed and sustain reform over time’ (p. ix). It 
also poses the more fundamental question as to whether the kind of oversight offered 
by these bodies is sufficiently ‘diagnostic’ to uncover the causes of the various 
complaints and problems they were established to address, so as to prevent their 
recurrence. 
 
The report suggests that a more promising route towards the improvement of policing 
standards may be through a structured liaison process between gardaí and local 
communities, citing an example of how this has been accomplished by a local 
community policing initiative established in Dublin’s north inner city. The North Inner 
City Community Policing Forum (CPF) was established in 1999 to facilitate a co-
ordinated strategy in response to drug dealing and drug-related anti-social behaviour in 
the north inner city (Connolly, Johnny 2002). The CPF brings together the local 
community and representatives of the Garda Síochána and Dublin City Council. The 
NESC report (National Economic and Social Council 2012) concludes that the CPF has 
been a ‘relatively successful model of engagement with citizens at a local level’ and 
that it has fostered a ‘greater culture of transparency’ between the community and the 
gardaí involved’ (p. 33). The community, according to the report ‘now have a more 
responsive police service and the gardaí have been able to tap into confidential 
information derived from the community’ (p. 34). 
 
Although highlighting the positive achievements of the CPF, the NESC report 
concludes that, when approaching all forms of policing service delivery in Ireland, there 
is a need for a more rigorous process of learning and analysis so as to encourage 
continuous improvement. It advocates a process referred to as ‘triple-loop learning’, 
described as a ‘need for learning to take place at a number of levels that reinforce each 
other: the level at which the service is delivered; at corporate level; and at the level of 
regulator or at national level’ (p. 5). According to the NESC report, because of the 
policing reforms introduced by the Garda Síochána Act 2005, ‘Ireland has all the “parts” 
necessary for a well-functioning system of quality policing… . But these parts have yet 
to be co-opted into a common regime of learning that is conducive to greater quality in 
policing’ (pp.ix–x). 
 
Southern Regional Drugs Task Force stresses new approach to policing 
As well as reporting on drug use in counties Cork and Kerry during 2011 and detailing 
the projects funded, together with the outputs and outcomes, the co-ordinator and chair 
of the Southern Regional Drugs Task Force (SRDTF) have used their 2011 annual 
report as a vehicle for setting out their vision of how the individual should be at the 
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centre of a task force’s responses to the illicit drugs problem (Black 2012). Co-ordinator 
Chris Black reports that, as well as focusing on its funded projects, the SRDTF has 
been involved in innovative development work that draws on international sources. He 
suggests this is ‘setting the seeds for a more user friendly, person centred and health 
based approach to drugs policy and drugs support’. Initiatives include a new style of 
policing that embraces human rights and harm reduction. This is the subject of a 
proposal being developed by the SRDTF in conjunction with the International Drug 
Policy Consortium (IDPC). The proposal encompasses work that the SRDTF has been 
progressing, such as an arrest referral process, and ‘a vision that drug users be viewed 
as having a health issue and in need of support, rather than being seen as criminals 
within the criminal justice system’. 
 
9.7 Drug use and problem drug use in prisons 
 
Although, as with any illicit drug market, it is impossible to accurately record the true 
extent of drug use, a number of data sources have been used here to provide a picture 
of the nature and general extent of prison drug use. 
 
Prison drug seizures 
 
Table 9.7.1 Total number of seizures of individual drugs in each prison, Ireland, 2010 to 2012 
Institution 2010 2011 2012 
Arbour Hill 0 2 0 
Castlerea 82 97 50 
Cloverhill 87 57 78 
Cork 52 73 49 
Dochas Centre 30 25 35 
Limerick 167 216 287 
Loughan House 46 21 15 
Midlands 90 121 115 
Mountjoy 683 387 235 
St Patrick’s 272 206 219 
Portlaoise 41 21 19 
Shelton Abbey 26 16 13 
Wheatfield 114 147 123 
Training Unit 49 28 18 
Total 1739 1417 1256 
Source: (Shatter 2013, January 23)  
 
Prison drug seizure figures for 2012 show that there were 1,256 seizures of drugs 
across the various institutions that make up the Irish prison estate. Total seizures have 
decreased by 28% since 2010. It is not possible to know whether this reflects a 
decrease in drug use, more effective supply reduction activity in terms of preventing 
drugs from entering the prison or, indeed, a decrease in supply reduction enforcement 
activity. Other data sources and research are needed to provide further context for 
these figures. 
 
Drug tests in prisons 
The Inspector of Prisons, in his annual report for 2012, stated that the availability of 
drugs remains a major issue in a number of prisons (Reilly 2013). In particular, he 
made reference to drug problems in Limerick Prison, a matter that was also raised by 
the Limerick Prison Visiting Committee in their annual report for 2012 (Prison visiting 
committees 2013). The Inspector also identified a number of issues of concern 
throughout the prison system, many of them drug-related. At present, for example, 
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approximately 25% of Irish prisoners are in secure 23-hour lock-up for their own 
protection. This is often linked to threats from drug gangs in prison or because of drug 
debts owed to individuals or gangs. One by-product of this prison reality is that it can 
undermine drug service provision for dependent drug users in prison. According to the 
Inspector: 
 
‘The reasons why prisoners are on protection vary. In certain cases prisoners 
request that they wish to go on protection as they are either under direct threat 
from others in the prison or perceive that they are under threat. In other 
instances they are on protection simply because they come from a particular 
geographic area of the Country or because of their cultural ethnicity. The 
prevalence of gangs in the prison, which reflects that which is on the outside, is 
also a problem as vulnerable prisoners can be forced to join a gang or do so of 
their own volition as they perceive that by doing this they are safer.’ (Reilly 
2013) (p. 13)  
 
The Inspector also points out that when prisoners are on 23 hour lock up they 
effectively have little or no contact with teachers or addiction services. 
 
 
9.8 Responses to drug-related health issues in prisons 
 
9.8.1 Drug treatment 
 
For a detailed consideration of drug health services in Irish prisons see (Health 
Research Board 2011) (Section 11).  
 
In 2012 the Drug Treatment Clinical Policy document issued by the Irish Prison Service 
(IPS) in 2008 was reviewed to ensure that services provided in prisons were equivalent 
to those provided in the community (Irish Prison Service 2008). In its annual report for 
2012, the IPS stated: 
 
The…Clinical Drug Policy was reviewed and amended during the course of 
2012 to reflect best practice guidelines and changes in practice in the 
community. This work involved consultation with prison and wider community 
providers of drug treatment services.’ (Irish Prison Service 2013)(p29) 
 
Further information on this review and on the available drug services in Irish prisons 
was provided by the Minister for Justice, Alan Shatter TD, in response to a number of 
Parliamentary Questions. Thus : 
 
The policy was examined in detail by a multidisciplinary group, including 
representatives from community, voluntary and statutory stakeholders, and Irish Prison 
Service healthcare staff. It was amended to reflect changes in legislation and practice 
in the community, including the statutory requirements in relation to HIV testing and 
notification, and the development of In Reach services for the treatment of Hepatitis C. 
The Drug Treatment Clinical Policy now encompasses the following: 
 
- Addiction Treatment Charter; 
- Clinical Interdisciplinary Care Planning; 
- Psychosocial Supports and Pharmacological Interventions for Opioid Dependence; 
- Drug Testing; 
- Dispensing and Administration of Methadone; 
- Viral Screening; 
- Immunisation Guidelines; 
- Assessment and Treatment of Benzodiazepine Addiction; 
- Assessment and Treatment of Alcohol Withdrawals; 
- Cocaine Treatment Policy; and 
- Nicotine Replacement Therapy Policy. (Shatter 2013, May 30) 
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In a separate response to a Parliamentary Question about drug detoxification, the 
Minister reported that ‘recent trends across prisons indicate a significant number of 
prisoners currently self-detoxing from methadone and a marked reduction in the 
average dose of methadone’ (Shatter 2013, February 6). 
 
The proposals of the 2012 review, which have been adopted by the Irish Prison Service 
and are currently being rolled out on a phased basis include the following: 
 
The establishment of a therapeutic Detoxification and Rehabilitation Treatment 
Programme (DRTP) with the allocation of 10 additional places from March 
2013. The DRTP will also operate in the Medical Unit (Mountjoy Prison) and will 
be in addition to the existing DTP which has 9 places; Circa 50 beds in the 
Medical Unit, Mountjoy Prison will be used exclusively for Drug Treatment 
Programmes including: 
 The Drug Treatment Programme (DTP) – 8 week duration; 
 Detoxification & Rehabilitation Treatment Programme (DRTP) – 6 week 
duration, 
 Slow Detoxification Programme – maximum duration 6 months, 
 Stabilisation Programme – maximum duration 6 months'. 
The Training Unit and Shelton Abbey are being designated as suitable for 
prisoners on methadone maintenance treatment. Loughan House will be 
designated as a facility for the treatment of prisoners seeking to return to a drug 
free lifestyle. (Shatter 2013, February 6). 
 
The Minister went on to state that ‘Progression from these programmes will include 
access to Drug Free Units, open prisons and ultimately the Community Return Scheme 
(See below), subject to normal operational considerations’ (Shatter 2013, February 6). 
 
Drug-free units, in accordance with the Irish Prison Service Strategic Plan 2012–2014, 
are due to be established in all closed prisons (Irish Prison Service 2012). Currently 
they exist in just four prisons: Mountjoy, Wheatfield, Cloverhill and St Patrick's 
Institution. Following sustained criticism of conditions in St Patrick’s young offenders’ 
institution over many years, the Minister for Justice announced in July 2013 that it was 
due to be closed within six months (Shatter 2013, July 3). 
 
 
9.8.2 Prevention and reduction of drug-related harm 
 
For latest information see (Health Research Board 2011) (Chapter 11) 
 
9.8.3 Prevention, treatment and care of infectious diseases 
 
For latest information see (Health Research Board 2011) (Chapter 11) 
 
9.8.4 Prevention of overdose-risk upon prison release 
 
For latest information see (Health Research Board 2011) (Chapter 11) 
 
 
9.9 Reintegration of drug users after release from prison 
Research on recidivism 
 
The Probation Service and Central Statistics Office established a partnership to 
conduct research on recidivism and related issues among offenders on supervision in 
the community. The report was published in November 2012 (Probation Service 
2012a). The first of its kind in Ireland, the study was based on anonymised offender 
and offence information relating to a 2007-cohort of offenders taken from the Probation 
Service supervision database. The study reports on recidivism within two years among 
that cohort, and on a four-year follow-up based on recorded crime and Court Service 
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data held by the Central Statistics Office. The study also examines variations in 
recidivism relating to type of original order, gender and age of the offender, category of 
original offence and of the subsequent offence.  
 
The study provides an overview of community sanctions and their outcomes including 
the following:  
 
 Almost 63% of offenders on Probation Service supervision had no conviction for a 
further offence committed within two years of the imposition of a Probation or 
Community Service order. The overall recidivism of offenders in the study was 
37.2%.  
 Reoffending was twice as likely to occur in the first rather than the second twelve 
months.  
 The recidivism rate decreased as offender age increased.  
 Male offenders represented 86% of the total population and had a higher recidivism 
rate than female offenders.  
 Public Order was the most common original offence and these offenders had the 
highest recidivism rate.  
 The three most common offences for which offenders were reconvicted were the 
same as the three most common original offences: Public Order, Theft and Drugs. 
 
The Irish Prison Service, in partnership with the Central Statistics Office, also published 
a report on recidivism rates among ex-prisoners in Ireland (Irish Prison Service and 
Central Statistics Office 2013). The report was published in May 2013.  It is based on a 
study of all prisoners released on completion of a sentence in 2007, using re-conviction 
data up to the end of 2010. The total population studied was 7,701.The study also 
assesses variations in recidivism based on the age and gender of the offender, as well 
as the category of both the original offence and the subsequent offence.  
 
The Prison study is not comparable to the Probation study described above as the 
former was based on a two-year period for reoffending and excluded a number of 
offence types. However, the Probation study showed a recidivism rate of 37.2% within 
two years of the imposition of a probation or community service order, while the Prison 
study showed a recidivism rate of 58.3% within two years of the completion of a prison 
sentence.  
 
The findings of the report include the following: 
 
 The overall recidivism rate of offenders within three years was 62.3%. 
 Two thirds of re-offences occurred within six months of release. Over 80% of re-
offending occurred within 12 months of release. 
 Males made up 92% of the total population studied and had a higher recidivism rate 
than females (63% as opposed to 57%). 
 The recidivism rate decreased as the offender age increased. While 68.5% of those 
under 21 years of age re-offended, the rate fell to 38.6% for the 51–60-years age 
category. 
 The highest rate of recidivism was among those who had served a sentence for 
burglary and related offences (79.5%). 
 The most common offence for which offenders were re-convicted was Public Order 
(1,281 or 27%). Almost 27% were reconvicted of the same offence. More than 34% 
of theft offenders committed a further theft offence. 
 More than 20% of drug offenders committed a further drug offence.  
 
The report concludes with the unsurprising observation that ‘for the majority of those 
incarcerated, similar criminogenic needs and risks exist. …Lack of employment, abuse 
of alcohol and drugs, anti-social attitudes and companions, emotional and personal 
difficulties, poor educational achievement, family problems and lack of housing’ (p. 18). 
Given the complexity of the problems many prisoners have, the authors raise the 
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question as to whether it is reasonable to expect the Irish Prison Service or the criminal 
justice system to provide solutions in terms of reintegration. The authors conclude,  ‘If 
we are to really succeed in reconnecting offenders back to their communities, … [then] 
we must devise a model which involves a multiplicity of state, community and voluntary 
agencies working in partnership on behalf of individual communities to bring about real 
change’ (p. 19). 
The Irish Prison Service and the Probation Service intend, in partnership with the 
Central Statistics Office, to jointly publish annual recidivism figures. Consistent with this 
new partnership approach, the Irish Prison Service and the Probation Service have 
agreed a joint service strategic plan for 2013–2015 (Irish Prison Service and Probation 
Service 2013). Included in this are measures aimed at enhancing sentence 
management from pre- to post-imprisonment in a way which will ‘facilitate improved 
prisoner outcomes’,  and at enhancing the roll-out of the Community Return scheme, 
discussed below.   
 
Community return 
The Community Return scheme is a joint Probation Service and Irish Prison Service 
initiative whereby selected prisoners are granted temporary release on condition they 
perform unpaid supervised work in the community. Eligible participants are those 
prisoners serving sentences of between one and eight  years. They must also have 
completed at least half their sentence. According to the 2012 annual report of the 
Probation Service, ‘A pilot programme commenced in October 2011 and a total of 365 
offenders were released on to the scheme between that time and the end of 2012’ 
((Probation Service 2013) p. 9). The Community Return scheme had a 90% 
compliance rate in 2012. It is reported that by the end of 2012, 221 persons had 
completed their allocated work, with approximately 10% (n=370) being returned to 
custody for non-compliance. The scheme involves a ‘two-strike’ rule whereby, if 
offenders fail to attend or are late for work on two separate occasions, they are 
regarded as in breach of the rules governing the scheme and are returned to custody 
to complete the entire balance of their sentence. According to the Probation Service 
2012 annual  report:  
 
The experience of all concerned has been very positive and many Community Return 
participants have been commended for their work ethic, punctuality and commitment. 
Initial feedback from participants has also been positive with many commenting on the 
supports and structure it gives them on their release and how it has assisted in their 
transition back into the community. (p. 9) 
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10. Drug Markets 
10.1 Introduction 
The first comprehensive study of illicit drug markets in Ireland is due to be published by 
the National Advisory Committee on Drugs and Alcohol (NACDA) and the Health 
Research Board (HRB) in late 2013. A detailed summary of the relevant findings from 
this study were presented in the National Report for 2011 (Health Research Board 
2011) (Section 10).  Data from that study are not yet available, however. Data from 
several other information sources which give indications of the nature and size of the 
market are presented here. 
 
Prevalence surveys may ask respondents about their access to illicit drugs and about 
the availability of various drugs. For example, the all-Ireland general population drug 
prevalence survey, described in detail in Section 2.1 of this report, asks respondents 
how they obtained individual substances  (who from and under what circumstances), 
where did they obtain them (in what type of location) and how easy were they to obtain. 
The European School Survey Project on Alcohol and Other Drugs (ESPAD), reported 
in last year’s National Report  (Health Research Board 2012) (Section 2.3), contains a 
question, the answer to which indicates the perceived availability of some illicit 
substances – ‘How difficult do you think it would be for you to get each of the following 
(cannabis, amphetamine, ecstasy)?’. 
 
Data on drug seizures by Customs Drug Law Enforcement (CDLE) and the Garda 
Síochána provide insights into the origins of drugs being brought into Ireland, and the 
nature of the market in terms of supply and availability. However, these data must be 
treated with caution as the number of drug seizures in any given period can be affected 
by such factors as law enforcement resources, strategies and priorities, and by the 
vulnerability of traffickers to law enforcement activities.  
 
Drug offence data published by the Central Statistics Office (CSO) can assist in 
understanding aspects of the operation of the illicit drug market in Ireland. With regard 
to the so-called middle market level, which involves the importation and internal 
distribution of drugs, data on drug supply offence prosecutions by Garda division are a 
possible indicator of national drug distribution patterns. While these data primarily 
reflect law enforcement activities and the relative ease of detection of different drugs, 
they may also provide an indicator of national drug distribution trends. These data can 
be compared with other sources such as drug treatment data, for example, to show 
trends in market developments throughout the State. Such data can also indicate 
trafficking patterns by showing whether there is a concentration of prosecutions along 
specific routes.  
 
For policing purposes Ireland is divided into six regions, each of which is commanded 
by an Assistant Commissioner. The six regions are: 
 Dublin Metropolitan Region  
 Northern Region  
 Western Region  
 Eastern Region  
 Southern Region  
 South Eastern Region 
 
Each region is divided into divisions commanded by a Chief Superintendent, and each 
division is then divided into districts commanded by a Superintendent, who is assisted 
by a number of Inspectors. The districts are divided into sub-districts, each normally the 
responsibility of a Sergeant.  
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Map 10.1.1 Irish Garda regions and divisions 
 
The Forensic Science Laboratory (FSL) provides impartial scientific evidence following 
examination of crime scenes, including seizures of drugs. However, not all drugs 
seized by the law enforcement agencies (the Garda Síochána or CDLE) are 
necessarily analysed and reported on by the FSL. For example, if no individual is 
identified in relation to the drug seizure, and no prosecution takes place, the drugs may 
not be sent for analysis and may be destroyed.  Moreover, drug purity data are not 
collated in a systematic way at different market levels in Ireland. The primary function 
of the FSL in this area relates to supporting the criminal justice system, and not to 
research. Only a very small proportion of drugs seized are tested to ascertain the 
percentage purity.  
 
Drug prices are also not regularly reported on in Ireland. However, An Garda Síochána 
monitors drug markets on a nationwide basis annually and records current drug values. 
These are reported in this chapter for the first time.  
 
10.2 Availability and supply 
 
10.2.1 Perceived availability of drugs, exposure, access to drugs e.g. in general 
population, specific groups/places/settings, problem drug users 
 
Bulletin 3 on the results of the 2010/11 general population drug prevalence survey, 
which surveyed a  representative sample of adults in Ireland aged between 15 and 64 
years in late 2010 and early 2011, reports on the findings with regard to cannabis use 
(National Advisory Committee on Drugs and Alcohol 2013) (see also section 2.?). The 
bulletin presents the results regarding lifetime use of cannabis (ever used), and last-
year (recent use) and last-month (current use) prevalence rates. Prevalence results are 
also presented for cannabis dependence and cannabis abuse. Finally, the bulletin 
reports on age at first use, frequency of use, methods of using, how cannabis was 
obtained and the profile of those who took it. The survey was carried out according to 
standards set by the EMCDDA.  
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Herb was the main type of cannabis used by current users. The share of herb users 
relative to resin users has reversed since 2006/7 when resin was the most common 
form reported. The majority of recent cannabis users said it would be easy for them to 
obtain cannabis in a given 24-hour period 
 
 
10.2.2 Drugs origin: national production versus imported 
 
A recent EU drug markets report, jointly published by the EMCDDA and Europol, is the 
first comprehensive overview of illicit drug markets in the European Union (European 
Monitoring Centre for Drugs and Drug Addiction and Europol 2013). The report 
highlights a number of factors relevant to the Irish illicit drugs market, and Ireland’s 
response to the ‘head shop’ phenomenon. A comparative study of this nature can be 
useful in trying to understand national developments in drug markets. For example, in 
late 2011, information was gathered in an attempt to understand anecdotal reports of a 
reduction in the supply of heroin in Europe: ‘Evidence of this phenomenon was 
collected between November 2010 and March 2011 from Bulgaria, Ireland, Hungary, 
Slovakia, the United Kingdom, Switzerland and some regions in Russia, whereas 
heroin remained available, with possible increases in purity, in Belgium and France’ (p. 
30). Although the causes of these developments remain unclear – they may point to a 
shift in demand towards alternative drugs, such as fentanyl, or to the possible 
disruption of heroin supply routes through Turkey owing to law enforcement efforts – 
research of this nature at an international level can help explain national trends.  
 
Ireland is also one of a number of countries that have experienced increases in the 
domestic cultivation of herbal cannabis in the last five years. Using drug seizure size as 
an indicator, the report also provides a useful picture of cannabis resin supply routes 
into and throughout Europe. It is reported that Ireland is a transit point for cannabis en 
route to the UK and onwards into mainland Europe:  
 
Average seizure sizes greater than 1kg suggest that Ireland is…an entry point 
for Moroccan resin into Europe. Resin seizures represent about 15% of 
estimated national consumption; it is likely that some of the resin entering 
Ireland eventually ends up in the United Kingdom, where the market for resin, 
although smaller than the market for herb, is still rather large, estimated to be 
about seven times the size of the Irish market. Seizures in the United Kingdom 
are on average smaller than in Ireland (under 1kg) and represent one-third of 
estimated national demand… (p. 62) 
 
The report also considers the involvement of organised crime groups (OCGs) in drug 
production and trafficking. With regard to herbal cannabis it is reported that 
‘Vietnamese OCGs have become prominent in the indoor cultivation of cannabis in 
many EU countries, particularly Belgium, the Czech Republic, Germany, Ireland, 
France, Hungary, the Netherlands, Poland, Slovakia and the United Kingdom’ (p. 64). 
These OCGs are described as ‘hierarchical in structure’, incorporating a range of 
specialised personnel, including ‘electricians, plumbers and managers of cultivation 
facilities’ (p. 64). The report also alludes to the social factors that can lead to people 
becoming involved with such illegal activities. In relation to herbal cannabis, ‘Gardeners 
tending the plants are often illegal migrants working to pay off their passage’ (p. 64). 
 
Synthetic drugs are produced mainly in Belgium and the Netherlands. However, the 
report states that police intelligence suggests ‘the growing prominence of Polish and 
Lithuanian OCGs in trafficking drugs obtained in the Netherlands to various Nordic and 
Baltic States, Ireland and the United Kingdom’ (p. 78).  
 
The report also looks at the increasing importance of the internet as a source of supply 
of new psychoactive substances and ‘legal highs’, an issue that has featured 
prominently on the political agenda in Ireland in recent years (Health Research Board 
2011) (Section 1.2). EMCDDA data included in the report show that the number of 
  144 
online shops offering these substances increased from 170 in January 2010 to 693 in 
January 2012. A recent Eurobarometer survey referred to in the report found that, 
among 15–24-year-olds, ‘lifetime use of “legal highs” in most Member States was 5% 
or less’, whereas ‘use in the United Kingdom, Latvia, Poland and Ireland was 8%, 9%, 
9% and 16% respectively’ (p. 106). The high rate in Ireland can be traced to the 
significant number of ‘head shops’ operating in this country in the years covered by the 
report. 
 
 
10.2.3 Trafficking patterns, national and international flows, routes, modi 
operandi; and organisation of domestic drug markets 
 
Drug offence data can assist in understanding aspects of the operation of the illicit drug 
market in Ireland. Data on drug offence prosecutions by Garda division are a possible 
indicator of national drug distribution patterns. While these data primarily reflect law 
enforcement activities and the relative ease of detection of different drugs, when 
compared with other sources, such as drug treatment data, they can show trends in 
market developments throughout the State. Such data can also indicate trafficking 
patterns by showing whether there is a concentration of prosecutions along specific 
routes. Figures 10.2.3.1 and 10.2.3.2 show trends in relevant legal proceedings for 
possession of drugs by Garda region. It should be noted that possession offences 
include both possession for personal use and possession for the purpose of supply. It 
is not possible to distinguish between these two offences in the data reported by Garda 
region. However, in the country as a whole, possession for personal use accounted for 
between 65% and 75% of all possession cases in the years 2004–2011 (see Figure 
9.3.1). 
 
As shown in Figure 10.2.3.1 an upward trend since 2004 in relevant legal proceedings 
for possession (for personal use and for supply) continued until 2008, and then 
decreased between 2008 and 2011. The majority of such proceedings were in the 
Dublin Metropolitan Region (DMR), where the number increased steadily from 1,515 in 
2004 to 5,270 in 2008. The number has fallen since then, with 3,773 such offences 
prosecuted in 2011, lower than the figure of 4,077 reported for 2007. 
 
 
Figure 10.2.3.1   Trends in relevant legal proceedings for possession of drugs for personal use and 
for sale or supply, nationally and in the Dublin Metropolitan Region, 2003–2011   
Source: (Central Statistics Office 2013) 
 
Figure 10.2.3.2 shows trends in supply offences by Garda region, excluding Dublin. 
Numbers have increased in all regions since 2005 This reflects the reality that drug 
markets are no longer primarily a Dublin-based phenomenon. Following this general 
increase throughout the country, the number of relevant legal proceedings for drug 
possession (for personal use and for supply) decreased in all regions between 2009 
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and 2011, with the exception of the Northern Region where the figure fluctuated slightly 
in that period. 
 
 
Figure 10.2.3.2 Trends in relevant legal proceedings for possession of drugs for personal use and 
for sale or supply, by region, excluding the DMR, 2003–2011  
Source: (Central Statistics Office 2013) 
 
In a recent report to the Joint Oireachtas Committee on Justice, Defence and Equality, 
the Garda Síochána Commissioner stated that there are approximately 25 OCGs 
operating throughout the State (Joint Committee on Justice Defence and Equality 2012 
).  The majority are centred in large urban areas such as Limerick, Cork, Galway, Sligo 
and Dublin. The Commissioner stated: 
 
…there is a high amount of interaction between the various organised crime 
groups throughout the country who regularly pursue joint enterprises, 
particularly drug imports. The vast majority of organised crime groups are drug 
trafficking groups who are prepared to use violence and intimidation to further 
their aims. Each of these organised crime groups is structured hierarchically 
and would typically consist of a leadership, a number of middle-managers and 
low level criminals who could carry out day-to-day running of these organised 
crime groups.(p. 3)  
 
The Commissioner also stated that OCGs in the State work closely with criminals in 
Northern Ireland, although he suggested that the ‘taxing and extortion of drug dealers 
by dissident republicans have occurred in recent years’. 
 
Two recent studies carried out in association with the business group Retail Ireland20 
have highlighted a link between the trade in illicit drugs and the illicit trade in other 
products such as fuel, illegal tobacco and alcohol and counterfeit medicines. The first 
report, by EPS Consulting for Retail Ireland, is based on findings from a range of earlier 
reports by business groups, information from the Revenue Commissioners and 
responses to Parliamentary Questions. The report characterises counterfeit medicines 
as ‘intentionally mislabelled with regard to either identity and/or source. …Many contain 
too much or too little of the active ingredient; have the wrong ingredients; or contain 
ingredients with misleading packaging’ (EPS Consulting 2012) (p. 19). The report 
estimates that counterfeit medicine sales in Ireland could be as high as €86 million and 
that 55% of medicines are purchased over the internet from websites outside the 
country. Referring to an earlier study, the report states that ‘upwards of 90% of 
medicines bought from internet sources that conceal their physical address are 
                                               
20
 Retail Ireland represents the retail sector in Ireland and is an affiliate member of the Irish 
Business and Employers Federation (IBEC). See www.retailireland.ie 
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counterfeit [and that] 600,000 people in Ireland willingly (or otherwise) put themselves 
at risk by purchasing prescription-only medicines without a prescription’ (p. 20).  
 
The follow-on report (Thornton, Grant 2013) is based on a process of consultation with 
stakeholders from a range of sectors across the economy. This included ‘stakeholders 
from sectors such as the retail sector, the producers in the legitimate markets, 
consumers, journalists, enforcement agencies and State agencies’ (p7). The report 
highlights the role of organised crime and refers to the diversification of criminal gangs 
from illicit drugs into other forms of illicit trade: ‘Drugs continue to be the primary area 
of focus for criminal gangs. …Evidence of the linkage across the various illicit trades is 
apparent from the seizures made by both the Police Service of Northern Ireland (PSNI) 
and An Garda Síochána who have encountered multiple products such as tobacco, 
alcohol, (illicit) drugs and fuel on a single raid’ (p. 15).  
 
The Garda National Drugs Unit (GNDU) has overall responsibility for drug law 
enforcement. It is reported in the 2012  annual report of the Garda Síochána that the 
GNDU liaises with police forces in the UK, Spain, Holland and Belgium, ‘where OCG’s 
affecting the Irish jurisdiction tend to be the most proactive’ (An Garda Síochána 2013) 
(p. 4). In 2012, the GNDU arrested 125 persons in connection with drug trafficking 
offences, 91 of whom were charged and are currently before the courts. Seventy-one 
‘significant seizures’ were made including one in June 2012 of 432 kg of cocaine with 
an estimated street value of €30.23 million, which was imported to Ireland from Bolivia 
via the Netherlands. CDLE and the US Drug Enforcement Administration were involved 
in this operation. According to the 2012 annual report of the Revenue Commissioners, 
three members of an Irish OCG were arrested during this operation (Revenue 
Commissioners 2013).  
 
Illicit street-level retail market in prescription drugs 
Under the Medicinal Products (Prescription and Control of Supply) Regulations, it is 
prohibited for a person to supply a prescription medicine except in accordance with a 
prescription, and the supply must be made from a registered pharmacy by or under the 
personal supervision of a registered pharmacist. A person who contravenes these 
regulations is guilty of an offence. However, the illegal street sale of prescription drugs 
has emerged as an important issue in the Irish drug scene in recent years (Health 
Research Board 2012) (Section 1.2). In response to a Parliamentary Question, Alex 
White TD, Minister of State at the Department of Health, stated: 
 
The Revenue Commissioner's Customs Service and the Irish Medicines Board 
(IMB) have shared competency in relation to the prevention and detection at 
importation of illicit medicines. In addition the IMB and the Customs Service 
have a Memorandum of Understanding (MOU) under which both organisations 
work closely to detain and prohibit prescription medicines purchased on-line 
from being imported. The IMB and the Customs Service deploy operational 
resources in a targeted and risk-based manner and as a result of specific 
intelligence. These approaches are reviewed and adjusted based on analysis 
and evaluation of national and international seizure trends, traffic frequency, 
routes and other risk indicators. Revenue's Customs Service also has 
Memoranda of Understanding with a number of express mail courier service 
providers and work[s] very closely with these companies, the IMB and the 
Gardaí to combat the importation of illicit medicines. In September 2012 the 
IMB, Revenue Customs Services and An Garda Síochána took part in an 
international week long operation ‘Pangea V’ which led to the detection of 
capsules and tablets with an estimated value in excess of €375,000. (White, A 
2013, May 8)  
 
The government is currently reviewing the Misuse of Drugs Regulations with a view to 
introducing additional controls on certain prescription drugs being traded illicitly (see 
Section 1.2.2). 
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10.3 Seizures 
10.3.1 Quantities and numbers of seizures of all illicit drugs 
The number of drug seizures in any given period can be affected by such factors as 
law enforcement resources, strategies and priorities, and by the vulnerability of 
traffickers to law enforcement activities. However, drug seizures are considered indirect 
indicators of the supply and availability of drugs (see Standard Table 13). 
 
Cannabis seizures account for the largest proportion of all drugs seized. Figure 
10.3.1.1 shows trends in cannabis-related seizures and total seizures between 2003 
and 2012. The total number of drug seizures increased from 5,299 seizures in 2004 to 
a peak of 10,444 seizures in 2007. Between 2008 and 2010, the number almost 
halved, to 5,477. This decrease can be explained primarily by the significant decrease 
in cannabis-type substances seized. Although, as explained in section 10.1 above, not 
all drugs seized by law enforcement are necessarily analysed and reported by the FSL, 
it is difficult to know if the reduction in cannabis-related seizures reflects a decline in 
cannabis use or a reduction in law enforcement activity. Following a slight increase in 
2011, in 2012 the number of cannabis seizures again decreased slightly. 
 
 
Figure 10.3.1.1 Trends in the total number of drug seizures and cannabis seizures, 2003–2012  
Sources: Central Statistics Office 2008, 2009, 2010, 2011, 2012, 2013 unpublished data  
 
The decrease in cannabis seizures between 2009 and 2010 may also be partly 
explained by a change in the nature of cannabis use, with people moving from resin to 
more potent forms of cannabis, such as herbal cannabis. For example, Figure 10.3.1.2 
shows that although seizures of cannabis resin decreased between 2009 and 2012, 
seizures of cannabis plants have increased steadily since 2006, with a slight decrease 
in 2012. Herbal cannabis seizures almost doubled between 2009 and 2011, from 981 
in 2009 to 1,833 in 2011, and then levelled off in 2012 (see Section 9.3 in relation to 
the increase in cultivation offences, and Section 10.3.3 in relation to Garda operation 
focused on cannabis cultivation). That there has been a move in consumption away 
from cannabis resin and towards more potent forms of cannabis is supported by the 
findings of the most recent publication of the all-Ireland prevalence survey on drug use 
(National Advisory Committee on Drugs and Alcohol 2013) (see Section 10.2.1). 
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Figure 10.3.1.2 Trends in the total number of drug seizures by cannabis type, 2006–2012 
Sources: Central Statistics Office 2008, 2009, 2010, 2011, 2012, 2013 unpublished data 
 
 
Other controlled drugs 
The reduction in the total number of reported seizures since 2008 shown in Figure 
10.3.1.1 may also be explained by a reduction in the number of seizures of other drugs 
since 2008. Figure 10.3.1.3 shows trends in seizures for a selection of drugs, excluding 
cannabis, between 2003 and 2012. There was a significant decline in seizures of 
cocaine and heroin between 2008 and 2011. In 2012, heroin seizures increased 
slightly, while cocaine seizures continued to decrease. Seizures of ecstasy-type 
substances also decreased significantly between 2008 and 2010. However, in 2011, 
they increased by more than 900%. This upward pattern has continued, albeit by a 
small margin, in 2012. 
 
 
Figure 10.3.1.3 Trends in the number of seizures of selected drugs, excluding cannabis, 2003–2012 
Sources: Central Statistics Office 2008, 2009, 2010, 2011, 2012, 2013 unpublished data 
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Table 10.3.1.1 All drugs seized that were reported on by the Forensic Science Laboratory, 1 
January 2012 to 31 December 2012 
Drug Quantity Number of 
Cases 
Alprazolam 8864 tablets 111 
Amphetamine 22,396 grams 90 
Buprenorphine 10 tablets 3 
BZP  6,233 tablets, 349 grams 16 
Cannabis 1,020,023 grams 1843 
Cannabis resin 1,185,154 grams 527 
Cannabis plants* 11,601 plants 542 
Clonazepam 750 tablets 15 
Cocaine 459,264 grams 391 
Diamorphine  (Heroin) 60,751 grams 766 
Diazepam 173,177 tablets 330 gram 463 
Dihydrocodeine 421 tablets 14 
Ephedrine 2708 tablets  8 
Ecstasy MDMA 148,195 tablets, 5,659 grams  311 
Flephedrone 696 grams 1 
Flunitrazepam (Rohypnol) 1,736 tablets 9 
Flurazepam 872  capsules, 51 tablets 52 
Ketamine 76 grams 13 
Lorazapam 27  tablets 1 
LSD 402 squares 24 
Methadone 8,992 mls  33 
Methylamphetamine 1,277 grams 53 
Temazepam 466 tablets 12 
Triazolam 467 tablets 11 
TFMPP 36,349 tablets 44 
Zolpidem 134 tablets 16 
Source: Central Statistics Office, unpublished data, 2012 
The list of drugs  is a record of main categories of drugs delivered to the FSL and reported on for 2012. There may be 
some large cannabis/cannabis resin cases without a suspect, in relation to which no analysis was conducted and no 
weight was determined.  
*The number of cannabis plants does not reflect the total number detected as only a sample of the plants is sent for 
analysis for practical reasons.  
 
 
10.3.2 Quantities and numbers of seizures of precursor chemicals used in the 
manufacture of illicit drugs 
See National Report 2010 for most recent information (Irish Focal Point (Reitox) 2010). 
 
10.3.3 Number of illicit laboratories and other production sites dismantled; and 
precise type of illicit drugs manufactured there 
The Garda Síochána 2012 annual report refers to the continuation of Operation 
Nitrogen. This is an investigation into industrial cannabis cultivation within the State. It 
is reported that ’38 cannabis cultivation sites were discovered and 50 persons were 
arrested’ during 2012 (An Garda Síochána 2013) (p. 5). 
 
 
10.4 Price/purity 
 
See National Report 2011 for most recent information (Health Research Board 2011). 
The Illicit drug market study referred to in that report and the data therein remains 
unpublished (Connolly, Johnny and Donovan In press). 
 
10.4.1 Price of illicit drugs at retail level 
 
The Garda annual report for 2012 reports that the GNDU carried out eight ‘test 
purchase’ operations targeted at low level dealers nationwide, which led to 71 people 
being arrested in respect of 281 criminal offences (An Garda Síochána 2013) (p. 5). A 
test purchase operation involves a garda officer posing as a potential buyer of drugs. 
The transaction is monitored carefully and at an appropriate moment the 
dealer/supplier is arrested.  
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Successful test purchase operations require up-to-date intelligence on street-level drug 
prices. An Garda Síochána monitors drug markets on a nationwide basis annually and 
records current drug values.  However, these values are not generally published. The 
Garda Síochána 2012 annual report provides estimated total values of drug seizures 
(An Garda Síochána 2013). From these figures estimated unit prices can be deduced. 
Further clarity was sought on these price estimates from the Garda National Drugs 
Unit, and these data are presented in Table 10.3.1.2.  
 
Table 10.3.1.2 Estimated drug prices for a selection of illicit drugs, 2013 
Drug Unit measurement Price 
Alprazolam 5mg/10mg pill €1/€2 
Amphetamine (Speed) 1g €15 
BZP  1 Pill €5 
Cannabis 1g €20 
Cannabis resin 1g €6 
Cannabis plants* 1 Plant €800 
Clonazepam 5mg/10mg pill €1/€2 
Cocaine 1g €70 
Crack 1g €100 
Diamorphine  (Heroin) 1g €150 
Diazepam 5mg/10mg pill €1/€2 
Ephedrine 1 pill €1 
Ecstasy MDMA/MDEA/MDA 1 pill/ 1g €8–€10/ €60 
Flunitrazepam (Rohypnol) 5mg/10mg pill €1/€2 
Flurazepam 5mg/10mg pill €1/€2 
GHB/GBL 50mls €30 
Ketamine 1g €70 
Khat 1kg €200 
Lorazapam 5mg/10mg pill €1/€2 
LSD 1 tablet €10 
Mescaline (S P 
Cactus/Peyote)** 
1 unit €30–€500 
Methadone 30 mls €10 
Methylamphetamine 1g €60 
New synthetic substances*** 1g €35 
Psilocybin (Magic mushrooms) 4g bag/pouch €20 
Synthetic cannabinoids (Spice) 1g €20 
Temazepam 5mg/10mg pill €1/€2 
Triazolam 5mg/10mg pill €1/€2 
TFMPP 1 Pill €5 
Other – Anabolic steroids pills/vials €60–€100/€12 
Sources: (An Garda Síochána 2013) and Personal Communication,  Garda National Drugs Unit, July 2013 
*Depending on plant maturity this may be a potential or actual market value 
** Depending on cactus size; also sold dried in bags 
***Mephedrone, Flephedrone, MDVP, Naphyrone, Flourotrocapacocaine, Butylone, Methedrone, Methcathinone, 
Methylone, Dimethocaine 
 
 
10.4.2 Price/potency of illicit drugs 
 
See National Report 2011 for most recent information (Health Research Board 2011). 
The Illicit drug market study referred to in the 2011 report and the data therein remains 
unpublished (Connolly, Johnny and Donovan In press).  
 
10.4.3 Composition of illicit drugs and drug tablets 
 
These data have never been reported in Ireland. 
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12.  Annexes 
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Standard Table 02 Methods and results of school surveys on drug use 
Standard Table 05 Direct drug-related deaths/Drug -induced deaths 
Standard Table 06 Evolution of direct drug-related deaths/Drug induced deaths 
Standard Table 07/8   National/local prevalence estimates on problem drug use  
Standard Table 09-1 Prevalence of hepatitis B/C and HIV infection among injecting  
drug users: methods 
Standard Table 09-2 Prevalence of hepatitis B/C and HIV infection among injecting 
drug users  
Standard Table 09-4 Notified cases of hepatitis C and B in injecting drug users 
Standard Table 10 Syringe availability 
Standard Table 11 Reports of drug law offences 
Standard Table 12 Drug use among prisoners 
Standard Table 13 Number and quantity of seizures of illicit drugs 
Standard Table 14 Purity/ Potency at street level of some illicit substances  
Standard Table 15 Composition of illicit drug tablets 
Standard Table 16 Price at street level of some illicit substances 
Standard Table 18 Overall mortality and causes of deaths among drug users 
Standard Table 24 Access to treatment 
Mustap 
Structured Questionnaire 25 Universal prevention 
Structured Questionnaire 26 Selective and indicated prevention 
TDI 34 TDI data 
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Figure 6.3.1.5   Overdose cases admitted to Irish hospitals, by classification, 2011 (N= 
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Figure 6.3.2.1 Rate of first admission of psychiatric cases with a diagnosis of drug 
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personal use and for sale or supply, nationally and in the Dublin 
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12.4 List of maps 
Map 10.1.1: Irish Garda regions and divisions  
 
12.5 List of legislation 
 
Laws 
The Childcare Act 1991 
The Criminal Justice (Drug Trafficking) Act 1996 
The Criminal Justice Act 1999 
The Criminal Justice Act of 2006  
The Criminal Justice (Amendment) Act 2009 
The Criminal Justice (Search Warrants) Act 2012 
The Education (Welfare) Act 2000 
The Europol Act 2012Misuse of Drugs Act (MDA) 1977  
The Housing (Miscellaneous Provisions) Act 2009 
The Law reform commission Act 1975 
The Mental Health Act 2001 
The Misuse of Drugs Act (MDA) 1984 
The Misuse of Drugs Regulations 1988 
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The Road Traffic Act 2010 
 
Bills 
The Fines (Payment and Recovery) Bill 2013 
The Road Traffic (No.2) Bill 2013 
The Spent Convictions Bill 2012 
 
12.6 List of abbreviations 
ADHD   Attention-Deficit Hyperactivity Disorder 
AIDS   Acquired Immunodeficiency Syndrome 
ALDP   Ana Liffey Drug Project 
ASRS   Adult ADHD Symptoms Rating Scale 
AUDIT   Alcohol Use Disorders Identification Test 
BAC   Blood Alcohol Concentration 
BBVs   Blood Borne Viruses 
BLIPS   Brief Limited Intermittent Psychosis 
BYAP   Ballymun Youth Action Project 
CAARMS  Comprehensive Assessment of At Risk Mental States 
CAMHS  Child and Adolescent Mental Health Service 
CAN   Swedish Council for Information on Alcohol and Other Drugs 
CBCS   Cognitive Behavioural Coping Skills therapy 
CBT   Cognitive Behaviour Therapy 
CD   Conduct Disorder 
CDLE   Customs Drug Law Enforcement 
CE   Community Employment 
CFSA   Child and Family Support Agency 
CHAID   Chi-squared Automatic Interaction Detection 
CIDR   Computerised Infectious Disease Reporting 
CLAR   areas of rural regeneration 
COD   Co-occurring Disorder 
CPF   Community Policing Forum 
CRA   Children’s Rights Alliance 
CRC   capture-recapture   
CSO   Central Statistics Office 
CSOs   Civil society organisations 
CTL   Central Treatment List 
DAIRU   Drugs and Alcohol Information and Research Unit (DHSSPS, NI) 
DAG   Drugs Advisory Group 
DATFs   Drugs and Alcohol Task Forces 
DCEGA Department of Community, Equality and Gaeltacht Affairs (since 
March 2010) 
DCYA   Department of Children and Youth Affairs 
DDD   Defined Daily Dosage 
DECLG Department of the Environment, Community and Local 
Government 
DES   Department of Education and Skills (since March 2010) 
DEIS   Delivering Equality of Opportunity in Schools 
DHSSPS  Department of Health, Social Services and Public Safety 
DIO   Drug Intentional Overdose 
DMFT   Decayed/ missing/ filled teeth 
DML   Dublin/Mid Leinster 
DMR   Dublin Metropolitan Region 
DNE   Dublin/North East 
DoH   Department of Health 
DoHC   Department of Health and Children 
DRPT   Detoxification and Rehabilitation Treatment Programme 
DSH   Deliberate Self Harm 
DTC   Drug Treatment Court 
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DTCB   Drug Treatment Centre Board 
DTF   Drugs Task Force 
DTP   Drug Treatment programme 
DUID   Driving Under the Influence of Drugs 
DUMP   Dispose of Unused Medications Properly 
Dundrum-DS  Drug Misuse and Dependence 
EIS   Europol Information System 
EMCDDA  European Monitoring Centre for Drugs and Drug Addiction 
ESPAD  European School Survey Project on Alcohol and Other Drugs 
ESRI   Economic and Social Research Institute 
EU   European Union 
Europol   European Police Office 
FSL   Forensic Science Laboratory 
FSA   Family Support Agency 
FSN   Family Support Network 
GMS   General Medical Services 
GNDU   Garda National Drugs Unit 
GP   General Practitioner 
GPI   Group Psychological Intervention 
GRO   General Register Office 
GYDP   Garda Youth Diversion Projects 
HBSC   Health Behaviour in School-aged Children Survey 
HCV   Hepatitis C Virus 
HIV   Human Immunodeficiency Virus 
HIPE   Hospital In-Patient Enquiry scheme 
HPSC   Health Protection Surveillance Centre 
HPU   Health Promotion Unit 
HRB   Health Research Board 
HSE   Health Service Executive 
IASP International ADHD in Substance Use Disorders Prevalence 
Study 
IBEC Irish Business and employers confederation 
ICASA  International Collaboration on ADHD and Substance Abuse 
ICGP   Irish College of General Practitioners 
ICT   Information and communication technologies 
IDIG   International Drug Issues Group 
IDUs   Injecting Drug Users 
IDO   Intentional Drug Overdose  
ILP   Individual Learner Plan 
IPRT   Irish Penal Reform Trust 
IPS   Irish Prison Service 
IYJS   Irish Youth Justice Service 
JPC   Joint Policing Committee 
JPF   Joint Policing Forum 
LDTF   Local Drugs Task Force 
LGBT   Lesbian, Gay, Bisexual and Transgender 
LIMS   Laboratory Information Management System 
LRC   Law Reform Commission 
LPF   Local Policing Fora 
MBRS   Medical Bureau of Road Safety 
MDA   Misuse of Drugs Act 
MTP   Methadone Treatment Protocol 
MQI   Merchants Quay Ireland 
NACD   National Advisory Committee on Drugs 
NACDA  National Advisory Committee on Drugs and Alcohol 
NATP   National Addiction Training Programme 
NAS   Neonatal Abstinence Syndrome 
NCC-DATF National Co-Ordinating Committee for Drug and Alcohol Task 
Forces  
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NCCA   National Council for Curriculum and Assessment 
NCPE   National Centre for Pharmacoeconomics 
NCRI   National Cancer Register Ireland 
NDRDI   National Drug Related Death Index 
NDS   National Drug Strategy 
NDTRS  National Drug Treatment Reporting System 
NEPS   National Educational Psychological Service 
NESC   National Economic and Social Council 
NDS   National Drugs Strategy 
NDRDI   National Drug-Related Deaths Index 
NDRIC   National Drugs Rehabilitation Implementation Committee 
NDRF   National Drugs Rehabilitation Framework 
NDTC   National Drug Treatment Centre 
NDTRS  National Drug Treatment Reporting System 
NOSP   National Office for Suicide Prevention 
NPIC   National Poisons Information Centre 
NPIRS   National Psychiatric Inpatient Reporting System 
NPIS   National Poisons Information Service 
NQSF   National Quality Standards Framework 
NSRF   National Suicide Research Foundation 
NSP   National Service Plan (of the Health Service Executive) 
NVRL   National Virus Reference Laboratory 
NYCI   National Youth Council of Ireland 
OFD   Oversight Forum on Drugs 
OMCYA  Office of the Minister for Children and Youth Affairs 
PCRS   Primary Care Re-imbursement Service 
PDUs   Problem Drug User 
PHIRB   Public Health Information and Research Branch 
PQ   Parliamentary Question 
PULSE  Police Using Leading Systems 
QFI   Quality Framework Initiative 
QuADS  Quality Standards in Alcohol and Drugs Services 
RAPID   Revitalising Areas by Planning Investment and Development 
RCPI   Royal College of Physicians of Ireland 
RCT   Randomised Controlled Trial 
RDTF   Regional Drugs Task Force 
ROSIE   Research Outcome Study in Ireland 
RTCs   Road Traffic Collisions  
SCID-1  Structured Clinical Interview for DSM-IV Axis 1 Disorders 
SDR   Standard Death Rates 
SLÁN   Survey of Lifestyle, Attitudes and Nutrition in Ireland 
SOFAS  Social and Occupational Functioning Scale 
SPHE   Social, Personal and Health Education 
SRDTF  Southern Regional Drugs Task Force 
SSIS   Suicide Support and Information System 
SSRIs   Selective Serotonin Reuptake Inhibitors 
STI   Sexually Transmitted Infection 
SUD   Substance Use Disorder 
SURF   Service Users Representative Forum 
SWHBA  South-Western Heath Board Area 
TAU   Treatment as Usual 
TCD   Trinity College Dublin 
TD   Teachta Dála (Member of Parliament) 
TDI   Treatment Demand Indicator 
THC   Tetrahydrocannabinol 
UCD   University of Dublin 
UHI   Universal Health Insurance 
UHR   Ultra High Risk 
UK   United Kingdom 
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WHO   World Health Organization 
YoDA   Youth Drug and Alcohol service 
YPFSF  Young People’s Facilities and Services Fund 
 
 
